text,chunk_id,title,publication_date,authors,disease
"Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series Tuberous Sclerosis complex (TSC) is a multisystemic neurocutaneous genetic condition characterized most commonly by cutaneous, renal, cardiac, neurological and ophthalmological abnormalities. TSC is an autosomal dominant condition with variable expression although neurological and renal complications are the main cause of morbidity and mortality associated with the condition [<xref",0_0,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"mortality associated with the condition [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The main neurological manifestation of TSC is epilepsy which is found in 70–90% of patients. Seizures which usually begin in the first three years of life are commonly the inciting event that leads patients to seek medical attention [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Approximately two-thirds of patients develop epilepsy refractory to antiepileptic drugs [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Neuroimaging at",0_1,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"rid=""CR3"">3</xref>]. Neuroimaging at the time of diagnosis may also detect cortical and subcortical tubers as well as subependymal nodules. Subependymal giant cell astrocytoma (SEGA) are observed in 5 to 15% of TSC patients and result in a large burden of morbidity and mortality as these may cause ventriculomegaly and hydrocephalus [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Renal angiomyolipomas are common benign tumors in TSC patients and are observed in 80% of cases. Within the first few years of life,",0_2,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"80% of cases. Within the first few years of life, these tend to progressively enlarge [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Besides angiomyolipomas, about 50% TSC patients have renal cysts ranging from microscopic glomerulocystic disease to polycystic renal disease. Despite both renal angiomyolipomas and cysts being benign manifestations, they are responsible for marked morbidity and mortality as patients develop loss of kidney function, hematuria, and risk of hemorrhage from larger lesions. In 2018,",0_3,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"risk of hemorrhage from larger lesions. In 2018, the Food and Drug Administration (FDA) approved everolimus for treatment of adult and pediatric patients above the age of 2 years old with tuberous sclerosis complex (TSC)-associated partial-onset seizures, subependymal giant cell astrocytoma (SEGA), and TSC-associated renal angiomyolipoma [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Everolimus is an inhibitor for mTORC1 and is believed to reduce abnormal brain cell growth, abnormal neuron spatial",0_4,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"brain cell growth, abnormal neuron spatial organization, and excess inflammatory mediators in the cerebral cortex [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. It has been shown to reduce seizures burden in TSC patients and rapidly reduce SEGA volume [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. A systemic review conducted on a total of 263 patients compared the effectiveness of everolimus and other rapalogs in patients with TSC to determine their ability to decrease other manifestations of the disease. In",0_5,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"decrease other manifestations of the disease. In this review, everolimus was shown to be effective against several manifestations of the disease such as decreasing skin lesion size, however its effect on renal cysts and the pediatric population is not mentioned [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. As such, the role of everolimus in the kidneys is less understood; however, estimated glomerular filtration rate (eGFR) remains stable with its use in adult patients therefore suggesting renal function",0_6,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"patients therefore suggesting renal function preservation [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. In this case series, we discuss three pediatric patients who were placed on everolimus for seizure and SEGA control that were consequently seen to have renal cyst size reduction and renal function preservation therefore exhibiting this drug’s utility in treating renal manifestations in pediatric populations, specifically cystic kidney disease. The first patient is a six-year-old male who was diagnosed at 6",0_7,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"is a six-year-old male who was diagnosed at 6 months of age. Two years after his diagnosis, brain magnetic resonance imaging (MRI) showed non enhancing superficial cortical lesions in the bilateral frontal and right parietal lobes and few enhancing subependymal nodules, most likely representing cortical tubers and subependymal tubers. It also showed a minimally enhancing 2 to 3 mm tuber in the right frontal horn near the Foramen of Monroe suspicious for a SEGA. He started everolimus 2 mg twice a day at",0_8,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"a SEGA. He started everolimus 2 mg twice a day at this time. Six months later, repeat brain MRI showed stable subependymal hamartomas and subcortical tubers, however the suspected SEGA was no longer visible. At the time of this patient’s first brain MRI, an abdominal MRI showed multiple small bilateral renal cysts, however after everolimus was started and at the same time as this patient’s second brain MRI, a repeat abdominal MRI also showed no evidence of intra-abdominal lesions, and the renal cysts were",0_9,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"intra-abdominal lesions, and the renal cysts were also no longer identifiable. All renal imaging since then has been unchanged. The second patient is a nine-year-old male who was diagnosed shortly after birth. Early in his disease course he was started on everolimus 3 mg once daily for seizure and SEGA control. A few years after his diagnosis a brain MRI showed a right SEGA measuring 1.0 × 0.6 × 0.7 cm which on repeat MRI 8 months later was found to be slightly smaller at 1.0 × 0.5 × 0.7 cm. Additionally,",0_10,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"smaller at 1.0 × 0.5 × 0.7 cm. Additionally, he has a history of complex partial seizures secondary to tuberous sclerosis. Everolimus was stopped in the context of increased risk of COVID-19 and related complications from the drug’s immunosuppressive qualities. A year after everolimus was stopped, a brain MRI redemonstrated the SEGA which was slightly increased in size and two years later the patient was restarted on everolimus 5 mg once daily to help decrease the size of the SEGA and prevent",0_11,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"to help decrease the size of the SEGA and prevent hydrocephalus. Concurrently, this patient underwent renal imaging along a similar timeline. Initially, during the year of his diagnosis a renal ultrasound showed a renal cyst at the superior pole of the kidney with glycoprotein deposition along the medullary collecting system consistent with stasis nephropathy and left pelvicaliectasis. Three years later, an abdominal MRI showed multiple small bilateral renal cysts consistent with polycystic kidney disease",0_12,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"cysts consistent with polycystic kidney disease and two years following this, a repeat abdominal MRI showed decreased number of renal cysts. Between these two MRI’s is when this patient was on everolimus therapy. Since then, all renal imaging has been unchanged even with the pause in everolimus therapy. The third patient is a four-year-old female who was diagnosed shortly after she was born. An MRI at the time of diagnosis showed multiple subependymal nodules with the largest at the frontal horn of the",0_13,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"with the largest at the frontal horn of the left lateral ventricle measuring 1.1 × 0.6 × 0.9 cm with homogenous enhancement concerning for a SEGA. She was started on everolimus 5 mg once a day. A few months later, an abdominal MRI showed multiple bilateral renal cysts consistent with ADPKD associated with TS and interestingly, after a year of everolimus therapy, a repeat MRI of the abdomen was unremarkable for any renal cysts. In all three of the patients, creatinine levels were monitored regularly to",0_14,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"creatinine levels were monitored regularly to observe kidney function and we have utilized the revised Schwartz equation to determine their eGFR. Following everolimus therapy, in all three patients, there was normalization in creatinine levels and improvement in overall kidney function. In the first patient, prior to everolimus therapy creatinine levels ranged from 0.24 to 0.27 mg/dL (ref: 0.40–0.66 mg/dL) which improved to 0.35–0.50 mg/dL (ref: 0.31–0.51 mg/dL), following everolimus therapy, which",0_15,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"following everolimus therapy, which correlates with an improved eGFR from 103 − 92 mL/min/1.73m<sup>2</sup> to 141 − 99 mL/min/1.73m<sup>2</sup>. In the second patient, creatinine levels ranged from 0.27 to 0.29 mg/dL (ref: 0.40–0.66 mg/dL) prior to everolimus, improving to 0.35–0.41 mg/dL (ref: 0.37–0.63 mg/dL) after, which correlates with an improved eGFR from 92 − 85 mL/min/1.73m<sup>2</sup> to 141 − 120 mL/min/1.73m<sup>2</sup>. The third patient started at 0.25–0.28 mg/dL (ref: 0.46–0.76 mg/dL) prior",0_16,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"at 0.25–0.28 mg/dL (ref: 0.46–0.76 mg/dL) prior to everolimus with an improvement to 0.35–0.45 mg/dL (ref: 0.37–0.67 mg/dL) following therapy. This correlates with an improved eGFR from 126 − 112 mL/min/1.73m<sup>2</sup> to 143 − 111 mL/min/1.73m<sup>2</sup>. Additionally, only one patient experienced adverse effects from the drug which included elevated lipid levels. The drug cost for all three patients were managed by the assistance of insurance companies. Current understanding of everolimus and its",0_17,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"Current understanding of everolimus and its application in TSC is substantially derived from two large scale randomized, double-blind, placebo-controlled phase III studies, EXIST-1 and EXIST-2. EXIST-2 compared renal angiomyolipoma response rate to everolimus versus a placebo in TSC patients or sporadic lymphangioleiomyomatosis. It was found that 42% of patients on everolimus had at least a 50% reduction in renal angiomyolipoma size as compared to 0% in the placebo group [<xref ref-type=""bibr""",0_18,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"to 0% in the placebo group [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. EXIST-2 was studied on patients aged 18 years or older and did not study the effect of everolimus on cystic kidney disease. Our patients exhibited similar findings but in diagnosed cystic kidney disease. In the first and third patient there was a complete disappearance of the renal cysts after everolimus therapy while in the second patient there was a reduction in the number of cysts. These findings suggest everolimus’ application in",0_19,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"These findings suggest everolimus’ application in cystic kidney disease in addition to renal angiomyolipomas. Additionally, in a study examining the effect of everolimus on the disease progression in a rat model of polycystic kidney disease, it was found that everolimus significantly reduced renal cyst volume and the decline of kidney function was reduced over 5 weeks [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. All three patients were also found to have an improvement in kidney function, normalization of",0_20,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"improvement in kidney function, normalization of creatinine levels, and improvement in their eGFR after everolimus therapy. These findings support the positive implications of everolimus on cystic kidney disease. Furthermore, studies have shown that once everolimus therapy is halted, SEGAs may resume growth which was shown in the second patient [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. However, this patient’s renal cyst burden remained stable even after everolimus was stopped, therefore raising an",0_21,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"everolimus was stopped, therefore raising an important question of if everolimus may lead to stability in renal function even after therapy is stopped or if there is a long-term benefit of everolimus on kidney cysts. This has important applications especially in the context of adverse effects requiring dose reduction or therapy cessation. Aside from the studies discussed, there is little research on the effects of everolimus on renal function in the pediatric population especially. This case series adds to",0_22,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"population especially. This case series adds to the rare body of literature exemplifying its promising effects on decreasing renal cyst burden in cystic kidney disease and potentially preventing long term consequences such as hematuria and hemorrhage from larger tumors. This case series also demonstrates the importance of starting patients on everolimus early, in the pediatric population, in order to potentially prevent these long-term consequences and preserve renal function. Some limitations of this case",0_23,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"renal function. Some limitations of this case series is that it only details three patients, therefore limiting the generalizability of this study. Additionally, there is no control group to compare the results, making it difficult to determine if the observed changes are directly attributable to everolimus. Finally, although the initial results are promising, longer-term follow-up is necessary to assess the sustainability to everolimus benefits and any long-term side effects. Therefore, future studies",0_24,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"long-term side effects. Therefore, future studies with more robust study designs are warranted to confirm the findings of this case series and assess this promising evidence on the use of everolimus in pediatric patients with TSC and cystic kidney disease. Everolimus is currently used to treat TSC for its main role in rapidly reducing SEGA volume and seizure burden, although mainly studied in the adult population. This case report illustrates the findings of everolimus in reducing renal cyst size in three",0_25,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"everolimus in reducing renal cyst size in three pediatric patients and its promising utility in cystic kidney disease in patients with TSC and preserving renal function. Given the promising evidence on the use of everolimus in pediatric patients with TSC and cystic kidney disease, future studies with more robust study deigns should be conducted to confirm these findings and assess the sustainability of the drug and longer term side effects.",0_26,Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series,24 10 2024,,Tuberous_Sclerosis
"DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity DYRK1A, a ubiquitously expressed kinase<italic toggle=""yes"">,</italic> is linked to the dominant intellectual developmental disorder, microcephaly, and Down syndrome in humans. It regulates numerous cellular processes such as cell cycle, vesicle trafficking, and microtubule assembly. DYRK1A is a critical regulator of organ growth; however, how it regulates organ growth is not fully understood. Here, we show that the knockdown",1_0,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"understood. Here, we show that the knockdown of <italic toggle=""yes"">DYRK1A</italic> in mammalian cells results in reduced cell size, which depends on mTORC1. Using proteomic approaches, we found that DYRK1A interacts with the tuberous sclerosis complex (TSC) proteins, namely TSC1 and TSC2, which negatively regulate mTORC1 activation. Furthermore, we show that DYRK1A phosphorylates TSC2 at T1462, a modification known to inhibit TSC activity and promote mTORC1 activity. We also found that the reduced cell",1_1,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"activity. We also found that the reduced cell growth upon knockdown of DYRK1A can be rescued by overexpression of RHEB, an activator of mTORC1. Our findings suggest that DYRK1A inhibits TSC complex activity through inhibitory phosphorylation on TSC2, thereby promoting mTORC1 activity. Furthermore, using the <italic toggle=""yes"">Drosophila</italic> neuromuscular junction as a model, we show that the <italic toggle=""yes"">mnb,</italic> the fly homologs of <italic toggle=""yes"">DYRK1A</italic>, is rescued by",1_2,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"toggle=""yes"">DYRK1A</italic>, is rescued by RHEB overexpression, suggesting a conserved role of <italic toggle=""yes"">DYRK1A</italic> in TORC1 regulation. The <italic toggle=""yes"">dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A</italic>) is a ubiquitously expressed kinase that belongs to the CMGC group (<underline>C</underline>yclin-dependent kinases, <underline>M</underline>itogen-activated protein kinase, <underline>G</underline>lycogen synthase kinases, and",1_3,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"synthase kinases, and <underline>C</underline>DK-like kinases group). <italic toggle=""yes"">DYRK1A,</italic> is located within the Down syndrome critical region (DSCR). The phenotypes associated with Down syndrome (<xref rid=""bib1"" ref-type=""bibr"">Antonarakis, 2017</xref>), including abnormal neurodevelopment (<xref rid=""bib23"" ref-type=""bibr"">Hämmerle et al., 2011</xref>; <xref rid=""bib41"" ref-type=""bibr"">Najas et al., 2015</xref>), and increased susceptibility to acute megakaryoblastic leukemia (<xref",1_4,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"to acute megakaryoblastic leukemia (<xref rid=""bib34"" ref-type=""bibr"">Malinge et al., 2012</xref>), have been reasoned to be due to an increased expression of <italic toggle=""yes"">DYRK1A</italic>. On the other hand, haploinsufficiency of <italic toggle=""yes"">DYRK1A</italic> causes DYRK1A syndrome, a rare autosomal dominant disease characterized by intellectual disability, intrauterine growth retardation, microcephaly, and stunted growth (<xref rid=""bib10"" ref-type=""bibr"">Courcet et al., 2012</xref>; <xref",1_5,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"et al., 2012</xref>; <xref rid=""bib27"" ref-type=""bibr"">Kay et al., 2016</xref>; <xref rid=""bib40"" ref-type=""bibr"">Møller et al., 2008</xref>). Mouse models heterozygous for <italic toggle=""yes"">Dyrk1a</italic> also show a reduction in brain and body size (<xref rid=""bib16"" ref-type=""bibr"">Fotaki et al., 2002</xref>; <xref rid=""bib17"" ref-type=""bibr"">Fotaki et al., 2004</xref>). In <italic toggle=""yes"">Drosophila</italic>, loss of <italic toggle=""yes"">mnb</italic>, the <italic",1_6,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"of <italic toggle=""yes"">mnb</italic>, the <italic toggle=""yes"">Drosophila</italic> homolog of DYRK1A, results in reduced organ size, including brain, legs, and wings (<xref rid=""bib11"" ref-type=""bibr"">Degoutin et al., 2013</xref>; <xref rid=""bib57"" ref-type=""bibr"">Tejedor et al., 1995</xref>). Therefore, <italic toggle=""yes"">DYRK1A</italic> is a critical regulator of organ growth (<xref rid=""bib20"" ref-type=""bibr"">Guedj et al., 2012</xref>); however, the cellular processes by which <italic",1_7,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"however, the cellular processes by which <italic toggle=""yes"">DYRK1A</italic> promotes organ growth are unclear. <italic toggle=""yes"">DYRK1A</italic> and its homologs have also been implicated in many cellular processes, such as cell cycle, signal transduction, gene expression, vesicle trafficking, and microtubule assembly (<xref rid=""bib2"" ref-type=""bibr"">Arbones et al., 2019</xref>). DYRK1A has been shown to extend the G1 phase of the cell cycle in neuroblastoma cells by phosphorylation and subsequent",1_8,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"cells by phosphorylation and subsequent degradation of cyclin D1 (<xref rid=""bib7"" ref-type=""bibr"">Chen et al., 2013</xref>). In glioblastoma cells, DYRK1A phosphorylates ubiquitin ligase CDC23, which mediates mitotic protein degradation, thereby promoting tumor growth (<xref rid=""bib46"" ref-type=""bibr"">Recasens et al., 2021</xref>). Furthermore, DYRK1A expression positively correlates with EGFR levels, and DYRK1A inhibitors reduce EGFR-dependent glioblastoma growth (<xref rid=""bib45"" ref-type=""bibr"">Pozo",1_9,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"growth (<xref rid=""bib45"" ref-type=""bibr"">Pozo et al., 2013</xref>). DYRK1A promotes the expression of several genes required for ribosomal biogenesis and protein translation (<xref rid=""bib14"" ref-type=""bibr"">Di Vona et al., 2015</xref>; <xref rid=""bib30"" ref-type=""bibr"">Li et al., 2018</xref>); for example, RPS6 ribosomal protein S6, a component of the 40 S subunit, and translation initiation factor, EIF4A3 (<xref rid=""bib59"" ref-type=""bibr"">Xue et al., 2021</xref>). However, if the regulation of these",1_10,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"2021</xref>). However, if the regulation of these genes by DYRK1A is physiologically significant, it is currently unknown. The mechanistic target of rapamycin complex 1 (mTORC1) is a key energy sensor and a master regulator of anabolic processes (<xref rid=""bib47"" ref-type=""bibr"">Rehbein et al., 2021</xref>). The mTORC1 promotes anabolic processes such as protein, nucleotide, and lipid synthesis and represses catabolic processes such as autophagy, thereby promoting cellular growth (<xref rid=""bib5""",1_11,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"promoting cellular growth (<xref rid=""bib5"" ref-type=""bibr"">Ben-Sahra and Manning, 2017</xref>; <xref rid=""bib50"" ref-type=""bibr"">Saxton and Sabatini, 2017</xref>). The mechanism of mTORC1-mediated regulation of multiple anabolic pathways has been studied extensively (<xref rid=""bib47"" ref-type=""bibr"">Rehbein et al., 2021</xref>; <xref rid=""bib5"" ref-type=""bibr"">Ben-Sahra and Manning, 2017</xref>; <xref rid=""bib50"" ref-type=""bibr"">Saxton and Sabatini, 2017</xref>). TSC consisting of TSC1, TSC2, and TBC1D7",1_12,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"TSC consisting of TSC1, TSC2, and TBC1D7 (TBC1 domain family member 7), integrates various extracellular signals and negatively regulates mTORC1 complex activity (<xref rid=""bib47"" ref-type=""bibr"">Rehbein et al., 2021</xref>; <xref rid=""bib12"" ref-type=""bibr"">Dibble et al., 2012</xref>). TSC2 is a GTPase-activating protein (GAP) and promotes the conversion of GTP-bound RHEB (Ras Homolog Enriched in Brain) to the GDP-bound state, thereby inhibiting it. When TSC2 is inhibited, the GTP-bound RHEB activates",1_13,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"TSC2 is inhibited, the GTP-bound RHEB activates mTORC1 (<xref rid=""bib29"" ref-type=""bibr"">Li et al., 2003</xref>; <xref rid=""bib56"" ref-type=""bibr"">Tee et al., 2003</xref>). The mTORC1 activation is controlled by extracellular stimuli, nutrients, energy status, and stress. For example, in response to insulin stimulation, AKT phosphorylates TSC2 at several sites, including S939 and T1462, suppressing its inhibitory effect on RHEB-GTP recycling, thus activating mTORC1 (<xref rid=""bib44""",1_14,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"thus activating mTORC1 (<xref rid=""bib44"" ref-type=""bibr"">Potter et al., 2002</xref>). Similarly, in response to growth factors, extracellular signal-regulated Kinase (ERK) (<xref rid=""bib33"" ref-type=""bibr"">Ma et al., 2005</xref>) and p90 ribosomal S6 kinase 1 (RSK1) phosphorylate TSC2 and activate mTORC1 (<xref rid=""bib48"" ref-type=""bibr"">Roux et al., 2004</xref>). MK2 (MAP kinase-activated protein kinase 2/MAPKAPK2) phosphorylates TSC2 at yet another site, S1210, in the presence of serum and leads to",1_15,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"S1210, in the presence of serum and leads to the inhibition of TSC2 activity, which allows the activation of mTORC1 (<xref rid=""bib29"" ref-type=""bibr"">Li et al., 2003</xref>). Catabolic signals, such as low energy levels during glucose scarcity, drive AMPK-mediated phosphorylation of TSC2 that promotes its GAP function and suppresses mTORC1 activity (<xref rid=""bib9"" ref-type=""bibr"">Corradetti et al., 2004</xref>). Several kinases regulating the TSC activity underscores the importance of investigating",1_16,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"underscores the importance of investigating novel kinases involved in its regulation, which may regulate mTORC1 activity in distinct cellular contexts. In this study, we discover that DYRK1A interacts with TSC1 and TSC2. We show that DYRK1A phosphorylates TSC2 at T1462 and is a possible positive regulator of mTORC1 activity and cell growth. Furthermore, we show that in <italic toggle=""yes"">Drosophila</italic>, both Mnb, the DYRK1A-homolog, and mTORC1 are required to promote neuromuscular junction (NMJ)",1_17,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"required to promote neuromuscular junction (NMJ) growth. Moreover, the activation of mTORC1 can rescue the NMJ growth phenotype of <italic toggle=""yes"">mnb</italic> loss of function, suggesting Mnb may regulate mTORC1 to promote neuromuscular junction morphology. We propose that DYRK1A-mediated regulation of mTORC1 activity is a conserved mechanism to regulate cell size and development.  This work shows that DYRK1A promotes cell size as a reduction in <italic toggle=""yes"">DYRK1A</italic> levels in both",1_18,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"toggle=""yes"">DYRK1A</italic> levels in both human and mouse cells results in small cell size (<xref rid=""fig1"" ref-type=""fig"">Figure 1A–D</xref>). mTORC1 is a key energy sensor and a master regulator of cell growth (<xref rid=""bib5"" ref-type=""bibr"">Ben-Sahra and Manning, 2017</xref>; <xref rid=""bib50"" ref-type=""bibr"">Saxton and Sabatini, 2017</xref>). We found that reduced levels of <italic toggle=""yes"">DYRK1A</italic> in cells result in decreased S6K and S6 phosphorylation, suggesting that DYRK1A",1_19,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"and S6 phosphorylation, suggesting that DYRK1A positively regulates mTORC1 (<xref rid=""fig3"" ref-type=""fig"">Figure 3</xref>). One of the key regulators of mTORC1 is the TSC complex, consisting of TSC1, TSC2, and TBC1D7 (TBC1 domain family member 7), which integrates various extracellular signals and negatively regulates mTORC1 complex activity (<xref rid=""bib47"" ref-type=""bibr"">Rehbein et al., 2021</xref>; <xref rid=""bib12"" ref-type=""bibr"">Dibble et al., 2012</xref>). DYRK1A physically interacts with the",1_20,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"DYRK1A physically interacts with the TSC complex through its kinase domain (<xref rid=""fig2"" ref-type=""fig"">Figure 2</xref>). TSC2 is a GTPase-activating protein (GAP) that promotes the conversion of GTP-bound RHEB to the GDP-bound state, thereby inhibiting it. When TSC2 is inhibited, the GTP-bound RHEB activates mTORC1 (<xref rid=""bib56"" ref-type=""bibr"">Tee et al., 2003</xref>; <xref rid=""bib25"" ref-type=""bibr"">Inoki et al., 2003</xref>). Phosphorylation at TSC2 at T1462 has been shown to inhibit TSC and",1_21,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"TSC2 at T1462 has been shown to inhibit TSC and promote TORC1 activity through RHEB (<xref rid=""bib35"" ref-type=""bibr"">Manning et al., 2002</xref>; <xref rid=""bib60"" ref-type=""bibr"">Zhang et al., 2009</xref>). Our study, for the first time, shows that DYRK1A phosphorylates TSC2 at the T1462 site, thereby promoting the mTORC1 pathway. We also show that the overexpression of <italic toggle=""yes"">RHEB</italic> could partially rescue the cell growth phenotypes exhibited by <italic toggle=""yes"">DYRK1A</italic>",1_22,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"exhibited by <italic toggle=""yes"">DYRK1A</italic> knockdown cells, indicating that the DYRK1A works upstream to RHEB. In DYRK1A syndrome, the loss of one copy of <italic toggle=""yes"">DYRK1A l</italic>eads to stunted growth and microcephaly in humans (<xref rid=""bib40"" ref-type=""bibr"">Møller et al., 2008</xref>). A recent report showing a reduction in mTOR signaling in mice cortex lacking <italic toggle=""yes"">Dyrk1a</italic> indicates that the DYRK1A-mTORC1 axis may regulate brain development (<xref",1_23,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"axis may regulate brain development (<xref rid=""bib28"" ref-type=""bibr"">Levy et al., 2021</xref>). In <italic toggle=""yes"">Drosophila</italic>, <italic toggle=""yes"">mnb</italic> is widely expressed in the developing central nervous system and has been linked to post-differentiation roles in neurons. For example, in flies, <italic toggle=""yes"">mnb</italic> has been linked to long-term memory formation (<xref rid=""bib26"" ref-type=""bibr"">Kacsoh et al., 2019</xref>). In humans and mice, <italic",1_24,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"et al., 2019</xref>). In humans and mice, <italic toggle=""yes"">DYRK1A</italic> has been linked to the neurite spine morphogenesis, and it has been suggested that the neurite spine phenotype may contribute to intellectual disability in Down syndrome (<xref rid=""bib22"" ref-type=""bibr"">Haas et al., 2013</xref>; <xref rid=""bib36"" ref-type=""bibr"">Martinez de Lagran et al., 2012</xref>; <xref rid=""bib43"" ref-type=""bibr"">Park and Chung, 2013</xref>). The phenomenon of NMJ morphogenesis in fruit flies is analogous",1_25,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"of NMJ morphogenesis in fruit flies is analogous to neurite spine morphogenesis. The TOR pathway is shown to promote NMJ development in flies (<xref rid=""bib13"" ref-type=""bibr"">Dimitroff et al., 2012</xref>; <xref rid=""bib42"" ref-type=""bibr"">Natarajan et al., 2013</xref>; <xref rid=""fig5"" ref-type=""fig"">Figure 5B and G</xref>). Similarly, <italic toggle=""yes"">mnb</italic> is also required for NMJ growth (<xref rid=""bib8"" ref-type=""bibr"">Chen et al., 2014</xref>); however, the mechanism of <italic",1_26,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"2014</xref>); however, the mechanism of <italic toggle=""yes"">mnb</italic>-mediated NMJ growth was unknown. Our results show that the reduction in NMJ size in <italic toggle=""yes"">mnb</italic> mutants can be rescued by <italic toggle=""yes"">RHEB</italic> overexpression, suggesting that Mnb positively regulates mTORC1. Our results are also supported by a study in <italic toggle=""yes"">Arabidopsis</italic> that showed YAK1, a DYRK kinase, regulates meristem activity through the mTOR pathway (<xref rid=""bib4""",1_27,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"through the mTOR pathway (<xref rid=""bib4"" ref-type=""bibr"">Barrada et al., 2019</xref>). Overall, our results suggest that the role of Mnb/DYRK1A in the regulation of the mTORC1 pathway is evolutionarily conserved, and the DYRK1A-mTORC1 axis plays a crucial role in neuronal morphogenesis and cellular growth.",1_28,DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity,22 10 2024,,Tuberous_Sclerosis
"Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex The Index for Facial Angiofibromas (IFA), a novel scoring system for angiofibromas, has been validated in patients with tuberous sclerosis complex (TSC). The objective of this analysis was to further validate the IFA using data from a clinical trial of topical sirolimus in patients with TSC. This was an analysis of photographs from a Phase",2_0,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"This was an analysis of photographs from a Phase III trial conducted in Japan (NCT02635789). Patients (<italic toggle=""no"">n</italic> = 62) were randomized 1:1 to receive sirolimus or placebo gel for 12 weeks. Changes in angiofibromas were independently assessed using the primary composite endpoint, the Facial Angiofibroma Severity Index (FASI), and the IFA. Thresholds for a clinically meaningful change in IFA score were evaluated using receiver operating characteristic (ROC) analysis. The IFA scores had",2_1,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"characteristic (ROC) analysis. The IFA scores had good‐to‐excellent inter‐assessor reliability, very high intra‐assessor reliability, and could be used to evaluate the distribution of disease severity at baseline. High correlations were observed between the categorized change from baseline in IFA scores and the primary composite endpoint (Kendall's coefficient of concordance, <italic toggle=""no"">W</italic> = 0.8655, <italic toggle=""no"">p</italic> < 0.0001), and between the change from baseline in IFA and",2_2,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"and between the change from baseline in IFA and FASI scores (Kendall's coefficient of concordance, <italic toggle=""no"">W</italic> = 0.745, <italic toggle=""no"">p</italic> < 0.0001). By ROC analysis, an optimal IFA cut‐off point of 1.667 was determined to distinguish patients with markedly improved or improved angiofibromas from those with slightly improved or unchanged angiofibromas (area under the curve 0.937) as determined by the primary composite endpoint. The IFA score is potentially clinically useful",2_3,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"The IFA score is potentially clinically useful because of its high validity and reliability. A decrease in score from baseline of ≥1.667 may be considered clinically meaningful. Tuberous sclerosis complex (TSC) is a rare, autosomal dominant, inherited disorder characterized by hamartomas throughout the body.<xref rid=""jde17220-bib-0001"" ref-type=""bibr"">",2_4,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>1</sup>
</xref> It is caused by mutations in the <italic toggle=""yes"">TSC1</italic> and <italic toggle=""yes"">TSC2</italic> genes, resulting in dysfunction of the tuberin–hamartin complex. This leads to constant activation of the downstream mechanistic target of rapamycin (mTOR complex 1), promoting cell growth and proliferation, and inhibiting apoptosis.<xref rid=""jde17220-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",2_5,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref> Facial angiofibromas are one of the main skin manifestations of TSC, affecting approximately 75% of patients. These hamartomas result from an increase in the connective tissue and vascular components of the skin.<xref rid=""jde17220-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref>
 Topical sirolimus, which is an mTOR complex 1 inhibitor, has been shown to be safe and effective for the treatment of facial angiofibromas.<xref rid=""jde17220-bib-0004"" ref-type=""bibr"">
<sup>4</sup>",2_6,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>4</sup>
</xref>, <xref rid=""jde17220-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref>, <xref rid=""jde17220-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref> A gel formulation was approved for use as a topical treatment for TSC skin lesions in Japan in 2018,<xref rid=""jde17220-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref> by the United States Food and Drug Administration in March 2022,<xref rid=""jde17220-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",2_7,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> by the National Medical Products Administration in China in March 2023,<xref rid=""jde17220-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref> and by the European Medicines Agency in May 2023.<xref rid=""jde17220-bib-0009"" ref-type=""bibr"">
<sup>9</sup>",2_8,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>9</sup>
</xref> The approval of sirolimus gel was based on the results of a Phase III, randomized controlled trial that demonstrated significant composite improvements in the size and color of angiofibromas with sirolimus gel compared with placebo after 12 weeks of treatment.<xref rid=""jde17220-bib-0006"" ref-type=""bibr"">
<sup>6</sup>",2_9,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"</xref> The primary endpoint of this trial was based on the relative changes between pre‐ and post‐treatment angiofibroma severity for each patient. However, this endpoint, focusing on relative changes from the baseline, had a limitation in that the absolute severity of the angiofibroma at baseline and the magnitude of improvement could not necessarily be determined. Several scoring systems have been developed to provide a quantitative evaluation of facial angiofibromas. The Facial Angiofibroma Severity",2_10,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"angiofibromas. The Facial Angiofibroma Severity Index (FASI) has been developed and validated for the assessment of facial angiofibroma lesions;<xref rid=""jde17220-bib-0010"" ref-type=""bibr"">",2_11,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>10</sup>
</xref> however, for this system, smaller changes are difficult to detect and score changes may not be observed for mildly affected patients.<xref rid=""jde17220-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref> Subsequently, the Index for Facial Angiofibromas (IFA) was designed and validated<xref rid=""jde17220-bib-0011"" ref-type=""bibr"">
<sup>11</sup>",2_12,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"</xref> to address the limitations of the FASI. The IFA is an eight‐item score that focuses on the angiogenic component of angiofibromas as well as the extent of the lesions and the facial areas affected. However, these results need to be confirmed using a larger sample size, and the utility of the IFA needs to be clarified in relation to the traditional scoring systems described above. The objective of this analysis was to confirm that the IFA score is a meaningful scoring method by comparing and",2_13,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"is a meaningful scoring method by comparing and examining the correlations and characteristics between the IFA score and other evaluation methods. In addition, thresholds for clinically meaningful changes in IFA scores were determined. In this study, the photographs taken during a previously reported Phase III trial (NCT02635789)<xref rid=""jde17220-bib-0006"" ref-type=""bibr"">",2_14,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
<sup>6</sup>,2_15,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"</xref> were evaluated using the IFA and FASI. The results were validated using statistical methods along with the results of the Phase III trial primary endpoint.  In this analysis, the IFA scores showed good‐to‐excellent inter‐assessor reliability and very high intra‐assessor reliability. In addition, the IFA allowed for the assessment of baseline severity and the scores strongly correlated with traditional evaluation methods (i.e., composite improvement in angiofibroma and FASI), and clinically",2_16,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"in angiofibroma and FASI), and clinically significant thresholds for the IFA score were established by ROC analysis. Using data from a Phase III, randomized controlled trial, high correlations were observed between the categorized change from baseline in IFA scores and the composite primary endpoint (Kendall's coefficient of concordance, <italic toggle=""yes"">W</italic> = 0.8655, <italic toggle=""yes"">p</italic> < 0.0001) as well as between the change from baseline in IFA scores and the change from baseline",2_17,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"in IFA scores and the change from baseline in FASI scores (Kendall's coefficient of concordance, <italic toggle=""yes"">W</italic> = 0.745, <italic toggle=""yes"">p</italic> < 0.0001). The results of this analysis suggest some clinical validity in the use of the IFA for evaluating fibrous angiofibromas with a decrease in IFA score from a baseline of ≥1.667 successfully distinguishing patients with a composite endpoint of improved or better from those with slightly improved or unchanged angiofibromas. For",2_18,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"slightly improved or unchanged angiofibromas. For example, an improvement of ≥2 points in the composite endpoint means that there is an improvement of 50%–75% of the lesion extent from baseline and that redness is fading. This would correspond to a general shrinkage or flattening of the lesion (approximately 50%–75% of the lesion size at baseline) and fading redness or partial disappearance of the lesion and significant fading of the redness. Previous research has indicated that a visible improvement would",2_19,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"has indicated that a visible improvement would correspond to a 2‐point reduction in the IFA score,<xref rid=""jde17220-bib-0011"" ref-type=""bibr"">",2_20,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"<sup>11</sup>
</xref> based on the intra‐assessor variance of 0.863 obtained through the Shrout and Fleiss<xref rid=""jde17220-bib-0012"" ref-type=""bibr"">
<sup>12</sup>",2_21,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"</xref> ICC (2,1) model, in which the same assessor should recognize a true improvement of 2 points in 87% of cases. Although the cut‐off point obtained in this study is lower at 1.667, its potential validity is supported by the fact that it was obtained through comparison with traditional indices. The results of this analysis also suggest that the IFA score may be a useful assessment method in addition to the composite endpoint as it is able to assess disease severity at baseline. This is particularly",2_22,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"severity at baseline. This is particularly relevant given the observed differences in baseline disease severity between the sirolimus and placebo groups in the Phase III trial, despite randomization. Such differences underscore the importance of considering baseline severity to achieve a more accurate assessment of treatment efficacy. This might be attributed to the limited number of established evaluation tools for facial angiofibromas at baseline. The IFA may be a more sensitive scoring system for",2_23,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"IFA may be a more sensitive scoring system for detecting smaller and earlier improvements in angiofibromas. This study had some limitations. First, TSC is a rare disease and, as such, the study population was small. Second, the study was limited to a Japanese population and may not be generalizable to a broader population. Finally, no case of exacerbation was identified and, therefore, changes in IFA scores in the case of exacerbation could not be assessed. To address these limitations, it would be",2_24,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"To address these limitations, it would be beneficial to conduct a trial in a larger and more diverse patient population. Our results support a previous validation study<xref rid=""jde17220-bib-0011"" ref-type=""bibr"">",2_25,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
<sup>11</sup>,2_26,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"</xref> and showed that the IFA scoring system had good‐to‐excellent inter‐assessor reliability and very high intra‐assessor reliability. The IFA is useful in assessing the response of patients to treatment in a clinical setting as it accurately measures the clinical severity of facial angiofibromas associated with TSC and can detect small changes in symptoms. Izumi Hamada, Yoshinori Yukutake, Yusuke Morita, Norifumi Ishikawa, and Kenji Shimizu are employees of Nobelpharma Co., Ltd. Mari Wataya‐Kaneda is",2_27,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"of Nobelpharma Co., Ltd. Mari Wataya‐Kaneda is the holder of an endowed professorship funded by Nobelpharma Co., Ltd.",2_28,Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex,15 4 2024,,Tuberous_Sclerosis
"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence Rheumatoid arthritis (RA) is a common autoimmune disease. Tuberous sclerosis complex(TSC) is a rare autosomal dominant disorder. We report a case of RA with TSC. The patient was a 46-year-old woman with polyarthritis and cough symptoms, rheumatoid arthritis associated interstitial lung disease (RA-ILD) was initially considered, and after more than 3 months of anti-rheumatic treatment, the patient",3_0,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"3 months of anti-rheumatic treatment, the patient still had cough, and further examination revealed that the patient had lymphangioleiomyomatosis in the lungs, hepatic and renal angiomyolipomas, multiple subependymal nodules, Vertebral osteosclerotic nodules, as well as facial angiofibromas and periungual fibroma, RA was finally diagnosed with TSC, and everolimus 10mg qd was added to anti-rheumatic therapy for 1 month, and the patient’s cough symptoms were relieved. The main manifestations of rheumatoid",3_1,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"relieved. The main manifestations of rheumatoid arthritis are symmetrical, invasive facet joint swelling and pain, and the basic pathological feature is synovitis, which often involves multiple joints, and gradually develops bone and joint destruction with the progression of the disease, resulting in a high disability rate. Extra-articular lesions can cause cardiovascular, respiratory, and hematologic damage. The global incidence of RA is about 1%, with two-thirds of women occurring. Tuberous sclerosis,",3_2,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"of women occurring. Tuberous sclerosis, also known as Bourneville’s disease, is inherited in an autosomal dominant manner and is caused by overactivation of the mammalian target of rapamycin complex 1 (mTORC1) pathway due to mutations in the TSC1 or TSC2 genes. The TSC1 gene is located on chromosome 9q24 and encodes the hamartin protein, and the TSC2 gene is located on chromosome 16p13 and encodes the potato protein tuberin. These two proteins together with TBC1 domain family member 7 (TBC1D7) protein form",3_3,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"TBC1 domain family member 7 (TBC1D7) protein form a TSC complex, negatively regulate the biological target Rheb protein of mTORC1, regulate cell cycle, apoptosis, autophagy and cytoskeletal reorganization, and lead to the formation of hamartomas in multiple organs, which can affect the skin, brain, kidney, lung, oral cavity and other organs in the body.TSC2 mutations are more common than TSC1 mutations, and TSC2 mutations often lead to more severe clinical manifestations. The vast majority of TSC1 variants",3_4,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"The vast majority of TSC1 variants are nonsense and frameshift variants, and the most common TSC2 variants are missense variants, followed by deletion or recombination of large fragments. The incidence of TSC is 1 in 6,000 to 10,000, and there are about 2 million people worldwide. Clinically, TSC is a rare disease, and there are no reports of RA complicated with TSC and everolimus in the effective treatment of two diseases. The patient is a 46-year-old female. Recurrent multi-joint swelling and pain for",3_5,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"Recurrent multi-joint swelling and pain for more than 3 years with cough for 1 year, and she was presented in June 2023. No history of smoking, no pneumoconiosis, no history of epilepsy. The patient did not have standardized treatment within 3 years of the onset of arthritis, and lung imaging showed cystic translucent opacity and ground-glass changes, and ILD was considered, and no standardized treatment was performed. At the time of hospitalization, she presented with swelling and tenderness in both wrist",3_6,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"with swelling and tenderness in both wrist joints, metacarpophalangeal joints of both hands, proximal interphalangeal joints, shoulder joints, and knee joints. Laboratory tests suggest rheumatoid factor 155.40 IU/ML and erythrocyte sedimentation rate 46 MM/H. C-reactive protein 37mg/L, anti-CCP antibody 185.9U/ml, IgG 17.6g/L,ANA and ANCA negative, PCT, T-SPOT, HIV, syphilis-related tests were normal, blood cell analysis, liver and kidney function and tumor markers were normal. The DAS28 (ESR) score was",3_7,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"markers were normal. The DAS28 (ESR) score was 7.46 and the DAS28 (CRP) score was 7.05, both of which were in high disease activity. Noncontrast magnetic resonance imaging of the hand suggests synovitis of the wrist joint, multiple bone marrow edema. Chest CT scan showed that the two lungs were scattered with cystic translucent opacities and ground-glass opacities. Initial consideration of rheumatoid arthritis, interstitial pneumonia. After 3 months of anti-rheumatic treatment with prednisone 30 mg once a",3_8,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"treatment with prednisone 30 mg once a day(Tapere), leflunomide 20 mg once a day, and hydroxychloroquine 0.2 g twice a day, the patient’s cough was not significantly relieved, and the patient’s joint swelling and pain recurred during the prednisone reduction process. Chest CT again and whole abdominal CT + enhancement showed that the two lungs were scattered with cystic translucent opacities and ground-glass opacities (<xref rid=""f1"" ref-type=""fig"">",3_9,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"<bold>Figure 1A</bold>
</xref>). multiple high-density nodules in the vertebral bones (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1B</bold>
</xref>); Renal magnetic resonance scan + contrast examination showed liver and kidney angiomyolipoma (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1C</bold>",3_10,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"<bold>Figure 1C</bold>
</xref>). CT enhancement showed very low-density opacities in the liver and kidney, multiple cysts in the liver and kidneys, liver hamartomas, mass and nodular shadows in both kidneys (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1D</bold>
</xref>). Cysts in both kidneys. CT of the head showed bilateral paraventricular nodular hyperdense opacities (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1E</bold>",3_11,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"<bold>Figure 1E</bold>
</xref>). Further examination reveals a few hemangiomatous rash on the patient’s face (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1F</bold>
</xref>), Fibroids on the fingers (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1G</bold>
</xref>) and the toes (<xref rid=""f1"" ref-type=""fig"">
<bold>Figure 1H</bold>",3_12,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"</xref>), and a history is followed up that the patient’s father and niece also have facial fibroids. The patient and his family did not pay attention to this facial lesion in the past, and no examination and treatment were performed. This time, it is necessary to determine whether there is a gene mutation. Tuberous sclerosis TCS1 and TSC2 gene testing was performed: no single nucleotide sequence variations, short insertion variants and copy number variations related to clinical phenotype were detected. In",3_13,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"related to clinical phenotype were detected. In the end, RA was diagnosed with TSC, and prednisone 10 mg qd, leflunomide 20 mg qd, hydroxychloroquine 0.2 bid, and everolimus 10 mg qd were treated for 1 month, and the patient’s joint swelling, pain and cough symptoms improved, and the arthritis symptoms of the patient continued to be relieved after 6 months of follow-up, erythrocyte sedimentation rate 20 MM/H; C-reactive protein 8.4mg/L,IgG was 11.52g/L, and the laboratory tests showed that the disease was",3_14,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"the laboratory tests showed that the disease was in gradual remission, with a DAS28 (ESR) score of 2.1 and a DAS28 (CRP) score of 1.77. CT scans of the lungs and kidneys showed no significant progress in the cystic changes of the lungs and kidneys, and vertebral osteosclerotic nodules still existed, but the ground-glass changes in the lungs were slightly reduced compared with before, the facial fibromatous lesions were reduced compared with before, and the periungual fibroids were partially reduced (<xref",3_15,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"periungual fibroids were partially reduced (<xref rid=""f2"" ref-type=""fig"">",3_16,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
<bold>Figure 2</bold>,3_17,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"</xref>). Unfortunately, We did not have post-treatment magnetic resonance imaging at the follow-up. During the follow-up process, the patient had menstrual disorders, mainly manifested in prolonged menstrual periods, and under the premise of excluding gynecological diseases, considering the adverse reactions of everolimus, the dose of everolimus was reduced to 5mg qd, prednisone was reduced to 5mg qd, leflunomide 10mg qd and hydroxychloroquine 0.2g qd, and the patient’s menstrual disorders disappeared. In",3_18,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"the patient’s menstrual disorders disappeared. In this case, 18 facet joints and 4 large joints were swollen and tender, blood tests showed positive rheumatoid factor and high titers of anti-CCP antibodies, ESR and CRP are elevated, and imaging of the diseased joints showed synovitis, which met the RA 2010 ACR/EULAR classification criteria. Due to the imaging manifestations of the lungs with round thin-walled cysts with different morphologies, RA-ILD was considered at the initial stage, and TSC was",3_19,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"was considered at the initial stage, and TSC was diagnosed according to the 2021 International Clinical Diagnostic Criteria for Tuberous Sclerosis, combined with facial angiofibromas and fibrous plaques of the forehead, periungual fibromas, subependymal multiple nodules, pulmonary lymphangiomyomas, hepatic and bilateral renal angiomyolipomas, multiple renal cysts, and vertebral osteosclerotic nodules. The clinical manifestations of TSC are complex and one of the few genetic disorders that can be diagnosed",3_20,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"the few genetic disorders that can be diagnosed based on clinical manifestations alone. The coexistence of RA and TSC has been reported very rarely. HLA-DR4 is associated with the pathogenesis of RA, while the pathogenesis of TSC is related to the tumor suppressor genes TSC1 or TSC2 (<xref rid=""B1"" ref-type=""bibr"">1</xref>). In some sporadic cases, mosaic mutations or no genetic mutations may be present. The pathogenesis of RA is not fully understood. Studies have shown that the mammalian target of",3_21,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"Studies have shown that the mammalian target of rapamycin (mTOR) signaling pathway is involved in the development of RA disease, and the abnormality of this pathway can recruit and activate immune cells and fibroblast-like synovial cells (FLS) at the arthritis site, resulting in the production of a variety of chemokines, pro-inflammatory cytokines, and cathepsin, degrading the extracellular matrix and cartilage, and causing persistent inflammation and tissue damage (<xref rid=""B2"" ref-type=""bibr"">2</xref>,",3_22,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"damage (<xref rid=""B2"" ref-type=""bibr"">2</xref>, <xref rid=""B3"" ref-type=""bibr"">3</xref>). The mTOR signal pathway is very complex and can be divided into two signaling pathways: LKB1/AMPK/TSC/mTOR and PI3K/Akt/TSC/mTOR. The main function of the LKBl/AMPK/TSC/mTOR pathway is to activate AMP-activated protein kinase (AMPK) to rapidly initiate negative regulatory mechanisms, inhibit lipid synthesis and reduce energy expenditure through activated AMPK. Aberrant signaling of this pathway can lead to enhanced",3_23,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"signaling of this pathway can lead to enhanced glycolysis, which in turn exacerbates metabolic disorders and leads to the development of autoimmune diseases. The PI3K/Akt/TSC/mTOR signaling pathway is involved in B cell activation and plays an important role in osteoclast differentiation and survival, and studies have demonstrated that mTOR activity is highly activated in synovial tissue, especially synovial osteoclasts, in patients with rheumatoid arthritis (<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref",3_24,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"(<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>), and inhibition of this pathway can prevent bone destruction in rheumatoid arthritis. The mTOR signaling pathway can also participate in the occurrence of immune diseases by changing the level of autophagy and oxidative stress. mTOR activity is increased in a variety of connective tissue diseases (<xref rid=""B6"" ref-type=""bibr"">6</xref>). At the same time, the mTOR signaling pathway is considered to be the key to the",3_25,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"pathway is considered to be the key to the development of TSC disease, and is involved in the process of various clinical manifestations of TSC: SEGA, renal AML, LAM, facial fibroids and other lesions. Henske EP et al.[<xref rid=""B7"" ref-type=""bibr"">7</xref>, <xref rid=""B8"" ref-type=""bibr"">8</xref>] mentioned that the mTOR signaling pathway was activated in LAM, and mTOR overexpression occurred, resulting in abnormal proliferation of LAM cells. Numerous studies have also shown that (<xref rid=""B9""",3_26,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"studies have also shown that (<xref rid=""B9"" ref-type=""bibr"">9</xref>, <xref rid=""B10"" ref-type=""bibr"">10</xref>) loss of Tsc1 in proximal tubular epithelial cells induces mTORC1 activation, which can induce cell proliferation and renal fibrosis. Hongdi Cao et al. (<xref rid=""B11"" ref-type=""bibr"">11</xref>) found that mTORC1 signaling can also mediate the progression of renal interstitial fibrosis by regulating glycolysis of proximal tubular epithelial cells, and inhibition with rapamycin can inhibit renal",3_27,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"and inhibition with rapamycin can inhibit renal tubular epithelial cell proliferation and block TGF-b1-induced tubular epithelial to mesenchymal transition. In the neurological manifestations associated with TSC, Paola Zordan et al. (<xref rid=""B12"" ref-type=""bibr"">12</xref>) found that the tumor progression from static subependymal nodules (SENs) to subependymal giant cell astrocytomas (SEGA) was accompanied by mTORC1 overactivation in a mouse model of TSC, and that sustained activation of Akt and mTORC2",3_28,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"and that sustained activation of Akt and mTORC2 in neural stem cells was a necessary step to induce SEN and SEGA. There are few clinical reports of immune diseases complicated with TSC. Only one case of Sjögren’s syndrome complicated with pulmonary lymphangioleiomyoma (LAM) was found (<xref rid=""B13"" ref-type=""bibr"">13</xref>). We reported this case of RA merging TSC, in addition to the currently known pathogenic factors, we reported that the overexpression of mTOR may occur due to the activation of mTOR,",3_29,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"of mTOR may occur due to the activation of mTOR, resulting in the recurrence of joint synovitis and the abnormal proliferation of LAM cells leading to multiple cystic changes in the lungs. At present, TSC cannot be completely cured, and symptomatic treatment is the mainstay. The mTOR inhibitors sirolimus and everolimus have been recognized by experts at home and abroad as effective drugs for the treatment of TSC (<xref rid=""B14"" ref-type=""bibr"">14</xref>). Masaki Hirose et al. (<xref rid=""B8""",3_30,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"Masaki Hirose et al. (<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>) showed that treatment with sirolimus reduced serum VEGF-D levels, a biomarker for the diagnosis and treatment of LAM, and stabilized lung function in LAM patients. In addition, Everolimus is also widely used in the treatment of SEGA and AML (<xref rid=""B16"" ref-type=""bibr"">16</xref>, <xref rid=""B17"" ref-type=""bibr"">17</xref>). mTORC1 inhibitors have been shown to be effective in reducing the size of",3_31,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"shown to be effective in reducing the size of angiomyolipomas (<xref rid=""B18"" ref-type=""bibr"">18</xref>). Studies have confirmed that the response to treatment of iveolimus is equivalent regardless of the patient’s TSC1 or TSC2 mutation status (<xref rid=""B19"" ref-type=""bibr"">19</xref>). One randomized, double-blind controlled study suggests that everolimus significantly reduces the frequency of TSC-related refractory seizures (<xref rid=""B20"" ref-type=""bibr"">20</xref>). There are also data to suggest",3_32,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"There are also data to suggest that sirolimus can be used to treat immune diseases such as RA, effectively alleviate arthritis symptoms and restore Th17/Treg cell balance during treatment (<xref rid=""B21"" ref-type=""bibr"">21</xref>, <xref rid=""B22"" ref-type=""bibr"">22</xref>). In this case, the patient developed menstrual irregularities during the treatment. The main drugs used in the treatment of patients were leflunomide, hydroxychloroquine, and everolimus. According to the instructions for leflunomide,",3_33,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"According to the instructions for leflunomide, the black box warning of the United States FDA for leflunomide is embryotoxicity and hepatotoxicity, and other common adverse reactions include diarrhea, itching, hair loss, rash, etc., and the reproductive toxicity mechanism may be related to its inhibition of dihydroorotate dehydrogenase activity; Hydroxychloroquine is less gonadal toxic, the mTOR inhibitor: everolimus can reduce progesterone levels in women and testosterone levels in men, which in turn can",3_34,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"and testosterone levels in men, which in turn can lead to menstrual disorders in women. A randomized, double-blind, placebo-controlled phase III trial, EXIST-2, reported multiple adverse effects associated with everolimus, including menstrual disorders (menorrhagia) accounting for 8% and vaginal bleeding unrelated to normal menstruation (7%) (<xref rid=""B23"" ref-type=""bibr"">23</xref>), In the EXIST-2 extension study, 31% of patients in United States experienced at least one episode of amenorrhea. Studies",3_35,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"at least one episode of amenorrhea. Studies have also shown that 23.35%~65% of female patients experienced menstruation-related adverse reactions, and some patients needed to receive hormone therapy (<xref rid=""B24"" ref-type=""bibr"">24</xref>, <xref rid=""B25"" ref-type=""bibr"">25</xref>). Therefore, it is considered that the heavy menstrual flow and prolonged menstrual period in this patient are closely related to everolimus, and the menstrual disorders of the patients disappeared after low-dose use of",3_36,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"of the patients disappeared after low-dose use of everolimus. At present, a number of studies at home and abroad have shown that low-dose mTOR inhibitors can effectively control the disease, reduce the possibility of adverse events with long-term use of everolimus, reduce the economic burden of patients, and bring better tolerability and economy. In this case, the patient was treated with leflunomide, hydroxychloroquine, and hormone immunosuppressive therapy, but still had recurrent cough and joint",3_37,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"therapy, but still had recurrent cough and joint swelling and pain, and was treated with mTOR inhibitor: everolimus, and the 6-month follow-up showed that the patient’s joint inflammation and cough symptoms continued to be relieved, and there was no obvious progress or deterioration in the imaging of the lungs and kidneys. mTOR inhibitors can induce autoimmune tolerance to reduce joint inflammation and are expected to be a new option for the treatment of RA.",3_38,"A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence",26 9 2024,,Tuberous_Sclerosis
"Radiosensitivity in individuals with tuberous sclerosis complex Benign tumors, but rarely cancer, are common in patients with tuberous sclerosis complex (TSC). Blood samples from patients undergoing treatment for TSC at our institution were analyzed for their individual sensitivity to ionizing radiation. Blood samples were collected from 13 adult patients with TSC. The samples were irradiated ex vivo and analyzed by 3-color fluorescence in situ hybridization. In each patient, aberrations were analyzed in",4_0,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"In each patient, aberrations were analyzed in 200 metaphases of chromosomes 1, 2, and 4 and scored as breaks. Radiosensitivity was determined by mean breaks per metaphase (B/M) and compared to both healthy donors and oncologic patients. The radiosensitivity (B/M) of the TSC patient cohort (n = 13; female: 46.2%, B/M: 0.48 ± 0.11) was clearly increased compared to healthy individuals of similar age (n = 90; female: 54.4%; B/M: 0.40 ± 0.09; p = 0.001). There was no difference compared to age-matched",4_1,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"There was no difference compared to age-matched oncological patients (n = 78; female: 67.9%; B/M 0.49 ± 0.14; p = 0.246). Similarly, the proportion of radiosensitive (B/M > 0.5) and distinctly radiosensitive individuals (B/M > 0.6) was increased in the TSC and oncological patient cohorts (TSC: 30.8% and 7.7%, oncological patients: 46.2% and 14.1%) compared to the healthy individuals (11.1% and 2.2%). Although patients with TSC develop mostly benign and rarely malignant tumors, they are similarly sensitive",4_2,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"malignant tumors, they are similarly sensitive to radiation as patients with malignant tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. It is a rare disease with a prevalence of ~ 1: 6000 [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The disease is characterized by tumorigenesis and is associated with neurological and behavioral abnormalities [<xref ref-type=""bibr"" rid=""CR4"">4</xref>].",4_3,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"[<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. One of the most common clinical manifestations of TSC is epilepsy, which occurs in approximately 80–90% of patients and results in high rates of drug-resistant epilepsy [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. De novo or inherited mutations in the TSC1 (9q34) or TSC2 (16p13.3) genes inactivate negative regulators of the mTOR tumor suppressor proteins hamartin and tuberin [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. This",4_4,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"[<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. This leads to hyperactivation of the mTOR kinase pathway. Normally, in response to nutrient and growth factor stimulation, this pathway regulates cell growth and anabolic processes [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. As a result, non-malignant tumors occur in many organs, including the brain, eyes, heart, kidney, skin, and lungs [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Accordingly, the clinical diagnostic criteria include cortical dysplasia,",4_5,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"diagnostic criteria include cortical dysplasia, subependymal nodules, subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, retinal hamartomas, pulmonary lymphangioleiomyomatosis (LAM), and facial angiofibromas [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>–<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. TSC2 gene inactivation is associated with a more severe disease manifestation [<xref ref-type=""bibr"" rid=""CR12"">12</xref>] and leads to a more",4_6,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"rid=""CR12"">12</xref>] and leads to a more severe epilepsy phenotype and neurological manifestations [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] than TSC1 gene inactivation. Additional patients with TSC2 mutations present symptoms at a younger age and have more severe symptoms, such as seizures, cortical tubera, and subependymal nodules [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Tumor predisposition syndromes are often associated with an increased risk of adverse therapeutic effects and secondary",4_7,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"risk of adverse therapeutic effects and secondary cancers due to increased tissue sensitivity when malignancies occur and radiation therapy is required [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>]. It is becoming increasingly clear that there are syndromes that mainly involve increased tissue sensitivity with no or only a slightly increased risk of tumor formation and secondary cancers [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. An example of this is Cockayne’s",4_8,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"An example of this is Cockayne’s syndrome with high tissue sensitivity and no increased risk of cancer [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Conversely, there are syndromes that are extremely susceptible to the development of tumors and secondary cancers induced by ionizing radiation, but are not otherwise associated with high tissue sensitivity [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. One of these is Li-Fraumeni syndrome, with an already high risk of primary cancer of 50% by the age of 31 for",4_9,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"of primary cancer of 50% by the age of 31 for female and 46 for male [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Secondary cancers are described in 30% of patients within 10.7 years after cancer treatment with ionizing radiation [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Most commonly, however, there is both increased susceptibility to tumors and increased tissue sensitivity. Examples are the classic radiosensitivity syndromes ataxia telangiectasia mutated and Nijmegen breakage syndrome. Both are",4_10,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"mutated and Nijmegen breakage syndrome. Both are characterized by an extremely high two to threefold increase in tissue sensitivity to ionizing radiation and a high risk of tumor development [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. This suggests that an increased susceptibility to benign tumors, as in the case of TSC, could also imply an increased risk of tissue sensitivity. Radiation sensitivity testing is not trivial. The goal is usually to determine tissue sensitivity prior to radiation therapy. It",4_11,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"tissue sensitivity prior to radiation therapy. It is very rare that tumor susceptibility testing is requested, which means testing to see if there is an increased risk of developing cancer or a secondary cancer due to cancer treatment. Chromosomal analysis of blood lymphocytes has proven useful in predicting radiation sensitivity [<xref ref-type=""bibr"" rid=""CR21"">21</xref>, <xref ref-type=""bibr"" rid=""CR22"">22</xref>]. This has the advantage that blood is easy to obtain and chromosomal aberrations are a",4_12,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"easy to obtain and chromosomal aberrations are a late endpoint where repair, signal transduction, cell cycle regulation and cell death control can be monitored. Chromosome analysis examines which chromosomal aberrations have occurred and scores them according to the number of underlying DNA double-strand breaks. The resulting value as breaks per metaphase then indicates how sensitive the patients are to ionizing radiation [<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr""",4_13,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Here we investigated whether patients with TSC have an increased susceptibility to ionizing radiation and studied this using chromosomal analysis. Our cohort of patients with TSC consisted of 13 patients from whom we took a blood sample (NH4-Heparin, Sarstedt, Nürnbrecht, Germany). All patients with TSC were treated at our institution between May 2020 and August 2023. All patients who consented to the study were consecutively enrolled at",4_14,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"to the study were consecutively enrolled at the Epilepsy Center of the University Hospital Erlangen-Nuremberg. Healthy individuals from a cohort previously published [n = 208, mean age = 50.3 (SD = 17.7)] as well as oncological patients treated at the department of Radiation Oncology of the University Hospital Erlangen-Nuremberg [n = 347, mean age = 60.2 (SD = 13.0)] served as controls [<xref ref-type=""bibr"" rid=""CR24"">24</xref>–<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Individuals having any other",4_15,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"Individuals having any other medical condition or taking drugs suspected to increase radiation sensitivity like metformin, chloroquine, efavirenz, chloroquine, nelfinavir, vemurafenib, or immunotherapy were excluded from this study [<xref ref-type=""bibr"" rid=""CR27"">27</xref>–<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Additionally, we retrospectively analysed clinical records of all patients with TSC treated at our institution between 01/2003 and 08/2023 for the occurrence of benign and malignant tumours.",4_16,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"the occurrence of benign and malignant tumours. This study was approved by the Ethics Committee of the Friedrich-Alexander-University Erlangen-Nuremberg (No. 21_19B). Written informed consent was obtained from all patients. Three-color fluorescence in situ hybridization (FiSH) assay was performed to study radiation sensitivity. Blood from each participant was divided into two portions: one portion served as an non-irradiated control sample to detect the number of background aberrations, while the other",4_17,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"number of background aberrations, while the other portion received a 2 Gy dose using a 6 MV linear accelerator (Mevatron, Siemens, Germany). This dose of 2 Gy is equivalent to a single daily dose that is often given in a fractionated radiotherapy regimen. Blood-lymphocytes were stimulated with phytohemagglutinin (Biochrom, AG, Berlin, Germany) and cultured at 37 °C in an incubator. After 45 h of culture, the lymphocytes were arrested with colcemid (Gibco, Waltham, MS, USA) in the metaphase of the first",4_18,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"Waltham, MS, USA) in the metaphase of the first cell division and chromosome preparation was performed. DNA hybridization with chromosome-specific probes was used to detect chromosomes 1, 2, and 4. Various fluorescent dyes were used for staining, and DAPI was used to counterstain the chromosomes. The entire procedure for three-color fluorescence in situ hybridization was performed as described previously [<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR25"">25</xref>]. A",4_19,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. A fluorescence microscope (Zeiss, Axioplan 2, Göttingen, Germany) controlled by Metasystems software (Metafer 4 V3.10.1, Altlussheim, Germany) was used to automatically locate chromosome metaphase spreads at 100× magnification. A single image of each metaphase was captured at 630× magnification. Black and white images for each color (red, green, and blue) were obtained and used for evaluation of each metaphase spread [<xref ref-type=""bibr"" rid=""CR32"">32</xref>].",4_20,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"[<xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Image analysis software (Biomas, Erlangen, Germany) was used to analyze a minimum of 200 metaphases. The assessment included scoring for translocations, dicentric chromosomes, acentric chromosomes, rings, deletions, insertions, and complex chromosomal rearrangements (CCRs). The data was then transferred to a spreadsheet (Excel, Microsoft Corporation, Redmond, WA, USA) and scores (breaks per metaphase, B/M) were calculated. Aberrations were scored based on the",4_21,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"calculated. Aberrations were scored based on the number of underlying chromosomal breaks according to the criteria of Savage and Simpson (33). The B/M score of the control sample was subtracted from the B/M score of the irradiated sample, to get the score for the 2 Gy dose. SPSS Statistics 22.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Two/One-tailed t-test with Welch’s correction and Mann–Whitney U-test were used to test for significant differences between groups, and p values < 0.05 were",4_22,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"between groups, and p values < 0.05 were considered significant. GraphPad Prism (2020) was used for data visualization and statistical analysis. A lognormal distribution was chosen for curve fitting for all data sets, as suggested by Shapiro–Wilk/Kolmogorov–Smirnov test. The individual regression curves in relation to the data histogram are shown in supplementary Figure S1. The goodness of fit (in r2) was p = 0.915 for the TSC curve (Figure S1 A), p = 0.975 for the healthy curve (Figure S1 B), p = 0.956",4_23,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"for the healthy curve (Figure S1 B), p = 0.956 for the oncological curve (Figure S1 C), p = 0.9818 for the young healthy curve (Figure S1 D) and p = 0.825 for the young oncological curve (Figure S1 E). The following subgroups in the TSC cohort were compared: mutation: TSC1 (n = 3) to TSC2 (n = 4); age: younger than the median age of 37.6 years (n = 6) to older (n = 7); sex, female (n = 7) to male (n = 6);desease burden: less disease burden (n = 7) was defined as having fewer than four major diagnostic",4_24,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"as having fewer than four major diagnostic criteria [<xref ref-type=""bibr"" rid=""CR4"">4</xref>] and more disease burden (n = 6) as having at least four criteria. Patients treated with the mTOR inhibitor Everolimus (n = 4) [<xref ref-type=""bibr"" rid=""CR33"">33</xref>] were compared to patients not treated with this drug (n = 9).  On average, the 13 TSC patients in our study had an increased sensitivity to ionizing radiation that was comparable to that of patients with malignant tumors in our study. In",4_25,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"patients with malignant tumors in our study. In contrast, almost all except for one of the 38 TSC patients treated at our hospital had tumors that were exclusively benign. An obvious comparison group were healthy individuals. Compared to them, TSC patients were significantly more sensitive to ionizing radiation. Age is the only factor in patient characteristics that clearly influences radiation sensitivity [<xref ref-type=""bibr"" rid=""CR25"">25</xref>], apart from the underlying diseases that defined the",4_26,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"from the underlying diseases that defined the groups. Therefore, we matched the cohorts only in this respect. Since most tumors are unlikely to occur in younger patients unless they have a genetic predisposition, the age restriction and matching process had a greater impact on the radiation sensitivity of the oncological patients than on the healthy individuals. This explains why the young oncological cohort was more sensitive to ionizing radiation than the unmatched oncological cohort of older patients.",4_27,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"unmatched oncological cohort of older patients. The young healthy cohort was slightly, but not significantly, less sensitive to radiation than the general healthy cohort, which we have previously observed [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. In this study, age had little effect on radiosensitivity, although it is generally accepted that repair capacity decreases [<xref ref-type=""bibr"" rid=""CR35"">35</xref>] and radiosensitivity increases with age [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. In",4_28,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"[<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. In addition to age, there are often gender differences. However, there are no gender differences in radiation sensitivity [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. We compared female with male TSC patients and did not find any difference (p = 0.469). The severity of the manifestations of TSC varies greatly from one individual to another and even from one identical twin to another. Differences in the mutations that occur in TSC1 versus TSC2 and other poorly",4_29,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"that occur in TSC1 versus TSC2 and other poorly defined factors are likely responsible for this phenotypic heterogeneity [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. Similarly, differences among the mutation spectrum and the genetic expression could lead to a difference in radiosensitivity. It is possible that patients with a higher burden of disease may have an increased sensitivity to radiation. We studied therefore whether the radiosensitive patients suffered more from the disease and had a higher",4_30,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"suffered more from the disease and had a higher disease burden. In the four radiosensitive TSC patients, however, we did not find a higher disease burden and patients with higher disease burden had no increased radiosensitivity. Mutations in TSC2 lead to a more severe form of the disease in multiple organs and to a higher disease burden [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Therefore, we also investigated whether TSC2 individuals are more sensitive to radiation. Due to the small number of known",4_31,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"to radiation. Due to the small number of known mutations in our cohort and the fact that the outlier patient had a mutation in TSC1, we could not find a difference between the radiosensitivity of TSC1 and TSC2 individuals. For a long time, only symptomatic therapies were available for patients with TSC. With the discovery of the pathogenesis of TSC as a negative regulator of the mTOR complex 1 and the corresponding therapy with mTOR inhibitors, specific treatment for the cause of the disease became",4_32,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"treatment for the cause of the disease became possible for the first time. The question is whether treatment with an mTOR inhibitor could also influence the radiosensitivity. Everolimus was less frequently used in the entire cohort (10.5%) because it is a relatively new drug and the 13 included patients were therefore more likely to receive it than the retrospective, older cohort (30.8%). We found no difference in radiosensitivity between the nine patients without the drug versus the four patients using",4_33,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"without the drug versus the four patients using the drug (p = 0.911), indicating that the mTOR inhibitor probably did not affect radiosensitivity in TSC patients in this study. However, the four patients with increased radiosensitivity were not taking the drug. Another drug suspected to increase radiosensitivity is valproic acid [<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Of the 13 patients, only one patient with normal radiosensitivity (0.415 B/M) was taking valproic acid and was therefore not",4_34,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"was taking valproic acid and was therefore not considered relevant for our analysis. Nevertheless, it is conceivable that the radiation sensitivity of patients who are already more sensitive due to TSC could be further increased by Valproate. The ability of the other drugs to influence radiosensitivity is not known. Molecularly, the TSC complex consisting of the proteins TSC1, TSC2 and TBC1D7 functions as an inhibitor to the mTOR complex 1 (mTORC1) by deactivating Rheb, which is needed to activate mTORC1.",4_35,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"Rheb, which is needed to activate mTORC1. mTORC1 controls a number of metabolic functions and inhibits apoptosis [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. Loss of TSC1/2 function causes mTORC1 to be constitutively active in the cells of TSC patients. This makes the cells insensitive to most growth-suppressing signals [<xref ref-type=""bibr"" rid=""CR38"">38</xref>]. In TSC competent cells, p53 responds to DNA damage by activating AMPK, which phosphorylates TSC2. This leads to a decrease in mTORC1 and",4_36,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"TSC2. This leads to a decrease in mTORC1 and therefore to a reduction of the cells metabolism and an increase in apoptosis rate [<xref ref-type=""bibr"" rid=""CR39"">39</xref>]. The increased radiosensitivity in patients with TSC mutations could be explained by the reduced ability of cells to respond to DNA damage in this way. Without TSC, mTORC1 is not inhibited and damaged cells do not undergo apoptosis. However, TSC function is incompletely understood and one of the most highly integrated signaling nodes",4_37,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"of the most highly integrated signaling nodes found in all cells. Its ability to perceive and relay cell intrinsic and extrinsic signals is key to the control of cell, tissue and organismal homeostasis and growth. There are other mechanisms that could lead to the increased radiosensitivity. One mechanism, indicated by Ferlazzo, is that phosphorylation and therefore activation of the repair protein ATM occurs delayed. Simultaneously radiation induced a higher number of MRE11 foci, which also indicates a",4_38,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"number of MRE11 foci, which also indicates a problem with repair [<xref ref-type=""bibr"" rid=""CR40"">40</xref>] An impairment of nucleoshuttling of the ATM protein to the nucleus and a delayed phosphorylation of ATM has been described in several diseases with neurological defects and cancer proneness [<xref ref-type=""bibr"" rid=""CR41"">41</xref>] e.g. Xeroderma Pigmentosum [<xref ref-type=""bibr"" rid=""CR42"">42</xref>], Huntington’s disease [<xref ref-type=""bibr"" rid=""CR43"">43</xref>] and Neurofibromatosis type",4_39,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"rid=""CR43"">43</xref>] and Neurofibromatosis type 1 [<xref ref-type=""bibr"" rid=""CR44"">44</xref>]. Another interesting aspect is that the TSC1 gene product hamartin is bound to the outer membrane of mitochondria and is involved in the regulation of apoptosis by binding to HSP70 [<xref ref-type=""bibr"" rid=""CR45"">45</xref>]. The TSC2 gene product tuberin is also associated with mitochondria. Mitochondrial regulation of these proteins may play an important role in mTOR activation and thus cell growth control",4_40,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"in mTOR activation and thus cell growth control [<xref ref-type=""bibr"" rid=""CR46"">46</xref>]. There are two implications for patients with increased radiosensitivity. One is that increased radiosensitivity is usually associated with increased susceptibility to cancer. The consequence is that patients undergoing X-ray diagnostics should be diagnosed with modern equipment that produces only low doses of imaging radiation [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. In addition, dose reduction algorithms",4_41,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"In addition, dose reduction algorithms should be used. The second are the deterministic risks associated with interventional diagnostics and radiotherapy. Radiotherapy, with its high doses of about 2 Gy per fraction and total doses of up to 76 Gy, has been made possible by powerful equipment that make adverse effects of radiotherapy rare. However, increased radiosensitivity increases the likelihood of treatment-related side effects in the individual patient [<xref ref-type=""bibr"" rid=""CR14"">14</xref>,",4_42,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"[<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR47"">47</xref>]. In those cases, it is possible to reduce the dose to reduce the risk of side effects. A large portion (30.8%) of the TSC patients in our study were at or above the threshold of 0.5 B/M, where we define increased radiosensitivity. We recommend reducing the fraction dose for radiotherapy of malignant tumors for individuals with B/M values above 0.55. Therefore, if a malignant",4_43,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"B/M values above 0.55. Therefore, if a malignant tumor was present and was to be treated with radiotherapy in our cohort, a dose reduction would only be recommended for two patients. For the patient with 0.59 B/M, we would recommend a dose reduction of 5–10% of the fraction dose. For the patient with the extreme radiation sensitivity of 0.81 B/M, we would recommend a reduction in the fraction dose of between 25–40%. We recommend reducing the fraction dose and keeping the number of fractions constant",4_44,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"dose and keeping the number of fractions constant because we argue that for a patient with a correspondingly reduced dose, the effect is the same as for a healthy patient in whom ionizing radiation has a normal effect. Of course, there is a degree of uncertainty in testing radiation sensitivity, which is a clear limitation. Therefore, our dose reduction is very careful to avoid underdosing and the occurrence of relapse. One of the unanswered questions about TSC is whether patients have an increased risk of",4_45,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"TSC is whether patients have an increased risk of malignant cancer in addition to the extremely high risk of developing benign tumors. Data on increased cancer rates with TSC are scarce. Renal cell carcinomas appear to be increased and the incidence of cancer to occur at younger ages [<xref ref-type=""bibr"" rid=""CR48"">48</xref>]. Conversely, low levels of TSC1 and TSC2 are associated with an unfavorable prognosis in breast cancer and some other cancers [<xref ref-type=""bibr"" rid=""CR49"">49</xref>]. In our",4_46,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"ref-type=""bibr"" rid=""CR49"">49</xref>]. In our retrospective analysis, one patient (1/38, 2.6%) was suffering from a malignant tumor. Interestingly, this patient’s age (64 years) was considerably higher than the mean age of our cohort, leaving the question open whether the carcinomas could be attributed to potentially increased radiosensitivity due to the underlying TSC disease or other risk factors. The small number of patients due to the rarity of the disease is a clear limitation of this study.",4_47,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"the disease is a clear limitation of this study. Nevertheless, our study shows that TSC patients have an increased radiation sensitivity comparable to patients with malignant tumors. In addition, there are probably individual outliers with significantly increased radiation sensitivity. Patients with TSC have a slightly increased risk of increased sensitivity to ionizing radiation. There may be a few individuals with TSC who are at high risk. Our findings are independent of clinical features such as age,",4_48,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"are independent of clinical features such as age, sex or disease severity, however, our sample size was small, making cautious interpretation of our results necessary.",4_49,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""12672_2024_1395_MOESM1_ESM.docx""><caption><p>Supplementary Material 1: Figure S1. Overlay of Histogram and fitted curve for sensitivity scores) against their relative frequency</p></caption></media></supplementary-material>",4_50,Radiosensitivity in individuals with tuberous sclerosis complex,4 10 2024,,Tuberous_Sclerosis
"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex Following the approval of Epidiolex® (cannabidiol; CBD) for the treatment of seizures associated with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), healthcare professionals (HCPs) have had substantial experience in treating patients with Epidiolex. However, confusion still remains among",5_0,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Epidiolex. However, confusion still remains among HCPs, caregivers, and patients regarding dosing, drug interactions, safety monitoring, and differentiation between Epidiolex and nonapproved CBD products. To establish consensus recommendations for Epidiolex treatment optimization in LGS, DS, and TSC, a panel of seven HCPs with expertise in epilepsy was convened. Panelists participated in a premeeting survey based on a literature review of Epidiolex for the treatment of LGS, DS, and TSC, and survey",5_1,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"for the treatment of LGS, DS, and TSC, and survey responses were compiled for discussion. A modified Delphi method was used to assess agreement among panelists regarding recommendation statements following two rounds of discussion. Panelists identified two broad themes – overcoming barriers to initiation and optimization of treatment for seizures associated with LGS, DS, and TSC – for consensus guidelines. Accurate identification of patients with these rare epilepsies is critical for optimization of",5_2,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"rare epilepsies is critical for optimization of Epidiolex treatment. Providers should differentiate Epidiolex from nonapproved CBD products and set expectations for the therapeutic effect and safety/tolerability of Epidiolex. Initial target dose and titration rate should be individualized by baseline variables, prior response to antiseizure medications, and therapeutic goals. Awareness of strategies to manage adverse events and concomitant medications, including drug–drug interactions, is critical.",5_3,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"including drug–drug interactions, is critical. Tracking response to the maximum tolerated dose is an important measure of effectiveness. These consensus recommendations provide real‐world experience from neurology HCPs with experience in prescribing Epidiolex and can inform optimal use of Epidiolex for the treatment of seizures associated with LGS, DS, and TSC. The pharmaceutical formulation of plant‐derived, highly purified cannabidiol (CBD; Epidiolex®) is approved in the United States (US) for the",5_4,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"is approved in the United States (US) for the treatment of seizures associated with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) in patients ≥1 year of age.<xref rid=""epi412956-bib-0001"" ref-type=""bibr"">",5_5,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>1</sup>
</xref> In the European Union and United Kingdom, Epidyolex® is approved for the treatment of LGS, DS, and TSC (in conjunction with clobazam [CLB] for LGS and DS) in patients ≥2 years of age.<xref rid=""epi412956-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref> These approvals were based on results from pivotal, randomized phase 3 trials, in which Epidiolex treatment led to reduced seizure frequency and had an acceptable safety profile.<xref rid=""epi412956-bib-0003"" ref-type=""bibr"">
<sup>3</sup>",5_6,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>3</sup>
</xref>, <xref rid=""epi412956-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""epi412956-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref>, <xref rid=""epi412956-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>",5_7,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Healthcare professionals (HCPs) have had substantial experience with Epidiolex dosing and adverse event (AE) management since initial approval of the drug in 2018. However, confusion still remains among HCPs, including neurologists, nurse practitioners, physician assistants, pharmacists, family practitioners/generalists, group home providers, and developmental disability care providers, regarding dosing, drug interactions, safety monitoring, and differentiation between Epidiolex and nonapproved CBD",5_8,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"between Epidiolex and nonapproved CBD products. This reflects an unmet need among HCPs for consensus recommendations on Epidiolex treatment optimization in patients with LGS, DS, and TSC. Consensus recommendations for the treatment of LGS and DS with Epidiolex were previously developed by five neurologists from Spain.<xref rid=""epi412956-bib-0007"" ref-type=""bibr"">",5_9,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
<sup>7</sup>,5_10,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"</xref> These recommendations included slow dose escalation, treatment continuation for ≥6 months if tolerated, and reduction in concomitant antiseizure medications (ASMs) if AEs arise. The term “Epidiolex” is used herein to distinguish the approved pharmaceutical product from unregulated, nonapproved CBD‐containing products, which will be referred to as “CBD.” For our analysis, a multidisciplinary panel of neurology HCPs with experience in prescribing Epidiolex was convened to establish consensus",5_11,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Epidiolex was convened to establish consensus recommendations for dose optimization and response assessment in the treatment of seizures associated with LGS, DS, and TSC in the US.   These recommendations are intended to address the major concerns that neurology HCPs with limited experience in prescribing Epidiolex may have. Despite increasingly widespread use of Epidiolex for the treatment of seizures associated with LGS, DS, and TSC, knowledge gaps in the optimization of Epidiolex treatment remain.",5_12,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"the optimization of Epidiolex treatment remain. Unlike TSC and DS, for which published diagnostic criteria exist,<xref rid=""epi412956-bib-0013"" ref-type=""bibr"">",5_13,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>13</sup>
</xref>, <xref rid=""epi412956-bib-0022"" ref-type=""bibr"">
<sup>22</sup>
</xref> there are currently no consensus guidelines for the diagnosis of LGS. LGS is classically characterized by the presence of multiple seizure types, cognitive impairments, and SSW activity on EEG.<xref rid=""epi412956-bib-0014"" ref-type=""bibr"">
<sup>14</sup>
</xref> Recently, there has been a shift in favor of less rigid, broader LGS diagnostic criteria.<xref rid=""epi412956-bib-0054"" ref-type=""bibr"">
<sup>54</sup>",5_14,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>54</sup>
</xref> The REST‐LGS is a valuable tool that can aid in differentiating between LGS and other refractory epilepsies and can be used effectively by both experts and nonexperts in the clinical setting.<xref rid=""epi412956-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref>",5_15,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>21</sup>
</xref>
 There is a need for more extensive studies investigating potential DDIs between Epidiolex and concomitant nonseizure medications, such as antidepressants, antipsychotics, and anticoagulants (including direct oral anticoagulants). Levels of midazolam, an anxiolytic benzodiazepine, are not increased when administered concomitantly with Epidiolex, suggesting a lack of pharmacokinetic interaction.<xref rid=""epi412956-bib-0047"" ref-type=""bibr"">
<sup>47</sup>",5_16,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"<sup>47</sup>
</xref> Additionally, Epidiolex does not appear to alter the safety and effectiveness of diazepam nasal spray when used as a rescue medication.<xref rid=""epi412956-bib-0055"" ref-type=""bibr"">
<sup>55</sup>
</xref>",5_17,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Panelists also reported a substantial knowledge gap regarding optimal dosing of Epidiolex. Because of relatively limited data on appropriate dosing regimens, some patients may not receive an optimized dose needed for seizure control. Clinical studies are needed to confirm efficacy and safety of once‐daily Epidiolex 10–20 mg/kg/day in the evening to reduce daytime somnolence. Improved education on personalized, optimal dosing of Epidiolex to yield maximum seizure control while minimizing AEs is critical.",5_18,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"seizure control while minimizing AEs is critical. The effect of Epidiolex on focal seizures associated with LGS, DS, and TSC is currently not well defined in specifically designed clinical trials. Although Epidiolex reduced the frequency of seizures associated with TSC, which included focal seizures,<xref rid=""epi412956-bib-0056"" ref-type=""bibr"">",5_19,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
<sup>56</sup>,5_20,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"</xref> further studies are needed to specifically evaluate the effect on focal seizures. This analysis had several limitations. Although recommendations are based on the available scientific evidence, prescribing panelists also used their clinical judgment, which could result in a potential for bias. Furthermore, there are no standards for the number of individuals or number of rounds of agreement on a Delphi panel. These recommendations provide consensus‐based guidance on the optimization of Epidiolex",5_21,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"guidance on the optimization of Epidiolex treatment for seizures associated with LGS, DS, and TSC. By providing real‐world experience from neurology HCPs with experience in prescribing Epidiolex, these recommendations can inform clinical decision‐making and support optimal usage of Epidiolex. All authors provided substantial contributions to the conception or design of the work or the acquisition, analysis, or interpretation of data for the work; drafted the work or revised it critically for important",5_22,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"the work or revised it critically for important intellectual content; and provided final approval of the version to be published. The consensus panel was sponsored by Jazz Pharmaceuticals, Inc. RW has been a clinical trial investigator for Aquestive, Biohaven, Cerevel, Eisai, Eliem, Engage, Epalex, Equilibre, Greenwich Biosciences, Jazz Pharmaceuticals, Inc., Longboard, Marinus, Neurelis, Otsuka, Rapport, Receptor Neuroscience, SK Life Science, ThirdRock, UCB Pharma, Xenon, and Zogenix; has served on",5_23,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"UCB Pharma, Xenon, and Zogenix; has served on advisory boards and/or carried out consulting work for Aquestive, Biohaven, Brain Sentinel, Catalyst, Cerevel, Eisai, Engage Pharma, Engrail, Greenwich Biosciences, Jazz Pharmaceuticals, Inc., Longboard, Marinus, Neureka, Neurelis, Novella, Otsuka, Rapport, SK Life Science, UCB Pharma, and Xenon; has received speaker bureau honoraria for Aquestive, Catalyst, Eisai, Greenwich Biosciences, Jazz Pharmaceuticals, Inc., Neurelis, SK Life Science, Sunovion, and UCB",5_24,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Neurelis, SK Life Science, Sunovion, and UCB Pharma; has served as Medical Director of the Epilepsy Center at St. Luke's Health System in Boise, ID; has pay‐for‐call arrangements with St. Luke's Health System in Boise, ID; is a member of the Epilepsy Study Consortium; is a member of the Executive Committee of the Consortium of Private Epilepsy Centers; and is past Board President of the Epilepsy Foundation of Idaho. DEB has received support from NeuroPace and has served as a paid consultant for NeuroPace,",5_25,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"has served as a paid consultant for NeuroPace, Inc. BEG received speaking honoraria from Eisai, Greenwich, and SK Life Science, and served as a consultant for UCB, Eisai, Greenwich, and Aquestive. AH has participated in advisory boards with Aquestive, Eisai, Greenwich, Jazz Pharmaceuticals, Inc., Marinus, and Supernus Pharmaceuticals; participated in a speaker bureau for Aquestive and Jazz Pharmaceuticals, Inc.; received honoraria from the American Epilepsy Society; served as an investigator in sponsored",5_26,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Society; served as an investigator in sponsored pharmaceutical studies with Eisai, Greenwich, Marinus, Neurocrine, Sage, UCB, and Zogenix. PEM has served as a speaker for Eisai, Greenwich, and Sunovion and on advisory boards to UCB, Neuropace, and Supernus. EAT served as a principal investigator on clinical trials for GW Research Ltd/Jazz Pharmaceuticals Inc., Zogenix/UCB and Stoke Therapeutics and as a consultant for Aquestive Therapeutics, Biocodex, Greenwich Biosciences/Jazz Pharmaceuticals Inc., and",5_27,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Biosciences/Jazz Pharmaceuticals Inc., and Zogenix/UCB, Takeda, LivaNova, Nobelpharma, Marinus, Stoke Therapeutics, SK Life Sciences. JV has received honoraria for speaking on behalf of LivaNova, Eisai, Sunovian, UCB, and Greenwich Pharmaceuticals, and has also provided advisory services to SK Life Sciences. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",5_28,"Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex",15 7 2024,,Tuberous_Sclerosis
"Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program Tuberous sclerosis complex (TSC) is a highly variable, autosomal dominant genetic disorder characterized by mostly benign hamartomas in multiple organ systems, including the brain, skin, lungs, and eyes.<xref rid=""epi413013-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref>, <xref rid=""epi413013-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",6_0,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref> TSC is primarily caused by mutations in the tumor suppressor genes <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic>, resulting in hyperactivation of the mammalian target of rapamycin pathway and subsequent excessive cell growth and proliferation.<xref rid=""epi413013-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",6_1,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref> TSC is estimated to occur in 1 of 6000 newborns annually in the United States and affects up to 2 million people worldwide.<xref rid=""epi413013-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref> Approximately, 85% of patients with TSC experience epilepsy, with onset typically occurring during infancy.<xref rid=""epi413013-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""epi413013-bib-0005"" ref-type=""bibr"">
<sup>5</sup>",6_2,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>5</sup>
</xref> Current treatment options for TSC‐associated seizures include antiseizure medications (ASMs), surgery, dietary therapies, vagus nerve stimulation, and other devices.<xref rid=""epi413013-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref> The majority of patients with TSC (approximately 63%) develop treatment‐resistant epilepsy (TRE), compared with approximately 23% in the general epilepsy population.<xref rid=""epi413013-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",6_3,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> TRE is associated with neurological disorders such as intellectual disability and autism.<xref rid=""epi413013-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref>, <xref rid=""epi413013-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref>",6_4,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref>
 A pharmaceutical formulation of plant‐derived, highly purified cannabidiol (CBD) (Epidiolex® 100 mg/mL oral solution) is approved in the United States for the treatment of seizures associated with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and TSC in patients aged ≥1 year.<xref rid=""epi413013-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref> For patients with TSC, CBD is recommended at the maximum maintenance dosage of 25 mg/kg/d.<xref rid=""epi413013-bib-0009"" ref-type=""bibr"">",6_5,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>9</sup>
</xref> The approval for CBD was based on the results from five double‐blind, placebo‐controlled, randomized phase 3 trials.<xref rid=""epi413013-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""epi413013-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref>, <xref rid=""epi413013-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>, <xref rid=""epi413013-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>, <xref rid=""epi413013-bib-0014"" ref-type=""bibr"">
<sup>14</sup>",6_6,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>14</sup>
</xref> Long‐term efficacy and safety were further evaluated in open‐label extension trials, in which CBD treatment continued to show reduction in seizure frequency and a safety profile that was consistent with the randomized controlled trials in patients with DS, LGS, and TSC.<xref rid=""epi413013-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref>, <xref rid=""epi413013-bib-0016"" ref-type=""bibr"">
<sup>16</sup>
</xref>, <xref rid=""epi413013-bib-0017"" ref-type=""bibr"">
<sup>17</sup>",6_7,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>17</sup>
</xref> While a large cohort of patients with mixed epilepsy diagnoses treated with CBD has been described,<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref> and one initial CBD study focused on patients with TSC,<xref rid=""epi413013-bib-0001"" ref-type=""bibr"">
<sup>1</sup>",6_8,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
</xref> long‐term safety and efficacy data for patients with TSC are needed. The CBD Expanded Access Program (EAP) was initiated in January 2014 to provide compassionate‐use CBD treatment to patients with TRE at 35 US epilepsy centers. The 4‐year pooled efficacy and safety data from 840 patients at participating EAP sites that agreed to share patient data showed that add‐on CBD was associated with seizure reduction through 192 weeks of treatment with a safety profile that was consistent with that observed,6_9,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"profile that was consistent with that observed in the clinical trials. These data suggested that CBD can be used as a long‐term treatment for seizures associated with TREs.<xref rid=""epi413013-bib-0015"" ref-type=""bibr"">",6_10,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>15</sup>
</xref>, <xref rid=""epi413013-bib-0016"" ref-type=""bibr"">
<sup>16</sup>
</xref>, <xref rid=""epi413013-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref>, <xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref> An interim analysis of patients with TSC at a single EAP site showed a reduction in seizure frequency (all types) after 3 months of CBD treatment.<xref rid=""epi413013-bib-0001"" ref-type=""bibr"">
<sup>1</sup>",6_11,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"</xref> In this analysis of the pooled data from patients with TSC in the EAP, we report the long‐term efficacy (up to 144 weeks) and safety (through 233 weeks) of add‐on CBD treatment.   In this analysis of the CBD EAP, long‐term use of add‐on CBD in a cohort of 34 patients with TSC was associated with a reduction in the frequency of convulsive, focal, and total seizures through 144 weeks of treatment. A substantial percentage of patients (>42%) had ≥50% reductions in convulsive, focal, and total seizures",6_12,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"in convulsive, focal, and total seizures across all 12‐week treatment intervals. Additionally, up to 65% of patients had a profound reduction of ≥75% in these seizure types, and up to 32% of patients remained seizure‐free across all 12‐week treatment intervals. Through 233 weeks of treatment, the safety profile of CBD was similar to that seen in the previously reported EAP analyses<xref rid=""epi413013-bib-0001"" ref-type=""bibr"">",6_13,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>1</sup>
</xref>, <xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref> and the randomized controlled phase 3 trial (GWPCARE6) and its open‐label extension.<xref rid=""epi413013-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>, <xref rid=""epi413013-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref>, <xref rid=""epi413013-bib-0020"" ref-type=""bibr"">
<sup>20</sup>",6_14,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>20</sup>
</xref> In the current analysis, the majority of patients had AEs that were mild or moderate in severity, consistent with a previous EAP analysis of 18 patients with TSC treated with CBD<xref rid=""epi413013-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref> and the GWPCARE6 trial.<xref rid=""epi413013-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>, <xref rid=""epi413013-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref>, <xref rid=""epi413013-bib-0020"" ref-type=""bibr"">
<sup>20</sup>",6_15,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>20</sup>
</xref> After 3 years of treatment with add‐on CBD in the open‐label extension of GWPCARE6, the most commonly reported AEs were diarrhea seizures, pyrexia, and decreased appetite; no patient experienced severe drug‐induced liver injury, and there was one death, which was deemed unrelated to treatment by the investigator.<xref rid=""epi413013-bib-0020"" ref-type=""bibr"">
<sup>20</sup>",6_16,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>20</sup>
</xref> In the 4‐year overall EAP population (consisting of patients with TREs, including TSC, DS, and LGS), the most common AEs included diarrhea and seizure, and no patient had drug‐induced liver injury.<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref> There were 20 deaths during the 4‐year EAP study of the overall population that were deemed unrelated to treatment by the investigator.<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",6_17,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"</xref> In the current EAP analysis, the most common AEs were somnolence and diarrhea. One patient had an abnormal liver function test of moderate severity that resolved without changes in study medication, and no deaths were reported in the TSC population of the EAP. Although the median maximum reported dose of CBD was 40 mg/kg/d in the current study, at most visit intervals the median dose remained below this dose. The median dose was 25 mg/kg/d (approved dose) through 36 weeks of treatment, after which",6_18,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"dose) through 36 weeks of treatment, after which the median dose increased to >30 mg/kg/d at most visit intervals. CBD doses of 25 and 50 mg/kg/d have been investigated in GWPCARE6 phase 3 trial, in which no difference was observed between the two doses in efficacy, while the higher dose was associated with greater incidences of AEs and serious AEs.<xref rid=""epi413013-bib-0013"" ref-type=""bibr"">",6_19,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>13</sup>
</xref> Most patients experienced dose reductions of concomitant ASMs during CBD treatment, though the reasons for dose reduction were not specifically monitored. Of the concomitant ASMs with adjusted doses, the highest percentage of dose reductions occurred with concomitant valproate (83% of patients) and clobazam (80% of patients), both of which are known to interact with CBD.<xref rid=""epi413013-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref>",6_20,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>21</sup>
</xref>
 Reduction in the frequency of convulsive, focal, and total seizures after initiation of CBD treatment and occurrence of AEs that were mostly mild or moderate in severity throughout the current EAP study may have contributed to a relatively high retention rate (76% vs. 64% in the overall EAP population<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",6_21,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>18</sup>
</xref>) and support the long‐term use of add‐on CBD in patients with TSC. Interestingly, most patients who discontinued CBD treatment did so during the first year of treatment (5/8 [63%]), and in the overall EAP population, withdrawals did not appear to occur more frequently at any time point.<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref>",6_22,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"<sup>18</sup>
</xref>
 Limitations of this study include its open‐label design, as well as the variability in data collection and reporting methods across sites.<xref rid=""epi413013-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",6_23,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"</xref> In addition, this subgroup analysis from the CBD EAP dataset had a relatively small number of patients, limiting the generalizability of the results. Furthermore, doses of CBD and concomitant ASMs were inconsistent across visit windows and between patients. Almost all patients in the EAP were taking multiple medications, which may have affected efficacy and safety outcomes. Additionally, although most patients had dose modifications of concomitant ASMs, the reasons for these modifications were not",6_24,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"the reasons for these modifications were not recorded; therefore, it is difficult to determine if the modifications were in response to AEs or improved seizure control after CBD initiation. The results of this pooled analysis of data from a cohort of patients with TSC in the CBD EAP show that add‐on CBD treatment was associated with a reduction in the frequency of seizures through 144 weeks of treatment, and its safety profile was similar to that observed in previously reported EAP analyses and clinical",6_25,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"in previously reported EAP analyses and clinical trials, supporting the long‐term use of CBD for patients with TSC. All authors provided substantial contributions to the conception or design of the work or the acquisition, analysis, or interpretation of data for the work; drafted the work or revised it critically for important intellectual content; and provided final approval of the version to be published. This study was funded by GW Research Ltd, now part of Jazz Pharmaceuticals, Inc. EMB received",6_26,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"part of Jazz Pharmaceuticals, Inc. EMB received support from Jazz Pharmaceuticals, Inc., as a site principal investigator during the conduct of the trial and serves as a consultant for Greenwich Biosciences (now part of Jazz Pharmaceuticals, Inc.) and Biocodex. DC and FS are employees of Jazz Pharmaceuticals, Inc., and hold stock and/or stock options in Jazz Pharmaceuticals, Inc. JPS has received funding from the National Institutes of Health, National Science Foundation, US Department of Defense, State of",6_27,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"Foundation, US Department of Defense, State of Alabama, Shor Foundation for Epilepsy Research, UCB Pharma, NeuroPace, Greenwich Biosciences (now part of Jazz Pharmaceuticals, Inc.), Biogen, Xenon Pharmaceuticals, and Serina Therapeutics; has served on consulting/advisory boards for Greenwich Biosciences (now part of Jazz Pharmaceuticals, Inc.), NeuroPace, Serina Therapeutics, LivaNova, UCB Pharma, iFovea, AdCel Biopharma, and Elite Medical Experts; serves as an editorial board member for <italic",6_28,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"serves as an editorial board member for <italic toggle=""yes"">Epilepsy & Behavior</italic>, <italic toggle=""yes"">Journal of Epileptology</italic> (associate editor), <italic toggle=""yes"">Epilepsy & Behavior Reports</italic> (editor‐in‐chief), <italic toggle=""yes"">Journal of Medical Science</italic>, <italic toggle=""yes"">Epilepsy Currents</italic> (contributing editor), and <italic toggle=""yes"">Folia Medica Copernicana</italic>. EAT serves as a principal investigator on clinical trials for GW Research Ltd.",6_29,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"on clinical trials for GW Research Ltd. (now part of Jazz Pharmaceuticals Inc.) and Zogenix/UCB; and has served as a consultant for Biocodex, Greenwich Biosciences (now part of Jazz Pharmaceuticals Inc.), Takeda, Stoke Therapeutics, LivaNova, Nobelpharma, Azurity, and Zogenix/UCB. The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",6_30,Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program,01 8 2024,,Tuberous_Sclerosis
"Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by heterozygous loss-of-function pathogenic variants in the tumour suppressor genes TSC1 and TSC2 encoding the tuberin and hamartin proteins, respectively. Both TSC1 and TSC2 inhibit the mammalian target of rapamycin (mTOR) complexes pathway, which is crucial for cell proliferation, growth, and differentiation, and is stimulated by",7_0,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"growth, and differentiation, and is stimulated by various energy sources and hormonal signaling pathways. Pathogenic variants in TSC1 and TSC2 lead to mTORC1 hyperactivation, producing benign tumours in multiple organs, including the brain and kidneys, and drug-resistant epilepsy, a typical sign of TSC. Brain tumours, sudden unexpected death from epilepsy, and respiratory conditions are the three leading causes of morbidity and mortality. Even though several therapeutic options are available for the",7_1,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"several therapeutic options are available for the treatment of TSC, there is further need for a better understanding of the pathophysiological basis of the neurologic and other manifestations seen in TSC, and for novel therapeutic approaches. This review provides an overview of the main current therapies for TSC and discusses recent studies highlighting the repurposing of approved drugs and the emerging role of novel targets for future drug design. Tuberous sclerosis complex (TSC) is a rare neurocutaneous",7_2,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"sclerosis complex (TSC) is a rare neurocutaneous disorder caused by heterozygous loss-of-function pathogenic variants in the tumour suppressor genes TSC1 and TSC2 encoding the tuberin and hamartin proteins, respectively [<xref rid=""B1-biomolecules-14-01190"" ref-type=""bibr"">1</xref>]. These proteins constitute, together with TBC1D7 protein, a heteromeric complex critical for the negative regulation of the mammalian target of rapamycin (mTOR), a highly conserved serine/threonine kinase involved in the",7_3,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"conserved serine/threonine kinase involved in the control of cell metabolism, protein synthesis, growth, differentiation, and migration in response to nutrients and growth factors [<xref rid=""B2-biomolecules-14-01190"" ref-type=""bibr"">2</xref>,<xref rid=""B3-biomolecules-14-01190"" ref-type=""bibr"">3</xref>]. The incidence of TSC generally falls between 1:6000 and 1:10,000 of live births [<xref rid=""B4-biomolecules-14-01190"" ref-type=""bibr"">4</xref>]. The TSC phenotype is characterized by multisystem",7_4,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"The TSC phenotype is characterized by multisystem hamartomas (benign tumours), most commonly involving the, brain, kidneys, lungs, heart, skin, and eyes, and is associated with seizures and intellectual disability [<xref rid=""B1-biomolecules-14-01190"" ref-type=""bibr"">1</xref>,<xref rid=""B5-biomolecules-14-01190"" ref-type=""bibr"">5</xref>]. Brain involvement in TSC includes epilepsy, cortical tubers, subependymal nodules (SENs), and/or subependymal giant cell astrocytomas (SEGAs). Cortical tubers are",7_5,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"cell astrocytomas (SEGAs). Cortical tubers are clusters of abnormal neurons and glial cells in the cortex, resulting from disrupted cellular differentiation and neuronal migration. They are found in 88% to 100% of patients [<xref rid=""B6-biomolecules-14-01190"" ref-type=""bibr"">6</xref>,<xref rid=""B7-biomolecules-14-01190"" ref-type=""bibr"">7</xref>], and may be linked to seizures and autism spectrum disorders [<xref rid=""B8-biomolecules-14-01190"" ref-type=""bibr"">8</xref>]. SENs are small lesions in the",7_6,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"SENs are small lesions in the subependymal space of the lateral ventricle, with histopathological features like SEGAs. SENs are asymptomatic nodules that may calcify or gradually grow until, by the second decade of life, they transform into formations ≥15 mm in diameter [<xref rid=""B3-biomolecules-14-01190"" ref-type=""bibr"">3</xref>,<xref rid=""B9-biomolecules-14-01190"" ref-type=""bibr"">9</xref>]. Compared to SEGAs, SENs are smaller, do not grow, and do not show contrast enhancement with gadolinium. SEGAs are",7_7,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"contrast enhancement with gadolinium. SEGAs are benign, low-grade, non-infiltrative tumours of glioneuronal origin. They are defined as caudothalamic sulcus lesions larger than 1 cm in size, or subependymal lesions in any location that show serial growth on consecutive images, regardless of size. SEGAs are often an important source of TSC-related morbidity and sometimes mortality [<xref rid=""B6-biomolecules-14-01190"" ref-type=""bibr"">6</xref>]. Their prevalence is up to 20% among TSC patients [<xref",7_8,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"prevalence is up to 20% among TSC patients [<xref rid=""B10-biomolecules-14-01190"" ref-type=""bibr"">10</xref>], and their onset and growth are more common in the first decades of life [<xref rid=""B11-biomolecules-14-01190"" ref-type=""bibr"">11</xref>]. Despite being benign, SEGAs can grow and, due to their proximity to the foramen of Monro, can obstruct cerebrospinal fluid flow, increasing intracranial pressure, exacerbating seizures, and leading to cognitive and behavioral decline [<xref",7_9,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"to cognitive and behavioral decline [<xref rid=""B12-biomolecules-14-01190"" ref-type=""bibr"">12</xref>]. Epilepsy is one of the most common neurologic symptoms in patients with TSC, with the reported incidence between 62% and 93% [<xref rid=""B5-biomolecules-14-01190"" ref-type=""bibr"">5</xref>,<xref rid=""B13-biomolecules-14-01190"" ref-type=""bibr"">13</xref>]. Epilepsy usually begins during the first months of life and, in most patients with TSC, before the first year, and is a significant cause of morbidity and",7_10,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"year, and is a significant cause of morbidity and mortality [<xref rid=""B9-biomolecules-14-01190"" ref-type=""bibr"">9</xref>,<xref rid=""B14-biomolecules-14-01190"" ref-type=""bibr"">14</xref>]. Although the current surgical and pharmacological management of seizures in TSC often provide significant benefits, about two-thirds of patients develop drug-resistant epilepsy, associated with increased rates of intellectual disability and other tuberous sclerosis-associated neuropsychiatric disorders (TAND), including",7_11,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"neuropsychiatric disorders (TAND), including autism and attention-deficit/hyperactivity disorder [<xref rid=""B13-biomolecules-14-01190"" ref-type=""bibr"">13</xref>]. The presence of cortical tubers, SENs, and SEGAs are mainly responsible for these neurologic manifestations [<xref rid=""B3-biomolecules-14-01190"" ref-type=""bibr"">3</xref>]. Renal disease, including renal angiomyolipomas (AMLs), is another leading cause of mortality in TSC patients [<xref rid=""B15-biomolecules-14-01190""",7_12,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"patients [<xref rid=""B15-biomolecules-14-01190"" ref-type=""bibr"">15</xref>]. Cardiac rabdomyomas, often asymptomatic, are also frequent, especially in children with TSC [<xref rid=""B1-biomolecules-14-01190"" ref-type=""bibr"">1</xref>]. Among other manifestations, patients with TSC may present with lung cysts and lymphangioleiomyomatosis (LAM) in the lungs. LAM is a slowly progressive, low-grade, metastasizing neoplasm mostly occurring in women of about 35 years of age, with an incidence of about 30% in",7_13,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"years of age, with an incidence of about 30% in patients with TSC [<xref rid=""B16-biomolecules-14-01190"" ref-type=""bibr"">16</xref>]. The mTOR pathway is an evolutionarily conserved intracellular signaling pathway that is regulated upstream by phosphatidylinositol 3-kinase (PI3K)–Akt signaling [<xref rid=""B3-biomolecules-14-01190"" ref-type=""bibr"">3</xref>]. The serine/threonine kinase mTOR exerts its functions through two distinct complexes [<xref rid=""B17-biomolecules-14-01190""",7_14,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"complexes [<xref rid=""B17-biomolecules-14-01190"" ref-type=""bibr"">17</xref>,<xref rid=""B18-biomolecules-14-01190"" ref-type=""bibr"">18</xref>], mTOR complex 1 and 2 (mTORC1 and 2, respectively; <xref rid=""biomolecules-14-01190-f001"" ref-type=""fig"">Figure 1</xref>); both are composed of mTOR acting as the catalytic core of the complex, but differ in their associated proteins and sensitivity to the inhibitor rapamycin. mTORC1 consists of two core components, regulatory-associated protein of mTOR (Raptor) and",7_15,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"protein of mTOR (Raptor) and mammalian lethal with SEC13 protein 8 (mLST8), and two inhibitory subunits, Akt/PKB substrate 40 kDa (PRAS40) and DEP domain-containing mTOR-interacting protein (Deptor). mTORC1 is a rapamycin-sensitive complex involved in the regulation of protein synthesis, lipid synthesis, autophagy, energy metabolism, and lysosome biogenesis, and receives inputs from upstream regulatory proteins that are influenced by growth factors (for example, insulin, insulin-like growth factor 1 and 2",7_16,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"insulin, insulin-like growth factor 1 and 2 (IGF1 and IGF2)), ATP concentrations, nutrients, and AMP-activated protein kinase (AMPK). When activated, mTORC1 promotes cell growth and survival via the regulation of mRNA translation, nucleotide biosynthesis, and autophagy. In the brain, mTORC1 has important functions related to synaptic transmission and plasticity, neural network activity, and neurogenesis. mTORC1 localizes to the surface of lysosomes and to the endoplasmic reticulum (ER) and Golgi apparatus",7_17,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"endoplasmic reticulum (ER) and Golgi apparatus (GA). mTORC2 shares mLST8 and Deptor with mTORC1, but has three unique elements: the Raptor-independent companion of mTOR (Rictor), the mammalian stress-activated protein kinase-interacting protein 1 (mSIN1), and the protein observed with Rictor (Protor). mTORC2 is a rapamycin-insensitive complex largely known for its role in regulating actin dynamics and cell migration [<xref rid=""B2-biomolecules-14-01190"" ref-type=""bibr"">2</xref>], and it is found in the",7_18,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">2</xref>], and it is found in the plasma membrane, mitochondria, and in a subset of endosomal vesicles [<xref rid=""B19-biomolecules-14-01190"" ref-type=""bibr"">19</xref>]. Both TSC1 and TSC2 inhibit the mTORC1 pathway under physiological conditions. Thus, loss-of-function pathogenic variants in TSC1 and TSC2 cause mTOR hyperactivation, leading to TSC [<xref rid=""B20-biomolecules-14-01190"" ref-type=""bibr"">20</xref>]. A multidisciplinary approach with regular follow-up from childhood to",7_19,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"approach with regular follow-up from childhood to adulthood is mandatory for the management of TSC [<xref rid=""B4-biomolecules-14-01190"" ref-type=""bibr"">4</xref>]. Several therapeutic options are available for the treatment of focal seizures and infantile spasms associated with TSC, including vigabatrin, hormonal therapy, epilepsy surgery, a ketogenic diet, and vagus nerve stimulation [<xref rid=""B9-biomolecules-14-01190"" ref-type=""bibr"">9</xref>,<xref rid=""B21-biomolecules-14-01190""",7_20,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"rid=""B21-biomolecules-14-01190"" ref-type=""bibr"">21</xref>]. However, about two-thirds of patients develop refractory epilepsies, associated with increased rates of intellectual disability and other TANDs [<xref rid=""B13-biomolecules-14-01190"" ref-type=""bibr"">13</xref>]. In recent years, mTOR inhibitors (mTORi), such as sirolimus and everolimus, have also been increasingly used for the treatment of the other various manifestations of TSC, including kidney AMLs, SEGAs, facial angiofibromas, and",7_21,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"kidney AMLs, SEGAs, facial angiofibromas, and lymphangioleiomas [<xref rid=""B15-biomolecules-14-01190"" ref-type=""bibr"">15</xref>,<xref rid=""B16-biomolecules-14-01190"" ref-type=""bibr"">16</xref>]. For some of these lesions, when necessary, nonpharmacological interventions, such as surgery and selective arterial embolization (for renal AMLs), are also available [<xref rid=""B4-biomolecules-14-01190"" ref-type=""bibr"">4</xref>] (<xref rid=""biomolecules-14-01190-t001"" ref-type=""table"">Table 1</xref>). While the",7_22,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"ref-type=""table"">Table 1</xref>). While the molecular mechanisms by which mTOR hyperactivity causes abnormal cell growth can be supposed, the precise molecular mechanisms by which mTOR hyperactivity causes neuronal hyperexcitability, seizures, and brain and kidney lesions remain to be fully defined. Recently, several studies using TSC patients’ biological samples and preclinical studies based on TSC animal models have addressed this issue, and have offered insight as well into new potential treatments and",7_23,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"insight as well into new potential treatments and targets. Several therapeutic options are available for the treatment of epilepsy and hamartomas associated with TSC. Though, there is still a need for novel therapeutic targets and approaches. In this context, an improved understanding of the molecular mechanisms underlying epileptogenesis, brain tumours, and kidney cysts formation has shed light on ion channels and other synaptic proteins, AMPK, inflammatory markers, and EGFR as potential drug targets to",7_24,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"markers, and EGFR as potential drug targets to restore hyperexcitability and cell growth, thus providing new avenues of drug discovery for TSC.",7_25,Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets,21 9 2024,,Tuberous_Sclerosis
"Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China The tuberous sclerosis complex (TSC)‐associated neuropsychiatric disorders (TAND) Checklist is a reliable global screening tool for TAND in clinical settings, with six dimensions and 12 sections. For Chinese individuals with TSC, the implementation of the TAND Checklist provides a comprehensive approach to evaluating potential manifestations across various domains.",8_0,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<boxed-text position=""anchor"" content-type=""graphic""><graphic http://www.w3.org/1999/xlink href=""PED4-8-171-g001.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",8_1,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"Tuberous sclerosis complex (TSC) is a genetic disorder characterized by abnormalities affecting various organ systems, including the skin, brain, kidneys, heart, lungs, and eyes. It presents with a diverse range of physical manifestations, necessitating continuous assessment, monitoring, and treatment.<xref rid=""ped412447-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref> The incidence of TSC is estimated to range between 1:6000 and 1:10 000 live births.<xref rid=""ped412447-bib-0002"" ref-type=""bibr"">",8_2,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref>
<italic toggle=""yes"">TSC2</italic> pathogenic variants typically result in a more severe phenotype compared to <italic toggle=""yes"">TSC1</italic> pathogenic variants.<xref rid=""ped412447-bib-0003"" ref-type=""bibr"">
<sup>3</sup>",8_3,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> The diagnosis of TSC is confirmed in a proband through genetic diagnostic criteria, which involves identifying a heterozygous pathogenic variant in either <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> using molecular genetic testing. Alternatively, clinical diagnostic criteria can be employed based on the presence and quantity of major and minor clinical features. Regular evaluation and monitoring are essential for the comprehensive management of individuals affected by",8_4,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"management of individuals affected by TSC.<xref rid=""ped412447-bib-0002"" ref-type=""bibr"">",8_5,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref>",8_6,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"The neuropsychiatric panel convened during the 2012 TSC Consensus Conference proposed the definition of TSC‐associated neuropsychiatric disorders (TAND), encompassing a range of difficulties across many levels including behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial. These encompass a spectrum of conditions, including autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), learning and cognitive impairments, disruptive behaviors, and",8_7,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"cognitive impairments, disruptive behaviors, and emotional issues, among others.<xref rid=""ped412447-bib-0004"" ref-type=""bibr"">",8_8,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>4</sup>
</xref> It is noteworthy that while the general population has an approximate 2% risk of ASD,<xref rid=""ped412447-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref> individuals with TSC face a significantly elevated risk ranging from 16% to 61%.<xref rid=""ped412447-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""ped412447-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref>, <xref rid=""ped412447-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",8_9,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref>, <xref rid=""ped412447-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref>, <xref rid=""ped412447-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""ped412447-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref>, <xref rid=""ped412447-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>, <xref rid=""ped412447-bib-0013"" ref-type=""bibr"">
<sup>13</sup>",8_10,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>13</sup>
</xref> Despite more than 90% of TSC individuals experiencing one or more TAND‐related disorders in their lifetime, only 20% have undergone evaluation and intervention for these challenges.<xref rid=""ped412447-bib-0014"" ref-type=""bibr"">
<sup>14</sup>
</xref>, <xref rid=""ped412447-bib-0015"" ref-type=""bibr"">
<sup>15</sup>",8_11,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>15</sup>
</xref> To address this, it is recommended that TAND screening be conducted at least annually, with a comprehensive formal evaluation performed at crucial developmental stages in the life of a TSC patient.<xref rid=""ped412447-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref> Seeking the expertise of qualified professionals is paramount for the proper management of TAND, which may involve consideration of medication for individuals with ADHD.<xref rid=""ped412447-bib-0016"" ref-type=""bibr"">",8_12,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>16</sup>
</xref>, <xref rid=""ped412447-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref>
 Vanclooster et al.<xref rid=""ped412447-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",8_13,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>18</sup>
</xref> conducted a comprehensive review of articles related to TAND, revealing that despite an increase in recent research on TAND, there is still a lack of adequate assessment, treatment, and research for TAND patients. There is room for improvement in human‐related studies, which can guide future research on TAND. de Vries et al.<xref rid=""ped412447-bib-0019"" ref-type=""bibr"">
<sup>19</sup>",8_14,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> put forth the International Consensus Recommendations for the Identification and Treatment of TAND in 2023, offering valuable guidance for the effective management of TAND. The overall suggestion is to “screen” for TAND at least annually, proceed with appropriate follow‐up steps for assessment and treatment, take action, and “repeat” this process to ensure early identification and intervention using the most appropriate biological, psychological, and social evidence‐informed approaches to support",8_15,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"social evidence‐informed approaches to support TSC patients and their families.<xref rid=""ped412447-bib-0019"" ref-type=""bibr"">",8_16,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>19</sup>
</xref>",8_17,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"This commentary article aims to achieve three primary objectives. First, it seeks to delineate the characteristics of the TAND Checklist along with the pertinent research findings. Secondly, it endeavors to facilitate the accessibility of the TAND Checklist in China. Lastly, it aims to advocate for the adoption and recognition of the TAND Checklist within the Chinese TSC patient community.  The TAND Checklist has been translated into 20 languages, including Spanish, German, Portuguese, Japanese, and",8_18,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"Spanish, German, Portuguese, Japanese, and Korean, among others (<ext-link http://www.w3.org/1999/xlink href=""https://tandconsortium.org/checklists/"" ext-link-type=""uri"">https://tandconsortium.org/checklists/</ext-link>). However, notably absent from this roster is a Chinese translation. In an effort to enhance the accessibility and utility of the TAND Checklist within China, the TAND Checklist development team is working to translate its English version into both simplified Chinese and traditional",8_19,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"into both simplified Chinese and traditional Chinese. The complete TAND Checklist in Chinese versions will be available soon. Following the establishment of recommendations and standards by the 2012 International TSC Consensus Conference and the subsequent update of international TSC diagnostic criteria, along with surveillance and management recommendations in 2021, the scientific diagnosis and treatment of TSC have been effectively implemented and disseminated in China.<xref rid=""ped412447-bib-0002""",8_20,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"in China.<xref rid=""ped412447-bib-0002"" ref-type=""bibr"">",8_21,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
<sup>2</sup>,8_22,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> This successful translation of scientific research findings into clinical practice has notably improved the quality of life for patients with this rare disease in China. This achievement is a testament to the collaborative efforts and advocacy of Chinese healthcare professionals and patients alike. The TSC community in China has navigated the challenges of lacking a cure, and Chinese medical experts have gradually developed a set of proven diagnostic and treatment programs.<xref",8_23,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"of proven diagnostic and treatment programs.<xref rid=""ped412447-bib-0028"" ref-type=""bibr"">",8_24,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
<sup>28</sup>,8_25,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> The translation of the TAND scale into Chinese reflects the recognition of the differences in language and culture that exist across the world. This is a significant step towards providing more effective care for individuals with TSC in China. However, it is important to acknowledge that there is still a pressing need for evidence‐based guidelines that are specifically tailored to the Chinese population. By continuing to refine and adapt these guidelines, we can ensure that the care and outcomes",8_26,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"we can ensure that the care and outcomes for individuals with TSC in China are optimized. This ongoing commitment to improving the guidelines will ultimately benefit those who are affected by this condition, and contribute to the overall advancement of healthcare in China. In recent years, specialized TSC treatment centers have been established within medical institutions in China, offering comprehensive diagnostic and treatment services. Peking Union Medical College Hospital, Peking University First",8_27,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"Medical College Hospital, Peking University First Hospital, Beijing Children's Hospital, Children's Hospital of Fudan University, Shenzhen Children's Hospital, and the PLA General Hospital are among the top hospitals in China for managing TSC. The PLA General Hospital, in particular, sees approximately 1000 TSC patients annually, making it one of the busiest in the country for this condition. These centers typically house multidisciplinary teams comprising neurologists, pediatricians, dermatologists,",8_28,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"neurologists, pediatricians, dermatologists, nephrologists, respiratory physicians, psychologists, and imaging physicians. For diagnostic purposes, a combination of clinical presentation, family history assessment, physical examination, and imaging modalities are commonly employed to ascertain the presence of TSC. Genetic testing is increasingly utilized to confirm diagnoses and provide genetic counseling. In terms of treatment, personalized plans are meticulously designed to address the specific symptoms",8_29,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"designed to address the specific symptoms and organ involvement associated with TSC. Common therapeutic approaches encompass the use of anti‐seizure medications, mammalian targets of rapamycin inhibitors, surgical interventions, and interventional therapies.<xref rid=""ped412447-bib-0029"" ref-type=""bibr"">",8_30,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
<sup>29</sup>,8_31,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> Additionally, comprehensive treatment measures, including rehabilitation and psychological support, are offered to enhance the overall well‐being of patients. This approach reflects a holistic strategy aimed at providing optimal care to individuals with TSC in China. Since the introduction of the term “TAND” in 2012, research in this domain has made notable progress. The updated international TSC diagnostic criteria in 2012, along with surveillance and management recommendations, underscored the",8_32,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"and management recommendations, underscored the significance of addressing TAND in individuals, particularly children. The guidelines recommended the implementation of behavioral, intellectual, and neuropsychiatric assessments at crucial developmental stages, with the provision of comprehensive evaluations in adulthood when deemed necessary.<xref rid=""ped412447-bib-0002"" ref-type=""bibr"">",8_33,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref> Chinese scholars have advocated for the use of objective assessment tools, such as scales, specifically tailored for patients with intellectual developmental disabilities. This proposal is grounded in an analysis of TSC literature published in China over the past 13 years.<xref rid=""ped412447-bib-0030"" ref-type=""bibr"">
<sup>30</sup>
</xref>",8_34,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"For Chinese individuals with TSC, the implementation of the TAND Checklist provides a comprehensive approach to evaluating potential manifestations across various domains. Following the assessment of TAND symptoms, engagement with relevant specialists is essential to initiate evidence‐based interventions as necessary. Additionally, it is crucial for parents and caregivers to undergo education and training on TAND, ensuring their ability to recognize symptoms promptly and seek timely interventions.",8_35,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"symptoms promptly and seek timely interventions. Throughout the diagnostic process, extending psychological and social support to families is paramount. This facilitates the acceptance of both the TSC and TAND diagnoses, fostering the development of coping strategies that contribute to the well‐being of caregivers. Furthermore, the adoption of a standardized TAND Checklist has the potential to alleviate significant disparities in healthcare access and quality between urban and rural areas in China. This",8_36,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"between urban and rural areas in China. This standardized approach not only enhances the consistency of care but also ensures that individuals with TSC, regardless of geographical location, receive equitable and timely interventions based on their TAND profiles. Chinese pediatric researchers are encouraged to pursue the comprehensive collection of clinical data, encompassing information on seizures, intelligence, ASD, and genotypes. Large‐scale cohort studies across multiple centers can significantly",8_37,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"studies across multiple centers can significantly contribute to advancing our understanding of TSC in the Chinese pediatric population. Once translated and validated, the Checklist must be actively utilized in the research conducted among the Chinese TSC cohort. Additionally, qualitative research is deemed necessary to address existing gaps in TAND research. Given the global impact of the COVID‐19 pandemic, there is an urgent need for digital solutions. It is recommended to integrate the TAND Checklist",8_38,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"It is recommended to integrate the TAND Checklist into smartphone applications, facilitating broader accessibility and efficient data collection. In 2022, Heunis et al.<xref rid=""ped412447-bib-0031"" ref-type=""bibr"">",8_39,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
<sup>31</sup>,8_40,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> introduced the new TAND Toolkit App. Once launched in China, it is poised to offer significant convenience to TSC patients, greatly aiding in the early identification and treatment of TAND. Establishing a global TAND alliance through networking is also advised, promoting collaboration and knowledge sharing among researchers, clinicians, and patients worldwide. This collaborative approach can potentially accelerate advancements in TAND research and improve outcomes for individuals affected by TSC on",8_41,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"outcomes for individuals affected by TSC on a global scale.<xref rid=""ped412447-bib-0031"" ref-type=""bibr"">",8_42,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"<sup>31</sup>
</xref>
 In conclusion, the TAND Checklist, a user‐friendly and cost‐free screening questionnaire intended for completion by patients or their caregivers, stands as a valid screening tool for TAND in clinical settings. Its widespread use has been observed across various regions globally. The introduction of the TAND‐SQ Checklist, further enhances its utility, as the questions within the TAND Checklist have been quantified.<xref rid=""ped412447-bib-0031"" ref-type=""bibr"">
<sup>31</sup>",8_43,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"</xref> This adaptation anticipates a more prominent role in both the screening and continuous monitoring of TAND‐related disorders. With the translation of the TAND Checklist into Chinese, our aim is to extend its applicability in China. This initiative seeks to unveil previously undetected psychological, psychiatric, and behavioral issues associated with TSC patients in China. Ultimately, this endeavor is poised to contribute to the delivery of a more comprehensive medical service for individuals",8_44,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
comprehensive medical service for individuals affected by TSC in the Chinese population. The authors declare no conflict of interest.,8_45,Enhancing the utility of tuberous sclerosis complex‐associated neuropsychiatric disorders checklist in China,31 7 2024,,Tuberous_Sclerosis
"Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis Facial angiofibromas (FAs) are a dermatological characteristic which are typically linked to tuberous sclerosis (TS). FAs can have a prevalence of up to 90% [<xref rid=""B1"" ref-type=""bibr"">1</xref>] and frequently lead patients to contact with specialists about cosmetic procedures to improve their appearance [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. FAs typically appear in",9_0,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"FAs typically appear in childhood, and the prevalence continues to increase into adulthood [<xref rid=""B3"" ref-type=""bibr"">3</xref>]. Treatments for FAs have included surgical excision, curettage, dermabrasion, laser ablation, pulse dye laser (PDL), electrocautery, cryosurgery, and topical rapamycin [<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B10"" ref-type=""bibr"">10</xref>]. Nowadays, no guidelines or recommendations on the management of FAs are available, and lesser information exists for other TS",9_1,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"and lesser information exists for other TS skin cancers like shagreen patch [<xref rid=""B11"" ref-type=""bibr"">11</xref>–<xref rid=""B13"" ref-type=""bibr"">13</xref>]. The use of mTOR inhibitors like sirolimus (rapamycin) has significantly improved the treatment of TS cutaneous symptoms [<xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>]. However, topical sirolimus rarely results in complete treatment of angiofibromas. Indeed, the adult patients with fully grown angiofibromas",9_2,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"the adult patients with fully grown angiofibromas respond less favourably to topical rapamycin treatment as demonstrated by Park et al. [<xref rid=""B8"" ref-type=""bibr"">8</xref>] who showed that the application of topical rapamycin was ineffective in the treatment of papules larger than 4 mm. In this instance, the large FAs can be effectively treated with rapamycin combined to laser therapy [<xref rid=""B16"" ref-type=""bibr"">16</xref>]. On the other hand, the cryotherapy or shave excision followed by",9_3,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"the cryotherapy or shave excision followed by dermabrasion is a simple procedure to use, but it presents various drawbacks, such as postoperative discomfort and hypopigmented scarring in susceptible patients [<xref rid=""B17"" ref-type=""bibr"">17</xref>]. As a result, physical treatment to diminish the size of both old and advanced lesions, especially for individuals who did not receive early care or who have had the condition for a long time, has been widely employed. Laser therapy is considered an effective",9_4,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"Laser therapy is considered an effective treatment for angiofibromas [<xref rid=""B18"" ref-type=""bibr"">18</xref>]. The existing literature already reported clinical cases in which the ablative and nonablative laser combination technique has led to good results in the resolution of TS-related angiofibroma lesions [<xref rid=""B19"" ref-type=""bibr"">19</xref>]. Especially, the combination of PDL and CO<sub>2</sub> laser was successfully used for vascular lesions management [<xref rid=""B20""",9_5,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"for vascular lesions management [<xref rid=""B20"" ref-type=""bibr"">20</xref>, <xref rid=""B21"" ref-type=""bibr"">21</xref>]. Herein, we discuss our experience, highlighting a rare occurrence of multiple FAs in young patient, successfully treated with ablative CO<sub>2</sub> laser combined with PDL therapy. We report a clinical case of a 23-year-old male patient affected by tuberous sclerosis (TS) who manifests neurological symptoms represented by a mild mental retardation. Patient presents multiple erythematous",9_6,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"Patient presents multiple erythematous and colored papules/nodules and raised erythematous elevated plaque located on the face, mainly concentrated around nose, perinasal area, cheeks, and chin area. The multiple papules measured up to 0.5 cm in size. The onset of TS symptoms occurred in adolescents, immediately prior to puberty. TS was confirmed by brain magnetic resonance imaging. Prior to the study, the patient did not receive any pharmaceutical therapies. Since redness and volume of the lesions were",9_7,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"Since redness and volume of the lesions were the main cause of patient's cosmetic problems, a combinational laser therapy, including the use of the ablative CO<sub>2</sub> laser (TetraPro—DEKA M.E.L.A, Calenzano, Italy) and a pulsed dye laser (Synchro VasQ—DEKA M.E.L.A, Calenzano, Italy), was administered. The patient underwent 3 sessions of combined treatment with CO<sub>2</sub> and pulsed dye laser. The intralesional dye laser treatment was administered immediately after the CO<sub>2</sub> laser session.",9_8,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"after the CO<sub>2</sub> laser session. The time interval between the combined laser treatments was approximately two months. A topic occlusive anaesthetic mask was applied 20 minutes before treatment with CO<sub>2</sub> laser. For CO<sub>2</sub> laser therapy, parameters were set to frequency 10 Hz, power 0.4-1.5 W, SP pulse. PDL was performed immediately after CO<sub>2</sub> laser, and parameters of spot size 10–12 mm and fluence 7 J/cm<sup>2</sup> were selected. A clinical photography-based assessment",9_9,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"selected. A clinical photography-based assessment of the Facial Angiofibromata Severity Index (FASI) was used to determine the effectiveness of the treatment at the baseline and four months following the final laser treatment session. The FASI scores range from 0 (the best) to 3 (the worst), encompassing erythema (0–3), size (0–3), and extent (0, 2, or 3). In addition, the Dermatology Life Quality Index (DLQI) before and four months following the final laser treatment session was administered to the",9_10,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"laser treatment session was administered to the patient in order to assess the patient's level of satisfaction. The final DLQI score ranges from 0 (no impact on quality of life) to 30 (maximum impairment). Following combined laser therapy, most of the facial angiofibromas have shown remarkable improvement in redness and size. After 4 months from the last laser treatment session, most of the facial erythematous and protruding lesions had improved, as clearly shown in <xref rid=""fig1"" ref-type=""fig"">Figure",9_11,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"shown in <xref rid=""fig1"" ref-type=""fig"">Figure 1</xref>. The PDL laser treatment interval was extended to a monthly frequency of 6 months as a maintenance therapy to avoid the reappearance of angiofibromas. Following these procedures, the patient did not experience complications or severe adverse reaction. Intense purpura on the face was observed immediately after the dye laser procedure (<xref rid=""fig2"" ref-type=""fig"">Figure 2</xref>), but these conditions considerably disappeared after a week. FASI",9_12,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"considerably disappeared after a week. FASI indicates that all variables (redness, size, and extension) in our clinical image were considerably improved. The FASI score decreased from 9 at the baseline to 0 at four months of follow-up from the last laser treatment session. DLQI scores varied from 25 at the baseline to 2 at four months follow-up from the last laser treatment session indicating a marked impairment on patient's quality of life following the laser therapy. At postoperative therapy, healing",9_13,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"laser therapy. At postoperative therapy, healing creams based on hyaluronic acid and an antibiotic cream were applied to the patient's face after careful cleaning of the wounds with gauze and saline solution. During and after the research study period, patients were also instructed to limit further photodamage by using sunscreen with a 50-sun protection factor. In conjunction with maintenance treatment with dye laser, the use of topical rapamycin can be recommended to the patient in order to avoid the",9_14,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"recommended to the patient in order to avoid the return of the vascular symptoms of angiofibromas. A laser combination therapy may be required for patients affected by angiofibromas [<xref rid=""B9"" ref-type=""bibr"">9</xref>]. Multiple laser treatment has been shown to reduce the risk of dyspigmentation and scarring while maximizing the therapeutic efficacy of each modality [<xref rid=""B13"" ref-type=""bibr"">13</xref>]. Among these, the combination of PDL laser and the CO<sub>2</sub> laser was successfully",9_15,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"and the CO<sub>2</sub> laser was successfully tested [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. PDL by targeting the vascular components of the FAs lesions, it is able to improve erythema in more than 90% of patients with predominant vascular components but without decreasing the fibrous component [<xref rid=""B9"" ref-type=""bibr"">9</xref>]. For this purpose, the ablative CO<sub>2</sub> laser therapy has been used for its effectiveness in reducing the size of the fibrous component compared with PDL. Indeed,",9_16,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"the fibrous component compared with PDL. Indeed, elevated lesions have been flattened using the CO<sub>2</sub> laser since it is the best option for accurate, safe ablation with good hemostasis; by creating a matrix-shaped microthermal damage, fractional CO<sub>2</sub> lasers stimulate the basic repair process in the dermis and in the epidermis, leading to skin regeneration and repairing. The present case report confirms the effectiveness of this combined laser technique where the global improvement of the",9_17,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"technique where the global improvement of the functional and aesthetic patient-reported outcomes was done by the CO<sub>2</sub> healing process through excision and tissue regeneration and the action of the nonablative 595 nm laser, which provides more control over the healing process. Our findings showed a great improvement of patient's skin lesions, and the results were evident immediately after the first treatment. All erythematous and prominent papules have exhibited notable improvements in size and",9_18,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"have exhibited notable improvements in size and redness at four months after the last laser therapy session as documented by clinical images and FASI results. According to DLQI scores, the results achieved after treatment at the follow-up revealed that the condition has completely lost its negative impact on the daily lives of the patient. Furthermore, the patient did not experience complications or recurrence. Usually, the rapamycin may have had an additive effect in lesion regression and maintenance due",9_19,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"effect in lesion regression and maintenance due to its antiangiogenic activity and by blocking proliferation of abnormal fibroblasts [<xref rid=""B22"" ref-type=""bibr"">22</xref>]. However, prospective research including 25 TS patients showed that topical rapamycin cream maintenance treatment administered three times a week was ineffective in preventing TSC recurrence [<xref rid=""B23"" ref-type=""bibr"">23</xref>]. Consequently, in our study, as a primary choice, we favoured the use of dye laser as a maintenance",9_20,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"we favoured the use of dye laser as a maintenance therapy to avoid the reappearance of FAs. However, under medical evaluation, in conjunction with maintenance treatment with dye laser, the topical rapamycin can be administered. In contrast in the study of Neamonitou et al. [<xref rid=""B24"" ref-type=""bibr"">24</xref>], patients who manifest recurrence were retreated with CO<sub>2</sub> laser. This research was not in line with our study protocol as the subjects received a triple laser therapy (CO<sub>2</sub>",9_21,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"received a triple laser therapy (CO<sub>2</sub> laser, erbium laser, and PDL) in one session, achieving good results. However, the CO<sub>2</sub> laser employed in our research offers an innovative technology which permits users to simulate the Er-YAG laser effect by modulating the power and pulse parameters. In this way, we can reduce the coagulative effect in order to obtain a superficial skin resurfacing and a reduction of skin lesion thickness. It represents a noninvasive and not painful technology",9_22,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"a noninvasive and not painful technology that did not require the use of anaesthesia, which is instead used in other studies [<xref rid=""B24"" ref-type=""bibr"">24</xref>, <xref rid=""B25"" ref-type=""bibr"">25</xref>]; this makes the system also suitable to treat individuals who exhibit neurological signs, such as our clinical case. A multiple combined session of different lasers was also used in the study of Fioramonti et al. [<xref rid=""B17"" ref-type=""bibr"">17</xref>] where all patients showed great",9_23,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"where all patients showed great improvement of their skin lesions with no complications or recurrence. The absence of skin biopsy specimen examination of the face papules and a longer follow-up period in order to monitor the recurrence rate were the primary study limitations. In conclusion, the combined use of the CO<sub>2</sub> and dye laser has been proved to be a safe and effective treatment for multiple FAs in the young patient affected by tuberous sclerosis.",9_24,Effective Technique Using Combined CO<sub>2</sub> Laser and Pulsed Dye Laser for Facial Angiofibromas Management in Tuberous Sclerosis,2024,,Tuberous_Sclerosis
"Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report Lymphangioleiomyomatosis (LAM) is a rare lung disease that primarily affects women. A patient with a medical history of Tuberous Sclerosis-Associated Lymphangioleiomyomatosis (TSC-LAM), a prior thyroidectomy for thyroid cancer, chronic hypertension, and a previous pulmonary thromboembolism was admitted to the hospital. Following the stabilization of her clinical condition, diaphragmatic",10_0,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"of her clinical condition, diaphragmatic exercises and incentive spirometers were implemented. This intervention significantly enhanced her respiratory status, prevented the need for invasive mechanical ventilation, and expediting pulmonary functional recovery. While further studies are needed, pulmonary rehabilitation has the potential to influence the clinical course of TSC-LAM patients in the ICU by improving respiratory capacity and reducing hospitalization time. Tuberous Sclerosis-Associated Pulmonary",10_1,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"time. Tuberous Sclerosis-Associated Pulmonary Lymphangioleiomyomatosis (TSC-LAM) is a rare condition characterized by the formation of benign tumors in multiple organs, especially in the lungs. This condition can occur sporadically (S-LAM) or in association with tuberous sclerosis complex (TSC-LAM) [<xref rid=""bib1"" ref-type=""bibr"">1</xref>]. Despite the European Respiratory Society acknowledging pulmonary rehabilitation as a means to manage dyspnea in LAM [<xref rid=""bib2"" ref-type=""bibr"">2</xref>], there",10_2,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"rid=""bib2"" ref-type=""bibr"">2</xref>], there is a shortage of literature specifically addressing physiotherapy approaches for LAM patients. Pulmonary rehabilitation has demonstrated a positive impact on the quality of life for individuals with chronic respiratory diseases. Although it is usually implemented post-hospital discharge [<xref rid=""bib3"" ref-type=""bibr"">3</xref>], the available literature on this topic remains limited [<xref rid=""bib4"" ref-type=""bibr"">4</xref>]. We present a case in which a",10_3,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"We present a case in which a patient received pulmonary rehabilitation therapy in the Intensive Care Unit (ICU), leading to a rapid recovery and improvement over time. A woman in her 30s presented at the emergency unit with dyspnea and subcostal retractions. Upon admission, her vital signs were as follows: blood pressure of 130/70, heart rate of 110, respiratory rate of 30, and oxygen saturation of 74 %. Physical examination revealed crackles in the pulmonary fields, predominantly at the posterior left",10_4,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"fields, predominantly at the posterior left base. Additionally, a pericardial friction rub was noted, with no apparent electrocardiographic changes. Furthermore, findings from the physical examination included angiofibromas on the face and neck. The patient received a TSC-LAM diagnosis six years ago and has been on continuous treatment, managed with prednisone 50mg (one tablet orally each day) and budesonide/formoterol (2 puffs every 12 hours). In the same year, she underwent a thyroidectomy due to a",10_5,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"same year, she underwent a thyroidectomy due to a history of thyroid cancer and manages this with levothyroxine (one tablet orally each day) for hypothyroidism, along with secondary post-surgical hypoparathyroidism. Two years after the TSC-LAM diagnosis, she developed and received treatment for chronic arterial hypertension, managed with irbesartan 300 mg (one tablet orally each day), plus amlodipine 5 mg (one tablet orally each day). One year before the current presentation, she experienced a pulmonary",10_6,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"current presentation, she experienced a pulmonary thromboembolism, which is being treated with rivaroxaban (one tablet orally each day) and gabapentin (one tablet orally each day). Her gynecological and obstetric history includes zero pregnancies and zero vaginal deliveries, with a history of dysmenorrhea and menarche at 13 years old. Additionally, it's noteworthy that she had been hospitalized just a week earlier due to an ulcer related to deep venous insufficiency. Laboratory test results revealed a",10_7,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"insufficiency. Laboratory test results revealed a leukogram with neutrophilia greater than 90 %, hyperfibrinogenemia, elevated D-dimer, and elevated ProBNP. Consequently, the patient was transferred to the Intensive Care Unit (ICU). A high-flow nasal cannula was placed at a flow rate of 60 L/minute with an FiO2 of 100 %, resulting in improved oxygen saturation (93 %), and a gradual reduction of subcostal retractions and dyspnea. Bronchodilators and steroids were prescribed, and Piperacillin/Tazobactam",10_8,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"were prescribed, and Piperacillin/Tazobactam (4.5 g IV every 6 hours) was initiated due to suspected pneumonia. A high-resolution computed tomography (HRCT) scan was performed, which showed generalized thickening of interstitial septa, panlobular emphysema, and a subpleural basal left bulla (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>a, left). Moreover, the presence of pericardial effusion was detected (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>b, right), and it was treated with diuretics.<fig",10_9,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"right), and it was treated with diuretics.<fig id=""fig1""><label>Fig. 1</label><caption><p>a) HRCT shows septal thickening, panlobular emphysema and a subpleural basal left bulla. b) Tomographic scan revealing the presence of pericardial effusion. c) Renal cysts with hematuria remnants are observed in the middle third of both the right and left kidneys. An adenopathy is observed at the aorto-caval region.</p></caption><alt-text id=""alttext0010"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink",10_10,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""></graphic></fig> On the third day, <italic toggle=""yes"">Klebsiella pneumoniae</italic> ESBL+ was detected in a bronchial secretion culture (MALDI-TOF MS Biotyper), necessitating a switch to Meropenem (1 g intravenous (for 3 hours) every 8 hours). On that same day, pulmonary rehabilitation was initiated with diaphragmatic exercises. No inspiratory exercises with CPAP (continuous positive airway pressure) were performed due to the presence of a",10_11,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"pressure) were performed due to the presence of a posterior giant bulla. On the fourth day, the patient was successfully transitioned to a Venturi mask (50 %). On the tenth day, a thoraco-abdominal CT scan was conducted, detecting renal cysts with hematic and perirenal fat remnants, resembling a cobweb-like appearance in both kidneys. An infiltrative-appearing lymphadenopathy at the aorto-caval interface was also identified (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>c). Respiratory exercises were",10_12,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"1</xref>c). Respiratory exercises were initiated in conjunction with the antibiotic treatment. These exercises started on the third day, and this program was implemented for the patient. Initially, it was administered once daily for a maximum of 20 minutes, adjusted according to the patient's tolerance and clinical advancement. Subsequently, the frequency of these exercises was gradually increased to twice daily, with a maximum duration of 45 minutes. Following improvement in the acute phase, the practice",10_13,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"improvement in the acute phase, the practice was restricted to a maximum of two sessions per day, each lasting 5 minutes for each type of exercise. The initial exercise centered on thoracic expansion, guiding the patient to inhale deeply while applying moderate pressure with their hands to expand the thoracic area. This procedure was supplemented by a brief pause in maximal inspiration, succeeded by a gradual exhalation. The second exercise, conducted in a supine position, emphasized abdominal breathing.",10_14,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"supine position, emphasized abdominal breathing. The patient took a deep breath through the nose, allowing the abdomen to press against the hand, and exhaled through pursed lips. The third exercise, referred to as pursed-lip breathing, entailed a gradual nasal inhalation with the mouth closed, succeeded by exhalation through partially closed lips, maintaining a duration ratio of twice the inspiration. The fourth exercise, diaphragmatic breathing, was conducted while seated. The patient inhaled deeply",10_15,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"while seated. The patient inhaled deeply through the nose with a closed mouth, followed by a slow and gentle exhalation through slightly parted lips, allowing the abdominal muscles to return to their initial position. The fifth exercise, aimed at lung expansion, required the patient to inhale deeply while applying pressure to the chest with their hands, followed by a controlled exhalation. At the end of exhalation, a gentle vibration was applied over the area. The sixth exercise, focusing on effective and",10_16,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"The sixth exercise, focusing on effective and controlled coughing, involved a deep breath followed by controlled exhalation, incorporating short and forceful coughs. The seventh exercise integrated the use of an upright incentive spirometer. The patient sealed their lips around the mouthpiece, took a deep breath, raising the marker to its upper limit, maintaining it there for as long as possible before releasing the mouthpiece and exhaling. Coughing was recommended after each session of this exercise.",10_17,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"recommended after each session of this exercise. After 21 days in the ICU, the patient moved to intermediate care for one day and then to internal medicine. Upon discharge, she received prescriptions for oral and inhaled medications along with diaphragmatic exercises. In patients with acute LAM caused by infections, it is essential to detect and treat infections early due to the high risk of developing acute respiratory failure and requiring mechanical ventilation. Consequently, timely treatment of",10_18,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"ventilation. Consequently, timely treatment of infections plays a fundamental role in this population. Chylothorax or pneumothorax complicating LAM requires surgical intervention, whereas lung transplantation becomes imperative in cases of advanced-stage LAM [<xref rid=""bib5"" ref-type=""bibr"">5</xref>]. The main treatment for LAM is mTORC1 inhibition with medications such as sirolimus, which stabilizes lung function and reduces the size of lung destruction, lymphangioleiomyomas (LLM), angiomyolipomas (AML),",10_19,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"(LLM), angiomyolipomas (AML), chylous effusions, and giant cell astrocytomas [<xref rid=""bib6"" ref-type=""bibr"">6</xref>,<xref rid=""bib7"" ref-type=""bibr"">7</xref>]. We conducted a search on PubMed (Medline) for the past 20 years (until March 16, 2024), focusing on reviews and original research papers related to lymphangioleiomyomatosis, published in English. We employed the terms ""lymphangioleiomyomatosis,"" ""LAM,"" and ""lymphangiomyomatosis"" in combination with ""tuberous sclerosis complex,"" ""TSC-LAM,”",10_20,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"with ""tuberous sclerosis complex,"" ""TSC-LAM,” ""pulmonary rehabilitation,"" "" exercise,” and ""physiotherapy."" A total of 18 papers meeting the criteria were identified. Most of these studies focus on exercise in the context of assessing functional capacity (13 papers). An example is the study conducted by Medeiros et al. [<xref rid=""bib8"" ref-type=""bibr"">8</xref>], which addresses the evaluation of sleep desaturation in patients with LAM and its correlation with various functional parameters. Furthermore,",10_21,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"with various functional parameters. Furthermore, Zafar et al. [<xref rid=""bib9"" ref-type=""bibr"">9</xref>] conducted low-intensity and progressive exercise echocardiograms on patients using an incremental protocol with a supine ergometer. This form of exercise echocardiography was employed to assess exercise-induced pulmonary hypertension, intracardiac shunts, and pulmonary vascular shunts in dyspneic patients. The document emphasizes the unexpected occurrence of intrapulmonary arteriovenous shunts (IPAVS)",10_22,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"of intrapulmonary arteriovenous shunts (IPAVS) in this patient group and underscores the need for further studies to comprehend the implications of these findings on desaturation, dyspnea, and exercise limitation. Additionally, Taveira-DaSilva et al. [<xref rid=""bib10"" ref-type=""bibr"">10</xref>] noted that the risk of pneumothorax associated with pulmonary function tests (PFT) or cardiopulmonary exercise tests (CPET) in patients with lymphangioleiomyomatosis (LAM) is low. The study involved 691 patients.",10_23,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"(LAM) is low. The study involved 691 patients. The research concludes that, although the risk is low, efforts associated with these tests may lead to pneumothorax, especially in patients with cystic lung diseases like LAM. Other papers focus on cardiopulmonary rehabilitation programs in stable patients. Initially, five studies met the criteria, and two were selected to avoid duplicative information (<xref rid=""tbl1"" ref-type=""table"">Table 1</xref>). Aerobic and strength training exercises are commonly used",10_24,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"and strength training exercises are commonly used as physiotherapy modalities in the rehabilitation of individuals with pulmonary disease [<xref rid=""bib11"" ref-type=""bibr"">11</xref>]. No documented cases have been found where individualized pulmonary rehabilitation was implemented in the ICU for patients with TSC-LAM.<table-wrap position=""float"" id=""tbl1""><label>Table 1</label><caption><p>Reports on the rehabilitation of Pulmonary Lymphangioleiomyomatosis.</p></caption><alt-text id=""alttext0015"">Table",10_25,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"id=""alttext0015"">Table 1</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Author, (year).</th><th>Country</th><th>Number of patients</th><th>Type of exercise</th><th>Main outcomes</th></tr></thead><tbody><tr><td align=""left"">Child et al. [<xref rid=""bib4"" ref-type=""bibr"">4</xref>]<break></break>2023</td><td align=""left"">United States of America</td><td align=""left"">15</td><td align=""left"">Aerobic and strength training</td><td align=""left"">The program improved submaximal exercise capacity,",10_26,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"program improved submaximal exercise capacity, muscular endurance, fatigue, and health-related quality of life in patients with LAM.<break></break>The program achieved high adherence, acceptability, and patient satisfaction, and no adverse events related to the study or changes in systemic inflammation or cardiac wall stress biomarkers were observed.</td></tr><tr><td rowspan=""4"" align=""left"">Medeiros et al. [<xref rid=""bib5"" ref-type=""bibr"">5</xref>]<break></break>2022</td><td align=""left"">Brazil [<xref",10_27,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"align=""left"">Brazil [<xref rid=""bib12"" ref-type=""bibr"">12</xref>]</td><td align=""left"">40</td><td align=""left"">Aerobic and muscle strength training sessions</td><td rowspan=""4"" align=""left"">The analyzed studies suggest that a cardiopulmonary rehabilitation program, encompassing both aerobic and strength training, stands out as the primary physiotherapeutic approach capable of improving lung function and exercise tolerance in individuals with LAM.</td></tr><tr><td align=""left"">United States of America",10_28,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"align=""left"">United States of America [<xref rid=""bib13"" ref-type=""bibr"">13</xref>]</td><td align=""left"">1</td><td align=""left"">Supervised aerobic exercise training</td></tr><tr><td align=""left"">China [<xref rid=""bib14"" ref-type=""bibr"">14</xref>]</td><td align=""left"">26</td><td align=""left"">24-week program of yoga class training</td></tr><tr><td align=""left"">Germany [<xref rid=""bib15"" ref-type=""bibr"">15</xref>]</td><td align=""left"">58</td><td align=""left"">Endurance and strength",10_29,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"align=""left"">Endurance and strength training</td></tr></tbody></table></table-wrap> Although there is no specific cardiopulmonary rehabilitation guideline for LAM, the European Respiratory Society asserts that the benefits of rehabilitation in COPD can be extrapolated to LAM [<xref rid=""bib16"" ref-type=""bibr"">16</xref>]. There is a scarcity of literature specifically addressing physiotherapy approaches for LAM patients. The trend is towards using remote technology, as well as the Internet of Things (IoT),",10_30,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"as well as the Internet of Things (IoT), to develop supervised home exercise programs for patients with pulmonary diseases [<xref rid=""bib17"" ref-type=""bibr"">17</xref>]. The main difference in this case, compared to interstitial lung disease (ILD) and COPD, was the early initiation of exercises, which were implemented during the first days of antibiotic treatment. The antibiotic regimen was not completed before starting; only hemodynamic stability and the absence of accessory muscle use during exercises",10_31,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"absence of accessory muscle use during exercises were considered. Additionally, unlike ILD and COPD, no inspiratory exercises were performed with CPAP or an incentive spirometer [<xref rid=""bib18"" ref-type=""bibr"">18</xref>,<xref rid=""bib19"" ref-type=""bibr"">19</xref>]. This decision was based on the individualization of the case, considering the weakened alveolar walls due to LAM and the patient's history of spontaneous pneumothorax. The program was adjusted according to the disease's pathophysiology. The",10_32,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"according to the disease's pathophysiology. The analysis of the reviewed studies indicates that a cardiopulmonary rehabilitation program for individuals with LAM, incorporating aerobic exercises and strength training, leads to improved pulmonary function, enhanced exercise tolerance, decreased dyspnea, and contributes to an overall improvement in quality of life. In summary, for patients with TSC-LAM, starting pulmonary rehabilitation early in the ICU, once the clinical condition stabilizes, should lead to",10_33,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"the clinical condition stabilizes, should lead to a quicker improvement in respiratory function compared to delayed implementation. However, further research on this topic is needed. Respiratory muscle exercises and strengthening of the thoracic cavity contribute to improving ventilatory function. Additionally, the early application of rehabilitation has been observed to correlate with a reduction in hospitalization days and the need for supplemental oxygen. No funding from an external source supported the",10_34,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"No funding from an external source supported the publication of this case report. <bold>Flor Castro-Rodriguez:</bold> Writing – review & editing, Writing – original draft, Supervision, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Yakdiel Rodriguez-Gallo:</bold> Writing – review & editing, Writing – original draft, Resources, Methodology, Investigation, Formal analysis, Conceptualization. The authors declare that they have no known competing financial interests or personal",10_35,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,10_36,Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report,05 10 2024,,Tuberous_Sclerosis
"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex Tuberous Sclerosis Complex (TSC), an autosomal dominant condition, is caused by heterozygous mutations in either the <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> genes, manifesting in systemic growth of benign tumors. In addition to brain lesions, neurologic sequelae represent the greatest",11_0,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"neurologic sequelae represent the greatest morbidity in TSC patients. Investigations utilizing <italic toggle=""yes"">TSC1/2</italic>-knockout animal or human stem cell models suggest that TSC deficiency-causing hyper-activation of mTOR signaling might precipitate anomalous neurodevelopmental processes. However, how the pathogenic variants of <italic toggle=""yes"">TSC1/2</italic> genes affect the longitudinal trajectory of human brain development remains largely unexplored. Here, we employed 3-dimensional",11_1,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"unexplored. Here, we employed 3-dimensional cortical organoids derived from induced pluripotent stem cells (iPSCs) from TSC patients harboring <italic toggle=""yes"">TSC2</italic> variants, alongside organoids from age- and sex-matched healthy individuals as controls. Through comprehensively longitudinal molecular and cellular analyses of TSC organoids, we found that <italic toggle=""yes"">TSC2</italic> pathogenic variants dysregulate neurogenesis, synaptogenesis, and gliogenesis, particularly for reactive",11_2,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"and gliogenesis, particularly for reactive astrogliosis. The altered developmental trajectory of TSC organoids significantly resembles the molecular signatures of neuropsychiatric disorders, including autism spectrum disorders, epilepsy, and intellectual disability. Intriguingly, single cell transcriptomic analyses on TSC organoids revealed that <italic toggle=""yes"">TSC2</italic> pathogenic variants disrupt the neuron/reactive astrocyte crosstalk within the NLGN-NRXN signaling network. Furthermore,",11_3,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"the NLGN-NRXN signaling network. Furthermore, cellular and electrophysiological assessments of TSC cortical organoids, along with proteomic analyses of synaptosomes, demonstrated that the <italic toggle=""yes"">TSC2</italic> variants precipitate perturbations in synaptic transmission, neuronal network activity, mitochondrial translational integrity, and neurofilament formation. Notably, similar perturbations were observed in surgically resected cortical specimens from TSC patients. Collectively, our study",11_4,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"from TSC patients. Collectively, our study illustrates that disease-associated <italic toggle=""yes"">TSC2</italic> variants disrupt the neurodevelopmental trajectories through perturbations of gene regulatory networks during early cortical development, leading to mitochondrial dysfunction, aberrant neurofilament formation, impaired synaptic formation and neuronal network activity. Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder caused by heterozygous pathogenic variants in the <italic",11_5,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"heterozygous pathogenic variants in the <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> genes. It affects multiple organ systems including the brain, skin, kidneys, and lungs, leading to a diverse range of clinical manifestations <sup><xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3"" ref-type=""bibr"">3</xref></sup>. In addition to the brain lesions such as cortical tubers, subependymal nodules, and subependymal giant cell astrocytoma, TSC causes significant neurologic morbidity",11_6,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"TSC causes significant neurologic morbidity and mortality typically due to epilepsy, autism spectrum disorders (ASD), intellectual disability, and TSC-associated neuropsychiatric disorders <sup><xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R4"" ref-type=""bibr"">4</xref>–<xref rid=""R6"" ref-type=""bibr"">6</xref></sup>. However, even patients without tubers can exhibit significant developmental deficits <sup><xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R8"" ref-type=""bibr"">8</xref></sup>, including",11_7,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">8</xref></sup>, including intellectual disability and autism, suggesting that neurological manifestations in TSC might stem from broader neurodevelopmental disruptions that extend beyond the visible lesions typically associated with the disorder and these symptoms may arise from mechanisms independent of cortical tubers. While neurological manifestations of TSC typically emerge in late adolescence to early adulthood <sup><xref rid=""R9"" ref-type=""bibr"">9</xref></sup>, it is posited that the",11_8,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"it is posited that the etiology is rooted in detrimental neuropathological events occurring during the early stages of brain development <sup><xref rid=""R10"" ref-type=""bibr"">10</xref></sup>. Despite significant advancements in elucidating the signaling pathways underlying TSC in animal models of <italic toggle=""yes"">TSC1/TSC2</italic> deficiency, the impact of disease-associated <italic toggle=""yes"">TSC1</italic> and <italic toggle=""yes"">TSC2</italic> variants on human brain development remains elusive.",11_9,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"on human brain development remains elusive. This gap in knowledge largely stems from the challenges in acquiring live, developing human cortical tissues for study. Human induced pluripotent stem cells (iPSCs), which capture identical risk alleles as the donor individual and have the capacity to differentiate into a myriad of human cell type, offer an unprecedented opportunity to recapitulate both normal and pathologic human development. Recent studies utilizing human iPSC models, including two-dimensional",11_10,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"human iPSC models, including two-dimensional cultures of neural progenitor cells (NPCs), neurons, or astrocytes, as well as three-dimensional brain organoids, have identified certain developmental impairments linked to TSC deficiency <sup><xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R11"" ref-type=""bibr"">11</xref>–<xref rid=""R18"" ref-type=""bibr"">18</xref></sup>. For instance, Eichmüller et al. identified caudal late interneuron progenitor (CLIP) cells as key contributors to cortical malformations and",11_11,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"as key contributors to cortical malformations and brain tumors in TSC <sup><xref rid=""R15"" ref-type=""bibr"">15</xref></sup>. However, these studies have predominantly concentrated on singular developmental stages or exclusively on atypical cell proliferation. A more thorough assessment of the effects of pathogenic <italic toggle=""yes"">TSC1</italic> and <italic toggle=""yes"">TSC2</italic> variants on the molecular and cellular progressions of human brain development is imperative. Such research is crucial for",11_12,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"is imperative. Such research is crucial for uncovering the underlying mechanisms of neuropsychiatric symptoms in TSC and for the identification of novel therapeutic targets. In this study, we developed human cortical organoids from patient-derived iPSCs carrying <italic toggle=""yes"">TSC2</italic> pathogenic variants and age- and sex-matched healthy controls, as well as three isogenic lines by introducing patient-specific <italic toggle=""yes"">TSC2</italic> variants into a wildtype control iPSC line.",11_13,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"variants into a wildtype control iPSC line. Longitudinal transcriptomic analysis of these cortical organoids, conducted at four distinct developmental stages, revealed disrupted developmental trajectories in TSC, encompassing critical processes such as neurogenesis, synaptogenesis, and gliogenesis. The divergent developmental trajectory observed in TSC organoids notably mirrors the molecular signatures characteristic of various neuropsychiatric disorders, including ASDs, epilepsy, and intellectual",11_14,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"including ASDs, epilepsy, and intellectual disability. Utilizing single-cell level analysis of cell-cell communication, we found that pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt intercellular interactions, specifically targeting neuron/reactive astrocyte communication within the NLGN-NRXN signaling network. Moreover, comprehensive cellular and electrophysiological evaluations of TSC cortical organoids, combined with in-depth proteomic analyses of synaptosomes, revealed that pathogenic",11_15,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"of synaptosomes, revealed that pathogenic <italic toggle=""yes"">TSC2</italic> variants induce disturbances in mitochondrial translational integrity, neurofilament formation, synaptic transmission, and the overall activity of neuronal networks. Notably, increased neurofilament formation, compromised mitochondrial integrity, and enhanced synapse formation were observed in cortical specimens surgically excised from TSC patients, underscoring their direct association with pathogenic <italic",11_16,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"their direct association with pathogenic <italic toggle=""yes"">TSC2</italic> variants. In summary, our study demonstrates that <italic toggle=""yes"">TSC2</italic> pathogenic variants disrupt the neurodevelopmental trajectories through perturbations of gene regulatory networks during early cortical development, leading to mitochondrial dysfunction, aberrant neurofilament formation, impaired synaptic formation, and compromised neuronal network activity.  Although substantial advancements have been achieved in",11_17,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"substantial advancements have been achieved in comprehending TSC signaling pathways in animal models, the precise effects of pathogenic <italic toggle=""yes"">TSC1/2</italic> variants on the progression of human brain development are still largely unclear. In this study, by conducting a thorough and longitudinal multi-omics and cellular analyses of TSC organoids, we demonstrate for the first time that pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt the neurodevelopmental trajectories through",11_18,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"the neurodevelopmental trajectories through perturbations of gene regulatory networks and cell-cell communications during early cortical development, leading to mitochondrial abnormalities, aberrant neurofilament formation, and impaired synaptic formation and neuronal network activity. Importantly, the key findings in TSC cortical organoids, particularly the mitochondrial abnormalities, elevated neurofilament levels, and increased synapse formation were corroborated in surgically removed cortical tissues",11_19,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"in surgically removed cortical tissues from TSC-affected brains. This validation underscores the significance of human iPSC-derived brain organoids as effective models for studying neuropsychiatric disorders. Brain development is characterized by a series of dynamic, distinct phases. Through longitudinal transcriptomic investigations, we can examine the modulation of gene regulatory networks by <italic toggle=""yes"">TSC2</italic> variants across developmental stages. This insight is vital for delineating",11_20,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"stages. This insight is vital for delineating the specific temporal and consequential impacts of these genetic modifications. We identified the highest number of DEGs on day 35 (<xref rid=""F1"" ref-type=""fig"">Fig. 1c</xref>–<xref rid=""F1"" ref-type=""fig"">d</xref>), suggesting that the impact of <italic toggle=""yes"">TSC2</italic> variants on the disease originates at an early stage. This knowledge is imperative for the strategic timing of therapeutic interventions to coincide with the most vulnerable phases",11_21,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"to coincide with the most vulnerable phases of cerebral development. Strikingly, the differentially expressed genes that keep increasing during development in TSC organoids are strongly associated with nervous system development and synaptic transmission. Indeed, TSC organoids exhibited accelerated differentiation of excitatory neurons, increased synapse formation, and hyperactive neuronal network activity. Conversely, the differentially expressed genes that were concomitantly decreasing in TSC organoids",11_22,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"were concomitantly decreasing in TSC organoids are largely enriched in cell cycle, DNA repair, and chromosomal functions (<xref rid=""F1"" ref-type=""fig"">Fig. 1i</xref>–<xref rid=""F1"" ref-type=""fig"">j</xref>). Therefore, <italic toggle=""yes"">TSC2</italic> variants significantly disrupt the developmental trajectories of the central nervous system. Mutations in the <italic toggle=""yes"">TSC2</italic> gene are implicated in the pathogenesis of TSC, predisposing individuals to a spectrum of neurological",11_23,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"individuals to a spectrum of neurological manifestations such as ASDs, epilepsy, intellectual disabilities, and TSC-associated neuropsychiatric disorders (TAND). Additionally, we identified that downregulated DEGs in TSC organoids are enriched in cytosolic ribosomes (<xref rid=""F3"" ref-type=""fig"">Fig. 3f</xref>), while downregulated DEPs in synaptosomes of TSC are enriched in mitochondrial ribosomes (<xref rid=""F5"" ref-type=""fig"">Fig. 5f</xref>). Furthermore, NLGN1 target genes include several ribosomal",11_24,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"NLGN1 target genes include several ribosomal protein genes (<xref rid=""F4"" ref-type=""fig"">Fig. 4e</xref>–<xref rid=""F4"" ref-type=""fig"">f</xref>). Ribosomal impairments and deficits in ribosome production have been observed in a range of neurodegenerative diseases, including Alzheimer’s, Huntington’s, amyotrophic lateral sclerosis (ALS), and frontotemporal lobe dementia (FTLD) <sup><xref rid=""R46"" ref-type=""bibr"">46</xref>–<xref rid=""R49"" ref-type=""bibr"">49</xref></sup>. These disruptions affect protein",11_25,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"These disruptions affect protein synthesis, contributing to the cellular dysfunction and degeneration characteristic of these disorders. This suggests that reduced ribosomal biogenesis may also contribute to the onset and progression of neurodevelopmental disorders. Our longitudinal transcriptomic analyses reveal marked disparities in the temporal expression patterns of genes linked to neurodevelopmental and neuropsychiatric disorders within TSC organoids. These findings illuminate the molecular pathways",11_26,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"These findings illuminate the molecular pathways affected by such variants, providing a deeper understanding of the pathophysiology underlying tuberous sclerosis complex. One hallmark we observed in TSC organoids is the increase of gliogenesis, in particular, reactive astrocytes. Indeed, analyses of postmortem tissues have revealed a pronounced accumulation of reactive astrocytes within the cortical and subcortical white matter regions of brains affected by TSC <sup><xref rid=""R50""",11_27,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"of brains affected by TSC <sup><xref rid=""R50"" ref-type=""bibr"">50</xref></sup>. Yet, the question remains whether the proliferation of reactive astrocytes in the TSC-afflicted brain arises as a secondary effect of cerebral lesions, including cortical tubers, subependymal nodules, and subependymal giant cell astrocytomas, or stems from mechanisms independent of tuber/tumor formation. Previous studies noted that astrocytes lacking <italic toggle=""yes"">TSC2</italic> expression or derived from TSC patients",11_28,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"expression or derived from TSC patients exhibit a higher saturation density and manifest enhanced proliferative behavior relative to control astrocytes <sup><xref rid=""R12"" ref-type=""bibr"">12</xref>,<xref rid=""R13"" ref-type=""bibr"">13</xref></sup>. Aligned with these studies, we observed increased levels of NNAT and S100B, markers for early-stage and mature astrocytes, respectively, in TSC organoids throughout development. Furthermore, cell type composition analysis conducted on single-cell RNA sequencing",11_29,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"analysis conducted on single-cell RNA sequencing datasets from TSC organoids corroborates the elevation of reactive astrocytes within these organoids (<xref rid=""F3"" ref-type=""fig"">Fig. 3b</xref>). Considering the absence of cortical tubers/tumors in TSC organoids during these developmental stages, our results imply that the proliferation of reactive astrocytes in brains affected by TSC originates intrinsically from the gene regulatory networks driven by <italic toggle=""yes"">TSC2</italic> pathogenic",11_30,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"by <italic toggle=""yes"">TSC2</italic> pathogenic variants, independent of tuber/tumor formation. This indicates a fundamental pathological process at play, distinct from the structural abnormalities traditionally associated with TSC, offering new insights into the disease’s etiology and potential therapeutic targets. Astrocytes are integral to the overall homeostasis of the brain’s microenvironment, influencing neuronal development and health, synaptic communication, and, ultimately, cognitive functions",11_31,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"and, ultimately, cognitive functions <sup><xref rid=""R51"" ref-type=""bibr"">51</xref>–<xref rid=""R53"" ref-type=""bibr"">53</xref></sup>. Neuron-astrocyte interactions are essential not only for the formation and maintenance of synapses but also for their dynamic modulation in response to neuronal activity <sup><xref rid=""R54"" ref-type=""bibr"">54</xref></sup>. In this study, we demonstrated, for the first time, that <italic toggle=""yes"">TSC2</italic> pathogenic variants disrupt the crosstalk between neurons and",11_32,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"disrupt the crosstalk between neurons and reactive astrocytes through the neuroligin (NLGN)-neurexin (NRXN) signaling network. NLGN1, a high-confidence ASD risk gene <sup><xref rid=""R55"" ref-type=""bibr"">55</xref>,<xref rid=""R56"" ref-type=""bibr"">56</xref></sup>, by interacting with neurexins or other related molecules, plays a pivotal role in synapse formation, stabilization, function, and maturation <sup><xref rid=""R36"" ref-type=""bibr"">36</xref>,<xref rid=""R57"" ref-type=""bibr"">57</xref>–<xref rid=""R59""",11_33,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">57</xref>–<xref rid=""R59"" ref-type=""bibr"">59</xref></sup>. The neuroligin signaling networks not only bridge pre- and post-synaptic neurons at synapses but also modulate astrocyte-neuron crosstalk which orchestrate functional synapse assembly <sup><xref rid=""R36"" ref-type=""bibr"">36</xref>–<xref rid=""R40"" ref-type=""bibr"">40</xref></sup>. In mouse models, genetic modification of NLGNs results in ASD-like behaviors, along with a disrupted excitatory to inhibitory (E/I) balance <sup><xref",11_34,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"excitatory to inhibitory (E/I) balance <sup><xref rid=""R60"" ref-type=""bibr"">60</xref>,<xref rid=""R61"" ref-type=""bibr"">61</xref></sup>. Notably, we identified a significant upregulation of <italic toggle=""yes"">NLGN1</italic> expression in TSC organoids and the TSC human brain, along with its binding partners including <italic toggle=""yes"">NRXN1</italic>, <italic toggle=""yes"">NRXN3</italic>, <italic toggle=""yes"">CNTN4</italic>, <italic toggle=""yes"">CNTNAP2</italic>, <italic toggle=""yes"">CNTN1</italic>,",11_35,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"<italic toggle=""yes"">CNTN1</italic>, <italic toggle=""yes"">CNTN2</italic>, <italic toggle=""yes"">CNTN3</italic>, <italic toggle=""yes"">CNTN5</italic>, <italic toggle=""yes"">CNTN6</italic>, <italic toggle=""yes"">CNTNAP4</italic>, and <italic toggle=""yes"">CNTNAP5</italic> (<xref rid=""F4"" ref-type=""fig"">Fig. 4a</xref>–<xref rid=""F4"" ref-type=""fig"">b</xref> and <xref rid=""F7"" ref-type=""fig"">Fig. 7h</xref>–<xref rid=""F7"" ref-type=""fig"">k</xref>). In particular, the ligand-receptor pairs NLGN1-NRXN1, NLGN1-NRXN3,",11_36,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"ligand-receptor pairs NLGN1-NRXN1, NLGN1-NRXN3, NLGN1-CNTNAP2, and NLGN1-CNTN4 are upregulated in TSC organoids. The ligand-receptor pairs NLGN1-NRXN1 and NLGN1-NRXN3 are increased in the TSC human brain. The upregulation of NLGN1 and other molecules in TSC organoids and TSC human brain may be mediated by the cap-dependent mRNA translation through the TSC1/2-mTORC1 pathway <sup><xref rid=""R62"" ref-type=""bibr"">62</xref></sup>. Indeed, previous studies have demonstrated that enhanced cap-dependent",11_37,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"have demonstrated that enhanced cap-dependent translation results in an increase in mRNA translation and Nlgn1 protein expression in mice, correlating with ASD-related social behavior deficits <sup><xref rid=""R62"" ref-type=""bibr"">62</xref>,<xref rid=""R63"" ref-type=""bibr"">63</xref></sup>. Through the cell-cell communication analyses, we further identified that the elevated NLGN1 signaling networks disrupt the neuron-astrocyte crosstalk in TSC organoids. Notably, the increased expression of <italic",11_38,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"Notably, the increased expression of <italic toggle=""yes"">NLGN1</italic> in TSC organoids could be rescued by rapamycin treatment. These observations underscore the significance of the NLGN1-mediated signaling network in the pathology of TSC, further positing the NLGN1-mediated signaling pathway as a viable therapeutic target for interventions in TSC. Mitochondria are crucial in sustaining synaptic transmission, primarily through the generation of ATP and the regulation of intracellular calcium levels",11_39,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"the regulation of intracellular calcium levels within the synapse. Dysfunctions or defects in mitochondrial operations are poised to exert broad impacts across various aspects of synaptic plasticity <sup><xref rid=""R64"" ref-type=""bibr"">64</xref>,<xref rid=""R65"" ref-type=""bibr"">65</xref></sup>. This underscores the mitochondria’s critical role in supporting the dynamic processes underpinning synaptic adaptation and strength, highlighting how mitochondrial anomalies can disrupt the delicate balance of neural",11_40,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"can disrupt the delicate balance of neural network function and plasticity. In this study, we found impaired mitochondrial translation integrity and mitophagy in synapses of TSC organoids and surgically excised cortical tissues from TSC-affected brains. Our results are consistent with previous studies showing impaired mitochondrial homeostasis and mitophagy in <italic toggle=""yes"">Tsc1/2</italic>-deficient neurons and mouse models <sup><xref rid=""R18"" ref-type=""bibr"">18</xref></sup>. Indeed, mitochondrial",11_41,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"Indeed, mitochondrial dysfunction has been demonstrated to contribute to the etiology of neuropsychiatric disorders such as autism spectrum disorders <sup><xref rid=""R66"" ref-type=""bibr"">66</xref>,<xref rid=""R67"" ref-type=""bibr"">67</xref></sup>, highlighting the importance of mitochondrial health in maintaining neural function. Among the most striking and novel characteristics observed in both TSC organoids and brains is the pronounced increase in neurofilament formation. Within the neurons of the central",11_42,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"formation. Within the neurons of the central nervous system (CNS), neurofilaments are structured as heteropolymers composed of four subunits: NEFL (neurofilament light chain), NEFM (neurofilament medium chain), NEFH (neurofilament heavy chain), and either α-internexin or peripherin. <sup><xref rid=""R29"" ref-type=""bibr"">29</xref>–<xref rid=""R31"" ref-type=""bibr"">31</xref></sup>. Neurofilaments, as intermediate filaments, primarily provide structural support to neuronal axons, ensuring their integrity and",11_43,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"to neuronal axons, ensuring their integrity and facilitating efficient signal transmission <sup><xref rid=""R30"" ref-type=""bibr"">30</xref></sup>. Neurofilament subunits are also located in postsynaptic terminal boutons, suggesting they may have a role in modulating neurotransmission, potentially influencing synaptic efficiency and plasticity <sup><xref rid=""R30"" ref-type=""bibr"">30</xref></sup>. Among neurofilaments, NEFL has been identified as a biomarker in a range of neurological disorders <sup><xref",11_44,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"in a range of neurological disorders <sup><xref rid=""R68"" ref-type=""bibr"">68</xref></sup>. For example, a previous study observed increased NEFL levels in both cerebrospinal fluid (CSF) and blood in diseases of the CNS and peripheral nervous system linked to axonal injury or degeneration <sup><xref rid=""R69"" ref-type=""bibr"">69</xref></sup>. Notably, the cohort with TSC displayed increased levels of NEFL in CSF in comparison to healthy control individuals <sup><xref rid=""R70""",11_45,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"healthy control individuals <sup><xref rid=""R70"" ref-type=""bibr"">70</xref></sup>. In this study, we provided the first direct evidence of elevated NEFL levels in both TSC organoids and brain specimens from TSC patients, highlighting a potential biomarker for TSC-related neural pathology. Future research is required to more precisely define the impact of elevated neurofilament levels on the pathogenesis of TSC, specifically regarding its involvement in TSC-associated neuropsychiatric disorders and epilepsy.",11_46,"Longitudinal multi-omics reveals pathogenic <italic toggle=""yes"">TSC2</italic> variants disrupt developmental trajectories of human cortical organoids derived from Tuberous Sclerosis Complex",11 10 2024,,Tuberous_Sclerosis
"Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case A 24-year-old male had a history of TSC. He had DRE beginning at 2 years of age, migraines, tension headaches, and learning disability. His seizure semiologies consisted of focal impaired awareness seizures, focal to bilateral tonic-clonic seizures, as well as focal motor seizures with left eye blinking and head turn to the left with",12_0,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"left eye blinking and head turn to the left with posturing of the left upper and lower extremities. His initial seizure frequency averaged 30 episodes per month. He was trialed on multiple ASMs including oxcarbazepine, phenytoin, levetiracetam, valproic acid, zonisamide, clobazam, and everolimus without adequate relief of disabling seizures. Since 2016, he had been on eslicarbazepine acetate 1600 mg once daily and valproic acid 1500 mg twice a day. The patient’s surgical history was extensive. In 2006, he",12_1,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"surgical history was extensive. In 2006, he had left-sided grids and strips placed to localize seizure activity, which resulted in 3 tuberectomies in the left central region along the motor strip. In 2007, he underwent subependymal giant cell astrocytoma resection. In 2010, left grids and strips were placed again, resulting in the resection of another tuber, followed by VNS placement. In 2014, he again had left grids and strips placed, followed by an extensive left frontal lobe resection. At this time, his",12_2,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"left frontal lobe resection. At this time, his focal motor aware seizures occurred 2–5 times per day and focal motor unaware seizures occurred 0–3 times per week. His VNS was deactivated in 2014 at the family’s request, as the device was not providing any apparent benefit and the side effect of intermittent aphonia was burdensome to the patient. In 2016, he underwent stereoelectroencephalography (SEEG) with bilateral depth electrode placement. Based on the results of SEEG, an RNS device (NeuroPace) was",12_3,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"results of SEEG, an RNS device (NeuroPace) was placed with depth electrodes at his left motor (LM) strip, right motor (RM) strip, and left frontal opercular (LFO) region. Both motor strip electrodes were placed close to the hand regions, as these areas were most active on his SEEG (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). The LFO and RM electrodes were initially connected to the generator, and the LM electrode was capped and placed subgaleally. After this initial placement, the patient experienced",12_4,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"this initial placement, the patient experienced overall shorter and less frequent events. He experienced 12 total seizures per month lasting 10–25 seconds captured from onset in both the left frontal orbital lead and RM region lead. Clinically, the patient experienced one large cluster seizure that did not require rescue medication, and he experienced multiple smaller events with eye blinking and focal motor seizures. In response, his RNS was adjusted by increasing the current magnitude by increments of",12_5,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"increasing the current magnitude by increments of 0.5 mA (<xref rid=""tbl1"" ref-type=""table"">Table 1</xref>).",12_6,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"<fig position=""float"" fig-type=""figure"" id=""fig1""><label>FIG. 1.</label><caption><p>Postoperative computed tomography images. <bold>A:</bold> RNS generator and electrodes visualized. <bold>B:</bold> Coronal view of depth electrodes placed in the LM strip, RM strip, and LFO regions. <bold>C:</bold> Axial view of cortical and depth electrodes.</p></caption><graphic http://www.w3.org/1999/xlink href=""CASE23411_figure_1"" position=""float""></graphic></fig>",12_7,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"<table-wrap position=""float"" id=""tbl1""><label>TABLE 1.</label><caption><p>Responsive neurostimulator therapy settings in 2016 and 2018</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Responsive Therapy Setting</th><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Polarity</th><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Current (mA)</th><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Frequency",12_8,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"valign=""bottom"" rowspan=""1"" colspan=""1"">Frequency (Hz)</th><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Pulse Width (μsec)</th><th align=""center"" valign=""bottom"" rowspan=""1"" colspan=""1"">Burst Duration (μsec)</th></tr></thead><tbody><tr><td align=""left"" valign=""top"" rowspan=""1"" colspan=""1"">9/2016 to 7/2018</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">RM++++/LFO− − − − −</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">0.5 to max of 4</td><td align=""center""",12_9,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"to max of 4</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">100</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">160</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">100</td></tr><tr><td align=""left"" valign=""top"" rowspan=""1"" colspan=""1"">After revision 8/2018 to current setting</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">LFO ++++/LM− − − − −</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">0.5 to 6</td><td align=""center"" valign=""top"" rowspan=""1""",12_10,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"6</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">100</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">160</td><td align=""center"" valign=""top"" rowspan=""1"" colspan=""1"">100</td></tr></tbody></table></table-wrap> In 2017, the RM lead was no longer recording his seizures at onset despite no alteration in impedance that would cause it to stop detecting seizures, indicating that he likely developed a pattern consistent with left-sided seizure onset. Accordingly, the patient underwent lead",12_11,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"onset. Accordingly, the patient underwent lead revision to disconnect the RM electrode and instead connect the LM electrode in an attempt to elicit a more robust response. His RNS detection parameters were not changed at that time. Following this procedure, the patient was seizure free for almost 3 years. Since this LM electrode was connected to his RNS device almost 6 years ago, he has had a total of 2 days with breakthrough seizures, both instances occurring almost immediately after medication doses were",12_12,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"almost immediately after medication doses were decreased. His seizure in 2020 was captured on RNS and showed a clear left-sided onset. In 2021, 3 days after the replacement of his RNS generator and the decrease of his valproic acid dose, he had 3 closely spaced seizures. His valproic acid had been decreased from 1500 mg twice per day to 1000 mg in the morning and 1500 mg in the evening. Electroencephalography (EEG) showed onset at the Fp1-F7-T3 region (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>). The",12_13,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"rid=""fig2"" ref-type=""fig"">Fig. 2</xref>). The seizures consisted of twitching of his right face and arm, followed by whole-body shaking consistent with focal motor impaired awareness seizures. After his valproic acid dose was brought back to 1500 mg twice per day, no further seizures were captured on scalp EEG monitoring. He has had no clinical seizures in the 2 years since then.",12_14,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"<fig position=""float"" fig-type=""figure"" id=""fig2""><label>FIG. 2.</label><caption><p>Sequential panels (<bold>A</bold>–<bold>C</bold>) of EEG tracings showing a seizure that the patient had 3 days after his RNS generator change, after his divalproex dose was decreased. Note the seizure onset seen at Fp1-F7-T3 and the evolution of the seizure at F3 and C3.</p></caption><graphic http://www.w3.org/1999/xlink href=""CASE23411_figure_2"" position=""float""></graphic></fig>  Dr. Wolf reported personal fees from",12_15,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"Dr. Wolf reported personal fees from LivaNova, UCB, Monteris, and Jazz; grants for drug study from Neurelis, UCB, Longboard, and Takeda; and grants for device study from NeuroPace outside the submitted work. Ms. McGoldrick reported research support from NeuroPace, LivaNova, Neurelis, Eisai, and SK Life; being a speaker for Jazz, Neurelis, and Marinus; and being on the advisory board for Jazz. Dr. Ghatan reported being an unpaid consultant to NeuroPace. Dr. Muh reported personal fees from LivaNova and",12_16,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"Dr. Muh reported personal fees from LivaNova and Monteris outside the submitted work. Conception and design: Muh, Brabant, Wolf, McGoldrick. Acquisition of data: all authors. Analysis and interpretation of data: Brabant, Beaudreault, Wolf, McGoldrick, Ghatan. Drafting the article: Muh, Brabant, Beaudreault, Wolf, McGoldrick. Critically revising the article: all authors. Reviewed submitted version of manuscript: Muh, Brabant, Wolf, McGoldrick, Ghatan. Approved the final version of the manuscript on behalf",12_17,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"the final version of the manuscript on behalf of all authors: Muh. Administrative/technical/material support: McGoldrick. Study supervision: Muh, Wolf. Carrie R. Muh: Westchester Medical Center, Valhalla, NY. <email>carrie.muh@wmchealth.org</email>.",12_18,Responsive neurostimulation of the frontal lobe for the detection and treatment of seizures in intractable epilepsy due to tuberous sclerosis complex: illustrative case,07 10 2024,,Tuberous_Sclerosis
"Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle  Insights from the TSC2 mouse model: Common aspects and differences from the clinical manifestations. TSC is a rare genetic disorder caused heterozygous mutations in either the <italic toggle=""no"">Tsc1</italic> or <italic toggle=""no"">Tsc2</italic> genes, typically leading to serious neurologic comorbidities, such as severe epilepsy. Similar to the clinical condition,",13_0,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"epilepsy. Similar to the clinical condition, rodents with a heterozygous genotype in <italic toggle=""no"">Tsc2</italic> display mTOR hyperactivation and autistic‐like features. Significantly, we showed that even though the TSC2 mouse model does not have spontaneous epileptic events or significant pathological brain abnormalities, <italic toggle=""no"">Tsc2</italic>",13_1,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""no"">+/−</italic>
</sup> animals are more vulnerable to KA‐induce seizures. Moreover, we further exposed a significant effect of sex and circadian cycle for seizure vulnerability. On one side, compared to controls, <italic toggle=""no"">Tsc2</italic>
<sup>
<italic toggle=""no"">+/−</italic>
</sup> males exhibit a constant higher susceptibility for both circadian phases. On the other, <italic toggle=""no"">Tsc2</italic>
<sup>
<italic toggle=""no"">+/−</italic>",13_2,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</sup> female when compared with control animals were generally more vulnerable to KA‐induced seizures during the dark phase and for the post‐ovulatory stage of their estrous cycle. The figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.<boxed-text position=""anchor"" content-type=""graphic"" id=""epi412955-blkfxd-0001""><graphic http://www.w3.org/1999/xlink href=""EPI4-9-1710-g003.jpg"" position=""anchor""",13_3,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"href=""EPI4-9-1710-g003.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",13_4,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"Tuberous sclerosis complex (TSC) is a rare genetic disorder that leads to serious neurologic comorbidities such as severe epilepsy, intellectual disability, and autistic features.<xref rid=""epi412955-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref> Epilepsy is the most common neurological complication of TSC, and up to 80%–90% of individuals with TSC develop seizures at some point in their lifetime.<xref rid=""epi412955-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",13_5,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref>, <xref rid=""epi412955-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref> Despite the continuous development of new drugs, pharmacoresistance in patients with TSC is common and a matter of concern,<xref rid=""epi412955-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref>, <xref rid=""epi412955-bib-0004"" ref-type=""bibr"">
<sup>4</sup>",13_6,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>4</sup>
</xref> and further studies are needed to better characterize epilepsy in TSC. This disease is caused by heterozygous mutations in either <italic toggle=""yes"">Tsc1</italic> or <italic toggle=""yes"">Tsc2</italic> genes, which usually function to suppress the mechanistic target of the rapamycin 1 (mTORC1) pathway.<xref rid=""epi412955-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref>, <xref rid=""epi412955-bib-0005"" ref-type=""bibr"">
<sup>5</sup>",13_7,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>5</sup>
</xref> In TSC, abnormal hyperactivation of mTORC1 promotes cell growth that contributes to tumor formation or focal lesions in brain tissue, including cortical tubers, which are often considered the foci of epileptic seizures.<xref rid=""epi412955-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref>, <xref rid=""epi412955-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""epi412955-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""epi412955-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",13_8,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> However, it remains controversial whether epileptic episodes can be triggered within the tubers, as in rare cases, they can arise entirely remotely from these lesions.<xref rid=""epi412955-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref>, <xref rid=""epi412955-bib-0009"" ref-type=""bibr"">
<sup>9</sup>",13_9,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>9</sup>
</xref> Similar to clinical conditions, rodents with a heterozygous genotype in either <italic toggle=""yes"">Tsc1</italic> or <italic toggle=""yes"">Tsc2</italic> display mTOR hyperactivation but without significant pathological brain abnormalities,<xref rid=""epi412955-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",13_10,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref> and therefore, can be used to study seizure occurrence in this condition without the presence of these lesions. Interestingly, heterozygous TSC models show autism‐like features, such as social, cognitive, and behavioral deficits indicating that gross pathological lesions and loss of heterozygosity are not necessary to cause these neurological symptoms.<xref rid=""epi412955-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref>, <xref rid=""epi412955-bib-0010"" ref-type=""bibr"">
<sup>10</sup>",13_11,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>10</sup>
</xref>, <xref rid=""epi412955-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref> Heterozygotic <italic toggle=""yes"">Tsc2</italic> mutations are the most prevalent and the most frequently associated with severe clinical manifestations such as epilepsy.<xref rid=""epi412955-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>, <xref rid=""epi412955-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref> Intriguingly, no spontaneous seizures have been detected in <italic toggle=""yes"">Tsc2</italic>
<sup>",13_12,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice. It is known that dysregulated mTOR signaling disrupts normal cellular processes that not only contribute to the formation of cortical tubers<xref rid=""epi412955-bib-0014"" ref-type=""bibr"">
<sup>14</sup>
</xref> but also to alterations in proliferation and synaptic plasticity, which influence neuronal excitability.<xref rid=""epi412955-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref>, <xref rid=""epi412955-bib-0016"" ref-type=""bibr"">
<sup>16</sup>",13_13,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>16</sup>
</xref>, <xref rid=""epi412955-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref> Importantly, our group recently reported that female <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice exhibit increased glutamate concentration in the prefrontal cortex (PFC).<xref rid=""epi412955-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",13_14,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>18</sup>
</xref> Furthermore, from a mechanistic standpoint, these models are also expected to have the propensity to show higher seizure susceptibility irrespective of the presence of lesions; however, little evidence is yet available to support this assumption. Given the high prevalence of <italic toggle=""yes"">Tsc2</italic> mutations and their association with severe epileptic episodes,<xref rid=""epi412955-bib-0019"" ref-type=""bibr"">
<sup>19</sup>",13_15,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>19</sup>
</xref>, <xref rid=""epi412955-bib-0020"" ref-type=""bibr"">
<sup>20</sup>
</xref> it is fundamental to characterize seizure susceptibility in the <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mouse model. Concerning sexual dimorphism, clinical and preclinical studies suggest that gonadal hormone status influences seizure occurrence in women/females with epilepsy.<xref rid=""epi412955-bib-0021"" ref-type=""bibr"">
<sup>21</sup>",13_16,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>21</sup>
</xref>, <xref rid=""epi412955-bib-0022"" ref-type=""bibr"">
<sup>22</sup>
</xref>, <xref rid=""epi412955-bib-0023"" ref-type=""bibr"">
<sup>23</sup>
</xref> Whereas estrogen has been identified as a proconvulsant, progesterone has been associated with anticonvulsant properties.<xref rid=""epi412955-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref>, <xref rid=""epi412955-bib-0022"" ref-type=""bibr"">
<sup>22</sup>
</xref>, <xref rid=""epi412955-bib-0024"" ref-type=""bibr"">
<sup>24</sup>",13_17,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>24</sup>
</xref> Accordingly, hormonal fluctuations during the menstrual cycle have been shown to affect the frequency and severity of epileptic episodes.<xref rid=""epi412955-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref> Furthermore, cumulative evidence suggests that behavioral outcomes differ across the circadian cycle in general epilepsy models.<xref rid=""epi412955-bib-0025"" ref-type=""bibr"">
<sup>25</sup>
</xref>, <xref rid=""epi412955-bib-0026"" ref-type=""bibr"">
<sup>26</sup>",13_18,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>26</sup>
</xref>, <xref rid=""epi412955-bib-0027"" ref-type=""bibr"">
<sup>27</sup>
</xref> Therefore, for the one‐step characterization of <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mouse seizure vulnerability, it is fundamental to consider biological sex and the circadian cycle as preponderant variables. To test the hypothesis of higher seizure susceptibility in the <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_19,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mouse model, acute models can be used as an initial screening tool before using long‐term models. And so, we investigated seizure susceptibility and severity in male and female <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice induced by Kainic acid (KA), a potent neuroexcitatory amino acid, that is commonly used to induce seizures in animal models.<xref rid=""epi412955-bib-0025"" ref-type=""bibr"">
<sup>25</sup>",13_20,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>25</sup>
</xref>, <xref rid=""epi412955-bib-0028"" ref-type=""bibr"">
<sup>28</sup>",13_21,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>28</sup>
</xref> Latency times, seizure severity and frequency, and exploratory and anxiety‐like behavior were analyzed during two circadian periods (light and dark phases) before and after acute KA injection.   Our work provides a detailed account of seizure susceptibility in response to a proconvulsant drug in the TSC2 mouse model, focusing on the influence of biological sex and circadian cycle. Our results demonstrate that <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_22,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice, post‐KA injection, require less time to present the first seizure and display more severe and frequent seizures compared with control animals. Based on evidence that the TSC2 animal model did not show significant pathological brain abnormalities,<xref rid=""epi412955-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",13_23,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref> our data support the notion that severity of seizures in TSC cannot be exclusively attributed to focal lesions in brain tissue, such as cortical tubers, which are commonly associated with epileptic onset.<xref rid=""epi412955-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref>, <xref rid=""epi412955-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""epi412955-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""epi412955-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",13_24,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> In other words, direct physiological impairments at cellular and circuit levels contribute irrespective of the presence of overt lesions. Furthermore, according to our previous data that showed that <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>
</sup> female mice exhibit increased cortical glutamate concentration,<xref rid=""epi412955-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",13_25,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</xref> our results on acute KA administration, a potent neuroexcitatory amino acid, suggest that disruption of <italic toggle=""yes"">Tsc2</italic> allele exacerbates the mechanisms of seizure occurrence. Remarkably, apart from the genetic background, we consistently found a significant effect of sex and the circadian cycle on vulnerability to KA‐induced seizures. Accordingly, some studies have reported that several behavioral and physiological differences between sexes are dependent on the circadian",13_26,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"between sexes are dependent on the circadian cycle.<xref rid=""epi412955-bib-0034"" ref-type=""bibr"">",13_27,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>34</sup>
</xref>, <xref rid=""epi412955-bib-0035"" ref-type=""bibr"">
<sup>35</sup>
</xref> However, although some previous studies have explored the involvement of these factors in induced epileptic models separately,<xref rid=""epi412955-bib-0026"" ref-type=""bibr"">
<sup>26</sup>
</xref>, <xref rid=""epi412955-bib-0027"" ref-type=""bibr"">
<sup>27</sup>
</xref>, <xref rid=""epi412955-bib-0036"" ref-type=""bibr"">
<sup>36</sup>
</xref>, <xref rid=""epi412955-bib-0037"" ref-type=""bibr"">
<sup>37</sup>",13_28,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>37</sup>
</xref>, <xref rid=""epi412955-bib-0038"" ref-type=""bibr"">
<sup>38</sup>
</xref>, <xref rid=""epi412955-bib-0039"" ref-type=""bibr"">
<sup>39</sup>
</xref> none have so far considered both factors in the same study. It has been showed that the circadian phases can impact neuronal excitability by causing oscillations in the E/I balance with synaptic excitation being exacerbated during the light phase.<xref rid=""epi412955-bib-0027"" ref-type=""bibr"">
<sup>27</sup>",13_29,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>27</sup>
</xref> Accordingly, several studies using epileptic agents have demonstrated that animals are more vulnerable to seizures during the light phase.<xref rid=""epi412955-bib-0026"" ref-type=""bibr"">
<sup>26</sup>
</xref>, <xref rid=""epi412955-bib-0036"" ref-type=""bibr"">
<sup>36</sup>
</xref> On other side, numerous publications support sex differences in seizure susceptibility.<xref rid=""epi412955-bib-0040"" ref-type=""bibr"">
<sup>40</sup>",13_30,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>40</sup>
</xref> Indeed, most data agree that, in experimental models, females are more vulnerable than males.<xref rid=""epi412955-bib-0037"" ref-type=""bibr"">
<sup>37</sup>
</xref>, <xref rid=""epi412955-bib-0038"" ref-type=""bibr"">
<sup>38</sup>
</xref>, <xref rid=""epi412955-bib-0039"" ref-type=""bibr"">
<sup>39</sup>",13_31,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>39</sup>
</xref> Here we explore the involvement of those factors (sex and circadian cycle) together and found that generally females were more vulnerable to KA induced seizures than males from both genotypes during the light phase, which agrees with the above‐mentioned studies on circadian cycle and biological sex. Moreover, while <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_32,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> males, compared with their controls, showed earlier seizure onset and aggravated seizure progression for both circadian phases, <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_33,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</sup> females only presented increased susceptibility for seizure onset and frequency during the dark phase. From those results, it is possible to infer that sexual dimorphisms exclusively occurred during light phase independently of animal's genetic background. Interestingly, while genotype‐specific differences in males were mostly not affected by circadian cycle, those differences in females were only present during dark phase, the circadian phase that corresponds to the absence of sexual dimorphisms.",13_34,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"corresponds to the absence of sexual dimorphisms. In females it has been proven that hormonal fluctuations can regulate circadian responses<xref rid=""epi412955-bib-0041"" ref-type=""bibr"">",13_35,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>41</sup>
</xref> and also interfere with epileptic episodes.<xref rid=""epi412955-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref>, <xref rid=""epi412955-bib-0022"" ref-type=""bibr"">
<sup>22</sup>
</xref>, <xref rid=""epi412955-bib-0042"" ref-type=""bibr"">
<sup>42</sup>
</xref> In fact, it is widely recognized that estrogen has proconvulsant while progesterone has anticonvulsant properties.<xref rid=""epi412955-bib-0022"" ref-type=""bibr"">
<sup>22</sup>",13_36,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>22</sup>
</xref> In specific that estrogen rising and progesterone decline aggravate seizure exacerbations and frequency in epileptic patients.<xref rid=""epi412955-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref>, <xref rid=""epi412955-bib-0024"" ref-type=""bibr"">
<sup>24</sup>",13_37,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</xref> Here, we found no significant effect of estrous cycle on seizure onset or frequency. Still, we reported a significant interaction between genotype, circadian phase, and estrous cycle stage for seizure severity. Specifically, vulnerability in WT female mice was intensified during the ovulatory phase, corresponding to progesterone decline and estrogen rise. Yet, that difference was only reported during the dark phase. Moreover, we reported increased severity during light phase compared with dark",13_38,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"severity during light phase compared with dark phase during post‐ovulatory stage. These results indicate that the post‐ovulatory phase provides protection for control females. Nevertheless, the circadian rhythm appears to have a stronger impact in here, affecting this protection in WT females during light phase. In contrast, even though for WT animals, females appear to be less vulnerable during the post‐ovulatory stage, the same was not observed in <italic toggle=""yes"">Tsc2</italic>",13_39,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice. A possible explanation for this distinct effect may be due to the fact that progesterone has been proven to be a suppressor of mTOR levels.<xref rid=""epi412955-bib-0043"" ref-type=""bibr"">
<sup>43</sup>
</xref>, <xref rid=""epi412955-bib-0044"" ref-type=""bibr"">
<sup>44</sup>
</xref>, <xref rid=""epi412955-bib-0045"" ref-type=""bibr"">
<sup>45</sup>
</xref>, <xref rid=""epi412955-bib-0046"" ref-type=""bibr"">
<sup>46</sup>",13_40,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>46</sup>
</xref> As for <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_41,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</sup> animals, there is a hyperactivation of mTOR pathway, the anticonvulsant effects of progesterone may be abolished as there is a parallel mechanism involving this hormone action. Ultimately, we can say that these results suggest that female vulnerability could be a result of hormonal fluctuations as well as the circadian cycle changes that highly depends on their genetic background. Moreover, our findings emphasize the importance of considering the estrous cycle phase and the circadian cycle in future",13_42,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"cycle phase and the circadian cycle in future investigations of epilepsy in this animal model. To our knowledge, this is the first data on how the estrous and circadian cycle affects seizure vulnerability in the TSC2 mouse model for KA‐induced seizures. Nevertheless, we acknowledge the preliminarily of our conclusions based on a small sample size for estrous cycle. We reinforce that further studies should be set to better address female's cycle influence. From exploratory behavior analysis, <italic",13_43,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"From exploratory behavior analysis, <italic toggle=""yes"">Tsc2</italic>",13_44,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> animals exhibited a significant increase in anxiety‐like behavior post‐KA compared with their saline condition, which generally was not observed for WT mice. In line with this result, a previous study reported increased anxiety‐related behaviors in a <italic toggle=""yes"">Tsc2</italic> mouse model.<xref rid=""epi412955-bib-0047"" ref-type=""bibr"">
<sup>47</sup>",13_45,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>47</sup>
</xref> Furthermore, we found that anxiety levels post‐KA were significantly influenced by circadian cycle and by an interaction between genotype, sex, and circadian cycle. In fact, sexual dimorphism in behavior outcomes has been reported in the literature,<xref rid=""epi412955-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref>, <xref rid=""epi412955-bib-0048"" ref-type=""bibr"">
<sup>48</sup>
</xref>, <xref rid=""epi412955-bib-0049"" ref-type=""bibr"">
<sup>49</sup>",13_46,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>49</sup>
</xref>, <xref rid=""epi412955-bib-0050"" ref-type=""bibr"">
<sup>50</sup>
</xref> but that did not account for the influence of circadian cycle. Specifically, it has been reported that female C57BL/6J mice displayed increased anxiety in different behavioral tests compared with males.<xref rid=""epi412955-bib-0048"" ref-type=""bibr"">
<sup>48</sup>
</xref>, <xref rid=""epi412955-bib-0049"" ref-type=""bibr"">
<sup>49</sup>",13_47,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>49</sup>
</xref> Moreover, previous data also support sexual dimorphism in behavior outcomes for the TSC2 mouse model, characterized by elevated anxiety levels for mutant females described as a stress‐coping strategy.<xref rid=""epi412955-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref>, <xref rid=""epi412955-bib-0050"" ref-type=""bibr"">
<sup>50</sup>
</xref> Accordingly, here, we only found a significant increase in anxiety for <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_48,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</sup> females compared to their control group. Yet, that specific difference was only reported during dark phase. And so, it appears that circadian cycle strongly affects anxiety‐like behavior according to the genetic background and biological sex. Nevertheless, as we further exposed that sex significantly interacts with genotype and circadian cycle for anxiety‐like behavior, apart from the circadian cycle, once again, hormonal levels in females could be preponderant factors for anxiety‐like behavior and",13_49,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"factors for anxiety‐like behavior and sexual dimorphisms for this measure. However, overall, we did not find a significant impact of the estrous cycle phase on behavior outcomes after KA administration. It is worth noting that the relationship between <italic toggle=""yes"">Tsc2</italic> mutation/mTOR pathway and estrogen/progesterone is still poorly understood, and further studies specifically focused on the role of this hormones are needed. Our work demonstrated for the first time the susceptibility of the",13_50,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"for the first time the susceptibility of the TSC2 mouse model to KA‐induced seizures and disclosed the effects of sex and the circadian cycle. Our results showed that genetic background significantly affects seizure susceptibility to KA administration. Specifically, although the TSC2 mouse model did not have spontaneous epileptic events or significant pathological brain abnormalities, we showed that <italic toggle=""yes"">Tsc2</italic>",13_51,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> animals are more vulnerable to KA‐induced seizures, indicating that other neurological alterations may be involved in seizure occurrence. And so, our study suggested that induced models of epilepsy/seizures in <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_52,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"<sup>
<italic toggle=""yes"">+/−</italic>
</sup> mice can be used to study some aspects involving epilepsy for this disorder. Additionally, in the TSC2 mouse model, in response to the proconvulsant drug, we found evidence for the involvement of the circadian cycle and biological sex in seizure occurrence and anxiety‐like behavior. In summary, our results validate that <italic toggle=""yes"">Tsc2</italic>
<sup>
<italic toggle=""yes"">+/−</italic>",13_53,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"</sup> mice are more vulnerable to display seizures after an acute administration of a proconvulsant drug and support the use of the TSC2 mouse model in future TSC‐related induced epilepsy research. Moreover, here we highlight the importance of assessing male and female mice and circadian cycle periods separately. Future studies using this model should consider these variables to develop future therapeutic strategies for TSC‐related epilepsy. Mariana Lapo Pais performed experiments and analyzed data.",13_54,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"Pais performed experiments and analyzed data. Mariana Lapo Pais, Miguel Castelo‐Branco and Joana Gonçalves designed the project and prepared the manuscript. Joana Gonçalves supervised the project. Mariana Lapo Pais, João Martins, Miguel Castelo‐Branco and Joana Gonçalves discussed results and reviewed the manuscript. All authors read and approved the final manuscript. This work was supported by Ph.D. Fellow 2020.06582.BD (<ext-link http://www.w3.org/1999/xlink href=""https://doi.org/10.54499/2020.06582.BD""",13_55,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"href=""https://doi.org/10.54499/2020.06582.BD"" ext-link-type=""uri"">10.54499/2020.06582.BD</ext-link>) from FCT and Strategic Plan UIDP/04950/2020, COMPETE and FEDER funds, FCT, Portugal, ICNAS‐P. None of the authors have any conflict of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",13_56,Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle,15 7 2024,,Tuberous_Sclerosis
"Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort Tuberous sclerosis complex (TSC) is a variable multisystem disorder. The “no mutations identified” (NMI) group are reportedly phenotypically milder than those with an identified molecular cause, and often have mosaic or intronic variants not detected by standard sequencing methods.",14_0,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"<boxed-text position=""anchor"" content-type=""graphic"" id=""mgg370017-blkfxd-0001""><graphic http://www.w3.org/1999/xlink href=""MGG3-12-e70017-g001.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",14_1,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"Tuberous sclerosis complex (TSC, [MIM:191100/613254]) is an autosomal dominant condition associated with neurodevelopmental disability and benign tumours in various organs, particularly brain, eye, skin and kidneys. The birth incidence is estimated between 1:6760–1:13520 (Yates et al. <xref rid=""mgg370017-bib-0038"" ref-type=""bibr"">2011</xref>; Ebrahimi‐Fakhari et al. <xref rid=""mgg370017-bib-0008"" ref-type=""bibr"">2018</xref>). TSC is caused by heterozygous pathogenic variants in either the <italic",14_2,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"pathogenic variants in either the <italic toggle=""yes"">TSC1</italic> [MIM:605284] or <italic toggle=""yes"">TSC2</italic> [MIM:191092] gene (van Slegtenhorst et al. <xref rid=""mgg370017-bib-0036"" ref-type=""bibr"">1997</xref>; European Chromosome 16 Tuberous Sclerosis Consortium <xref rid=""mgg370017-bib-0003"" ref-type=""bibr"">1993</xref>). Approximately 10%–15% of individuals who meet diagnostic criteria have no pathogenic variants identified, commonly referred to as the “no mutations identified” (NMI) group",14_3,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"to as the “no mutations identified” (NMI) group (Curatolo et al. <xref rid=""mgg370017-bib-0006"" ref-type=""bibr"">2015</xref>; Chung et al. <xref rid=""mgg370017-bib-0004"" ref-type=""bibr"">2017</xref>; Tyburczy et al. <xref rid=""mgg370017-bib-0035"" ref-type=""bibr"">2015</xref>; Nellist et al. <xref rid=""mgg370017-bib-0022"" ref-type=""bibr"">2015</xref>; Martin et al. <xref rid=""mgg370017-bib-0021"" ref-type=""bibr"">2017</xref>). Although TSC remains mainly a clinical diagnosis, finding a pathogenic variant may",14_4,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"diagnosis, finding a pathogenic variant may restore reproductive confidence and provides reproductive options for the parents and for the affected individual, as well as potentially allowing access to targeted therapies (Northrup et al. <xref rid=""mgg370017-bib-0023"" ref-type=""bibr"">2021</xref>). Timing of testing depends on the reasons for seeking the information. If the individual does not fully meet diagnostic criteria, then a molecular diagnosis might also allow for therapeutic options. The use of",14_5,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"also allow for therapeutic options. The use of massively parallel sequencing (MPS) at high read depth (deep sequencing) has resulted in an increasing number of the NMI being been found to have mosaic or intronic variants in <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> (Tyburczy et al. <xref rid=""mgg370017-bib-0035"" ref-type=""bibr"">2015</xref>; Nellist et al. <xref rid=""mgg370017-bib-0022"" ref-type=""bibr"">2015</xref>; Qin et al. <xref rid=""mgg370017-bib-0028""",14_6,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"Qin et al. <xref rid=""mgg370017-bib-0028"" ref-type=""bibr"">2010</xref>; Ye et al. <xref rid=""mgg370017-bib-0039"" ref-type=""bibr"">2022</xref>). However, such sequencing is not widely available in a clinical diagnostic setting. We aimed to describe the clinical features of a cohort of people with a clinical diagnosis of TSC and NMI group and compared their phenotypes with those with an identified variant and previously published NMI groups. Subsequently we sought to develop a high‐yield and cost‐effective",14_7,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"sought to develop a high‐yield and cost‐effective testing strategy.    In conclusion, we were able to achieve a good diagnostic yield in our TSC NMI group using amplicon‐based MPS at a target read depth of 500×, suggesting that all TSC NMI individuals should have deep sequencing to look for mosaic variants. We determined that by using multiple samples, a lower target read depth can still result in a good diagnostic yield. This is likely to be more cost‐viable for a diagnostic laboratory to implement. A",14_8,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"for a diagnostic laboratory to implement. A deep sequencing panel at a read depth of 500× is now clinically available in our local diagnostic laboratory. C.W.T.C. and D.M. conceptualized the project. C.W.T.C., D.M., and E.P.K. designed the study methodology. C.W.T.C. and E.P.K. performed the investigation and data analysis. A.M.B. and S.T.C. performed RNA studies and data analysis. C.W.T.C., L.C.D.C., V.S., J.L., S.E.K. and D.M. collected clinical data for phenotyping. C.W.T.C. wrote the original",14_9,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"data for phenotyping. C.W.T.C. wrote the original manuscript draft. All authors reviewed, edited and approved the final manuscript. The authors declare no conflicts of interest.",14_10,Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex “No Mutations Identified” Cohort,01 10 2024,,Tuberous_Sclerosis
"mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis Mechanistic target of rapamycin (mTOR) signaling cascade plays crucial roles in various physiological processes including cell survival, proliferation, and differentiation. This pathway is frequently dysregulated in many human diseases, including tuberous sclerosis complex (TSC) [<xref ref-type=""bibr"" rid=""CR1"">1</xref>–<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. TSC is an autosomal dominant",15_0,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"rid=""CR3"">3</xref>]. TSC is an autosomal dominant inherited multiorgan disorder manifesting renal angiomyolipoma (AMLs) and cysts, brain subependymal giant cell astrocytomas (SEGAs), malformations of the cerebral cortex (tubers), cardiac rhabdomyomas, pulmonary lymphangioleiomyomatosis (LAM), and so on. This disease is caused by inactivating mutations of either <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> and subsequent activation of mTOR signaling [<xref ref-type=""bibr""",15_1,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"of mTOR signaling [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. The first generation of mTOR inhibitors, the macrolide rapamycin (sirolimus) and its analogue everolimus (RAD001), have become standard therapy for TSC [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. However, cytostatic nature of rapalogs due to reactivation of AKT/protein kinase B (PKB) and mitogen-activated protein kinase (MAPK) warrants novel therapeutic",15_2,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"protein kinase (MAPK) warrants novel therapeutic strategies [<xref ref-type=""bibr"" rid=""CR11"">11</xref>–<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. mTOR forms two distinct complexes, mTOR complex 1 (mTORC1) and mTORC2. As a component of mTORC1, PRAS40 (encoded by <italic toggle=""yes"">AKT1S1</italic>) is phosphorylated at Serine 183 by mTOR [<xref ref-type=""bibr"" rid=""CR14"">14</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Elucidating the role of PRAS40 in mTOR signaling pathway may offer novel",15_3,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"PRAS40 in mTOR signaling pathway may offer novel insights into the diseases with abnormal mTOR signaling. mTOR is capable of regulating miRNA expression to fulfill its function [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. miR-142-3p modulates the proliferation and differentiation of hematopoietic cells and inhibits the formation and development of cancer [<xref ref-type=""bibr"" rid=""CR21"">21</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. Serum miRNA",15_4,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"rid=""CR23"">23</xref>]. Serum miRNA profiling in patients with TSC revealed a decline in miRNA levels, including miR-142-3p. Patients with TSC treated with everolimus had elevated serum miR-142-3p [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Whether miR-142-3p and its targets are involved in mTOR signaling transduction and TSC development is unknown. In this study, we discovered the mTOR/miR-142-3p/PRAS40 signaling cascade and evaluated its significance in TSC2 deficiency-induced renal cyst formation.",15_5,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"in TSC2 deficiency-induced renal cyst formation. PRAS40 was increased while miR-142-3p was decreased in TSC2-deleted tissues and cell lines. The pharmacological induction of miR-142-3p expression or depletion of PRAS40 impaired renal cystogenesis caused by active mTOR. Therefore, targeting miR-142-3p/PRAS40 may treat active mTOR-related diseases.   Abnormal mTOR signaling triggers numerous diseases including TSC. TSC-associated renal AMLs and cysts are the most common causes of death in patients with TSC",15_6,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"most common causes of death in patients with TSC [<xref ref-type=""bibr"" rid=""CR49"">49</xref>, <xref ref-type=""bibr"" rid=""CR50"">50</xref>]. Here, we presented that mTOR activation led to renal cystogenesis by increasing PRAS40 expression through repression of miR-142-3p expression. Depletion of PRAS40 or increasing miR-142-3p expression via inhibition of DNA methylation could be potential therapeutic strategies for TSC-associated renal cysts (Fig. <xref rid=""Fig6"" ref-type=""fig"">6</xref>).<fig",15_7,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"rid=""Fig6"" ref-type=""fig"">6</xref>).<fig id=""Fig6""><label>Fig. 6</label><caption><p>Schematic graph representing the pathogenesis of TSC-associated renal cystogenesis. Me, methyl. →, promotion; ┤, suppression</p></caption><graphic http://www.w3.org/1999/xlink href=""11658_2024_638_Fig6_HTML"" id=""MO6""></graphic></fig> PRAS40 is a component of mTORC1 and is phosphorylated by mTOR [<xref ref-type=""bibr"" rid=""CR14"">14</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. It either negatively or positively",15_8,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"It either negatively or positively regulates mTOR pathway signaling in a context-dependent manner [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR43"">43</xref>, <xref ref-type=""bibr"" rid=""CR51"">51</xref>]. In this study, we found that mTOR activation increased mRNA and protein levels of PRAS40. Therefore, the regulation of PRAS40 by mTOR is multidimensional, including direct phosphorylation and",15_9,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"including direct phosphorylation and indirect upregulation of PRAS40 expression. In addition, PRAS40 contributed to the proliferation of <italic toggle=""yes"">Tsc2</italic><sup>−/−</sup> MEFs and the renal cyst epithelial cells, and cystogenesis of <italic toggle=""yes"">Tsc2</italic>-deleted mouse kidneys. Therefore, PRAS40 is essential for fulfilling the function of mTOR signaling pathway in cell proliferation and renal cystogenesis. However, the phosphorylation of mTOR downstream factor S6 was not changed",15_10,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"of mTOR downstream factor S6 was not changed by PRAS40 deletion in <italic toggle=""yes"">Tsc2</italic>-deleted cells and kidneys, indicating that PRAS40 works either downstream of S6 or in parallel with S6. Nevertheless, these data suggest that PRAS40 can be targeted for TSC-associated cystogenesis. Consistent with the effects of PRAS40 in tumor cells [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR43"">43</xref>, <xref ref-type=""bibr"" rid=""CR44"">44</xref>], PRAS40 promoted AKT",15_11,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"rid=""CR44"">44</xref>], PRAS40 promoted AKT phosphorylation in <italic toggle=""yes"">Tsc2</italic>-depleted MEFs and mouse kidneys. Since PRAS40 overexpression increased AKT phosphorylation caused by mTOR knockdown, PRAS40 stimulation of AKT phosphorylation should not be related to mTORC2 activation. Therefore, PRAS40 deletion inhibits cell proliferation and renal cystogenesis not only by hindering mTOR signaling, but also by suppressing AKT activation. Moreover, PRAS40 shRNA enhanced rapamycin inhibition of",15_12,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"PRAS40 shRNA enhanced rapamycin inhibition of cell proliferation, likely by abolishing rapamycin-induced AKT phosphorylation. Thus, targeting PRAS40 could combine with mTOR inhibition for the treatment of mTOR hyperactivated diseases such as TSC. The next question is how PRAS40 expression is upregulated by mTOR activation. mTOR signaling alters miRNA expression [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. miR-142-3p was decreased in serum of patients with TSC",15_13,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"was decreased in serum of patients with TSC but restored to baseline level in control serum by treatment of mTOR inhibitor [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Our data showed that miR-142-3p was suppressed by mTOR activation. miR-142-3p suppresses cell proliferation by binding to PRAS40's 3'UTR and reducing PRAS40 expression. Thus, mTOR activation upregulates PRAS40 through inhibiting miR-142-3p. On the basis of the previous serum data and our MEF results, this mTOR/miR-142-3p/PRAS40 regulatory",15_14,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"results, this mTOR/miR-142-3p/PRAS40 regulatory axis may extend beyond the kidney to other organs. Further investigation using additional TSC models including AML is warranted to confirm this hypothesis. DNA methylation decreases miR-142-3p expression [<xref ref-type=""bibr"" rid=""CR46"">46</xref>, <xref ref-type=""bibr"" rid=""CR47"">47</xref>]. Here, decitabine increased miR-142-3p expression and decreased PRAS40 expression in <italic toggle=""yes"">Tsc2</italic><sup>−/−</sup> MEFs and <italic",15_15,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"MEFs and <italic toggle=""yes"">Tsc2</italic>-depleted kidneys. Consequently, decitabine inhibited renal cell proliferation and cystogenesis in <italic toggle=""yes"">Tsc2</italic>-deleted mice. These data not only confirmed the upregulation of PRAS40 by mTOR through suppression of miR-142-3p, but also provided a proof-of-concept of restoring miR-142-3p for treating TSC-associated renal cysts. Additionally, more specific strategies targeting the DNA methylation of miR-142-3p may offer more precise therapeutic",15_16,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"of miR-142-3p may offer more precise therapeutic intervention. The mechanism underlying TSC-associated renal cystogenesis remains complex. Various research has revealed that downstream effectors of mTOR, such as TFEB and TFE3, play crucial roles in this disease [<xref ref-type=""bibr"" rid=""CR30"">30</xref>, <xref ref-type=""bibr"" rid=""CR52"">52</xref>, <xref ref-type=""bibr"" rid=""CR53"">53</xref>]. PRAS40 is a novel one; future therapeutic strategies could consider targeting these factors in combination. In this",15_17,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"targeting these factors in combination. In this study, we find that PRAS40 is a novel downstream effector of mTOR signaling pathway. Targeting PRAS40 directly or suppressing PRAS40 expression indirectly through enhancement of miR-142-3p impairs the formation of TSC-associated renal cysts, which may provide promising therapeutic approaches for diseases with hyperactivated mTOR signaling.",15_18,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""11658_2024_638_MOESM1_ESM.docx""><caption><p>Additional file 1.</p></caption></media></supplementary-material>",15_19,mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis,27 9 2024,,Tuberous_Sclerosis
"Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study Introduction: Tuberous sclerosis complex (TSC) is a neurocutaneous disease with a high incidence of epilepsy and damaging effects on cognitive development. To understand the mechanisms leading to abnormal cognitive development, diffusion tensor imaging (DTI) techniques have begun to be used in recent years. The present study is the first to investigate differences",16_0,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"study is the first to investigate differences in the microstructure and integrity of white matter tracts in adult patients with TSC and with and without epilepsy. Method: A total of 37 patients with TSC (18 with epilepsy, median age 36 years; 19 without epilepsy, median age 35 years) without intellectual disability and autism spectrum disorder were included in the study. The control group (median age 34 years) comprised 37 individuals without psychiatric or neurodevelopmental disorders and neurological and",16_1,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"neurodevelopmental disorders and neurological and cardiovascular diseases, diabetes, or addictions. A magnetic resonance imaging (MRI) DTI sequence was applied. Results: There were differences in the average values of DTI parameters between patients with TSC and epilepsy and patients with TSC but without epilepsy in five white matter bands. When comparing the average values of DTI parameters between patients with TSC and epilepsy and healthy controls, we found differences in 15 of 20 analysed white matter",16_2,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"differences in 15 of 20 analysed white matter fibres. White matter tracts in patients with TSC and epilepsy had more abnormalities than in patients with TSC but without epilepsy. The former group presented abnormalities in longer white matter fibres, especially in the left hemisphere. However, the latter group presented abnormalities in more medial and shorter white matter fibres. Conclusion: This DTI study documents the changes in the brain white matter of patients with TSC associated with the presence of",16_3,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"patients with TSC associated with the presence of epilepsy. Tuberous sclerosis complex (TSC) is a rare multisystem neurocutaneous disorder that is associated with the formation of hamartomatous lesions in various organs, including the brain [<xref rid=""B1-biomedicines-12-02061"" ref-type=""bibr"">1</xref>]. Conventional magnetic resonance imaging (MRI) in TSC has revealed three types of brain lesions: cortical tubers (present in 90% of individuals with TSC), subependymal nodules (SENs; present in 80% of",16_4,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"subependymal nodules (SENs; present in 80% of individuals with TSC), and subependymal giant cell astrocytomas (SEGAs; present in up to 15% of individuals with TSC) [<xref rid=""B2-biomedicines-12-02061"" ref-type=""bibr"">2</xref>,<xref rid=""B3-biomedicines-12-02061"" ref-type=""bibr"">3</xref>]. Further histological examinations of these brain hamartomas have revealed characteristics of aberrant neuronal and astrocyte expansion and cell enlargement such as microdysgenesis and abnormal cortical layering [<xref",16_5,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"and abnormal cortical layering [<xref rid=""B4-biomedicines-12-02061"" ref-type=""bibr"">4</xref>]. Four unique patterns can be found in MRI of white matter (WM) lesions: (1) wedge-shaped lesions, (2) non-specific conglomerate foci, (3) straight or curved radial bands extending from the ventricle through the cerebral WM toward the cortex, and (4) cerebellar radial bands [<xref rid=""B5-biomedicines-12-02061"" ref-type=""bibr"">5</xref>,<xref rid=""B6-biomedicines-12-02061"" ref-type=""bibr"">6</xref>,<xref",16_6,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">6</xref>,<xref rid=""B7-biomedicines-12-02061"" ref-type=""bibr"">7</xref>]. One of the limitations of conventional MRI is the inability to obtain the microstructural characterisation of tissues, including abnormal differentiation, migration, organisation, myelination, and structural connectivity. Changes in the structure of the brain, in turn, give rise to the clinical manifestations of epilepsy, which is the most prevalent neurological symptom in patients with TSC and affects 70–90% of",16_7,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"in patients with TSC and affects 70–90% of patients [<xref rid=""B8-biomedicines-12-02061"" ref-type=""bibr"">8</xref>,<xref rid=""B9-biomedicines-12-02061"" ref-type=""bibr"">9</xref>]. There are different types of convulsions, such as focal, multifocal, infantile, or a combination of these and others. Infantile spasms can occur in up to 30% of people affected by TSC. People with TSC frequently have multiple seizures that do not improve with medication [<xref rid=""B10-biomedicines-12-02061""",16_8,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"medication [<xref rid=""B10-biomedicines-12-02061"" ref-type=""bibr"">10</xref>]. Epileptogenic foci can occur in different parts of the brain at different times. In longitudinal studies, changes in the morphology of the seizures have been observed in more than half of the patients. The deficiency of GABAergic interneurons explains the early onset and severe course of TSC-related seizures; thus, the GABA transaminase inhibitor vigabatrin is proven to be effective in approximately 95% of patients [<xref",16_9,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"effective in approximately 95% of patients [<xref rid=""B11-biomedicines-12-02061"" ref-type=""bibr"">11</xref>]. Other anti-epileptic drugs are less effective in TSC. Some researchers suggest that white matter disruption is related with epilepsy in TSC [<xref rid=""B12-biomedicines-12-02061"" ref-type=""bibr"">12</xref>]. Diffusion tensor imaging (DTI) is a method that uses MRI’s capacity to assess the direction and amount of water diffusion in tissues while they are still in motion [<xref",16_10,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"in tissues while they are still in motion [<xref rid=""B13-biomedicines-12-02061"" ref-type=""bibr"">13</xref>]. This provides a view of microscopic tissue architecture and is used to obtain information about the value and direction of the diffusion of hydrogen ions of water molecules, which allows for a broader diagnosis of changes in the microstructure of the brain in vivo. Several DTI parameters reflect the integrity of the WM, including the fractional anisotropy coefficient (FA), a measure of diffusion",16_11,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"coefficient (FA), a measure of diffusion directionality; radial diffusivity (RD) and axial diffusivity (AD), which are indicators of myelin degeneration and of axonal damage [<xref rid=""B14-biomedicines-12-02061"" ref-type=""bibr"">14</xref>], respectively; and mean diffusivity (MD), which determines the general properties of the tissue [<xref rid=""B15-biomedicines-12-02061"" ref-type=""bibr"">15</xref>]. More precisely, FA is interpreted as a quantitative biomarker of WM ‘integrity’. A confirmation for this",16_12,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"of WM ‘integrity’. A confirmation for this interpretation is the fact that pathological studies tend to show a reduction in FA associated with neurogenerative processes [<xref rid=""B16-biomedicines-12-02061"" ref-type=""bibr"">16</xref>,<xref rid=""B17-biomedicines-12-02061"" ref-type=""bibr"">17</xref>]. RD is often more sensitive to myelin changes; however, an increase in RD can indicate myelin loss, axonal loss, or decreased axonal packing density [<xref rid=""B18-biomedicines-12-02061""",16_13,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"density [<xref rid=""B18-biomedicines-12-02061"" ref-type=""bibr"">18</xref>]. AD is a measure of the extent of diffusion along the direction of fibre tracts. A decrease in AD can indicate axonal damage, reduced axonal thickness, or less organised axonal orientation. Research suggests that AD is unaffected by myelin [<xref rid=""B19-biomedicines-12-02061"" ref-type=""bibr"">19</xref>]. Finally, an overall increase in MD generally indicates an increase in water content (such as from oedema and inflammation),",16_14,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"content (such as from oedema and inflammation), leading to reduced resistance and, consequently, higher diffusion rates [<xref rid=""B20-biomedicines-12-02061"" ref-type=""bibr"">20</xref>]. The initial studies showing impaired diffusion in individuals with TSC focused on subcortical tubers. They revealed reduced FA and increased MD, as confirmed by histopathological findings of tuber tissue (dysmorphic, dysplastic, disorganised, and enlarged cells) [<xref rid=""B21-biomedicines-12-02061""",16_15,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"cells) [<xref rid=""B21-biomedicines-12-02061"" ref-type=""bibr"">21</xref>]. However, abnormalities visualised by DTI are not limited to the WM surrounding tubers [<xref rid=""B22-biomedicines-12-02061"" ref-type=""bibr"">22</xref>,<xref rid=""B23-biomedicines-12-02061"" ref-type=""bibr"">23</xref>], as abnormalities in myelination, migration, and neuronal differentiation go beyond discrete borders of tubers visible on conventional MRI. Normal-appearing white matter (NAWM) refers to areas around WM lesions (e.g.,",16_16,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"(NAWM) refers to areas around WM lesions (e.g., cortico–subcortical tubers) that appear normal with conventional MRI but may show low perfusion or microstructural changes [<xref rid=""B24-biomedicines-12-02061"" ref-type=""bibr"">24</xref>,<xref rid=""B25-biomedicines-12-02061"" ref-type=""bibr"">25</xref>,<xref rid=""B26-biomedicines-12-02061"" ref-type=""bibr"">26</xref>]. This has important implications because in addition to multifocal neuropathology in the form of tubers, these abnormalities reflect a global or",16_17,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"tubers, these abnormalities reflect a global or diffuse microstructural pathology of WM, also confirmed in neuropathological studies of TSC [<xref rid=""B23-biomedicines-12-02061"" ref-type=""bibr"">23</xref>]. An increasing number of researchers are using DTI to describe WM abnormalities that appear unaltered on conventional imaging [<xref rid=""B27-biomedicines-12-02061"" ref-type=""bibr"">27</xref>,<xref rid=""B28-biomedicines-12-02061"" ref-type=""bibr"">28</xref>,<xref rid=""B29-biomedicines-12-02061""",16_18,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"rid=""B29-biomedicines-12-02061"" ref-type=""bibr"">29</xref>,<xref rid=""B30-biomedicines-12-02061"" ref-type=""bibr"">30</xref>,<xref rid=""B31-biomedicines-12-02061"" ref-type=""bibr"">31</xref>,<xref rid=""B32-biomedicines-12-02061"" ref-type=""bibr"">32</xref>]. Typically, DTI studies have included small or mixed groups (children and adults, with and without epilepsy), which is not sufficient to obtain detailed data on microstructural changes specific to clinically different patients [<xref",16_19,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"specific to clinically different patients [<xref rid=""B30-biomedicines-12-02061"" ref-type=""bibr"">30</xref>,<xref rid=""B32-biomedicines-12-02061"" ref-type=""bibr"">32</xref>,<xref rid=""B33-biomedicines-12-02061"" ref-type=""bibr"">33</xref>,<xref rid=""B34-biomedicines-12-02061"" ref-type=""bibr"">34</xref>,<xref rid=""B35-biomedicines-12-02061"" ref-type=""bibr"">35</xref>]. In the present study, we evaluated WM microstructure and structural connections of the brain in high-functioning (without autism spectrum disorder",16_20,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"(without autism spectrum disorder and intellectual disability) adults with TSC, depending on the presence or absence of epilepsy. To date, no conventional imaging biomarker reliably relates to this neurophenotype. Our study is the first to use magnetic resonance tractography to determine the characteristics of the diffusion coefficients of NAWM fibres in the brain of patients with TSC, comparing individuals with and without epilepsy. This study protocol was approved by the Ethics Committee of the Medical",16_21,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"approved by the Ethics Committee of the Medical University of Gdańsk (NKEBN/682/2018-2019). All participants and/or caregivers were informed about the study objectives and procedure and signed a written consent form. Two independent observers assessed the WM fibres based on MRI scans in the FLAIR sequence. Kendall’s coefficient of concordance confirmed agreement between the observers (W = 0.93). In each patient with TSC, each observer decided, independently, whether the 20 analysed WM fibres were NAWM or",16_22,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"whether the 20 analysed WM fibres were NAWM or whether there were structural abnormalities. The number of fibres marked as NAWM in the groups is presented in <xref rid=""biomedicines-12-02061-t001"" ref-type=""table"">Table 1</xref>. In the EpiTSC and NEpiTSC groups, the observers noted microstructural differences in NAWM that could be visualised by DTI. Moreover, there were significant differences between these groups. Myelin and axonal abnormalities were more pronounced in the EpiTSC group. In the EpiTSC and",16_23,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"pronounced in the EpiTSC group. In the EpiTSC and NEpiTSC groups, fibres linking distant lobes of the brain, especially frontal circuits, were disrupted. When comparing the average values of the DTI parameters for the EpiTSC and NEpiTSC groups, there were significant differences in five NAWM bands. Specifically, there were MD differences in three WM pathways: the left inferior fronto-occipital fasciculus (IFOF) and the left and right inferior longitudinal fasciculus (ILF). Two NAWM pathways showed higher",16_24,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"fasciculus (ILF). Two NAWM pathways showed higher MD and lower FA in the EpiTSC group compared with the NEpiTSC group. There were significant differences in RD only in the left upper longitudinal bundle and for AD only in the left IFOF. <xref rid=""biomedicines-12-02061-t002"" ref-type=""table"">Table 2</xref> provides detailed data on significant differences in the diffusion parameters of NAWM for the EpiTSC and NEpiTSC groups. When comparing the DTI results between the individuals with TSC and healthy",16_25,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"between the individuals with TSC and healthy subjects, we observed more microstructural changes within the NAWM in the EpiTSC group compared with the NEpiTSC group. In the EpiTSC group, the diffusion coefficients for the majority of the analysed NAWM fibres differed from the control group. In the EpiTSC group, the most significant differences were related to MD. When comparing the average values of the DTI parameters between the EpiTSC and control groups, there were significant differences for 15 of the 20",16_26,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"were significant differences for 15 of the 20 analysed WM fibres. MD was higher in 12 NAWM fibres in the EpiTSC group compared with the control group. There were similar differences in four and five WM tracts for AD and RD, respectively. FA significantly differentiated six NAWM pathways between the EpiTSC and control groups. The average FA for the EpiTSC group was lower than the NEpiTSC and control groups. All DTI parameters were significantly different in the left anterior thalamic radiation and the left",16_27,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"the left anterior thalamic radiation and the left superior longitudinal fasciculus. There were also significant differences in RD, FA, and MD in the left uncinate fasciculus. In the remaining NAWM pathways, one or two diffusion coefficients differed significantly between the EpiTSC and control groups. <xref rid=""biomedicines-12-02061-t003"" ref-type=""table"">Table 3</xref> provides detailed data on significant differences in the diffusion parameters of the NAWM fibre bands between the EpiTSC and control",16_28,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"NAWM fibre bands between the EpiTSC and control groups. When comparing the NEpiTSC and control groups, we noted significant differences in the diffusion coefficients for six NAWM fibres. Two NAWM fibres—the right cingulum and forceps minor—showed higher MD in the NEpiTSC group. RD and AD were higher in four and three NAWM fibres, respectively, in the NEpiTSC group compared with the control group. However, FA was significantly lower in only one of the analysed NAWM fibres in the NEpiTSC group compared with",16_29,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"NAWM fibres in the NEpiTSC group compared with the control group. None of the analysed fibres differed significantly in terms of all four DTI indices. Only the forceps minor (RD, MD, and AD) and right cingulum (cingulate gyrus; RD, FA, and MD) differed significantly in three analysed parameters. Similarly to the EpiTSC group, there were differences in RD, indicating myelin damage, in the forceps minor, the right anterior thalamic radiation, and the right cingulum. We also noted differences between the",16_30,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"cingulum. We also noted differences between the NEpiTSC and control groups in one left-hemisphere tract: the IFOF. There were differences in AD, indicative of axonal damage, in the forceps minor and the left cingulum, the corticospinal tract, and the superior longitudinal fasciculus (temporal part). FA was significantly lower in the right cingulum of the NEpiTSC group compared with the control group. None of the analysed fibres differed significantly between the groups in terms of all four DTI indices. The",16_31,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"the groups in terms of all four DTI indices. The most abnormal fibres compared with the healthy group were the lesser forceps (higher RD, MD, and AD) and the right cingulum (higher RD and MD, and lower FA), each of which showed significant differences in three DTI parameters. The NEpiTSC group presented higher RD and AD in four WM fibres. <xref rid=""biomedicines-12-02061-t004"" ref-type=""table"">Table 4</xref> presents detailed data on significant differences in the diffusion parameters of the NAWM fibres",16_32,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"in the diffusion parameters of the NAWM fibres between the NEpiTSC and control groups. We aimed to determine the characteristics of the DTI parameters of NAWM fibres in the brains of high-functioning individuals with TSC, comparing those with and without epilepsy. Our three main findings are as follows: (1) NAWM shows more abnormalities in individuals with TSC and epilepsy than in individuals with TSC but without epilepsy; (2) in individuals with TSC and epilepsy, NAWM abnormalities are present in longer",16_33,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"NAWM abnormalities are present in longer WM fibres, especially in the left hemisphere; and (3) individuals with TSC but without epilepsy present NAWM abnormalities in more medial and shorter WM fibres compared with individuals with TSC and epilepsy. These findings indicate more severe abnormalities in the NAWM of individuals with TSC and epilepsy than in individuals with TSC but without epilepsy. These abnormalities are present especially in long WM fibres and refer to both axonal and myelin damage.",16_34,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"and refer to both axonal and myelin damage. Despite the fact that the centrifugal pattern of WM diffusion abnormalities likely indicates astrogliosis and microstructural disruption associated with seizure activity near the focus [<xref rid=""B39-biomedicines-12-02061"" ref-type=""bibr"">39</xref>], research has highlighted the epilepsy burden in the ipsilateral WM distant networks. Campos et al. [<xref rid=""B40-biomedicines-12-02061"" ref-type=""bibr"">40</xref>] evaluated WM changes in focal epileptic lesions",16_35,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"evaluated WM changes in focal epileptic lesions not related to TSC. They found that the variable distribution of WM damage in these patients indicates that the location of epileptic networks might influence the WM burden and that the underlying cause of epilepsy is likely an additional factor that contributes to this WM damage. Furthermore, Yasuda et al. [<xref rid=""B41-biomedicines-12-02061"" ref-type=""bibr"">41</xref>] found differences in the FA of all 10 tracts in individuals with temporal lobe epilepsy",16_36,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"tracts in individuals with temporal lobe epilepsy versus controls. Thus, the existence of more severe WM abnormalities in patients with TSC and epilepsy relative to the cognitive profile of individuals with TSC but not epilepsy is not surprising considering the deteriorating effect of epileptic discharges on the structure of the brain [<xref rid=""B42-biomedicines-12-02061"" ref-type=""bibr"">42</xref>]. These findings might explain the behavioural, cognitive, and affective problems in individuals with TSC, a",16_37,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"and affective problems in individuals with TSC, a conclusion also drawn by Sato et al. [<xref rid=""B33-biomedicines-12-02061"" ref-type=""bibr"">33</xref>]. Researchers have claimed that the disruption of WM integrity can lead to reduced connectivity between cortical and subcortical brain regions. Our results are consistent with previous studies: we mostly found differences in directionality in individuals with TSC and epilepsy compared with healthy controls in long WM fibres of the left hemisphere. The",16_38,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"in long WM fibres of the left hemisphere. The observed changes in individuals with TSC and epilepsy in AD and RD may indicate axonal and myelin damage, respectively [<xref rid=""B19-biomedicines-12-02061"" ref-type=""bibr"">19</xref>]. In the case of individuals with TSC and epilepsy, it is difficult to rule out WM damage caused by seizures. The individuals with TSC and epilepsy showed differences in medial and short WM fibres compared with the healthy controls. These results indicate that epilepsy is not the",16_39,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"These results indicate that epilepsy is not the only cause of WM disruption in TSC. In the individuals with TSC but without epilepsy, AD and RD, rather than FA, showed the most pronounced differences, indicating that both myelin and axonal damage are present in the NAWM fibres in those individuals. Surprisingly, the integrity of NAWM fibres is less affected than other microstructural aspects. Those results suggest an underlying biological process in TSC WM alternations. Consistently, Gruper et al. [<xref",16_40,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"alternations. Consistently, Gruper et al. [<xref rid=""B43-biomedicines-12-02061"" ref-type=""bibr"">43</xref>] examined patient-derived primary oligodendroglial cells and TSC2 knockout cells and concluded that oligodendroglial maturation and proper myelin sheath production are hindered due to disturbances in the mammalian target of the rapamycin (mTOR) pathway. Therefore, the oligodendroglial pathology may represent a direct consequence of an abnormal genetic program rather than merely being an inactive",16_41,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"program rather than merely being an inactive byproduct of chronic epilepsy [<xref rid=""B44-biomedicines-12-02061"" ref-type=""bibr"">44</xref>]. Our findings indicate that in individuals with TSC, regardless of whether they also have epilepsy, there are microstructural differences in NAWM that can be visualised by DTI. The quantification of WM alterations by advanced diffusion MRI may be an additional biomarker for TSC and may be advantageous as a complementary MR protocol for the evaluation of that group of",16_42,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
MR protocol for the evaluation of that group of patients. Further research should focus on the analysis of DTI parameters in comparison to cognitive phenotypes and extend the diagnostics to include myelin networks. These studies could provide important information to understand the pathomechanism and to identify specific phenotypes of patients in whom effective therapies could be adapted to their structural and functional disorders. This study represents the first attempt to use magnetic resonance,16_43,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
the first attempt to use magnetic resonance tractography to characterise the diffusion coefficients of NAWM fibres in the brains of individuals with TSC and with or without epilepsy. A crucial aspect of this study was our comparison of the mean values of DTI parameters between patient groups in an attempt to elucidate the underlying causes of different clinical phenotypes in individuals with TSC. The analysis revealed more pronounced myelin and axonal abnormalities in individuals with TSC and epilepsy.,16_44,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"in individuals with TSC and epilepsy. Additionally, we observed most severe alternations in fibres connecting distant brain lobes in individuals with TSC and epilepsy. Furthermore, these individuals presented NAWM abnormalities in longer WM fibres, especially in the left hemisphere. These findings could potentially shed light on the behavioural, cognitive, and affective issues experienced by individuals with TSC. Future research should delve into comparing DTI parameters with cognitive phenotypes and",16_45,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"DTI parameters with cognitive phenotypes and expanding diagnostics to include myelin networks. Such investigations hold promise for providing valuable insights into the pathomechanisms underlying TSC and identifying specific patient phenotypes. Ultimately, this could lead to the development of tailored therapies that address both structural and functional abnormalities in affected individuals.",16_46,Differences between Tuberous Sclerosis Complex Patients with and without Epilepsy: The Results of a Quantitative Diffusion Tensor Imaging Study,10 9 2024,,Tuberous_Sclerosis
"Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report Lymphangioleiomyomatosis is a rare disease characterized by abnormal smooth muscle cell growth. It primarily occurs in the lungs but can also rarely occur in other organs, in which case it is classified as extrapulmonary lymphangioleiomyomatosis. It often accompanies tuberous sclerosis complex. This report concerns a case of uterine lymphangioleiomyomatosis with spontaneous uterine rupture in a young woman with",17_0,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"spontaneous uterine rupture in a young woman with tuberous sclerosis complex. A 27-year-old nulligravida patient presented to the emergency room with vaginal bleeding. She had a history of clinical diagnosis of tuberous sclerosis complex and pulmonary lymphangioleiomyomatosis. Initially, abdominopelvic computed tomography and magnetic resonance imaging suggested a hemorrhagic necrosis and rupture of degenerated uterine myoma. She underwent emergency exploratory laparotomy. The right side of her",17_1,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
exploratory laparotomy. The right side of her normal-sized uterus were ruptured without any specific mass. Active bleeding and hematoma from the ruptured uterus and partially ruptured right ovary were noted. The procedure included total hysterectomy and right salpingo-oophorectomy. Pathological analysis confirmed lymphangioleiomyomatosis in the uterine serosa and myometrium. Lymphangioleiomyomatosis mainly occurs in women of reproductive age and worsens with estrogen. Early diagnosis and careful follow-up,17_2,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"estrogen. Early diagnosis and careful follow-up are necessary due to the risk of worsening gynecological symptoms or even uterine rupture during pregnancy. This case enhances our understanding of extrapulmonary lymphangioleiomyomatosis and highlights the importance of comprehensive evaluation in complex clinical scenarios. <list list-type=""simple"" id=""l0005""><list-item id=""li0005""><label>•</label><p id=""p0005"">This report presents a case of a premenopausal woman with a history of tuberous sclerosis complex",17_3,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"with a history of tuberous sclerosis complex (TSC).</p></list-item><list-item id=""li0010""><label>•</label><p id=""p0010"">The patient was found to have spontaneous uterine rupture, requiring a total abdominal hysterectomy.</p></list-item><list-item id=""li0015""><label>•</label><p id=""p0015"">The pathological diagnosis was uterine lymphangioleiomyomatosis (LAM).</p></list-item><list-item id=""li0020""><label>•</label><p id=""p0020"">Uterine LAM is a rare manifestation of TSC, and only less than 30 cases of uterine",17_4,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"of TSC, and only less than 30 cases of uterine LAM have been reported worldwide.</p></list-item><list-item id=""li0021""><label>•</label><p id=""p0021"">LAM occurs mainly in women of reproductive age and is worsened by estrogen, so early diagnosis and careful follow-up are necessary.</p></list-item></list> Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal smooth muscle cell growth, occurring mainly in women of reproductive age [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. It is now",17_5,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"rid=""bb0005"" ref-type=""bibr"">1</xref>]. It is now considered a part of the family of perivascular epitheloid cell tumors (PEComa), which often infiltrate the smooth muscle of the blood vessels [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. While most PEComas are benign, malignant forms can metastasize or recur. LAM primarily affects the lung parenchyma, leading to cystic destruction and respiratory failure [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. However, it can also occur at extrapulmonary sites",17_6,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"it can also occur at extrapulmonary sites (EPLAM) along the axial lymphatic pathway in the abdominopelvic cavity, such as lymph nodes, retroperitoneum, and reproductive organs [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. The clinical features of EPLAM vary based on organ involvement, from asymptomatic cases to abdominal pain or genital bleeding [<xref rid=""bb0015"" ref-type=""bibr"">[3]</xref>, <xref rid=""bb0020"" ref-type=""bibr"">[4]</xref>, <xref rid=""bb0025"" ref-type=""bibr"">[5]</xref>]. To date, fewer than",17_7,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">[5]</xref>]. To date, fewer than 30 cases of uterine LAM have been reported worldwide [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. LAM occurs sporadically in 1 in 400,000 adult women but is found in up to 40 % of women with tuberous sclerosis complex (TSC) [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. TSC is a disease-causing tumor in various organs due to mutation in the TSC genes [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>]. Uterine LAM is a rare manifestation of TSC. This report",17_8,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"LAM is a rare manifestation of TSC. This report concerns a case of uterine LAM with spontaneous rupture in a young woman with TSC. A 27-year-old nulligravida woman presented to the emergency room with dizziness and vaginal bleeding. She had a history of clinical diagnosis of TSC, neurosurgical treatment for subependymal giant cell astrocytoma, LAM and multifocal micronodular pneumocyte hyperplasia (MMPH) in lung, multiple bilateral renal angiomyolipomas (AMLs), hypomelanotic macule, and angiofibromas. No",17_9,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"hypomelanotic macule, and angiofibromas. No mutation was detected in the TSC2 gene. However, she had not visited the hospital for 3 years and was receiving no ongoing diagnostic evaluation or treatment. Her vital signs were stable, and she reported vague abdominal pain. However, her initial hemoglobin level was 6.0 g/dL, requiring transfusion of five packs of red blood cells. Abdominopelvic computed tomography (CT) and magnetic resonance imaging (MRI) demonstrated a hemorrhagic necrosis and rupture of",17_10,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"a hemorrhagic necrosis and rupture of degenerated uterine myoma into the endometrial and extrauterine cavity with massive hemoperitoneum (<xref rid=""f0005"" ref-type=""fig"">Fig. 1</xref>). Additionally, multiple AMLs up to 4 cm were noted in both kidneys. Compared to 3 years ago, no acute intracranial lesions, nor changes in pulmonary LAM and MMPH in brain CT and chest CT were observed, respectively.<fig id=""f0005""><label>Fig. 1</label><caption><p>Coronal contrast-enhanced abdominopelvic computed tomography",17_11,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"abdominopelvic computed tomography images (A, B) revealed a lobulated, thick-walled mass like lesion (arrows) communicating with a dilated endometrial cavity filled with hematometra (asterisk) and massive hemoperitoneum up to diaphragm (open asterisk). Multiple angiomyolipomas up to 4 cm are present in the right kidney (triangle). Axial T1-weighted image (C) and axial T2-weighted image (D) show mixed low and high signal intensity of a lobulated mass suggestive of hematoma (open arrows) in right pelvic",17_12,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"of hematoma (open arrows) in right pelvic cavity, with a focal uterine wall rupture on the right side of the uterus. The uterine cavity (asterisk) is dilated and filled with hematoma.</p></caption><alt-text id=""al0005"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""lk0005""></graphic></fig> Surgery was performed in light of the stable vital signs and the findings on imaging. The patient had no sexual experience and had no wish to become pregnant. However, because she was a young woman",17_13,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"pregnant. However, because she was a young woman of reproductive age, the possibility of hysterectomy was fully explained to her and her guardian before the surgery, and informed consent was obtained. She underwent an exploratory laparotomy under general anesthesia. More than 2 L of coagulated blood was removed. The right side of normal-sized uterus were ruptured without any specific mass. Bleeding and hematoma from the ruptured uterus and partially ruptured right ovary were noted. Small friable nodules",17_14,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"right ovary were noted. Small friable nodules were observed on the surface of the uterus and ovaries. The mass presumed to be a myoma rupture on imaging was actually a large hematoma with irregular margins and heterogenous echogenicity at the rupture site. A total hysterectomy and right salpingo-oophorectomy were performed. Upon cutting the uterus lengthwise, it was found to be full of hematoma inside. The pathological findings were as follows. The uterus measured 9 × 6 × 4 cm with hemorrhage and rupture",17_15,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"measured 9 × 6 × 4 cm with hemorrhage and rupture of the myometrium in the right lateral wall of the uterine body. No diagnostic abnormalities in the right ovary and fallopian tube were noted. A 4.6 × 3.5 × 3 cm poorly demarcated infiltrative mass-like lesion was found in the uterine serosa, myometrium, and round ligament with mild cytologic atypia. Necrosis was not identified, and mitotic activity was <1/50 high-power fields (HPFs). Immunohistochemical (IHC) staining showed that the lesions were diffusely",17_16,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"staining showed that the lesions were diffusely positive for human melanoma black-45 (HMB-45), a highly specific marker for LAM. An additional marker, smooth muscle α-actin (SMA), and estrogen receptor (ER) were also positive (<xref rid=""f0010"" ref-type=""fig"">Fig. 2</xref>).<fig id=""f0010""><label>Fig. 2</label><caption><p>Macroscopic and microscopic features of uterine lymphangioleiomyomatosis (LAM). (A) Grossly, tumor is located at the uterine serosa-myometrium with a trabeculated appearance (closed",17_17,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"with a trabeculated appearance (closed arrowheads). (B) Microscopically, diffuse infiltration of tumor is seen (closed arrowheads), showing numerous slit-like spaces with bundles of fascicles. (C) Adjacent normal myometrium (left) differs from LAM (right), which is composed of lymphatic channels and spindled-epithelioid cells. (D) High-power magnification of LAM shows spindled-epithelioid cells (closed arrowheads) within delicate lymphatic vessels (open arrowheads). LAM cells are positive for (E) HMB-45",17_18,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"LAM cells are positive for (E) HMB-45 and (F) SMA, and (G) D2–40 is immunopositive for lymphatic vessels surrounding LAM.</p></caption><alt-text id=""al0010"">Fig. 2</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""lk0010""></graphic></fig> The patient's postoperative recovery was uneventful, and no unusual findings were noted during an outpatient visit 3 months after discharge. However, the patient strongly indicated that she did not want further diagnostic evaluation, treatment, or follow-up",17_19,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"diagnostic evaluation, treatment, or follow-up at the tertiary hospital due to the distance and cost, so no outpatient visits were done thereafter. The patient did, though, report no abnormalities in medical examinations and no unusual findings in a more recent gynecological examination at a local clinic. Although the uterus is a common site of LAM involvement, uterine LAM is a very rare, with fewer than 30 histopathologically confirmed cases reported globally [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>].",17_20,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"[<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. A previous literature review indicates that 40 % of uterine LAM are associated with TSC [<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. Therefore, uterine LAM should be considered in patients with a history of TSC presenting with vague gynecological symptoms. The clinical manifestations of uterine LAM can vary from being asymptomatic to causing symptoms such as dysmenorrhea, heavy menstrual bleeding, abnormal uterine bleeding or pelvic pain [<xref rid=""bb0035""",17_21,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"bleeding or pelvic pain [<xref rid=""bb0035"" ref-type=""bibr"">[7]</xref>, <xref rid=""bb0040"" ref-type=""bibr"">[8]</xref>, <xref rid=""bb0045"" ref-type=""bibr"">[9]</xref>]. The definitive imaging features of uterine LAM remain elusive. Ultrasound reveals a heterogeneous echogenic mass within the uterus; however, it may also appear as a solid mass with high vascularity [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. Even CT and MRI scans may present only nonspecific images: a diffuse, indistinct lesion lacking",17_22,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"images: a diffuse, indistinct lesion lacking clear demarcation [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. Similar to this case, Kim et al. described the radiological imaging findings of uterine LAM: multiple large, lobulated cystic uterine masses and a dilated endometrial cavity filled with fluid on contrast-enhanced CT [<xref rid=""bb0055"" ref-type=""bibr"">11</xref>]. On MRI, irregularly shaped uterine masses with high signal intensity were observed on the fat-suppressed T1-weighted images suggesting a",17_23,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"fat-suppressed T1-weighted images suggesting a hemorrhagic component. Due to its rarity and nonspecific symptoms and imaging studies, uterine LAM is often misdiagnosed as hemorrhagic or degenerative uterine leiomyomas, uterine malignancies, or adenomyosis [<xref rid=""bb0040"" ref-type=""bibr"">8</xref>,<xref rid=""bb0055"" ref-type=""bibr"">11</xref>]. In this case, too, it was initially misdiagnosed as a ruptured degenerated myoma. However, in similar future cases, uterine LAM should be considered when multiple",17_24,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"uterine LAM should be considered when multiple cystic uterine masses are present in patients with TSC or pulmonary LAM. The diagnosis of uterine LAM can be confirmed through characteristic pathologic features and specific immunohistochemical stains. In particular, HMB-45 and SMA are recommended for accurate diagnosis, while the ER and progesterone receptor can aid in diagnosis [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. Additionally, other markers such as vimentin and desmin can help differentiate LAM",17_25,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"as vimentin and desmin can help differentiate LAM from other diseases [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>]. LAM is considered one of the PEComa family: mesenchymal tumors with distinct IHC features, positive for both smooth muscle and melanocytic markers [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. The cells of these tumors aggregate and infiltrate vascular muscles at multiple sites. PEComas range from benign to malignant, though the latter are rare. Malignant PEComa can be suspected when two",17_26,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"rare. Malignant PEComa can be suspected when two or more of the following seven parameters are met: size >5 cm, high cellularity, high-grade nuclear atypia, mitotic activity >1/50 HPFs, necrosis, infiltrative margin, and vascular invasion [<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. This case met only the infiltrative margin criterion, suggesting a benign character. The etiology of LAM is related to genetic mutations in the tumor suppressor genes TSC1 and TSC2; these mutations are associated with",17_27,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"and TSC2; these mutations are associated with pulmonary LAM and renal AML [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>,<xref rid=""bb0065"" ref-type=""bibr"">13</xref>], but mutations in TSC genes can nevertheless often be found in cases of sporadic LAM [<xref rid=""bb0040"" ref-type=""bibr"">8</xref>]. TSC mutations cause overexpression of the mammalian target of rapamycin (mTOR) complex, forming benign tumors in various organs [<xref rid=""bb0065"" ref-type=""bibr"">[13]</xref>, <xref rid=""bb0070""",17_28,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">[13]</xref>, <xref rid=""bb0070"" ref-type=""bibr"">[14]</xref>, <xref rid=""bb0075"" ref-type=""bibr"">[15]</xref>]. This patient underwent only TSC2 testing due to cost concerns, as TSC2 mutations are more common (70 %) than TSC1 mutations (20 %) and are associated with more severe phenotypes [<xref rid=""bb0080"" ref-type=""bibr"">16</xref>,<xref rid=""bb0085"" ref-type=""bibr"">17</xref>]. Although this patient did not have a mutation in the TSC2 gene, this does not rule out a diagnosis of TSC; this is",17_29,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"does not rule out a diagnosis of TSC; this is because gene mutations are not found in up to 15 % of patients with TSC [<xref rid=""bb0065"" ref-type=""bibr"">13</xref>]. Recently, estrogen has been considered another possible cause of LAM [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. LAM mainly occurs in women of reproductive age, worsens with estrogen, and ER is confirmed in about half of cases. Therefore, hormonal changes during pregnancy may cause uterine LAM to enlarge and exacerbate symptoms. According",17_30,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"LAM to enlarge and exacerbate symptoms. According to reported cases of PEComas during pregnancy, even previously small and asymptomatic uterine PEComas can grow rapidly, leading to uterine rupture by 30 weeks of gestation [<xref rid=""bb0090"" ref-type=""bibr"">18</xref>]. Another case report describes spontaneous hemoperitoneum resulting from a ruptured PEComa of the round ligaments at 34 weeks of gestation [<xref rid=""bb0095"" ref-type=""bibr"">19</xref>]. However, not all PEComas cause rupture during",17_31,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"However, not all PEComas cause rupture during pregnancy, as some are disguised as retained placenta after a delivery [<xref rid=""bb0100"" ref-type=""bibr"">20</xref>]. Fertility preservation and management in patients with uterine LAM are important due to the risk of worsening gynecological symptoms or even uterine rupture during pregnancy. However, there is no established standard treatment for LAM or EPLAM. Medical treatments such as mTOR inhibitors or antiestrogen strategies are available; however, there",17_32,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"strategies are available; however, there is no firm data on their efficacy against the diseases [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. Therefore, early diagnosis and careful follow-up are necessary. In conclusion, uterine LAM is a rare but important disease. It is generally considered a benign tumor that does not require further treatment [<xref rid=""bb0040"" ref-type=""bibr"">8</xref>,<xref rid=""bb0060"" ref-type=""bibr"">12</xref>]. However, as in this case, it can suddenly rupture in young women, with",17_33,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"it can suddenly rupture in young women, with serious consequences, and occasionally present a malignant condition such as metastasis or sarcomatous transformation [<xref rid=""bb0045"" ref-type=""bibr"">9</xref>]. Therefore, when a patient with a history of TSC presents with abnormal uterine bleeding or abdominal pain, uterine LAM should be suspected and investigated. With few reported cases, this case enhances our understanding of uterine LAM and also highlights the need for further research due to its",17_34,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
the need for further research due to its diverse presentation and diagnostic difficulties.,17_35,Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report,12 9 2024,,Tuberous_Sclerosis
"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study Angiomyolipomas (AML) is a benign mesenchymal tumor consisting of aberrant thick‐walled blood vessels, smooth muscle cells, and adipose tissue.<xref rid=""cam470181-bib-0001"" ref-type=""bibr"">
<sup>1</sup>",18_0,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>1</sup>
</xref> AML can arise on its own or, in many cases, in association with the tuberous sclerosis complex (TSC). Indeed, approximately 80% of TSC lesions, which may grow from a common progenitor cell that has both alleles of either TSC1 or TSC2 inactivated, will suffer renal AMLs.<xref rid=""cam470181-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",18_1,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>2</sup>
</xref> AML symptoms include abdominal pain, a palpable lump, macroscopic hematuria, and hypertension; however, the majority of patients are asymptomatic through to their tumors grow big.<xref rid=""cam470181-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref> The most concerning complication of AMLs are their proclivity to rupture and bleed spontaneously, with a potential risk of mortality.<xref rid=""cam470181-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>",18_2,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>4</sup>
</xref>
 The primary objective in patients with renal AMLs is to avoid bleeding and enlargement of AMLs, as well as preserve renal function. The main treatment methods for this disease include active surveillance, surgical resection, embolization, and drug treatment. Mammalian target of rapamycin (mTOR) inhibitors can achieve satisfactory results in treating TSC, which has been recommended as a first‐line treatment option in NCCN guidelines<xref rid=""cam470181-bib-0005"" ref-type=""bibr"">",18_3,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>5</sup>
</xref> The efficacy of mTOR inhibitor everolimus in AML was broadly investigated in recent studies with a reduced the AML volume by ≥50% in more than 50% patients with TSC and a ≥25% reduction in tumor volume in 71.4% patients in non‐TSC AML at 6 months of administration.<xref rid=""cam470181-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""cam470181-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",18_4,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> The problem with long‐term everolimus treatment is that it shrinks AMLs but does not cure them, and it raises the chance of developing gonadal dysfunction, interstitial lung disease, and immunosuppression‐related complications.<xref rid=""cam470181-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref>, <xref rid=""cam470181-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref>",18_5,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>9</sup>
</xref>
 Patients with TSC‐associated AMLs have multifocal and bilateral lesions, as well as a significant recurrence rate when compared to sporadic AMLs. As a result, comprehensive therapy is required for TSC‐associated AML.<xref rid=""cam470181-bib-0010"" ref-type=""bibr"">
<sup>10</sup>",18_6,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>10</sup>
</xref> Previous case reports indicated that preoperative mTOR inhibitor therapy for TSC‐associated AML may lower the incidence of recurrence and the difficulty of partial nephrectomy (PN).<xref rid=""cam470181-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""cam470181-bib-0011"" ref-type=""bibr"">
<sup>11</sup>",18_7,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>11</sup>
</xref> While everolimus exhibits good efficacy in AMLs, the addition of surgery procedure maximizes the possibility of cure and therefore, avoid potential toxicity from long‐term everolimus administration. For patients with sporadic renal AML who need treatment, embolization and surgery are optional treatment options. Although embolization is more minimally invasive, the drawback was high recurrence rate.<xref rid=""cam470181-bib-0012"" ref-type=""bibr"">
<sup>12</sup>",18_8,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>12</sup>
</xref> In comparison, PN showed more durable efficacy for long‐term control. The long‐term recurrence rate was only 0%–3% in sporadic AML patients receiving PN.<xref rid=""cam470181-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>",18_9,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"The relatively high recurrence rate of embolization led to the consideration of surgery treatment. However, it seems challenge to perform PN in large and complex renal AML. To our knowledge, no study reports the outcome of renal AMLs that introduces neoadjuvant therapy to shrink the tumor and create timing for PN leading to a low level of evidence for guidelines in this population. Herein, we conduct a multicenter retrospective study to evaluate the outcomes of neoadjuvant everolimus in renal AMLs with or",18_10,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"of neoadjuvant everolimus in renal AMLs with or without TSC.   Our study shows that everolimus was clinically active in the neoadjuvant setting in renal AML patients with 55.9% patients achieving a ≥25% tumor volume reduction. These promising results are particularly important in patients with TSC compared to non‐TSC. 61.0% and 41.5% of TSC‐AMLs patients experienced a ≥25% and a ≥50% volume reduction, respectively, while 44.4% and 18.5% of non‐TSC AMLs showed a ≥25% and a ≥50% volume reduction,",18_11,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"AMLs showed a ≥25% and a ≥50% volume reduction, respectively. Tolerance was well with a 10.3% rate of grade 3–4 AEs related to systemic treatment and no severe intraoperative and postoperative complication occurring. Everolimus is now the first‐line option for TSC treatment due to advances in genetic and molecular biology. It can suppress mTOR activity and prevent renal AMLs from enlarging. The EXIST2 trial (Everolimus for AMLs associated with TSC or sporadic lymphangioleiomyomatosis) found that 42% of",18_12,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"lymphangioleiomyomatosis) found that 42% of subjects in the everolimus group had ≥50% reduction of lesion size, in comparison with 0% in placebo group.<xref rid=""cam470181-bib-0006"" ref-type=""bibr"">",18_13,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>6</sup>
</xref> A recent study enrolling subjects with sporadic AMLs showed a ≥25% reduction in tumor volume at 4 months in 10/18 subjects and at 6 months in 10/14 subjects.<xref rid=""cam470181-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref> Although the efficacy of everolimus is remarkable, following analysis of EXIST2 trial indicated that a part of patients underwent regrowth of tumor 48 weeks after everolimus discontinuation.<xref rid=""cam470181-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",18_14,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref> Two patients in Geynisman, D. M. et al. study also showed notable regrowth at 12 months after demonstrating a ≥50% lesion size reduction at 4 months.<xref rid=""cam470181-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",18_15,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> For sporadic AMLs, PN provided long‐term tumor control. But unfortunately, PN may be impossible for patients with large and complex tumors. Although neoadjuvant and pre‐surgical everolimus may shrink primary tumors, no study illustrates the ability of this therapy to facilitate PN in sporadic AML. Therefore, comprehensive treatment with the goal to achieve durable control is attractive for AMLs with or without TSC. Herein, we performed a multi‐center, retrospective study to explore the feasibility,",18_16,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"retrospective study to explore the feasibility, effectiveness, and practicality of using neoadjuvant everolimus followed by PN for patients with AMLs, regardless of the presence of TSC. The advantages of this strategy include: (1) Neoadjuvant everolimus reduces tumor volume to some extent, lowering the incidence the difficulty of performing PN, while also providing an opportunity for patients who are unable to undergo immediate PN; (2) It provides favorable renal function preservation and achieves durable",18_17,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"renal function preservation and achieves durable tumor control with low recurrence rate simultaneously, ensuring the postoperative life quality for these patients; (3) It avoids the need for long‐term administration of everolimus, therefore reduces the risk of late adverse events and potential financial burden. Everolimus targeting the pathogenesis of AML induced a deep shrinkage of tumor, particularly in TSC‐associated disease. In our study, 90.2% patients in TSC group and 81.5% patients in non‐TSC group",18_18,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"in TSC group and 81.5% patients in non‐TSC group showed a decrease of lesion as compared with baseline. More than half of patients in TSC group showed a ≥50% lesion size reduction. The deep response of TSC tumor indicated a strong sensitivity for everolimus, which may suggest a dominant role of mTOR pathway in TSC tumor development. The primary outcomes of this study were comparable with EXIST2 trial and Geynisman, D. M. et al. study.<xref rid=""cam470181-bib-0006"" ref-type=""bibr"">",18_19,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>6</sup>
</xref>, <xref rid=""cam470181-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",18_20,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>7</sup>
</xref> Indeed, many patients with renal AMLs were identified as unable or hard to perform a PN with the causes such as technically impossible in large confluent lesions, or uncertain malignancy. Initial surgery and embolization usually fail in up to 20% of TSC‐related AML tumors, which leads to the requirement of repeat surgery or embolization and restricts their value in the treatment of TSC‐AML.<xref rid=""cam470181-bib-0014"" ref-type=""bibr"">
<sup>14</sup>",18_21,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>14</sup>
</xref>, <xref rid=""cam470181-bib-0015"" ref-type=""bibr"">
<sup>15</sup>",18_22,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> In this scenario, neoadjuvant everolimus with high efficacy in inducing AML shrinkage will set the stage for surgery. Our observation further confirmed this concept that 10 of 17 patients unfit for PN at baseline were transferred to PN after 3 to 4 months of everolimus administration. Overall, preoperative everolimus facilitated the feasibility of PN and simplified operation difficulty. A decline in renal function has been reported as the natural history of renal AML patients with TSC.<xref",18_23,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"history of renal AML patients with TSC.<xref rid=""cam470181-bib-0012"" ref-type=""bibr"">",18_24,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>12</sup>
</xref>, <xref rid=""cam470181-bib-0016"" ref-type=""bibr"">
<sup>16</sup>",18_25,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> Either PN or embolization alone led to the inevitable loss of renal function. The embolization restricts the acquirement of histologic diagnosis. Unilateral nephrectomy results in substantial loss of renal function. In comparison, PN provides unequivocal management of AML for histologic confirmation. Moreover, dynamic analysis for eGFR suggested neoadjuvant everolimus induced limited loss of ΔeGFR, and renal function maintained well for a long‐term. Another issue for embolization is the potential",18_26,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"Another issue for embolization is the potential high recurrence rate, particularly in AML with TSC.<xref rid=""cam470181-bib-0012"" ref-type=""bibr"">",18_27,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
<sup>12</sup>,18_28,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> In our retrospective cohort, only one of 97 patients experienced recurrence in median follow‐up of 24 months. Although the efficacy and safety of everolimus has been confirmed, the challenges remained in some situations. mTOR inhibitors have potent antiproliferative and immunosuppressive effects, causing their usage to be with dose interruptions or adjustments. And after discontinuation of everolimus, 31.3% of patients experienced regrowth of AML.<xref rid=""cam470181-bib-0008"" ref-type=""bibr"">",18_29,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
<sup>8</sup>,18_30,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> Indeed, late AE management and the risk of regrowth contribute to expense increases and AE suffering. Many patients take personal values and preferences/individual situations into the consideration of treatment selections. For examples, the medical institution is far away from home, the expense of treatment is high, and the patient expects to be durable control in a defined course. Neoadjuvant everolimus followed by PN will be considered in these situations. In our respective study, most patients",18_31,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"In our respective study, most patients received PN after three or 4 months of everolimus. Consistently, EXIST2 trials show a median time to AML response of 2.9 months.<xref rid=""cam470181-bib-0006"" ref-type=""bibr"">",18_32,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"<sup>6</sup>
</xref>, <xref rid=""cam470181-bib-0017"" ref-type=""bibr"">
<sup>17</sup>",18_33,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"</xref> All the data above indicated that neoadjuvant everolimus could create a chance for surgery within a stable time pried. The major limitation of our study was the small sample size, which was attributable to the rarity of AML with or without TSC. Otherwise, with the nature of retrospective study, we only just collected the information from investigator's perspective to identify whether patients were fit for PN. Nonetheless, our analysis provides the largest series and unique perspective to identify",18_34,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"largest series and unique perspective to identify the clinical value of neoadjuvant everolimus in AML. In conclusion, neoadjuvant everolimus followed by PN is an attractive option for AML patients with high efficacy, maximized renal function preservation and a low burden of long‐term management.",18_35,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
<bold>Jiwei Huang:</bold> Conceptualization (equal); funding acquisition (equal); investigation (equal); supervision (equal); validation (equal); writing – original draft (equal). <bold>Ruopeng Su:</bold> Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); writing – original draft (equal). <bold>Tingxuan Huang:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Liangyou Gu:</bold> Data curation,18_36,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
(equal). <bold>Liangyou Gu:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Zhihong Liu:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Pinghong Dao:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Lin Yao:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing –,18_37,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
(equal); investigation (equal); writing – original draft (equal). <bold>Xiaoyi Hu:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Guanghou Fu:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Jitao Wu:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Thibault Tricard:</bold> Investigation (equal);,18_38,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
Tricard:</bold> Investigation (equal); methodology (equal); validation (equal). <bold>Guangyu Wu:</bold> Formal analysis (equal); investigation (equal); methodology (equal). <bold>Minfeng Chen:</bold> Conceptualization (equal); supervision (equal). <bold>Chancan Li:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal). <bold>Zhiyang Huang:</bold> Data curation (equal); formal analysis (equal); investigation (equal); writing – original draft (equal).,18_39,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
(equal); writing – original draft (equal). <bold>Bing Zheng:</bold> Data curation (equal); formal analysis (equal); writing – original draft (equal). <bold>Yonghui Chen:</bold> Conceptualization (equal); investigation (equal); methodology (equal); supervision (equal). <bold>Wei Xue:</bold> Conceptualization (equal); project administration (equal); supervision (equal). <bold>Yige Bao:</bold> Project administration (equal); supervision (equal); validation (equal). <bold>Gang Guo:</bold> Project,18_40,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"(equal). <bold>Gang Guo:</bold> Project administration (equal); supervision (equal). <bold>Pei Dong:</bold> Methodology (equal); project administration (equal); supervision (equal); validation (equal). <bold>jin zhang:</bold> Formal analysis (equal); investigation (equal); project administration (equal); supervision (equal); validation (equal). This study was supported by Shanghai Science and Technology Commission Research Project (21ZR1438900), Basic Oncology Research Program from Bethune Charitable",18_41,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"Oncology Research Program from Bethune Charitable Foundation (BCF‐NH‐ZL‐20201119‐024), Wu Jieping Medical Foundation (320.6750.2022‐19‐92), and the Incubating Program for Clinical Research and Innovation of Renji Hospital (PYXJS16‐008, PYIII20‐07). The authors report no conflict of interest. This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by ethics committee of Ren Ji Hospital and all other participating institutions (KY2021‐102). The data was",18_42,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
institutions (KY2021‐102). The data was retrieved from electronic medical records of 11 participating institutions and informed consent was obtained from the participants involved.,18_43,"Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study",15 9 2024,,Tuberous_Sclerosis
"The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by multiple organ lesions resulting from mutations in either TSC1 or TSC2 genes. The protein products of these genes negatively regulate the mammalian target of rapamycin (mTOR) signaling pathway [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. TSC-related renal lesion",19_0,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"rid=""CR2"">2</xref>]. TSC-related renal lesion is prevalent among TSC patients, with up to 80% exhibiting renal abnormality, among which angiomyolipoma is the most common, affecting 56% of boys and 66% of girls [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Renal disease also is reported as a leading cause of mortality in these TSC patient [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Renal angiomyolipoma associated with TSC (TSC-RAML) predominantly affects younger individuals and is characterized by larger,",19_1,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"individuals and is characterized by larger, faster-growing, multiple, and bilateral lesions, posing a higher risk of renal rupture and hemorrhage compared to sporadic renal angiomyolipoma (S-RAML) [<xref ref-type=""bibr"" rid=""CR5"">5</xref>–<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Treatment options were historically limited until the emergence of everolimus as a promising therapy in recent years [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Several clinical studies have demonstrated the efficacy of",19_2,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"studies have demonstrated the efficacy of everolimus, an mTOR inhibitors, in reducing TSC-RAML volume, preventing tumor rupture and bleeding, and preserving renal function. Discontinuation of everolimus results in tumor rebound, necessitating its continuous administration to suppress tumor growth [<xref ref-type=""bibr"" rid=""CR9"">9</xref>–<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. However, the use of everolimus is associated with significant side effects that can diminish a patient's quality of life,",19_3,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"that can diminish a patient's quality of life, necessitating dose adjustments or treatment discontinuation [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Studies indicate that everolimus administration in TSC-RAML patients may increase hematologic risks, but understanding of its specific impact on hematologic parameters remains limited [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. In this study, we aim to elucidate the dynamic changes in hematologic parameters",19_4,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"the dynamic changes in hematologic parameters during one year of everolimus treatment among TSC-RAML patients. Furthermore, we investigate how these changes vary based on gender and age within the patient population. We anticipate that our research will provide valuable insights and guidance for optimizing everolimus management in TSC-RAML patients, thereby minimizing potential risks associated with treatment.  A total of 55 patients were included in this analysis, comprising 15 patients from clinical",19_5,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"analysis, comprising 15 patients from clinical trial 1 (out of the initially enrolled 18 patients, 3 patients discontinued the study within the first year) and 40 patients from clinical trial 2. The demographic and clinical characteristics of the patients are presented in Table <xref rid=""Tab1"" ref-type=""table"">1</xref>. The mean age of the patients was 31, with 30 patients being above 30 years old. Of the patients, 36 were male, while 4 female patients presented with lymphangioleiomyomatosis (LAM). Four",19_6,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"with lymphangioleiomyomatosis (LAM). Four patients were diagnosed with subependymal giant cell astrocytoma (SEGA), and all 55 patients exhibited skin lesions.",19_7,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Demographics and baseline characteristics</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Characteristics</th><th align=""left"">Clinical trial 1</th><th align=""left"">Clinical trial 2</th><th align=""left"">Total</th></tr></thead><tbody><tr><td align=""left"">Number of patients</td><td align=""left"">15</td><td align=""left"">40</td><td align=""left"">55</td></tr><tr><td align=""left"">Age in years, median (range)</td><td",19_8,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">Age in years, median (range)</td><td align=""left"">30 (20–46)</td><td align=""left"">33 (18–60)</td><td align=""left"">31 (18–60)</td></tr><tr><td align=""left""> ≦ 30y</td><td align=""left"">8 (53.3%)</td><td align=""left"">17 (42.5%)</td><td align=""left"">25 (45.5%)</td></tr><tr><td align=""left""> > 30y</td><td align=""left"">7 (46.7%)</td><td align=""left"">23 (57.5%)</td><td align=""left"">30 (54.5%)</td></tr><tr><td align=""left"" colspan=""4"">Sex</td></tr><tr><td align=""left""> Female</td><td align=""left"">11",19_9,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left""> Female</td><td align=""left"">11 (73.3%)</td><td align=""left"">26 (65.0%)</td><td align=""left"">37 (67.3%)</td></tr><tr><td align=""left""> Male</td><td align=""left"">4 (26.6%)</td><td align=""left"">14 (35.0%)</td><td align=""left"">18 (32.7%)</td></tr><tr><td align=""left"" colspan=""4"">Race (n, %)</td></tr><tr><td align=""left""> Asian</td><td align=""left"">15 (100%)</td><td align=""left"">40 (100%)</td><td align=""left"">55 (100%)</td></tr><tr><td align=""left""> Presence of SEGA</td><td align=""left"">0",19_10,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"of SEGA</td><td align=""left"">0 (0%)</td><td align=""left"">3 (7.5%)</td><td align=""left"">3 (5.5%)</td></tr><tr><td align=""left""> Diagnosis of LAM</td><td align=""left"">5 (40.0%)</td><td align=""left"">13 (32.5%)</td><td align=""left"">18 (32.7%)</td></tr><tr><td align=""left""> Skin lesion (≥ 1)</td><td align=""left"">15 (100%)</td><td align=""left"">40 (100%)</td><td align=""left"">55 (100%)</td></tr></tbody></table><table-wrap-foot><p><italic toggle=""yes"">SEGA</italic> subependymal giant cell astrocytoma, <italic",19_11,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"subependymal giant cell astrocytoma, <italic toggle=""yes"">LAM</italic> lymphangioleiomyomatosis</p></table-wrap-foot></table-wrap> Significant reductions were observed in hemoglobin, white blood cells (WBC), lymphocytes, neutrophils, and platelets during everolimus treatment (P < 0.05). However, the decreases in hemoglobin, WBC, and neutrophils attenuated in the 12th month (P > 0.05) (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>A, B, E, F). Importantly, lymphocytes exhibited a persistent and significant",19_12,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"exhibited a persistent and significant decrease throughout the entire year of treatment (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>C). Conversely, monocytes showed a consistent increasing trend, although this change was not statistically significant (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>D).<fig id=""Fig1""><label>Fig. 1</label><caption><p>Changes in hematologic parameters in TSC-RAML patients during everolimus treatment</p></caption><graphic http://www.w3.org/1999/xlink",19_13,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"http://www.w3.org/1999/xlink href=""12672_2024_1329_Fig1_HTML"" id=""MO1""></graphic></fig> Aspartate transaminase (AST), alanine transferase (ALT), and total cholesterol (TC) exhibited a sharp and significant increase during the initial 3 months of treatment (P < 0.05), and these levels remained significantly elevated thereafter (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>G, H, K). Triglyceride levels showed a significant increase starting from the 3rd month and continued to rise throughout the treatment",19_14,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"and continued to rise throughout the treatment period, despite a subsequent decrease after peaking in the 6th month (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>L). Although creatinine and glucose levels displayed a general increasing trend over the one-year treatment period, these changes were not statistically significant (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>I, J). The differences in the changes in hematologic parameters between female and male patients are presented in Table <xref rid=""Tab2""",19_15,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"patients are presented in Table <xref rid=""Tab2"" ref-type=""table"">2</xref>. The age difference between females and males was not statistically significant (31 vs 33, P = 0.620). Male patients exhibited a significantly greater decrease in hemoglobin compared to female patients (− 15 vs − 6, P = 0.010). The increase in AST was significantly higher in male patients compared to female patients (7.0 vs 3.0, P = 0.041), and a similar trend was observed for ALT, indicating a higher increase in male patients.",19_16,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"indicating a higher increase in male patients. Furthermore, female patients exhibited a higher increase in creatine, glucose, total cholesterol (TC), and triglycerides, although these differences were not statistically significant. The gender distribution between younger and older patients were not statistically significant (female/male: 18/7 vs 18/12, P = 0.351). However, Table <xref rid=""Tab3"" ref-type=""table"">3</xref> demonstrates that the decrease in platelet count (− 50 vs − 14, P = 0.020) was",19_17,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"in platelet count (− 50 vs − 14, P = 0.020) was significantly greater in younger patients (≦30 years old) compared to older patients (> 30 years old).",19_18,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"<table-wrap id=""Tab2""><label>Table 2</label><caption><p>Differences in hematologic parameter changes between females and males</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Parameter</th><th align=""left"">Female (n = 29)</th><th align=""left"">Male (n = 16)</th><th align=""left"">P</th></tr></thead><tbody><tr><td align=""left"">Hemoglobin (g/L)</td><td align=""left"">− 6 (− 12, − 4)</td><td align=""left"">− 15 (− 20, − 5)</td><td char="".""",19_19,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">− 15 (− 20, − 5)</td><td char=""."" align=""char""><bold>0.010</bold></td></tr><tr><td align=""left"">WBC (× 109/L)</td><td align=""left"">− 0.64 ± 0.93</td><td align=""left"">− 0.62 ± 1.98</td><td char=""."" align=""char"">0.965</td></tr><tr><td align=""left"">Lymphocyte (× 109/L)</td><td align=""left"">− 0.20 ± 0.41</td><td align=""left"">− 0.20 ± 0.70</td><td char=""."" align=""char"">0.998</td></tr><tr><td align=""left"">Monocyte (× 109/L)</td><td align=""left"">0.052 ± 0.136</td><td",19_20,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">0.052 ± 0.136</td><td align=""left"">− 0.001 ± 0.143</td><td char=""."" align=""char"">0.191</td></tr><tr><td align=""left"">Neutrophil (× 109/L)</td><td align=""left"">− 0.38 (− 0.84, 0.12)</td><td align=""left"">− 0.43 (− 2.06, 1.27)</td><td char=""."" align=""char"">0.614</td></tr><tr><td align=""left"">Platelet (× 109/L)</td><td align=""left"">− 32 ± 59</td><td align=""left"">− 30 ± 51</td><td char=""."" align=""char"">0.899</td></tr><tr><td align=""left"">AST (U/L)</td><td align=""left"">3.0 (0.3, 7.0)</td><td",19_21,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"(U/L)</td><td align=""left"">3.0 (0.3, 7.0)</td><td align=""left"">7.0 (3.0, 16.0)</td><td char=""."" align=""char""><bold>0.041</bold></td></tr><tr><td align=""left"">ALT (U/L)</td><td align=""left"">4.5 (0.3, 8.8)</td><td align=""left"">13.0 (− 1.0, 30.0)</td><td char=""."" align=""char"">0.132</td></tr><tr><td align=""left"">Creatine (μmol/L)</td><td align=""left"">3.0 (− 2.0, 7.3)</td><td align=""left"">1.5 (− 6.8, 5.0)</td><td char=""."" align=""char"">0.388</td></tr><tr><td align=""left"">Glucose (nmol/L)</td><td",19_22,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">Glucose (nmol/L)</td><td align=""left"">0.13 (− 0.20, 0.58)</td><td align=""left"">− 0.06 (− 0.40, 0.30)</td><td char=""."" align=""char"">0.150</td></tr><tr><td align=""left"">TC (nmol/L)</td><td align=""left"">1.47 ± 1.03</td><td align=""left"">1.02 ± 1.01</td><td char=""."" align=""char"">0.151</td></tr><tr><td align=""left"">Triglyceride (nmol/L)</td><td align=""left"">1.07 (0.52, 1.73)</td><td align=""left"">0.75 (− 0.07, 1.16)</td><td char="".""",19_23,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">0.75 (− 0.07, 1.16)</td><td char=""."" align=""char"">0.084</td></tr></tbody></table><table-wrap-foot><p><italic toggle=""yes"">WBC</italic> white blood cell, <italic toggle=""yes"">TC</italic> Total cholesterol</p></table-wrap-foot></table-wrap><table-wrap id=""Tab3""><label>Table 3</label><caption><p>Differences in hematologic parameter changes between the younger and older</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Parameters</th><th align=""left"">Younger (≦ 30 y,",19_24,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">Younger (≦ 30 y, n = 25)</th><th align=""left"">Elder (> 30 y, n = 30)</th><th align=""left"">P</th></tr></thead><tbody><tr><td align=""left"">Hemoglobin (g/L)</td><td align=""left"">− 6 ± 11</td><td align=""left"">− 11 ± 16</td><td char=""."" align=""char"">0.265</td></tr><tr><td align=""left"">WBC (× 109/L)</td><td align=""left"">− 0.39 ± 1.13</td><td align=""left"">− 0.85 ± 1.49</td><td char=""."" align=""char"">0.223</td></tr><tr><td align=""left"">Lymphocyte (× 109/L)</td><td align=""left"">− 0.15 (− 0.60,",19_25,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"(× 109/L)</td><td align=""left"">− 0.15 (− 0.60, 0.09)</td><td align=""left"">− 0.19 (− 0.44, 0.12)</td><td char=""."" align=""char"">0.703</td></tr><tr><td align=""left"">Monocyte (× 109/L)</td><td align=""left"">0.019 ± 0.117</td><td align=""left"">0.039 ± 0.144</td><td char=""."" align=""char"">0.608</td></tr><tr><td align=""left"">Neutrophil (× 109/L)</td><td align=""left"">− 0.46 ± 1.27</td><td align=""left"">− 0.60 ± 1.73</td><td char=""."" align=""char"">0.366</td></tr><tr><td align=""left"">Platelet (× 109/L)</td><td",19_26,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">Platelet (× 109/L)</td><td align=""left"">− 50 ± 54</td><td align=""left"">− 14 ± 54</td><td char=""."" align=""char""><bold>0.020</bold></td></tr><tr><td align=""left"">AST (U/L)</td><td align=""left"">4.0 (0, 8.0)</td><td align=""left"">4.0 (1, 12.5)</td><td char=""."" align=""char"">0.407</td></tr><tr><td align=""left"">ALT (U/L)</td><td align=""left"">7.0 (2.5, 20)</td><td align=""left"">3.5 (− 3.0, 10.0)</td><td char=""."" align=""char"">0.095</td></tr><tr><td align=""left"">Creatine (μmol/L)</td><td",19_27,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"align=""left"">Creatine (μmol/L)</td><td align=""left"">2.32 ± 7.02</td><td align=""left"">5.63 ± 16.80</td><td char=""."" align=""char"">0.355</td></tr><tr><td align=""left"">Glucose (nmol/L)</td><td align=""left"">0.07 ± 0.41</td><td align=""left"">0.20 ± 0.67</td><td char=""."" align=""char"">0.420</td></tr><tr><td align=""left"">TC (nmol/L)</td><td align=""left"">1.35 ± 0.90</td><td align=""left"">1.32 ± 1.16</td><td char=""."" align=""char"">0.913</td></tr><tr><td align=""left"">Triglyceride (nmol/L)</td><td align=""left"">0.94 (0.42,",19_28,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"(nmol/L)</td><td align=""left"">0.94 (0.42, 1.49)</td><td align=""left"">0.84 (0.42, 1.60)</td><td char=""."" align=""char"">0.933</td></tr></tbody></table><table-wrap-foot><p><italic toggle=""yes"">WBC</italic> white blood cell, <italic toggle=""yes"">TC</italic> Total cholesterol</p></table-wrap-foot></table-wrap> The TSC1-TSC2 complex, composed of hamartin and tuberin encoded by the TSC1 and TSC2 genes, respectively, is a crucial inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1). Mutations in",19_29,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"of rapamycin complex 1 (mTORC1). Mutations in either TSC1 or TSC2 can lead to the functional loss of the TSC1-TSC2 complex, resulting in unregulated and constitutive activation of mTORC1. This dysregulation causes uncontrolled protein synthesis, cellular growth, proliferation, and angiogenesis [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Everolimus, an mTOR inhibitor, has shown efficacy in reducing tumor size, preventing tumor rupture and bleeding, and preserving renal function, making it the recommended",19_30,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"renal function, making it the recommended first-line therapy for TSC patients [<xref ref-type=""bibr"" rid=""CR9"">9</xref>–<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. However, the potential risks associated with its treatment cannot be overlooked. Our study specifically examined the potential hematologic impact and risks of everolimus in patients with TSC-RAML. Many hematologic parameters were significantly impacted by everolimus throughout the treatment period, with most blood cells, except for monocytes,",19_31,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"with most blood cells, except for monocytes, as well as hemoglobin showing significant decreases. A published study on the effectiveness and safety of everolimus treatment in TSC patients also demonstrated that anemia and leukopenia were the most frequent laboratory abnormalities during the entire treatment period [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. In our study, hemoglobin, WBC, neutrophil, and platelet exhibited significant decreases followed by rebound increases, which may be attributed to the",19_32,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"rebound increases, which may be attributed to the homeostatic regulation of blood cells to maintain parameter fluctuations around a certain level [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Hemoglobin and lymphocyte exhibited significant decreases in a shorter duration (≤ 3 months) compared to WBC, neutrophils, and platelets, suggesting that hemoglobin and lymphocytes were more susceptible to the effects of everolimus. This vulnerability may be due to the dynamic turnover of these cell types. Notably,",19_33,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"dynamic turnover of these cell types. Notably, red blood cells and lymphocytes have longer lifespans than neutrophils and platelets [<xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR19"">19</xref>], indicating lower turnover activity in red blood cells and lymphocytes, and thus resulting in significant decreases within a shorter timeframe under the influence of everolimus. The decrease may be associated with inhibition on the cell cycle and subsequent proliferation of normal cells",19_34,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"and subsequent proliferation of normal cells when everolimus suppresses tumor progression. Additionally, mTOR inhibitors block the interleukin-2 receptor and CD28-dependent signaling pathways, which could further contribute to the observed myelosuppression and inhibition of blood cell proliferation [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. Everolimus also is used as an immune system suppressor in transplantation recipients, inhibiting the ability of white blood cells (WBC) to reject the transplanted",19_35,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"blood cells (WBC) to reject the transplanted organ [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. The significant decrease in WBC, lymphocyte, and neutrophil levels, indicating immune suppression and toxicity of everolimus, may weaken the anti-infection capacity of TSC-RAML patients undergoing everolimus treatment. It is important to note that lymphocyte levels consistently decrease during the treatment and may further decline with continued therapy. Hematological toxicity and bone marrow suppression are",19_36,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"toxicity and bone marrow suppression are common side effects of mTOR inhibitor treatment. Thrombocytopenia and neutropenia rarely lead to clinically significant bleeding or infection, and thus usually do not require platelet transfusions or growth factor support. However, in cases of grade 3 toxicity, it is necessary to interrupt the treatment and reduce the dose when resuming. Additionally, everolimus should be discontinued immediately if any life-threatening toxicity occurs [<xref ref-type=""bibr""",19_37,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"toxicity occurs [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. Everolimus undergoes extensive metabolism primarily through the cytochrome P450 system (CYP3A4) and P-glycoprotein in the liver [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. Liver injury may result from the direct effects of everolimus or intermediate toxicity generated during its metabolism. Both ALT and AST, key markers of liver function in clinical practice, showed a significant increase after 3 months and remained elevated throughout the",19_38,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"3 months and remained elevated throughout the treatment period. Therefore, careful monitoring of liver function is essential in TSC-RAML patients during treatment, especially when everolimus is co-administered with inhibitors or inducers of cytochrome P450 drug-metabolizing enzymes, as potential drug interactions may occur. Many studies have also documented hyperlipidemia as another common adverse effect of everolimus [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR12"">12</xref>].",19_39,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Lipid levels, including total cholesterol (TC) and triglycerides (TG), also exhibited significant increases in the short term, specifically within less than 3 months in our study. Research has shown that everolimus can significantly elevate serum lipid levels by reducing lipoprotein lipase activity [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. On the other hand, the metabolism of apolipoprotein B (apoB) is mediated through the mTOR signaling pathway, and the",19_40,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"through the mTOR signaling pathway, and the catabolism of apoB-containing lipoproteins is diminished by mTOR inhibitors [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Both cholesterol and triglycerides are apoB-containing particles, and the increased levels of apoB lipoproteins may contribute to elevated lipid levels [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. We recommend drug intervention for severe hyperlipidemia or grade 3 liver injury. However, elevated lipid levels, particularly in TSC-RAML patients",19_41,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"lipid levels, particularly in TSC-RAML patients with comorbidities such as hyperlipidemia, hyperglycemia, and hypertension, may significantly increase the risk of cardiovascular and cerebrovascular diseases [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. Limited studies have investigated hematologic response differences among TSC-RAML patients of different genders and age groups to everolimus treatment. Our analysis revealed that male patients experienced a greater decrease in hemoglobin levels and a greater",19_42,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"decrease in hemoglobin levels and a greater increase in AST levels due to everolimus treatment. Estrogen has the potential to stimulate hematopoiesis in females and enhance the proliferation of hematopoietic stem cells (HSCs) and various blood cell types, including erythrocytes [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. The higher renewal capacity of erythrocytes in females may help mitigate the side effects on hemoglobin levels. Although females are generally considered to be at higher risk for",19_43,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"are generally considered to be at higher risk for drug-induced liver injury [<xref ref-type=""bibr"" rid=""CR28"">28</xref>], gender disparities in drug-induced liver injury vary depending on the specific drugs, with a higher frequency of reported drug-induced liver events in males for certain medications [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. Our findings indicated that male patients exhibited higher elevations in alanine aminotransferase (ALT) levels, suggesting a potentially greater risk of",19_44,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"levels, suggesting a potentially greater risk of drug-induced liver injury associated with everolimus in males. Our results also revealed a greater decrease in platelet levels among younger patients. The tortuous aneurysmal vessels within the angiomyolipoma, which are more susceptible to rupture and bleeding compared to normal vessels, constitute a high-risk factor for tumor hemorrhage [<xref ref-type=""bibr"" rid=""CR30"">30</xref>]. Tumor rupture and hemorrhage pose a significant life-threatening risk for",19_45,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"pose a significant life-threatening risk for TSC-RAML patients. The decrease in platelet count may further enhance the risk of hemorrhage due to the potential platelet-related coagulation dysfunction. Everolimus is an immune inhibitor that can potentially result in immune system dysfunction. Besides inhibiting platelet proliferation, it remains uncertain whether the decrease in platelets is related to drug-induced immune thrombocytopenia, as everolimus may lead to possible immune dysfunction. Furthermore,",19_46,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"lead to possible immune dysfunction. Furthermore, significant differences exist in the immune systems of younger and older individuals, which may contribute to the varying platelet decreases observed between younger and older patients. Additional research is necessary to further elucidate this potential relationship. There are several limitations in our study: (1) The sample size was relatively small due to the rarity of TSC-RAML. (2) The generalizability of our findings might be limited because all",19_47,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"of our findings might be limited because all patients included were Asians. (3) Hematologic parameters can be affected by various factors, such as active infection or inflammation. These factors might have influenced the accuracy of our results, although measures were taken to minimize potential influences as much as possible. Hemoglobin, WBC, neutrophil, platelet and lymphocytes underwent a significant decrease during everolimus treatment in TSC-RAML patients, whereas AST, ALT, TC, and TG demonstrated",19_48,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
"whereas AST, ALT, TC, and TG demonstrated significant increases. Male patients exhibited higher vulnerability to everolimus-induced decreases in hemoglobin and platelet counts, while younger patients showed greater susceptibility to everolimus-induced platelet reduction.",19_49,The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex,12 9 2024,,Tuberous_Sclerosis
Atypical case of tuberous sclerosis with isolated neurologic findings: A case report Tuberous sclerosis (TSC) is an autosomal dominant neurocutaneous disorder. This case highlights rare isolated neurologic finding in a TSC patient emphasizing the need for heightened suspicion even in the absence of any cutaneous findings and family history. Tuberous sclerosis complex (TSC) is a rare inherited neurocutaneous disorder with autosomal dominant inheritance. It is characterized by diverse features involving,20_0,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"It is characterized by diverse features involving multiple organ systems, including the development of benign hamartomas in the brain, eyes, heart, lungs, liver, kidneys, and skin.<xref rid=""ccr39379-bib-0001"" ref-type=""bibr"">",20_1,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>1</sup>
</xref>, <xref rid=""ccr39379-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref> While Bourneville provided the first detailed description of the neurological symptoms and gross pathology in the central nervous system in 1880, it is important to note that this disorder is rare, and estimated to have incidence of 1 in 10,000 live births. TSC affects all age groups and races with no gender predilection.<xref rid=""ccr39379-bib-0003"" ref-type=""bibr"">
<sup>3</sup>",20_2,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>3</sup>
</xref>, <xref rid=""ccr39379-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""ccr39379-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref>",20_3,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"TSC was first depicted in 1835 when Pierre Francis Olive Rayer published color drawing showing small erythematous papules that resemble “facial angiofibroma.” In 1862, Von Recklinghausen then reported cases of cardiac myomatas and cerebral sclerosis in newborns who died just after birth. Bourneville then noted partial and generalized seizures, sclerotic areas on cerebral convolutions, vesiculo‐papular eruption on nose, renal tumors on a mentally subnormal 15 year old girl. He then coined the term",20_4,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"15 year old girl. He then coined the term “sclerose tubereuse des circonvolutions cerebrales.”<xref rid=""ccr39379-bib-0006"" ref-type=""bibr"">",20_5,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>6</sup>
</xref> These are some of the earliest evidences of manifestations of tuberous sclerosis complex, when it was not completely understood. Mutations in the TSC1 or TSC2 gene are identified as the cause of TSC.<xref rid=""ccr39379-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref>, <xref rid=""ccr39379-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",20_6,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>8</sup>
</xref> This discovery was made in the 1990s. These mutations dysregulate the mammalian target of rapamycin (mTOR) signaling cascade, leading to abnormal cell proliferation and the formation of hamartomas with multisystem involvement.<xref rid=""ccr39379-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref> With understanding of these disease pathology, mTORC1 inhibitors like everolimus, sirolimus has been approved for various manifestations of TSC.<xref rid=""ccr39379-bib-0010"" ref-type=""bibr"">",20_7,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>10</sup>
</xref> Recently, genetic testing to diagnose tuberous sclerosis complex has been introduced and with this, a new diagnostic criteria depending on genetic test has been accepted as well. The diagnosis of TSC is made by the “TSC diagnostic criteria consensus statement,” which consists of “clinical diagnostic criteria” using clinical signs and radiologic findings, and “genetic diagnostic criteria” by detecting pathogenic TSC gene mutations.<xref rid=""ccr39379-bib-0011"" ref-type=""bibr"">",20_8,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>11</sup>
</xref>",20_9,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"As a rare disorder, isolated neurological findings may be a rare presentation of TSC necessitating a high degree of suspicion. Here, we present a case of TSC with isolated neurological findings presenting with hypokalemia and seizures diagnosed by imaging findings. We present the case of an 18‐year‐old male who presented with fever, myalgia, and generalized weakness for 7 days. Upon investigation, a potassium level of 2.9 was noted, leading to admission for the correction of hypokalemia. No abnormalities",20_10,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"the correction of hypokalemia. No abnormalities were observed in other blood parameters (Table <xref rid=""ccr39379-tbl-0001"" ref-type=""table"">1</xref>). However, on day 1 of admission, the patient suddenly experienced one episode of left‐sided complex partial seizure with postictal altered consciousness. Following this new event, an MRI was performed, revealing radial bands, subependymal nodules, and cortical tubers. These findings fulfilled two major clinical criteria of tuberous sclerosis, allowing us to",20_11,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"criteria of tuberous sclerosis, allowing us to make a definitive diagnosis. Surprisingly, upon further examination, no cutaneous manifestations were noted, making this case intriguing. A detailed examination of the patient's family history did not identify any prior cases of tuberous sclerosis. Ultrasonography, echocardiography, and fundoscopy were performed, but no significant findings were observed. A CSF examination was done which was normal. The patient was started on tablet oxcarbazepine 300 mg twice",20_12,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"was started on tablet oxcarbazepine 300 mg twice a day and kept in regular follow‐up. The findings of the MRI are given in Figures <xref rid=""ccr39379-fig-0001"" ref-type=""fig"">1</xref> and <xref rid=""ccr39379-fig-0002"" ref-type=""fig"">2</xref>. Absence of cutaneous features in face can be noted in Figure <xref rid=""ccr39379-fig-0003"" ref-type=""fig"">3</xref>. While cortical tubers, radial bands, and subependymal nodules are characteristic imaging findings in TSC, we performed a clinical and radiological",20_13,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"in TSC, we performed a clinical and radiological differential diagnosis to rule out other potential causes. Multiple sclerosis (MS) was excluded due to the absence of pericallosal signal changes with the characteristic “Dawson finger” appearance and a normal spinal cord MRI. Similarly, neuromyelitis optica (NMO) was ruled out by the lack of optic nerve involvement on imaging and the absence of any related optic nerve symptoms in the patient. Finally, focal cortical dysplasia (FCD) can occasionally mimic",20_14,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"cortical dysplasia (FCD) can occasionally mimic isolated cortical and subcortical tubers with radial bands. However, the absence of cortical thickening and any abnormal gyral‐sulcal pattern on imaging argued against FCD. Our patient was started on tablet oxcarbazepine 300 mg twice a day and kept on regular follow up. Patient has recovered well and has not reported any seizures in 3 months. Tuberous Sclerosis is an autosomal dominant neurocutaneous syndrome, with high penetrance but variable",20_15,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"syndrome, with high penetrance but variable expressivity.<xref rid=""ccr39379-bib-0012"" ref-type=""bibr"">",20_16,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"<sup>12</sup>
</xref> Our case does not have a family history of tuberous sclerosis. Cutaneous manifestation is noted in nearly all patients and in past literature, features like hypopigmented macules have been noted in up to 97% of cases of children with tuberous sclerosis.<xref rid=""ccr39379-bib-0013"" ref-type=""bibr"">
<sup>13</sup>",20_17,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"</xref> But the lack of cutaneous findings in this patient doesn't align with the usual pattern of tuberous sclerosis. This emphasizes importance of high degree of suspicion for TSC even without cutaneous features. Since affected individuals can present with various clinical patterns and it is a progressive disease, it reflects the importance of thorough evaluation and regular screening of relevant conditions, once diagnosis is made. D. P. E. Kingsley has reported 18 cases out of 110 cases presenting with",20_18,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"18 cases out of 110 cases presenting with radiographic features but no clinical features. Out of them, two patients went on to develop skin findings later on.<xref rid=""ccr39379-bib-0014"" ref-type=""bibr"">",20_19,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
<sup>14</sup>,20_20,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"</xref> This also highlights importance of continuing follow‐up in TSC. This patient had a complex partial seizure, consistent with common clinical presentation in tuberous sclerosis. This adds to the existing literature on the high prevalence of seizure and epilepsy in patients with tuberous sclerosis. But majority of patient with tuberous sclerosis present with infantile spasms or seizure onset on early years of life. Our patient had no history of seizure before and has presented with first episode of",20_21,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"before and has presented with first episode of seizure at 18 years of age. Nevertheless, it has been reported that majority of TSC patients with even just one episode of seizure develop epilepsy.<xref rid=""ccr39379-bib-0015"" ref-type=""bibr"">",20_22,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
<sup>15</sup>,20_23,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"</xref> This adds to the rationale behind anti‐seizure medication after seizure onset in tuberous sclerosis. On our case, we started patient on oxcarbazepine and kept him on regular follow up. Patient has recovered well and has not reported any seizures in 3 months. In conclusion, this case highlights the diverse and often atypical presentations of TSC. Our patient's isolated neurological symptoms, including hypokalemia and seizures, in the absence of the classic cutaneous manifestations or family history,",20_24,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"cutaneous manifestations or family history, underscore the importance of maintaining a high index of suspicion for TSC. Clinicians should consider TSC in the differential diagnosis of any unexplained neurological presentation. Prioritizing early recognition through a comprehensive assessment that incorporates both clinical and genetic criteria is crucial for timely management and improved patient outcomes. Due to the rarity of TSC and the potential for misdiagnosis, cases like this one are vital to",20_25,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"misdiagnosis, cases like this one are vital to increase awareness of the condition and ensure accurate diagnosis and optimal patient care.",20_26,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
<bold>Shritik Devkota:</bold> Conceptualization; formal analysis; investigation; methodology; resources; supervision; validation; visualization. <bold>Om Prakash Bhatta:</bold> Data curation; formal analysis; investigation; software; supervision; writing – original draft. <bold>Arun Kalikote:</bold> Data curation; formal analysis; investigation; software; supervision; writing – original draft. <bold>Prakash Gyawali:</bold> Conceptualization; formal analysis; investigation; supervision; validation.,20_27,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
analysis; investigation; supervision; validation. <bold>Samiksha Lamichhane:</bold> Conceptualization; formal analysis; investigation; resources; supervision; validation. No sources of funding. Authors declare no conflict of interest. Patient anonymity is maintained and consent was obtained for publication from the patient. Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.,20_28,Atypical case of tuberous sclerosis with isolated neurologic findings: A case report,03 9 2024,,Tuberous_Sclerosis
"Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex Tuberous Sclerosis Complex (TSC) is a lynchpin disorder, as it results in overactive mammalian target of rapamycin (mTOR) signaling, which has been implicated in a multitude of disease states. TSC is an autosomal dominant disease where 90% of affected individuals develop epilepsy. Epilepsy results from aberrant neuronal excitability that leads to recurring seizures. Under neurotypical conditions, the coordinated activity",21_0,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"neurotypical conditions, the coordinated activity of voltage-gated ion channels keep neurons operating in an optimal range, thus providing network stability. Interestingly, loss or gain of function mutations in voltage-gated potassium, sodium, or calcium channels leads to altered excitability and seizures. To date, little is known about voltage-gated ion channel expression and function in TSC. However, data is beginning to emerge on how mTOR signaling regulates voltage-gated ion channel expression in",21_1,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"regulates voltage-gated ion channel expression in neurons. Herein, we provide a comprehensive review of the literature describing common seizure types in patients with TSC, and suggest possible parallels between acquired epilepsies with known voltage-gated ion channel dysfunction. Furthermore, we discuss possible links toward mTOR regulation of voltage-gated ion channels expression and channel kinetics and the underlying epileptic manifestations in patients with TSC. Tuberous sclerosis complex (TSC) is an",21_2,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"with TSC. Tuberous sclerosis complex (TSC) is an autosomal dominant disease affecting roughly 1 in 6000 live births, with an estimated prevalence of 1 in 14,000 to 1 in 25,000 (<xref rid=""B24"" ref-type=""bibr"">Curatolo and Moavero, 2012</xref>; <xref rid=""B50"" ref-type=""bibr"">Kothare Sanjeev et al., 2014</xref>). Disease causing mutations in either the <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> gene lead to loss of protein function (<xref rid=""B67"" ref-type=""bibr"">O’Callaghan",21_3,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"(<xref rid=""B67"" ref-type=""bibr"">O’Callaghan et al., 2004</xref>; <xref rid=""B25"" ref-type=""bibr"">Curatolo et al., 2008</xref>). TSC1 and TSC2 form dimers to inhibit the activity of mammalian target of rapamycin (mTOR), composed of two complexes mTORC1 and mTORC2. Loss of either TSC1 or TSC2 leads to hyperactive mTOR signaling and tuberous malformations. More than 90% of affected individuals experience seizures over the course of their lifetime (<xref rid=""B67"" ref-type=""bibr"">O’Callaghan et al.,",21_4,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"rid=""B67"" ref-type=""bibr"">O’Callaghan et al., 2004</xref>; <xref rid=""B48"" ref-type=""bibr"">Kelleher and Bear, 2008</xref>; <xref rid=""B88"" ref-type=""bibr"">Stafstrom et al., 2017</xref>). As the etiology as TSC is well established, mechanism based treatments such as the mTORC1 inhibitor, rapamycin and other “rapalogues”, has been the focus of several clinical trials to treat TSC-related seizures (<xref rid=""B38"" ref-type=""bibr"">Franz et al., 2018</xref>). TSC patients suffer from both focal and generalized",21_5,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"patients suffer from both focal and generalized epilepsy syndromes including febrile seizures, infantile spasms, focal seizures, and absence seizures (<xref rid=""B50"" ref-type=""bibr"">Kothare Sanjeev et al., 2014</xref>). Seizures may arise in TSC in two possible ways. Some studies speculate that seizure activity is generated by brain malformations that result from cortical tubers, which are composed of dysmorphic neurons and gliotic cells and are commonly seen in TSC patients (<xref rid=""B88""",21_6,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"commonly seen in TSC patients (<xref rid=""B88"" ref-type=""bibr"">Stafstrom et al., 2017</xref>; <xref rid=""B112"" ref-type=""bibr"">Zou et al., 2017</xref>). The tubers may be surgically removed to provide temporary relief from the seizures (<xref rid=""B10"" ref-type=""bibr"">Bollo et al., 2008</xref>). Second, some studies suggest that hyperactive mTOR signaling itself can disrupt the excitatory/inhibitory (E/I) balance among neuronal networks (<xref rid=""B5"" ref-type=""bibr"">Bateup et al., 2013</xref>). Thus, in",21_7,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"et al., 2013</xref>). Thus, in the absence of tubers, TSC patients may be susceptible to seizure-like activity and downstream neuronal damage due to hyperactive mTORC1 signaling, further disrupting mRNA translation and protein expression (<xref rid=""B5"" ref-type=""bibr"">Bateup et al., 2013</xref>). Cortical tuber development has been widely studied in TSC [previously reviewed in <xref rid=""B98"" ref-type=""bibr"">Wong (2008)</xref> and <xref rid=""B57"" ref-type=""bibr"">Lu et al. (2018)</xref>]; however, little",21_8,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"et al. (2018)</xref>]; however, little is known regarding the molecular underpinnings of hyperexcitable networks downstream of mTOR signaling, that underlie epilepsy in TSC, in the absence of cortical tubers. For decades, dysregulation of ion channels, such as voltage-gated potassium, calcium, and sodium channels, has been suggested to be the leading cause of shifts in neuronal excitability, that underlie epilepsy (<xref rid=""B71"" ref-type=""bibr"">Poolos and Johnston, 2012</xref>). Recently, evidence",21_9,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"and Johnston, 2012</xref>). Recently, evidence linking mTOR signaling to ion channel expression in neurons has emerged [reviewed further in <xref rid=""B73"" ref-type=""bibr"">Raab-Graham and Niere (2017)</xref>]. Together, these findings have led us to ask the question of whether voltage-gated ion channels are contributing to TSC-related seizures. Herein, we discuss known voltage-gated ion channels currently associated with acquired epilepsies, but not yet understood in the context of TSC. The goal of this",21_10,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"in the context of TSC. The goal of this review will be to extrapolate and expand on the current findings of voltage-gated channels implicated in other epilepsies, where aberrant mTOR signaling occurs, while surmising their role in TSC-related seizures. As mentioned above, loss of function mutations in the <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> genes results in hyperactive mTOR signaling (<xref rid=""B25"" ref-type=""bibr"">Curatolo et al., 2008</xref>; <xref rid=""B20""",21_11,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"et al., 2008</xref>; <xref rid=""B20"" ref-type=""bibr"">Cho, 2011</xref>; <xref rid=""B99"" ref-type=""bibr"">Wong, 2013</xref>; <xref rid=""B88"" ref-type=""bibr"">Stafstrom et al., 2017</xref>). mTOR consist of two protein complexes, mTORC1 and mTORC2. Herein, we will focus on mTORC1 signaling as it is a serine/threonine kinase that regulates mRNA translation (<xref rid=""B25"" ref-type=""bibr"">Curatolo et al., 2008</xref>; <xref rid=""B24"" ref-type=""bibr"">Curatolo and Moavero, 2012</xref>; <xref rid=""B26""",21_12,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"and Moavero, 2012</xref>; <xref rid=""B26"" ref-type=""bibr"">Curatolo et al., 2015</xref>; <xref rid=""B78"" ref-type=""bibr"">Roach, 2016</xref>; <xref rid=""B73"" ref-type=""bibr"">Raab-Graham and Niere, 2017</xref>), which may alter the expression of epilepsy associated ion channels in neurons (<xref rid=""F1"" ref-type=""fig"">Figure 1</xref>). mTORC1’s downstream signaling is required for many forms of synaptic plasticity, synapse formation, and recently ? Site specific expression of ion channels in neuronal",21_13,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"specific expression of ion channels in neuronal dendrites (<xref rid=""B74"" ref-type=""bibr"">Raab-Graham et al., 2006</xref>; <xref rid=""B20"" ref-type=""bibr"">Cho, 2011</xref>; <xref rid=""B12"" ref-type=""bibr"">Brewster et al., 2013</xref>; <xref rid=""B61"" ref-type=""bibr"">Meng et al., 2013</xref>; <xref rid=""B99"" ref-type=""bibr"">Wong, 2013</xref>). Thus, an emerging theory is that mTORC1 activity may serve as a “voltage-sensor” turning on and off to maintain the membrane potential in an optimal range, through",21_14,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"membrane potential in an optimal range, through protein synthesis and repression of ion channel mRNAs (<xref rid=""F1"" ref-type=""fig"">Figure 1</xref>; <xref rid=""B65"" ref-type=""bibr"">Niere and Raab-Graham, 2017</xref>). Thus, if mTOR activity is constitutive, as in the case of TSC, ion channel expression/repression that promotes neuronal excitability will go unchecked (<xref rid=""B53"" ref-type=""bibr"">Lasarge and Danzer, 2014</xref>). Epilepsy has been classically considered a disorder of ion channel",21_15,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"classically considered a disorder of ion channel dysfunction (<xref rid=""B71"" ref-type=""bibr"">Poolos and Johnston, 2012</xref>). Together, these data may explain why independent studies suggest that overactive mTOR signaling itself can lead to epilepsy (<xref rid=""B108"" ref-type=""bibr"">Zeng et al., 2008</xref>; <xref rid=""B26"" ref-type=""bibr"">Curatolo et al., 2015</xref>; <xref rid=""B85"" ref-type=""bibr"">Sosanya et al., 2015</xref>; <xref rid=""B65"" ref-type=""bibr"">Niere and Raab-Graham, 2017</xref>). To",21_16,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"and Raab-Graham, 2017</xref>). To date, the literature is sparse in its consolidation of excessive mTOR signaling and ion channel dysfunction in TSC-related epilepsies. The most common type of seizure in children with TSC are infantile spasms, occurring between 3 and 9 months after birth (<xref rid=""B70"" ref-type=""bibr"">Pellock et al., 2010</xref>; <xref rid=""B3"" ref-type=""bibr"">Appleton, 2011</xref>; <xref rid=""B77"" ref-type=""bibr"">Randle, 2017</xref>). Many different semiologies can be observed such as",21_17,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"different semiologies can be observed such as eye deviation as well as sudden bilateral and symmetrical tonic contractions, which last a few seconds (<xref rid=""B28"" ref-type=""bibr"">Curatolo et al., 2001</xref>). It has long been hypothesized that if these seizures are left untreated, children suffering from infantile spasms will experience impairment in developmental progress and more severe neurologic problems, such as autism spectrum disorder (<xref rid=""B70"" ref-type=""bibr"">Pellock et al., 2010</xref>,",21_18,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">Pellock et al., 2010</xref>, <xref rid=""B1"" ref-type=""bibr"">Alliance, 2020</xref>). Interestingly, several clinical trials have since discovered contrary findings with respect to targeting early life infantile spasms in TSC patients. One such trial found that preventative treatment with vigabatrin, the first line of treatment for infantile spasms which targets gamma-amino butyric acid (GABA)-transaminase, ultimately increases the concentration of GABA present in the brain (<xref rid=""B104""",21_19,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"of GABA present in the brain (<xref rid=""B104"" ref-type=""bibr"">Yum et al., 2013</xref>). However, treatment did not delay or lower the incidence of other seizure types, such as focal and drug resistant epilepsy nor improve neurocognitive outcome at 24 months of age in TSC children (<xref rid=""B6"" ref-type=""bibr"">Bebin et al., 2024</xref>). On the other hand, TSC patients who showed signs of epileptiform activity before seizure onset, and were treated with vigabatrin, took longer to display clinical seizure",21_20,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"took longer to display clinical seizure and the preventative treatment reduced the risk of other clinical seizures (<xref rid=""B51"" ref-type=""bibr"">Kotulska et al., 2021</xref>); however, neurocognition was not determined. Further research targeting the underlying mechanisms of infantile spasms. The second most common seizure type is focal onset seizures, previously called focal or partial seizures, as they originate at some specific point in the brain. These seizures differ from infantile spasms in that",21_21,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"seizures differ from infantile spasms in that they can be either awareness or impaired awareness with non-motor onset or motor onset (<xref rid=""B2"" ref-type=""bibr"">Almobarak et al., 2018</xref>). These seizures can precede or coexist with infantile spasms, or even evolve from infantile spasms (<xref rid=""B104"" ref-type=""bibr"">Yum et al., 2013</xref>). While the cause of focal seizures is not fully understood, some suggest that focal insults are caused by brain malformations resulting from structural tuber",21_22,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"malformations resulting from structural tuber alterations (<xref rid=""B87"" ref-type=""bibr"">Stafstrom and Carmant, 2015</xref>; <xref rid=""B27"" ref-type=""bibr"">Curatolo et al., 2018</xref>). To mimic focal seizures in a mouse model of TSC, pups <italic toggle=""yes"">in utero</italic> underwent electroporation to focally express constitutively active Rheb (Rheb<italic toggle=""yes""><sup>CA</sup></italic>), to augment mTOR activity only in the selected area. Indeed, this model is similar to a model of cortical",21_23,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"this model is similar to a model of cortical dysplasia that experiences focal seizures as a result of expressing Rheb<italic toggle=""yes""><sup>CA</sup></italic> (<xref rid=""B43"" ref-type=""bibr"">Hsieh et al., 2016</xref>). The authors found that varying the concentration of Rheb led to high levels of mTOR activity, which increased seizure frequency and correlated with the degree of disease severity (<xref rid=""B64"" ref-type=""bibr"">Nguyen et al., 2019</xref>). These findings further the notion that focal",21_24,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"These findings further the notion that focal seizures, in the absence of tuber abnormalities, is thought to be caused by select mTOR-afflicted neurons, and results in altered network excitability and seizures. TSC patients may also suffer from generalized onset, formerly known to encompass tonic seizures, myoclonic seizures, and absence seizures (<xref rid=""B3"" ref-type=""bibr"">Appleton, 2011</xref>; <xref rid=""B49"" ref-type=""bibr"">Kiriakopoulos and Osborne, 2017</xref>). These seizures can begin focally",21_25,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"2017</xref>). These seizures can begin focally and bilaterally expand to larger aspects of the cortex, although not necessarily the entire cortex. Patients with generalized onset seizures present with stiffened muscles, rhythmical jerking, and impaired awareness (<xref rid=""B87"" ref-type=""bibr"">Stafstrom and Carmant, 2015</xref>, <xref rid=""B2"" ref-type=""bibr"">Almobarak et al., 2018</xref>). There is a substantial portion of TSC patients that continue to have seizures despite maximum aggressive",21_26,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"to have seizures despite maximum aggressive anti-seizure treatment. For these patients, new approaches to management are needed. For example, if focal seizures coexist or precede infantile spasms, vigabatrin treatment can be less effective or have no effect. This is thought to be due to the medication only targeting one seizure type (<xref rid=""B104"" ref-type=""bibr"">Yum et al., 2013</xref>). Thus, it is imperative to determine the “molecular origin” of seizure onset, in order to better determine the course",21_27,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"onset, in order to better determine the course of treatment for a TSC affected individual. A few studies have examined the transcriptome of human cortical tubers removed from patients with TSC (<xref rid=""B9"" ref-type=""bibr"">Boer et al., 2010</xref>; <xref rid=""B62"" ref-type=""bibr"">Mills et al., 2017</xref>). <xref rid=""T1"" ref-type=""table"">Table 1</xref> lists transcripts associated with voltage-gated channel expression (<xref rid=""B40"" ref-type=""bibr"">Heinemann et al., 1996</xref>; <xref rid=""B34""",21_28,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"et al., 1996</xref>; <xref rid=""B34"" ref-type=""bibr"">Escayg et al., 1998</xref>; <xref rid=""B33"" ref-type=""bibr"">Ebert et al., 2008</xref>; <xref rid=""B111"" ref-type=""bibr"">Zhang et al., 2015</xref>). Interestingly, all the genes listed code for auxiliary subunits that serve to increase the surface expression of the pore-forming subunit or change the ion channel kinetics. These data further convey the need to investigate the expression and function of the pore forming subunits in neuronal models of TSC.",21_29,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"pore forming subunits in neuronal models of TSC. While mRNA does not necessarily mean changes in protein expression, others have demonstrated that mTOR is overactive in other models of epilepsy, similar to TSC, and these genes that code for these mTOR-dependent ion channels are summarized in <xref rid=""T2"" ref-type=""table"">Table 2</xref> (<xref rid=""B92"" ref-type=""bibr"">Wang et al., 1993</xref>; <xref rid=""B59"" ref-type=""bibr"">McCormack et al., 1995</xref>; <xref rid=""B14"" ref-type=""bibr"">Burkhalter et",21_30,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"<xref rid=""B14"" ref-type=""bibr"">Burkhalter et al., 2006</xref>; <xref rid=""B44"" ref-type=""bibr"">Imbrici et al., 2007</xref>; <xref rid=""B21"" ref-type=""bibr"">Christel et al., 2012</xref>; <xref rid=""B54"" ref-type=""bibr"">Lee et al., 2014</xref>; <xref rid=""B101"" ref-type=""bibr"">Xie et al., 2014</xref>; <xref rid=""B91"" ref-type=""bibr"">Villa and Combi, 2016</xref>; <xref rid=""B72"" ref-type=""bibr"">Punetha et al., 2019</xref>; <xref rid=""B30"" ref-type=""bibr"">Dahimene et al., 2022</xref>). Finally, in <xref",21_31,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"et al., 2022</xref>). Finally, in <xref rid=""T3"" ref-type=""table"">Table 3</xref>, we propose a list of putative voltage-gated ion channels that may be dysregulated in TSC (<xref rid=""B81"" ref-type=""bibr"">Serôdio and Rudy, 1998</xref>; <xref rid=""B95"" ref-type=""bibr"">Wappl et al., 2002</xref>; <xref rid=""B46"" ref-type=""bibr"">Jarnot and Corbett, 2006</xref>; <xref rid=""B68"" ref-type=""bibr"">Ogiwara et al., 2007</xref>, <xref rid=""B69"" ref-type=""bibr"">2018</xref>; <xref rid=""B35"" ref-type=""bibr"">Estacion et",21_32,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"<xref rid=""B35"" ref-type=""bibr"">Estacion et al., 2010</xref>; <xref rid=""B84"" ref-type=""bibr"">Smets et al., 2015</xref>; <xref rid=""B94"" ref-type=""bibr"">Wang et al., 2016</xref>; <xref rid=""B100"" ref-type=""bibr"">Wormuth et al., 2016</xref>; <xref rid=""B36"" ref-type=""bibr"">Fan et al., 2017</xref>; <xref rid=""B110"" ref-type=""bibr"">Zhang et al., 2020</xref>). Although, currently, there is no direct evidence of the potential role of dysfunction in the following voltage-gated ion channels leading to the",21_33,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"voltage-gated ion channels leading to the hyperexcitable pathology in TSC, we speculate that these channels may play a role in the different seizure types present in TSC patients throughout their lives. In conclusion, the disruption of voltage-gated ion channels leads to different types of seizures. mTOR, downstream of the TSC, has been shown to be involved in regulating ion channel expression, and may contribute to epileptogenesis. Because of the complexity each voltage-gated ion channel, there are many",21_34,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"each voltage-gated ion channel, there are many unanswered questions of their role in TSC. Yet, understanding the contribution from each voltage-gated ion channel may provide insight into the heterogeneity of seizures in TSC and possibly determine new therapeutic targets of interest. Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder that results in hyperactive mammalian/mechanistic target of rapamycin (mTOR) signaling leading to altered neuronal excitability and seizures; however, the",21_35,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"neuronal excitability and seizures; however, the underlying mechanisms remain a mystery. Several potassium, sodium, or calcium voltage-gated channels have been found to be causative in disorders that result in aberrant neuronal excitability and seizures. Surprisingly, these channels remain understudied in TSC-associated neuronal dysfunction. The coordination of these ionic conductances, dictated by the channel’s expression, subcellular localization, and biophysical properties, keep neurons operating in an",21_36,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"properties, keep neurons operating in an optimal range, providing network stability. Our review examines the current TSC literature describing common seizure types, clinical trials, and genomic studies that potentially implicate potassium, sodium, and calcium voltage-gated channel dysfunction in TSC. Notably, the expression of several voltage-gated ion channels and auxiliary subunits have been shown to be regulated by mTOR signaling, arguing for further studies of ion channel dysfunction in TSC. <italic",21_37,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"of ion channel dysfunction in TSC. <italic toggle=""yes"">Frontiers in Molecular Neuroscience-Molecular Signalling and Pathways</italic> is particularly interested in topics that pertain to brain disease mechanisms such as TSC, molecular signaling pathways such as mTOR, and synaptic and cellular proteins such as voltage-gated ion channels. The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author. HE-B:",21_38,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"be directed to the corresponding author. HE-B: Conceptualization, Data curation, Writing – original draft, Writing – review and editing. RS: Writing – review and editing. KR-G: Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review and editing.",21_39,Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex,26 8 2024,,Tuberous_Sclerosis
"Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland Tuberous sclerosis complex (TSC) is a rare autosomal dominant, multisystem genetic disorder, affecting approximately. 1:6000–1:10,000 live births [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. It is caused by a pathogenic variant in the TSC1 or TSC2 gene, resulting in the dysregulation of the mTOR pathway, and the growth of benign tumours",22_0,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"mTOR pathway, and the growth of benign tumours (hamartomas) in numerous organ systems, including the brain, lungs, kidney, heart, eyes, oral cavity, endocrine and skeletal systems [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Significant manifestations include epilepsy 84%, renal complications 50%, pulmonary involvement (primarily in females) 80%, and associated neuropsychological disorders (TAND) 90%, which encompass psychiatric, intellectual, behavioural, neuropsychiatric, psychosocial and academic",22_1,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"neuropsychiatric, psychosocial and academic difficulties [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. TSC occurs in both genders, and all ethnic groups and symptoms of TSC vary considerably from mild to severe, with symptoms emerging and changing throughout the person’s lifetime and may lead to death [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Considerable progress in the understanding of TSC has led to the development of novel targeted therapeutics with remarkable",22_2,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"of novel targeted therapeutics with remarkable results. Mammalian target rapamycin (mTOR) inhibitors have emerged as the cornerstone of TSC tumour management, generating disease control and improved outcomes [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. It is vital that individuals with TSC obtain an early diagnosis and receive optimal personalised care for their condition throughout their entire lifespan [<xref",22_3,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"condition throughout their entire lifespan [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR12"">12</xref>]. International and United Kingdom (UK) TSC Consensus Clinical Recommendations define the best approach to diagnosis, surveillance and management [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>, <xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Due to the multiorgan and complex nature of the disease, personalised care, ideally delivered through TSC",22_4,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"personalised care, ideally delivered through TSC clinics/hubs of expertise, is recommended [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Based on an estimated international prevalence of 1:6000–1:10,000, there should be approximately 600 individuals with a diagnosis of TSC in the Republic of Ireland (ROI). These patients do not have access to a specialist TSC clinic/hub or formalised network of TSC expertise in the ROI, and there is a paucity of information",22_5,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"in the ROI, and there is a paucity of information concerning their identity, well-being, and the healthcare they are receiving. The aim of this study was to evaluate the baseline care of patients with TSC attending epilepsy services in The Republic of Ireland (ROI) against UK TSC consensus recommendations and inform service improvements. This coordinated care approach improves patient care and safety and is in line with the World Health Organisation (WHO) guidelines, where patient safety within healthcare",22_6,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"where patient safety within healthcare systems is seen as a framework of organised activities creating cultures, environments, behaviour, processes and procedures that lower risks and reduce the occurrence of avoidable harm [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Patients with a diagnosis of TSC attending eight adult and four paediatric epilepsy services in the Republic of Ireland (ROI) were identified through the Epilepsy Electronic Patient Record (EEPR), Fitzsimons et al. [<xref ref-type=""bibr""",22_7,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"(EEPR), Fitzsimons et al. [<xref ref-type=""bibr"" rid=""CR16"">16</xref>] and chart review. The UK TSC consensus recommendations were used to create an audit tool of 46 questions, which included patient characteristics, genetics, central nervous system, kidney, lung, heart, eyes, skin, liver, pancreas and access to specialists and treatments. Clinical audits measured the care of 83 of the 135 identified patients against this tool. An initial audit of two adult epilepsy services <italic",22_8,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"audit of two adult epilepsy services <italic toggle=""yes"">n</italic> = 41, was described by Behan et al. [<xref ref-type=""bibr"" rid=""CR17"">17</xref>] and a follow-up study extended the audit nationally to a further six adult and four paediatric services over a 6-month period in 2022. Ethical approval was obtained from Trinity College Dublin. Audit participation was granted at each site and data-sharing agreements were put in place. Patient and site identifiers were removed, and data was uploaded",22_9,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"identifiers were removed, and data was uploaded anonymously to a Qualtrics platform by the participating healthcare practitioners at each site. The final data set amalgamates the two audits and was analysed on IBM SPSS 28 at Trinity College Dublin. The rational for conducting the audit in epilepsy services as opposed to within a different speciality, was based on a number of factors. Epilepsy occurs in approx. 84% of people with TSC [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. A National Epilepsy",22_10,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"rid=""CR18"">18</xref>]. A National Epilepsy Electronic Patient Record (EEPR), Fitzsimons et al. [<xref ref-type=""bibr"" rid=""CR16"">16</xref>] is available across epilepsy services in the ROI and facilitated the execution of the audit. There is no national individual patient identifier or electronic health record system in the ROI and no registry of TSC patients. One hundred thirty-five TSC patients attending twelve epilepsy centres were identified. The care of a subset of 83 patients was audited. This number",22_11,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"a subset of 83 patients was audited. This number was due to the work demands on staff subsequent to the COVID-19 pandemic and the difficulties using electronic information material due to a cyber-attack on the Health Service Executive (HSE) Information Technology (IT) systems. Demographic participant information is summarised in Table <xref rid=""Tab1"" ref-type=""table"">1</xref> and Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>.",22_12,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Demographic characteristics of audit participants. Overall (<italic toggle=""yes"">N</italic> = 83)</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Age categories</th><th align=""left"">Gender</th><th align=""left"" colspan=""2"">Age/mean/range/max/min</th></tr></thead><tbody><tr><td align=""left"" rowspan=""4"">Under age 18</td><td align=""left"" rowspan=""2"">Male</td><td align=""left""><italic toggle=""yes"">N</italic></td><td",22_13,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"toggle=""yes"">N</italic></td><td align=""left"">10</td></tr><tr><td align=""left"">Mean age</td><td align=""left"">7.60</td></tr><tr><td align=""left"" rowspan=""2"">Female</td><td align=""left""><italic toggle=""yes"">N</italic></td><td align=""left"">10</td></tr><tr><td align=""left"">Mean age</td><td align=""left"">10.60</td></tr><tr><td align=""left"" rowspan=""10"">Age 18–75</td><td align=""left"" rowspan=""5"">Male</td><td align=""left""><italic toggle=""yes"">N</italic></td><td align=""left"">39</td></tr><tr><td align=""left"">Mean",22_14,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"align=""left"">Mean age</td><td align=""left"">39.95</td></tr><tr><td align=""left"">Range</td><td align=""left"">55</td></tr><tr><td align=""left"">Minimum</td><td align=""left"">18</td></tr><tr><td align=""left"">Maximum</td><td align=""left"">73</td></tr><tr><td align=""left"" rowspan=""5"">Female</td><td align=""left""><italic toggle=""yes"">N</italic></td><td align=""left"">24</td></tr><tr><td align=""left"">Mean age</td><td align=""left"">38.46</td></tr><tr><td align=""left"">Range</td><td align=""left"">43</td></tr><tr><td",22_15,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"align=""left"">43</td></tr><tr><td align=""left"">Minimum</td><td align=""left"">19</td></tr><tr><td align=""left"">Maximum</td><td align=""left"">62</td></tr></tbody></table></table-wrap><fig id=""Fig1""><label>Fig. 1</label><caption><p>Age profile of audit participants</p></caption><graphic http://www.w3.org/1999/xlink href=""44162_2024_49_Fig1_HTML"" id=""MO1""></graphic></fig> The findings of baseline investigations are summarised in Fig. <xref rid=""Fig2"" ref-type=""fig"">2</xref>.<fig",22_16,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"rid=""Fig2"" ref-type=""fig"">2</xref>.<fig id=""Fig2""><label>Fig. 2</label><caption><p>Comparing baseline investigations of adult and paediatric TSC patients, to that recommended by UK TSC consensus recommendations, in 12 epilepsy centres in the Republic of Ireland. <italic toggle=""yes"">MRI</italic> magnetic resonance imaging, <italic toggle=""yes"">TAND</italic> tuberous sclerosis neuropsychiatric disorder, <italic toggle=""yes"">SUDEP</italic> sudden unexpected death in epilepsy, <italic toggle=""yes"">BP</italic>",22_17,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"in epilepsy, <italic toggle=""yes"">BP</italic> blood pressure, <italic toggle=""yes"">OPH</italic> ophthalmology, <italic toggle=""yes"">HRCT</italic> high-resolution computerised tomography, <italic toggle=""yes"">ECHO</italic> echocardiogram, <italic toggle=""yes"">ECG</italic> electrocardiogram</p></caption><graphic http://www.w3.org/1999/xlink href=""44162_2024_49_Fig2_HTML"" id=""MO2""></graphic></fig> The presence of three manifestations of TSC are summarised in Fig. <xref rid=""Fig3"" ref-type=""fig"">3</xref>.<fig",22_18,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"rid=""Fig3"" ref-type=""fig"">3</xref>.<fig id=""Fig3""><label>Fig. 3</label><caption><p>Subependymal giant cell astrocytoma (SEGA), renal angiomyolipoma (AML). Facial angiofibroma</p></caption><graphic http://www.w3.org/1999/xlink href=""44162_2024_49_Fig3_HTML"" id=""MO3""></graphic></fig> Brain MRIs were carried out for 89% of adults and 100% of children. Sudden unexpected death in epilepsy (SUDEP) was discussed in 15% of adults and 25% of children. TAND (tuberous sclerosis-associated neuropsychiatric disorders)",22_19,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"sclerosis-associated neuropsychiatric disorders) which affects 90% of patients were not assessed with the TAND assessment tool in any adult or paediatric services. However, other neuropsychological assessments were carried out in 47% of adults and 25% of paediatric cases as well as developmental status assessments in 44% of adult and 85% of children. Seventeen percent of females of childbearing age were documented as having had an HRCT and 5% of all patients had an MRI of the liver and pancreas. MRI is the",22_20,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"had an MRI of the liver and pancreas. MRI is the recommended diagnostic tool for renal imaging, but ultrasound was used in 13.3%, and computed tomography (CT) and ultrasound in 3.5%. The main finding of this audit is that many baseline investigations were completed, especially in the paediatric services. However, care appears fragmented and separate referrals were required to access services and treatments even within the same hospital. Free text comments of participating staff indicated lengthy referral",22_21,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"of participating staff indicated lengthy referral times, particularly to CAHMS and there was no centralised care coordination. The epilepsy centres where the audit was conducted are staffed by highly qualified Advanced Nurse Practitioners (ANPs) in Epilepsy care, who deliver specialised care to their patients for all of their neurological issues. It is not considered their remit to be coordinators of the extensive multidisciplinary care needs of TSC patients. Subsequently, coordination of the many",22_22,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"patients. Subsequently, coordination of the many investigations and consultations required to manage TSC frequently falls on the shoulders of the patients, families and carers to navigate their care and healthcare system. This is not conducive to the International or UK TSC recommendations where lifelong, personalised, multidisciplinary care by a coordinated team of TSC experts is recommended. Nor is it in line with the WHO guidance on safe systems of care to improve patient safety and reduce avoidable",22_23,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"to improve patient safety and reduce avoidable harm [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. The National Rare Diseases Office is developing rare disease care pathways, including one for TSC; however, it is not known when this will be completed [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. The low numbers attending epilepsy services is unexpected (<italic toggle=""yes"">n</italic> = 135). Based on the frequency of epilepsy in TSC (84%) [<xref ref-type=""bibr"" rid=""CR18"">18</xref>] and a prevalence of TSC",22_24,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"rid=""CR18"">18</xref>] and a prevalence of TSC 1:6000–1:10,000, an estimated 400 patients would be expected to attend epilepsy services. The epidemiological data would suggest that in excess of 600 patients should be attending some type of surveillance services for their disease. It is possible that a number of patients are attending neurologists elsewhere, e.g., privately or having their epilepsy managed by their general practitioner (GP) or paediatrician. However, given the high rate of refractory",22_25,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"However, given the high rate of refractory epilepsy in TSC the numbers are still less than expected. While the national epilepsy services use a national electronic health record, in general, patients with multisystem diseases like TSC are not catered for in a common record and the lack of this as well as the use of telehealth and other digital health and remote monitoring systems is a significant failure in the Irish health system [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Of note, is that over a 5-year",22_26,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"Of note, is that over a 5-year period 2016–2020, Doody et al. [<xref ref-type=""bibr"" rid=""CR22"">22</xref>] looked at the presenting problems of patients with an intellectual disability who were admitted to acute hospitals. TSC was the fifth most common condition and many of the categories of presenting problems were relevant to TSC. This begs the question of whether patients are having their care needs addressed in a proactive surveillance model or a reactive acute unscheduled care model. Everolimus, an",22_27,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"acute unscheduled care model. Everolimus, an mTOR inhibitor, is approved in many countries for the treatment of renal angiomyolipoma, lymphangioleiomyomatosis (LAM) and/or partial-onset epilepsy associated with TSC in addition to SEGA [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. The European Medicines Agency (EMA) has granted a licence for its use in TSC in Europe [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. However, a subsequent application for its use in the",22_28,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"a subsequent application for its use in the ROI has not been made and Everolimus is currently being prescribed off-label for the care of patients with TSC. The audit was limited in that it captured the UK and International TSC baseline recommendations and not ongoing surveillance. Due to the COVID-19 pandemic and the Health Service Executive (HSE) cyber-attack, staff workload and difficulty in accessing files affected their capacity to audit all of the TSC patients attending their services. The absence of",22_29,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"patients attending their services. The absence of an electronic patient record system in Ireland also impacted the study. The number of TSC patients attending epilepsy services is lower than expected (<italic toggle=""yes"">n</italic> = 135). The UK, TSC consensus baseline recommendations are broadly adhered to. Specialist services and treatments for TSC are available, however, these require intra and inter-hospital and service referrals with no clear feedback system of their outcomes. TSC care is fragmented",22_30,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"system of their outcomes. TSC care is fragmented and lacks a formal TSC clinic or network to provide TSC care for this multiorgan complex disease as urged by international and UK TSC clinical recommendations. Coordinated care ideally in a centre of excellence would facilitate healthcare professionals with TSC expertise to provide lifelong personalised care to TSC patients and support to their HCP colleagues. There would be an amplification in TSC awareness, increased patient safety and outcomes, improved",22_31,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"increased patient safety and outcomes, improved patient and provider satisfaction and a reduction in healthcare costs.",22_32,Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland,19 8 2024,,Tuberous_Sclerosis
"Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway The mTOR-inhibitor everolimus is a precision drug with antiepileptogenic properties approved for treatment of epilepsy in persons with tuberous sclerosis complex (TSC) in combination with other antiseizure medications (ASMs). However, the pharmacokinetic variability of everolimus is scarcely",23_0,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"variability of everolimus is scarcely described, and the available information on pharmacokinetic interactions is scarce. The purpose of this study was to investigate pharmacokinetic variability of everolimus in patients with TSC, and the impact of age, sex and comedication. In this retrospective observational study we used anonymized data from medical records of patients with TSC using everolimus in Norway and Denmark, 2012 to 2020. Long-term therapeutic drug monitoring (TDM) identified inter-patient and",23_1,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"monitoring (TDM) identified inter-patient and intra-patient variability. The study included 59 patients, (36 females (61%)), median age 22 (range 3–59 years). Polytherapy was used in 50 patients (85%). The most frequently used ASMs were lamotrigine (n = 21), valproate (n = 17), and levetiracetam (n = 13). Blood concentrations of everolimus were measured in all patients. Pharmacokinetic variability of everolimus between patients was extensive, as demonstrated by a 24-fold variability from minimum–maximum",23_2,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"by a 24-fold variability from minimum–maximum concentration/dose (C/D)-ratios. The coefficient of variation (CV) for intra-patient (n = 59) and inter-patient variability (n = 47, ≥3 measurements) was 40% and 43%, respectively. The C/D-ratio of everolimus was 50% lower in 13 patients (22%) using enzyme-inducing ASMs compared to the 30 patients who did not (0.7 vs 1.4 ng/mL mg, <italic toggle=""yes"">P</italic> < .05). Age and sex were not significantly associated with changes in C/D-ratios of everolimus.",23_3,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"with changes in C/D-ratios of everolimus. Long-term TDM identified extensive variability in concentrations over time for everolimus both within and between patients, where comedication with enzyme-inducing ASMs was an important contributing factor. The findings suggest a need for TDM in patients with TSC treated with everolimus. Tuberous sclerosis complex (TSC) is a rare, autosomal dominant genetic disorder causing benign tumors in different organs, such as the brain, kidneys, lungs, and heart, and about",23_4,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"the brain, kidneys, lungs, and heart, and about 80% develop focal epilepsy.<sup>[<xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R2"" ref-type=""bibr"">2</xref>]</sup> Early onset epilepsy is associated with an increased risk of neurodevelopmental disorders, such as autism spectrum disorders and intellectual disability.<sup>[<xref rid=""R1"" ref-type=""bibr"">1</xref>]</sup> Many TSC patients have refractory epilepsy, and polytherapy with antiseizure medications (ASMs) is common, increasing the risk of drug",23_5,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"(ASMs) is common, increasing the risk of drug interactions. Everolimus is a selective inhibitor of the mTOR-signaling pathway and consequently, of growth and proliferation of cells involved in TSC, in addition to reduction of glutamatergic excitation.<sup>[<xref rid=""R3"" ref-type=""bibr"">3</xref>]</sup> Thus, everolimus is considered a precision drug with antiepileptogenic properties.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>–<xref rid=""R6"" ref-type=""bibr"">6</xref>]</sup> The efficacy of everolimus for",23_6,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"The efficacy of everolimus for focal seizures in patients with epilepsy secondary to TSC was demonstrated in a randomized clinical trial (EXIST-3).<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> Everolimus is approved as adjunctive treatment for patients from 2 years with TSC and refractory focal seizures.<sup>[<xref rid=""R7"" ref-type=""bibr"">7</xref>]</sup> The use of therapeutic drug monitoring (TDM) may help to individualize drug treatment by adjusting dosages to account for pharmacokinetic",23_7,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"adjusting dosages to account for pharmacokinetic variability related to age, sex and use of comedication.<sup>[<xref rid=""R8"" ref-type=""bibr"">8</xref>–<xref rid=""R12"" ref-type=""bibr"">12</xref>]</sup> Long-term TDM in patients with multiple drug measurements has recently been used as a tool to investigate intra-patient and inter-patient pharmacokinetic variability of ASMs used in specific epilepsy syndromes as juvenile myoclonic epilepsy and Dravet syndrome.<sup>[<xref rid=""R13""",23_8,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"and Dravet syndrome.<sup>[<xref rid=""R13"" ref-type=""bibr"">13</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref>]</sup> There are few studies that focus on pharmacokinetic variability of everolimus in a clinical setting, but systematic surveillance is important due to a narrow therapeutic index and numerous adverse effects of everolimus.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> The purpose of the present study was therefore to investigate pharmacokinetic variability of everolimus in patients with",23_9,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"variability of everolimus in patients with TSC, and the impact of age, sex, and comedication with ASMs.   The present study include a large number of TSC patients treated with everolimus and concomitant ASMs in Norway and Denmark. TDM was routinely applied in all patients, from frequent to more moderate intervals of follow-up. Long-term TDM revealed pronounced pharmacokinetic variability of everolimus over time and extensive use of polytherapy with ASMs which cause significant pharmacokinetic interactions",23_10,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"cause significant pharmacokinetic interactions with everolimus, such as the combination with enzyme inducers of the CYP3A4/5 pathways. This study demonstrates that there was extensive pharmacokinetic variability of everolimus in patients with TSC and in most cases, also epilepsy. The most common concomitant ASMs included lamotrigine, valproate, and levetiracetam, but 22% used enzyme inducers, which reduced the C/D-ratio of everolimus significantly, and the doses were not increased accordingly. The use of",23_11,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"doses were not increased accordingly. The use of long-term TDM demonstrated unpredictable and extensive intra-patient and inter-patient pharmacokinetic variability in blood concentrations over time of about 40%. Long-term TDM may be used to follow and improve treatment outcome, taking comedication with enzyme inducers and overall pharmacokinetic variability into account. We would like to acknowledge Svein I. Johannessen, PhD, emeritus researcher, Margrete Larsen Burns, MD, PhD, Head of Section for Clinical",23_12,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"Burns, MD, PhD, Head of Section for Clinical Pharmacology, The National Center for Epilepsy, Oslo University Hospital, and Katrine Heger, MSc Pharm, PhD candidate at the Department of Pharmacy, Oslo Metropolitan University, for fruitful discussions of the present results, evaluations of statistical analyses and language improvements. We are also grateful to Nils Tore Vethe, PhD, Head of Section for Clinical Pharmacology, Oslo University Hospital for performing the analyses of everolimus in Norway as part",23_13,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"the analyses of everolimus in Norway as part of their routine service. <bold>Data curation:</bold> Kjersti Kirkeby, Christina Engel Hoei-Hansen, Lotte Holst, Mikkel G. Fredriksen, Cecilie Johanessen Landmark. <bold>Formal analysis:</bold> Kjersti Kirkeby, Cecilie Johanessen Landmark. <bold>Investigation:</bold> Kjersti Kirkeby, Ine Cockerell, Jakob Christensen, Christina Engel Hoei-Hansen, Lotte Holst, Mikkel G. Fredriksen, Caroline Lund, Cecilie Johanessen Landmark. <bold>Visualization:</bold> Kjersti",23_14,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"Landmark. <bold>Visualization:</bold> Kjersti Kirkeby, Cecilie Johanessen Landmark. <bold>Writing – review & editing:</bold> Kjersti Kirkeby, Ine Cockerell, Jakob Christensen, Christina Engel Hoei-Hansen, Lotte Holst, Mikkel G. Fredriksen, Caroline Lund, Cecilie Johanessen Landmark. <bold>Conceptualization:</bold> Ine Cockerell, Jakob Christensen, Caroline Lund, Cecilie Johanessen Landmark. <bold>Methodology:</bold> Jakob Christensen, Cecilie Johanessen Landmark. <bold>Validation:</bold> Jakob Christensen,",23_15,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"<bold>Validation:</bold> Jakob Christensen, Caroline Lund, Cecilie Johanessen Landmark. <bold>Project administration:</bold> Cecilie Johanessen Landmark. <bold>Supervision:</bold> Cecilie Johanessen Landmark. <bold>Writing – original draft:</bold> Cecilie Johanessen Landmark.",23_16,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway,09 8 2024,,Tuberous_Sclerosis
"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex A renal angiomyolipoma (AML) is a rare, usually benign tumor consisting of smooth muscle cells, abnormal blood vessels, and fat tissue. Although AMLs are often asymptomatic, they can present with flank pain, hematuria, and a palpable mass in the abdomen. A significant complication involves rupture and hemorrhage into the retroperitoneal cavity, which can be life-threatening. The treatment approach has",24_0,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"be life-threatening. The treatment approach has evolved from surgical removal to more conservative management, such as nephron-sparing embolization and mammalian target of rapamycin (mTOR) inhibitors for tuberous sclerosis complex (TSC)-associated AML. In March 2024, a 36-year-old female patient diagnosed with TSC was admitted to our department and underwent several endovascular embolizations after a life-threatening hemorrhage from a ruptured multilocular AML. The treatment was successful, with complete",24_1,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"AML. The treatment was successful, with complete exclusion of the AMLs from circulation and without any complications during the postoperative period. This case emphasizes the effectiveness of selective arterial embolization using the Onyx liquid embolic system in managing AMLs and highlights the importance of preserving renal function. Methods used in AML diagnosis include ultrasound and computed tomography scans, with magnetic resonance imaging and biopsy recommended in difficult cases. Treatment depends",24_2,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"recommended in difficult cases. Treatment depends on aspects such as tumor size, symptoms, and patient's general condition, with options ranging from active surveillance for small, asymptomatic AMLs to more invasive procedures for larger, symptomatic tumors. The main goal is to minimize symptoms and preserve renal function. A renal angiomyolipoma (AML) is a relatively rare tumor, with a prevalence of 0.2% in the general population, commonly consisting of smooth muscle cells, abnormal blood vessels, and fat",24_3,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"muscle cells, abnormal blood vessels, and fat tissue in different proportions [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. AMLs are typically regarded as benign, with a very low risk of becoming malignant and developing aggressive behavior [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Patients with renal AML often experience no symptoms, nevertheless, they may also present with flank pain, gross hematuria, palpable mass, and bleeding in the retroperitoneum. The main and high mortality complication of renal",24_4,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"The main and high mortality complication of renal AMLs is their rupture and hemorrhage into the retroperitoneal cavity [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. The management of AML has evolved over the years. Initially, renal AMLs were surgically removed, but later a more conservative approach emerged, involving nephron-sparing embolization. Eventually, the mammalian target of rapamycin (mTOR) inhibitors proved effective in halting tuberous sclerosis complex (TSC)-associated renal AMLs [<xref",24_5,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"complex (TSC)-associated renal AMLs [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. We present a case of a young woman diagnosed with numerous AMLs in both kidneys who underwent multiple endovascular embolizations. In March 2024, a 36-year-old female patient diagnosed with TSC was admitted to our clinic for preventive embolization of a nodular lesion in the right kidney. Her prior medical history revealed cholelithiasis, resection of a benign thyroid tumor, and epilepsy in childhood. Moreover, significant",24_6,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"and epilepsy in childhood. Moreover, significant bleeding occurred due to a ruptured right renal AML in January 2024. At that time, the patient was treated conservatively with the transfusion of two units of packed red blood cells and two units of plasma. On general examination, the blood pressure was 130/85 mm Hg with a regular pulse rate of 78 beats per minute. The abdomen was soft and painless, and there was no peripheral edema. The laboratory results indicated mild anemia with preserved kidney function",24_7,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"mild anemia with preserved kidney function (Table <xref rid=""TAB1"" ref-type=""table"">1</xref>).  Computed tomography angiography revealed multiple focal AML lesions in both kidneys (Figure <xref rid=""FIG1"" ref-type=""fig"">1</xref>). Due to the patient's young age, the potential for pregnancy, and the minimally invasive nature of the procedure, the decision was made to proceed with the surgery. In March 2024 through right common femoral artery endovascular access, selective embolization of the previously",24_8,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"access, selective embolization of the previously ruptured lesion (Figure <xref rid=""FIG2"" ref-type=""fig"">2</xref>) and three additional lesions in the right kidney parenchyma (Figure <xref rid=""FIG3"" ref-type=""fig"">3</xref>) was performed using three ampoules of Onyx-20 liquid embolic agent. A small pseudoaneurysm was visible within the post-hemorrhagic lesion, which was closed during tumor embolization. Control angiography revealed partial filling of a fragment of the tumor located in the upper pole of",24_9,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"of the tumor located in the upper pole of the right kidney (incomplete embolization) (Figure <xref rid=""FIG4"" ref-type=""fig"">4</xref>). Additionally, single focal lesions were visible in the lower parts of both kidneys (Figure <xref rid=""FIG4"" ref-type=""fig"">4</xref>, <xref rid=""FIG5"" ref-type=""fig"">5</xref>), classified for possible future embolization, the size of the lesion in the lower pole of the right kidney was approximately 1.8 cm, so embolization was not pursued. The arterial endovascular access",24_10,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"was not pursued. The arterial endovascular access site in the right inguinal area was secured using the FEMOSEAL occlusion system with an additional pressure dressing. During the procedure, 5,000 units of heparin were administered. The postoperative period was uncomplicated. The puncture site of the right common femoral artery healed properly and a pulse was palpable. The patient was discharged home on the third postoperative day. In May 2024, the patient underwent the next stage of the treatment. Under",24_11,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"underwent the next stage of the treatment. Under local anesthesia, via the left common femoral artery selective embolization of an AML lesion in the lower left renal pole was performed (Figures <xref rid=""FIG6"" ref-type=""fig"">6</xref>, <xref rid=""FIG7"" ref-type=""fig"">7</xref>). In the subsequent phase, lesions in the right kidney's lower pole were embolized with the utilization of two ampoules of the Onyx-18 liquid embolic system (Figure <xref rid=""FIG8"" ref-type=""fig"">8</xref>).  Vascular access was",24_12,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"ref-type=""fig"">8</xref>).  Vascular access was secured with the FEMOSEAL occlusion system. Control angiography revealed complete exclusion of AMLs from circulation (Figure <xref rid=""FIG9"" ref-type=""fig"">9</xref>). Etiology and epidemiology Classified as a perivascular epithelioid cell tumor, the AML is one of the most frequent benign mesenchymal renal neoplasms, predominantly found in females rather than males [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. Renal AMLs can be divided into two main categories:",24_13,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"AMLs can be divided into two main categories: sporadic and syndromic AMLs. The sporadic form includes triphasic benign AMLs, which encompasses classic AMLs and fat-poor AMLs, as well as epithelioid AMLs. The syndromic form includes AMLs associated with TSC and lymphangioleiomyomatosis [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. TSC-AMLs, found in younger age, are prone to more rapid growth, a higher risk of bleeding, a greater chance of malignancy, and multilocular localization [<xref rid=""REF5""",24_14,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"and multilocular localization [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. Sporadic AMLs, most commonly found in patients between 50 and 60 years old, are characterized by slow expansion and unilateral localization. The age and gender of our patient align with the higher prevalence of renal AMLs in younger females with TSC. Clinical manifestation Approximately 80% of AML cases remain asymptomatic and are commonly found accidentally, while the remaining 20% usually present typical symptoms: abdominal pain,",24_15,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"usually present typical symptoms: abdominal pain, hematuria, and palpable mass in the abdomen [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. The main indication of AML is non-traumatic, spontaneous, life-threatening bleeding into the retroperitoneal cavity, commonly known as Wunderlich’s syndrome, often accompanied by Lenk's triad: acute flank pain, flank mass, and hypovolemic shock [<xref rid=""REF8"" ref-type=""bibr"">8</xref>]. AML bleeding and rupture are highly correlated with tumor vascularization, its",24_16,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"highly correlated with tumor vascularization, its size, and the existence of intratumoral aneurysms larger than 0.5 cm [<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. The patient's presentation with a ruptured right renal AML is consistent with the main complication observed in TSC-associated AMLs, which due to their vascular nature are prone to bleeding. Diagnostics Technologies most frequently used to diagnose and choose the appropriate treatment for renal masses include ultrasound (US), computed tomography",24_17,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"include ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. On US, because of the presence of macroscopic fat, the AML resembles a hyperechoic lesion that cannot be differentiated from other renal tumors [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. CT is commonly the first imaging method utilized, frequently conducted for other purposes, and can be sufficient for adequate diagnosis [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. In",24_18,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"[<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. In CT scans, AML typically appears as distinct renal cortical nodules with well-defined borders, displaying a pyramidal and outward growth pattern, containing varying amounts of fat (ranging from -10 to -120 Hounsfield Units) and regions of soft density that become more pronounced after contrast administration [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. MRI is recommended in difficult cases, however, aspects such as the absence of radiation and additional",24_19,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"such as the absence of radiation and additional information supplied by specific sequences make it a convincing alternative to CT [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. A fat-rich AML, on T2-weighted MRI scans, is usually hyperintense in comparison to renal parenchyma. Fat-poor is slightly hypointense compared with renal parenchyma; however, the distribution of fat might affect the features of imaging. In cases of fat-invisible AML, the lesion is homogeneously hypointense relative to renal",24_20,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"is homogeneously hypointense relative to renal parenchyma and the signal intensity might be caused by the main component of the lesion, which is muscle [<xref rid=""REF14"" ref-type=""bibr"">14</xref>]. Another useful tool is renal biopsy. Indications for renal biopsy include intratumoral cysts, solitary fat-poor AMLs, intratumoral calcifications, or uncertain MRI images. Biopsy may be particularly helpful in patients with coexisting AMLs and atypical lesions to assess tumor characteristics [<xref rid=""REF15""",24_21,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"assess tumor characteristics [<xref rid=""REF15"" ref-type=""bibr"">15</xref>]. Diagnostic tools applied to our patient provided detailed visualization of the lesions. The findings of multiple focal AMLs are typical in TSC patients. Treatment When choosing the treatment option, factors such as clinical presentation, the number and size of the tumor, existing medical conditions, renal function, and the risk of malignancy should be taken into account. The tumor’s diameter primarily determines the treatment",24_22,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"diameter primarily determines the treatment choice; an AML smaller than 4 cm usually presents no symptoms and the patient can remain under active surveillance [<xref rid=""REF16"" ref-type=""bibr"">16</xref>]. When the tumor exceeds 4 cm and the symptoms become persistent, the therapeutic goal should be focused on preserving renal function to the maximum achievable degree, involving mesenchymal-sparing treatment such as partial nephrectomy, selective arterial embolization (SAE), ablation, and mTOR inhibitors",24_23,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"embolization (SAE), ablation, and mTOR inhibitors in patients with TSC-associated AMLs [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. SAE has many advantages over surgical treatment. This procedure leads to less physical trauma and a quicker recovery period. Less invasive treatment is also suitable for patients with high surgical risk caused by other comorbidities. It helps to significantly decrease the risk of severe complications [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. The decision to use SAE in our",24_24,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
The decision to use SAE in our patient is consistent with the current approach for symptomatic or complicated AMLs. Unique aspects of this case include quick progression from presentation to multiple staged embolizations within a short period of time. This highlights the importance of timely intervention in effective management of multiple lesions and the prevention of recurrent hemorrhage. Another important aspect is consideration of our patient's young age and potential for pregnancy in the treatment,24_25,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"age and potential for pregnancy in the treatment planning process. This is particularly significant, as it ensures that applied treatment options address not only immediate clinical needs but also long-term reproductive health. A renal AML is an uncommon benign tumor, usually not causing clinical manifestations, and is diagnosed accidentally. The risk of AML rupture is believed to increase with the tumor’s size. The management of this tumor relies on the patient's clinical symptoms and should be customized",24_26,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
"clinical symptoms and should be customized to each individual, ranging from close surveillance to more invasive interventions.",24_27,"Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex",5 8 2024,,Tuberous_Sclerosis
2024 Canadian Urological Association endorsement of an expert report: Kidney involvement in tuberous sclerosis complex Full text not available in PMC,25_0,2024 Canadian Urological Association endorsement of an expert report: Kidney involvement in tuberous sclerosis complex,8 2024,,Tuberous_Sclerosis
"Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report Tuberous sclerosis complex is a rare genetic neurocutaneous autosomal dominant syndrome in humans, caused by mutations in TSC1 or TSC2 gene. It is characterized by the growth of benign tumors (hamartomas) in multiple locations, including organs such as the skin, brain, kidneys, heart, and lungs. Heart benign tumors resulting from tuberous sclerosis complex are called cardiac rhabdomyomas, composed of normal heart tissue",26_0,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"rhabdomyomas, composed of normal heart tissue (rhabdo) that grows in a disorganized mass (myoma) (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref2"" ref-type=""bibr"">2</xref>). Unlike hamartomas that occur in other organs, cardiac rhabdomyomas are most prevalent in infants and very young children with tuberous sclerosis complex. In fact, these are the only lesions that regress over time in tuberous sclerosis, in some cases disappearing entirely (<xref rid=""ref3"" ref-type=""bibr"">3</xref>, <xref",26_1,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"(<xref rid=""ref3"" ref-type=""bibr"">3</xref>, <xref rid=""ref4"" ref-type=""bibr"">4</xref>). In rare cases, large or several cardiac rhabdomyomas that grow on or near the heart valves can disrupt heart rhythm or blood flow, causing angina symptoms and possibly death (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). Clinically, up to 64% of patients present the syndrome asymptomatically, and a smaller percentage (approximately 35%) present symptoms expressed by arrhythmias and Wolff–Parkinson–White syndrome. The",26_2,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"and Wolff–Parkinson–White syndrome. The estimated mortality associated with cardiac rhabdomyomas due to cardiac complications has been estimated to be close to 2% in cohorts of patients (<xref rid=""ref5"" ref-type=""bibr"">5–8</xref>). Abnormalities within the echocardiogram have been reported in up to 39%, with focal areas of intramyocardial hyperechogenicity being the most prevalent (<xref rid=""ref9"" ref-type=""bibr"">9</xref>). We present a case of tuberous sclerosis complex accompanied by cardiac",26_3,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"tuberous sclerosis complex accompanied by cardiac rhabdomyomas with symptomatic expression in adulthood. A 22-year-old male patient of Afro-descendant, diagnosed with tuberous sclerosis complex in childhood, presented with refractory epilepsy and was treated only with 100 mg lacosamide every 12 h. He has an opioid allergy (tramadol). His family history includes a father with obesity and type 2 diabetes mellitus, a mother with high blood pressure, and a maternal grandfather with prostate cancer. He has no",26_4,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"grandfather with prostate cancer. He has no family history of tuberous sclerosis. Previous interventions identified unspecified epilepsy on electroencephalogram 8 years ago (2015), with no past surgical interventions. The patient sought medical consultation for a 1-year history of episodic, persistent chest pain in the sternal region, lasting 1 to 5 min and exclusively associated with physical effort. There is no relief with any specific factor. On physical examination, the examination of the left eye",26_5,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"examination, the examination of the left eye fundus revealed slightly elevated yellowish-white xanthochromic lesions at the end of the upper temporal arch, suggestive of and compatible with retinal hamartomas. The abdominal cavity showed no alterations. A cardiac examination revealed a systolic murmur in the mitral and aortic focus, grade III/IV. The respiratory system showed no abnormalities. The skin and integumentary system exhibited multiple elevated lesions without inflammatory changes, which were not",26_6,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"without inflammatory changes, which were not painful and compatible with angiofibromas located on the face and head (<xref rid=""fig1"" ref-type=""fig"">Figure 1</xref>). Given the patient’s condition, the initial electrocardiogram showed no alterations. Consequently, diagnostic studies, including a brain MRI a few weeks later, were performed. The MRI revealed small bilateral subependymal lesions, the largest measuring 1.6 × 1.6 cm on the lateral wall of the occipital extension of the right lateral ventricle.",26_7,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"extension of the right lateral ventricle. Additionally, approximately 4 months later, renal ultrasound and echocardiogram were performed. The renal ultrasound showed bilateral renal involvement with multiple rounded masses of variable size (ranging between 12.5 mm and 4 mm) at the parenchymal level, characteristic of angiomyolipomas (<xref rid=""fig2"" ref-type=""fig"">Figure 2</xref>). Echocardiography revealed a non-dilated left ventricle with several rounded masses of high echogenicity without pedicles at",26_8,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"masses of high echogenicity without pedicles at the apical level, the largest measuring 14 × 11 mm. These masses were retractile, with mobility toward the ventricular wall, consistent with cardiac rhabdomyomas (<xref rid=""fig3"" ref-type=""fig"">Figure 3</xref>). No contractility disorders were observed, and the ejection fraction was 60% (Simpson’s biplane method). The atria, valves, and the right ventricle showed no abnormalities. At the diagnosis of a cardiac rhabdomyoma in the left ventricle, the patient",26_9,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"rhabdomyoma in the left ventricle, the patient received symptomatic management for the chest precordial pain using neuromodulators (Pregabalin). Cardiological surveillance was initiated, which, after 4 months (March 2024) of management, has shown improvement in pain without other significant symptoms. Tuberous sclerosis or Bourneville’s disease of autosomal dominant genetic origin is a very rare syndrome (5–7/10,000 live births) (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). The spectrum of clinical",26_10,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"The spectrum of clinical manifestations of the syndrome includes neurological manifestations, such as autism spectrum disorders, cortical tuberomas, epilepsy, and intellectual disability, with the latter being the most common (<xref rid=""ref11"" ref-type=""bibr"">11</xref>, <xref rid=""ref12"" ref-type=""bibr"">12</xref>). Main cutaneous manifestations include facial angiofibromas (formerly sebaceous adenomas), periungual fibromas, ash-leaf spots, and hypochromic macules (up to 80%). Cutaneous clinical",26_11,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"macules (up to 80%). Cutaneous clinical manifestations are essential for reliably approximating the clinical diagnosis of the disease (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). Cardiac manifestations encompass cardiac rhabdomyomas, which are benign tumors considered the most common since perinatal diagnosis (60%). They can be detected ultrasonographically even in the prenatal period (between 20 and 30 weeks), with the most common location being in the ventricles (70%) (<xref rid=""ref13""",26_12,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"being in the ventricles (70%) (<xref rid=""ref13"" ref-type=""bibr"">13</xref>). These tumors usually behave asymptomatically; however, they can interfere with valvular function, alter the ventricular inflow or outflow tract, generate anomalies in the cardiac conduction system, or occlude the adequate irrigation of the coronary system. This can lead to myocardial ischemic events, triggering heart failure and arrhythmias in up to 43.3% (<xref rid=""ref13"" ref-type=""bibr"">13</xref>, <xref rid=""ref14""",26_13,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">13</xref>, <xref rid=""ref14"" ref-type=""bibr"">14</xref>). In this case, although the patient shares characteristics similar to those reported in the literature, such as the clinical diagnosis of tuberous sclerosis based on common manifestations, including neurological (epilepsy), cutaneous (angiofibromas), and ocular (hamartomas) during childhood, a distinctive aspect of this report is that the key clinical manifestation for discovering cardiac rhabdomyomas occurred in young adulthood",26_14,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"cardiac rhabdomyomas occurred in young adulthood (21 years). This manifestation presented as chest pain of prolonged duration (1 year), which, along with findings from the initial examination and the patient’s history, led to a transthoracic echocardiographic study. This study revealed multiple lesions, leading to the diagnosis of cardiac rhabdomyomas, without evidence of damage to cardiac conduction, highlighting a very unusual presentation. It is important to note that the nature of the case reflects the",26_15,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"to note that the nature of the case reflects the patient’s environment with limited resources, living in a rural area with difficult access to healthcare, which contributed to the prolonged progression and delay in obtaining a definitive diagnosis. This case is of interest because, according to the recent review by Frudit et al. (<xref rid=""ref13"" ref-type=""bibr"">13</xref>), it could be the second to date of a young adult with tuberous sclerosis that had a late diagnosis of cardiac rhabdomyomas,",26_16,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"had a late diagnosis of cardiac rhabdomyomas, characterized only by chest pain. The only previous report was by Enbergs et al. (<xref rid=""ref15"" ref-type=""bibr"">15</xref>) in 1996 on a 23-year-old patient accompanied by ventricular tachycardia. Although a relationship between ethnicity and the syndrome or its accompanying features has not been established, apparently, presentation in individuals of African descent is rare (<xref rid=""ref16"" ref-type=""bibr"">16</xref>, <xref rid=""ref17""",26_17,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">16</xref>, <xref rid=""ref17"" ref-type=""bibr"">17</xref>). This case broadens the phenotypic picture of tuberous sclerosis associated with cardiac rhabdomyomas by presenting in an individual of African descent ethnicity. It proposes considering ethnicity as a variable to study in future patients’ reports with tuberous sclerosis complex with rare features. Despite not all patients with tuberous sclerosis presenting with cardiac rhabdomyomas, this case highlights the importance of active",26_18,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"this case highlights the importance of active cardiac screening for these patients during the disease, given the potential complications even in adulthood. In this context, the standard of choice is cardiac echocardiography with a complete Doppler study, which shows well-circumscribed, nodular, multiple masses in the myocardium, which usually project into the ventricular chamber (<xref rid=""ref14"" ref-type=""bibr"">14</xref>). Their diagnosis can be difficult if they present atypical locations such as the",26_19,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"if they present atypical locations such as the atria or present as solitary tumors (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). Additionally, the clinician may opt for cardiac MRI, which, although not widely available in developing settings like this case, can provide a more accurate description of the masses when the echocardiographic diagnosis is unclear and as a useful adjunct when surgical resolution is planned (<xref rid=""ref14"" ref-type=""bibr"">14</xref>). The follow-up of this entity is usually based",26_20,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"The follow-up of this entity is usually based on growth monitoring with echocardiography and electrocardiograms every 3 to 5 years to assess possible conduction disorders and risks of disease progression such as heart failure (<xref rid=""ref18"" ref-type=""bibr"">18</xref>). The late onset of cardiac rhabdomyomas in adulthood among patients with tuberous sclerosis is particularly rare and may manifest symptomatically with a variety of presentations, ranging from simple to complex. Regular clinical inspections",26_21,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"simple to complex. Regular clinical inspections should be conducted for individuals with tuberous sclerosis complex, even in adulthood, to monitor the emergence of benign cardiac masses. The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author. Written informed consent was obtained directly from the patient. Written informed consent was obtained from the participant/patient(s) for the publication of",26_22,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"the participant/patient(s) for the publication of this case report. HN-C: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing – original draft. JQ: Conceptualization, Data curation, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft. OM: Conceptualization, Data curation, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft. MA-I:",26_23,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"Visualization, Writing – original draft. MA-I: Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft. FM: Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – review & editing. JI-C: Data curation, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.",26_24,Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report,31 7 2024,,Tuberous_Sclerosis
"Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex Tuberous sclerosis is a genetic disorder that affects multiple organs and has an estimated incidence of 1 in 10,000 to 1 in 6,000 newborns (<xref rid=""B33"" ref-type=""bibr"">Northrup et al., 1993</xref>; <xref rid=""B32"" ref-type=""bibr"">Northrup et al., 2021</xref>). It is characterized by the presence of benign tumors in multiple organs, such as the brain, kidneys, skin, heart, lungs, and eyes, and",27_0,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"brain, kidneys, skin, heart, lungs, and eyes, and is associated with a range of neuropsychiatric symptoms like epilepsy, intellectual disability, and autism spectrum disorder (<xref rid=""B33"" ref-type=""bibr"">Northrup et al., 1993</xref>; <xref rid=""B11"" ref-type=""bibr"">Ekong et al., 2016</xref>). If left untreated, central nervous system tumors and renal disease can lead to significant morbidity and mortality, and therefore, early diagnosis and regular monitoring and treatment are essential (<xref",27_1,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"monitoring and treatment are essential (<xref rid=""B32"" ref-type=""bibr"">Northrup et al., 2021</xref>). In 2012 and 2021, the clinical diagnostic criteria were developed and updated for diagnosing individuals with suspected tuberous sclerosis (<xref rid=""B9"" ref-type=""bibr"">Davis et al., 2017</xref>; <xref rid=""B32"" ref-type=""bibr"">Northrup et al., 2021</xref>). These criteria enable the classification of patients into “definite TSC” or “possible TSC” depending on the number of major and minor clinical",27_2,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"on the number of major and minor clinical features they exhibit. Notably, the clinical manifestations of tuberous sclerosis can significantly vary between and within families and may evolve over time and at different ages (<xref rid=""B9"" ref-type=""bibr"">Davis et al., 2017</xref>; <xref rid=""B18"" ref-type=""bibr"">Kingswood et al., 2017</xref>). Molecular diagnosis of tuberous sclerosis is established through the identification of a pathogenic variant of <italic toggle=""yes"">TSC1</italic> or <italic",27_3,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"of <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic>, regardless of the clinical findings (<xref rid=""B21"" ref-type=""bibr"">Krueger et al., 2013</xref>; <xref rid=""B32"" ref-type=""bibr"">Northrup et al., 2021</xref>). As technology has advanced, various techniques have been used for genetic testing of tuberous sclerosis, such as Sanger sequencing (<xref rid=""B2"" ref-type=""bibr"">Au et al., 2007</xref>), single-strand conformational analysis (<xref rid=""B2"" ref-type=""bibr"">Au et al.,",27_4,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"(<xref rid=""B2"" ref-type=""bibr"">Au et al., 2007</xref>), denaturing high-performance liquid chromatography (<xref rid=""B8"" ref-type=""bibr"">Dabora et al., 2001</xref>), long-range PCR (<xref rid=""B8"" ref-type=""bibr"">Dabora et al., 2001</xref>), multiplex ligation-dependent probe analysis (MLPA), targeted next-generation sequencing (NGS) (<xref rid=""B31"" ref-type=""bibr"">Nellist et al., 2015</xref>), deep sequencing (<xref rid=""B48"" ref-type=""bibr"">Ye et al., 2022</xref>; <xref rid=""B4""",27_5,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"et al., 2022</xref>; <xref rid=""B4"" ref-type=""bibr"">Blasco-Perez et al., 2023</xref>; <xref rid=""B19"" ref-type=""bibr"">Klonowska et al., 2023</xref>), and whole-exome sequencing and genome sequencing (<xref rid=""B34"" ref-type=""bibr"">Ogorek et al., 2020</xref>). Generally, a vast majority of patients (85%–90%) are identified as carrying a heterozygous germline pathogenic variant in either <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> (<xref rid=""B8"" ref-type=""bibr"">Dabora et al.,",27_6,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"(<xref rid=""B8"" ref-type=""bibr"">Dabora et al., 2001</xref>; <xref rid=""B37"" ref-type=""bibr"">Peron et al., 2018</xref>). In addition, the majority of the remaining patients may be identified as having mosaic variants via deep sequencing (<xref rid=""B39"" ref-type=""bibr"">Qin et al., 2010</xref>; <xref rid=""B25"" ref-type=""bibr"">Manzanilla-Romero et al., 2021</xref>; <xref rid=""B4"" ref-type=""bibr"">Blasco-Perez et al., 2023</xref>). However, few patients have “no mutation identified” (NMI) results even after",27_7,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"“no mutation identified” (NMI) results even after using various techniques. Our hypothesis is that the causal variant in these patients with NMI may be a structural variant or a deep intronic variant, which cannot be identified by the standard, NGS-based techniques. In recent years, various approaches have been developed to enhance the ability to detect structural variation, such as long-read sequencing and optical genome mapping (OGM) (<xref rid=""B40"" ref-type=""bibr"">Shieh et al., 2021</xref>). The",27_8,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">Shieh et al., 2021</xref>). The long-read sequencing technology can generate reads that span from 1,000 to >1 million base pairs (bp) (<xref rid=""B24"" ref-type=""bibr"">Logsdon et al., 2020</xref>; <xref rid=""B26"" ref-type=""bibr"">Mastrorosa et al., 2023</xref>), resulting in better detection of structural variations than possible with NGS, the traditional short-read sequencing technology. In 2023, Ura et al. reported a novel intron retention in a patient with tuberous sclerosis complex using",27_9,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"a patient with tuberous sclerosis complex using cDNA long-read sequencing (<xref rid=""B44"" ref-type=""bibr"">Ura et al., 2023</xref>). Therefore, long-read sequencing is considered an effective way to discover unknown pathogenic variants in Mendelian diseases (<xref rid=""B29"" ref-type=""bibr"">Merker et al., 2018</xref>). In this work, we conducted genetic analyses of full <italic toggle=""yes"">TSC1</italic> and <italic toggle=""yes"">TSC2</italic> in 26 patients with NMI having definite TSC using a targeted",27_10,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"with NMI having definite TSC using a targeted long-read sequencing approach based on the PacBio SMRT platform (Pacific Biosciences of California Inc., Menlo Park, CA, United States) to identify missed pathogenic variants.   Herein, we report on our analysis of 26 patients having TSC who were not identified as having a pathogenic variant through conventional molecular diagnostic analyses of <italic toggle=""yes"">TSC1</italic> and <italic toggle=""yes"">TSC2</italic>. We were able to identify the variant with a",27_11,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"We were able to identify the variant with a high suspicion of pathogenicity in 14 cases (53.8%). Of these 14 patients, 8 patients were found to have SVs: four had InDels, two had splice variants. Notably, the majority (57.1%) of the identified pathogenic variants (8/14, 57.1%) were mosaic variants, which is consistent with previous studies of patients having tuberous sclerosis with NMI (<xref rid=""B43"" ref-type=""bibr"">Tyburczy et al., 2015</xref>; <xref rid=""B13"" ref-type=""bibr"">Giannikou et al.,",27_12,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"<xref rid=""B13"" ref-type=""bibr"">Giannikou et al., 2019</xref>; <xref rid=""B48"" ref-type=""bibr"">Ye et al., 2022</xref>; <xref rid=""B19"" ref-type=""bibr"">Klonowska et al., 2023</xref>). Ye et al. (<xref rid=""B48"" ref-type=""bibr"">Ye et al., 2022</xref>) and Tyburczy et al. (<xref rid=""B43"" ref-type=""bibr"">Tyburczy et al., 2015</xref>) reported in their studies that 5.5% and 7.5% of patients with tuberous sclerosis had mosaic pathogenic variants, respectively. Our study provides further evidence that mosaicism",27_13,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"study provides further evidence that mosaicism occurs in a higher proportion of TSC patients than expected. In recent years, research involving patients having tuberous sclerosis with NMI has mainly been devoted to taking advantage of deep sequencing, leading to the identification of numerous mosaic and deep intronic variants (<xref rid=""B28"" ref-type=""bibr"">Mayer et al., 1999</xref>; <xref rid=""B46"" ref-type=""bibr"">Weren et al., 2015</xref>; <xref rid=""B48"" ref-type=""bibr"">Ye et al., 2022</xref>; <xref",27_14,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">Ye et al., 2022</xref>; <xref rid=""B19"" ref-type=""bibr"">Klonowska et al., 2023</xref>); however, the pathogenic variants of some patients remained undiscovered. To address this, we chose long-read sequencing in our study to identify different pathogenic variants. Moreover, half of the cases we included had already undergone deep sequencing. Consequently, the variants we found were mainly SVs, such as mosaic large deletions, complex SVs, and retrotransposon insertions, which are hard to",27_15,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"and retrotransposon insertions, which are hard to detect using short-read sequencing. Our findings indicated the presence of various pathogenic variants in patients having tuberous sclerosis with NMI that would be overlooked in clinical genetic testing, such as mosaic small variants, mosaic structure variants, deep intron variants, retrotransposon insertions, and complex structural variations. Furthermore, it was proposed that mosaic structural variations and special variant types like Alu element",27_16,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"and special variant types like Alu element insertions are challenging to identify using second-generation sequencing and MLPA, and long-read sequencing may be a potential choice for cases of tuberous sclerosis with NMI. We used a combination of molecular analytic tools, including targeted long-read sequencing, Sanger sequencing, OGM, and ONT-WGS, to accurately detect a mosaic complex structural variant that spanned ∼83 kb in TSC-T5. Targeted long-read sequencing revealed the complex structural variation,",27_17,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"revealed the complex structural variation, whereas OGM, with its high read length of 250 kb, allowed for the conformation of the true size of the variant. With an average read length of 50 kb, although ONT-WGS could not show the full picture of the entire variant in one read, but it could provide more information about the breakpoint junction sequences than targeted long-read sequencing, which allowed us to identify the variant. Finally, Sanger sequencing allowed us to verify the authenticity of the",27_18,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"allowed us to verify the authenticity of the connections and the insertion of few bases in the connection fragments. This approach successfully presented the variant and provided a useful strategy for verifying other structural variations in the future. SVs arise from various mutational processes, such as DNA recombination-, replication- and repair-related processes (<xref rid=""B5"" ref-type=""bibr"">Carvalho and Lupski, 2016</xref>). The structural variant in TSC-T5 is novel and nonrecurrent. Its underlying",27_19,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"TSC-T5 is novel and nonrecurrent. Its underlying mechanism, however, still needs to be confirmed. We discovered two different retrotransposon insertions in our cases, including an intronic Alu element in TSC-T20 and an exonic SVA insertion in TSC-T27. To our knowledge, this is the first report of retrotransposon insertions in <italic toggle=""yes"">TSC2</italic> in the context of tuberous sclerosis. Alu element and SVA belong to non-LTR retrotransposons, and there is clear evidence that non-LTR",27_20,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"and there is clear evidence that non-LTR retrotransposons are still active in humans, as demonstrated in the dozens of reported cases of <italic toggle=""yes"">de novo</italic> insertions that are associated with genetic disorders (<xref rid=""B45"" ref-type=""bibr"">Wallace et al., 1991</xref>; <xref rid=""B35"" ref-type=""bibr"">Oldridge et al., 1999</xref>; <xref rid=""B6"" ref-type=""bibr"">Claverie-Martin et al., 2003</xref>; <xref rid=""B7"" ref-type=""bibr"">Cordaux and Batzer, 2009</xref>; <xref rid=""B1""",27_21,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"and Batzer, 2009</xref>; <xref rid=""B1"" ref-type=""bibr"">Ade and Roy-Engel, 2016</xref>). Alu elements, which are primate-specific retrotransposons, were formed by the 50-to-30 fusion of the 7SL RNA gene and have been present in the human genome for over 65 million years, with the total number of copies surpassing one million (<xref rid=""B14"" ref-type=""bibr"">Hasler and Strub, 2006</xref>; <xref rid=""B20"" ref-type=""bibr"">Kriegs et al., 2007</xref>). <italic toggle=""yes"">De novo</italic> Alu insertions close",27_22,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"novo</italic> Alu insertions close to the splice acceptor and splice donor sites can reportedly disrupt splicing, resulting in disease-causing alleles (<xref rid=""B45"" ref-type=""bibr"">Wallace et al., 1991</xref>; <xref rid=""B42"" ref-type=""bibr"">Tighe et al., 2002</xref>; <xref rid=""B12"" ref-type=""bibr"">Gallus et al., 2010</xref>; <xref rid=""B36"" ref-type=""bibr"">Payer et al., 2019</xref>). Moreover, Alu elements that are antisense to a gene can provide splice acceptor sites (<xref rid=""B41""",27_23,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"provide splice acceptor sites (<xref rid=""B41"" ref-type=""bibr"">Sorek et al., 2004</xref>; <xref rid=""B22"" ref-type=""bibr"">Krull et al., 2005</xref>). The RNA Splicer developed by the Research Institute of Tsinghua predicted that the Alu element insertion of TSC-T20 would lead to an 82-bp pseudo-exon insertion in the RNA. We assume that the pathology caused by this Alu element insertion is due to the disruption of splicing. SVAs are the youngest retrotransposon family in the human genome (<xref rid=""B38""",27_24,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"family in the human genome (<xref rid=""B38"" ref-type=""bibr"">Pfaff et al., 2022</xref>) and typically measure ∼2 kb in length with ∼3,000 copies present (<xref rid=""B7"" ref-type=""bibr"">Cordaux and Batzer, 2009</xref>). The full-length SVA identified in TSC-T27 is 3 kb in length and located in exon 12 of <italic toggle=""yes"">TSC2</italic>. Thus far, more than 10 cases of exonic SVA insertions have been linked to Mendelian diseases (<xref rid=""B38"" ref-type=""bibr"">Pfaff et al., 2022</xref>). These insertions",27_25,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"et al., 2022</xref>). These insertions can lead to pathogenic conditions in two main ways. First, SVAs contain stop codons which can introduce a premature stop codon or cause a frameshift mutation when inserted into exons (<xref rid=""B30"" ref-type=""bibr"">Nakamura et al., 2015</xref>; <xref rid=""B10"" ref-type=""bibr"">Delvallee et al., 2021</xref>; <xref rid=""B47"" ref-type=""bibr"">Yamamoto et al., 2021</xref>; <xref rid=""B15"" ref-type=""bibr"">Hiraide et al., 2022</xref>). Second, SVA insertion may interfere",27_26,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"2022</xref>). Second, SVA insertion may interfere with the normal splicing of the gene, thus disrupting its normal function (<xref rid=""B30"" ref-type=""bibr"">Nakamura et al., 2015</xref>; <xref rid=""B16"" ref-type=""bibr"">Jones et al., 2020</xref>; <xref rid=""B47"" ref-type=""bibr"">Yamamoto et al., 2021</xref>). This study has several potential limitations. First, we studied a relatively small number of patients and made phenotype comparisons among them based on their pathogenic variant detection status",27_27,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"on their pathogenic variant detection status (heterozygous, mosaic, and negative). Although the average number of major features with statistically significant differences between negative and mosaic variant cases is notable, it is essential to consider the limited sample size. Second, to ensure a reliable confirmation of mosaicism in a patient, the use of two different methodologies is recommended. We used various techniques, including Sanger sequencing, OGM, long-read whole-genome sequencing by Oxford",27_28,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"OGM, long-read whole-genome sequencing by Oxford Nanopore technology, ddPCR, and MLPA, to verify the mosaic variants identified; however, except for ddPCR, none of these techniques can accurately ascertain the VAF of the mosaic variants, and thus, the VAF should be interpreted with caution. Third, even though we used the RNA Splicer (<ext-link http://www.w3.org/1999/xlink href=""https://rddc.tsinghua-gd.org/ai/rna-splicer"" ext-link-type=""uri"">https://rddc.tsinghua-gd.org/ai/rna-splicer</ext-link>) to",27_29,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"to predict the effect of Alu element insertion on RNA which occurred <italic toggle=""yes"">de novo</italic>, we could not acquire patient sample for RNA analysis to corroborate our predictions. Fourth, 8 cases remain unsolved, possibly due to the following limitations of our study. 1) Mosaic variants are limited to the affected organs (kidney and brain) and not detectable in peripheral blood samples used in this study (<xref rid=""B19"" ref-type=""bibr"">Klonowska et al., 2023</xref>). 2) Mosaic SVs that have",27_30,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"et al., 2023</xref>). 2) Mosaic SVs that have at least one breakpoint in <italic toggle=""yes"">TSC2</italic> or <italic toggle=""yes"">TSC1</italic> with a VAF lower than 2% and small variants with a VAF below 5% were below the limit of detection using our methods. 3) mosaic SVs that encompass the entire <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> may have been missed by our methods because the junction sequence could not be captured by the probes. In our research, we used",27_31,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"captured by the probes. In our research, we used long-read sequencing in patients with tuberous sclerosis in whom a pathogenic or likely pathogenic variant of <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> could not be identified using short-read sequencing or other traditional methods, and we have been able to detect a pathogenic variation in <italic toggle=""yes"">TSC1</italic> or <italic toggle=""yes"">TSC2</italic> in the majority of these patients using long-read sequencing. Our",27_32,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"of these patients using long-read sequencing. Our findings broaden the range of pathogenic variants associated with tuberous sclerosis, particularly in terms of complex SVs and retrotransposon insertions that have never been documented in tuberous sclerosis patients. It appears much more likely that rather than having an additional gene causing typical tuberous sclerosis, individuals who have persistently had NMI have either a mosaic variation that was not present in blood or an extremely mosaic variant,",27_33,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"present in blood or an extremely mosaic variant, which our methods could not reveal. Owing to the current high costs and limited availability of long-read sequencing, we recommend next-generation sequencing as the primary genetic testing method for individuals with tuberous sclerosis. However, given the ability of long-read sequencing to uncover mosaic large deletions, complex structural variations, retrotransposon insertions, and other typical variants, it may be a suitable approach for patients having",27_34,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"it may be a suitable approach for patients having tuberous sclerosis with NMI, particularly when patients seek to identify the pathogenic variation for reproductive planning. Additionally, our findings are applicable to various other genetic disorders, thus emphasizing the importance of using long-read sequencing to identify variants in unresolved cases wherein a causative variant could not be identified.",27_35,Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex,31 7 2024,,Tuberous_Sclerosis
"Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis Tuberous sclerosis complex (TSC) is a genetic disorder manifesting as an autosomal dominant neurocutaneous syndrome that affects many tissues or organs concurrently or sequentially, including the skin, lungs, kidneys, heart, and central nervous system (CNS). Approximately 22.6% of individuals with TSC have a family history of the condition (<xref rid=""r1"" ref-type=""bibr"">1</xref>). Mutations in the <italic",28_0,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"Mutations in the <italic toggle=""yes"">TSC1</italic> gene, which encodes hamartin on chromosome 9, and/or the <italic toggle=""yes"">TSC2</italic> gene, which encodes tuberin on chromosome 16, are presently thought to be associated with TSC (<xref rid=""r2"" ref-type=""bibr"">2</xref>). However, mutations of these genes are not found in 14.4% of patients with TSC (<xref rid=""r1"" ref-type=""bibr"">1</xref>). The mammalian target of rapamycin (mTOR) is an essential mediator of cell proliferation and a",28_1,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"an essential mediator of cell proliferation and a serine/threonine kinase that is exceptionally conserved among eukaryotes. It is implicated in protein synthesis, gene transcription and translation, and ribosome formation (<xref rid=""r3"" ref-type=""bibr"">3</xref>). During the embryonic phase, the hyperactivation of the mTOR signaling pathway, driven by mutations in the <italic toggle=""yes"">TSC1</italic> and/or <italic toggle=""yes"">TSC2</italic> genes, leads to the formation of hamartomas. This",28_2,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"genes, leads to the formation of hamartomas. This hyperactivation results in aberrant proliferation, differentiation, and unregulated apoptosis of ectodermal, mesodermal, and endodermal cells. The CNS is the most frequently affected organ, with histopathological manifestations of cortical or subcortical nodules, subependymal nodules, subependymal giant cell astrocytomas, and white matter migration lines (<xref rid=""r4"" ref-type=""bibr"">4</xref>). These manifestations typically result in clinical symptoms",28_3,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"typically result in clinical symptoms such as epileptic seizures and neurological deficits. However, there are significant differences in clinical manifestations among patients with different genetic phenotypes. Patients with <italic toggle=""yes"">TSC2</italic> gene mutations have a younger onset age of epilepsy, and higher rates of focal and refractory epilepsy (<xref rid=""r5"" ref-type=""bibr"">5</xref>). Even among patients with the same genetic phenotype, clinical manifestations vary greatly due to",28_4,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"clinical manifestations vary greatly due to differences in affected organs. Epileptic seizures typically manifest as infantile spasms and focal seizures, with the latter being the most prevalent, affecting 83.6% of TSC patients of all ages, albeit such seizures are most frequently observed in infancy (<xref rid=""r6"" ref-type=""bibr"">6</xref>,<xref rid=""r7"" ref-type=""bibr"">7</xref>). TSC-associated epilepsy is often refractory and requires a combination of treatment approaches. Thus, for the early detection,",28_5,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"approaches. Thus, for the early detection, management, and prognosis of TSC-associated epilepsy, it is critical to leverage bioinformatics methodologies and gene chip technology to systematically identify and analyze novel biomarkers (<xref rid=""r8"" ref-type=""bibr"">8</xref>). This study utilizes the Gene Expression Omnibus (GEO) database and employs bioinformatics analysis methods to further explore differentially expressed genes (DEGs), disease-related signaling pathways, and protein-protein interaction",28_6,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"pathways, and protein-protein interaction (PPI) networks in TSC-related epilepsy. The aim is to identify key genes that may play significant roles in the progression of TSC-related epilepsy at the molecular level, thereby providing a theoretical basis for understanding the molecular mechanisms underlying the disease. We present this article in accordance with the STREGA and ARRIVE reporting checklists (available at <ext-link http://www.w3.org/1999/xlink",28_7,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"at <ext-link http://www.w3.org/1999/xlink href=""https://tp.amegroups.com/article/view/10.21037/tp-24-211/rc"" ext-link-type=""uri"">https://tp.amegroups.com/article/view/10.21037/tp-24-211/rc</ext-link>).   As an autosomal dominant genetic disorder, TSC is predominantly caused by mutations in the hamartin- and tuberin-encoding tumor suppressor genes <italic toggle=""yes"">TSC1</italic> (9q34) or <italic toggle=""yes"">TSC2</italic> (16p13.3). These mutations result in protein deficiencies, aberrant heterodimer",28_8,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"in protein deficiencies, aberrant heterodimer formation, and the stimulation of the mTOR complex 1 signaling pathway, which promotes the development of hamartomas in various organs, including the brain, skin, heart, kidneys, liver, and lungs, which in turn adversely affects the functionality of these organs (<xref rid=""r10"" ref-type=""bibr"">10</xref>,<xref rid=""r11"" ref-type=""bibr"">11</xref>). The TSC phenotype displays a wide range of characteristics, of which epileptic seizures are a prevalent",28_9,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"of which epileptic seizures are a prevalent neurological symptom and the main reason for patient consultations. Studies have reported that the occurrence rate of seizures in individuals with TSC is 62–93% (<xref rid=""r12"" ref-type=""bibr"">12</xref>,<xref rid=""r13"" ref-type=""bibr"">13</xref>), the incidence is similar between both genders, and the onset of epileptic-like seizures typically occurs before the age of 1 year. Seizures may appear as focal events preceding spasms or may occur simultaneously with or",28_10,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"spasms or may occur simultaneously with or progress into spasms (<xref rid=""r14"" ref-type=""bibr"">14</xref>-<xref rid=""r16"" ref-type=""bibr"">16</xref>). The main cause of TSC-associated epilepsy is not fully understood. However, several potential risk factors for TSC-associated epilepsy have been identified, including chromosomal abnormalities, genetic alterations, changes in the cellular microenvironment, and immune regulation (<xref rid=""r17"" ref-type=""bibr"">17</xref>,<xref rid=""r18""",28_11,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">17</xref>,<xref rid=""r18"" ref-type=""bibr"">18</xref>). Gene chips, which allow for the comprehensive analysis of gene expression profiles, have recently become a widely used tool in the study of various diseases (<xref rid=""r19"" ref-type=""bibr"">19</xref>). In this study, we aimed to identify DEGs that are consistently upregulated in TSC-associated epilepsy from gene chip datasets in the GEO database using bioinformatics techniques. These DEGs were then subjected to functional enrichment",28_12,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"DEGs were then subjected to functional enrichment analyses to explore their roles in biological pathways relevant to the disease. The identification of such biomarkers is crucial as it can provide a theoretical foundation for understanding the disease and potentially guide the development of targeted therapies. In this study, we used bioinformatics techniques to retrieve and analyze data sets related to TSC-associated epilepsy from the GEO database. Our analysis identified 151 upregulated common DEGs. The",28_13,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"identified 151 upregulated common DEGs. The DAVID online tool was used to perform GO and KEGG enrichment analyses to investigate the biological roles of the DEGs. The KEGG signaling pathway enrichment analysis revealed that the overexpressed DEGs were primarily associated with complement and coagulation pathways, glycosaminoglycans in cancer, and interactions between ECM receptors. Previous studies have reported similar findings, including a negative correlation between cortical glucose metabolism in",28_14,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"between cortical glucose metabolism in TSC-associated epilepsy and delta-slowing and peak frequency (<xref rid=""r20"" ref-type=""bibr"">20</xref>), that histone deacetylase inhibitors can restore normal synaptic plasticity in the hippocampus and increase the seizure threshold in mice models of TSC (<xref rid=""r21"" ref-type=""bibr"">21</xref>), and that adenosine analogue AppCH2ppA inhibits seizures by stimulating adenosine signaling in the cortex (<xref rid=""r22"" ref-type=""bibr"">22</xref>). These findings",28_15,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">22</xref>). These findings indirectly support the accuracy and research value of our study. The <italic toggle=""yes"">PDPN</italic> gene, which was identified using Cytoscape software, encodes a protein that is expressed in various tissues and cell types, including tumor and immune cells. It is implicated in various processes that contribute to the formation and progression of tumors, including angiogenesis, metastasis, and tumor cell migration. Previous research has shown that <italic",28_16,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"Previous research has shown that <italic toggle=""yes"">PDPN</italic> expression levels are positively correlated with glioma grading in diffuse astrocytomas (<xref rid=""r23"" ref-type=""bibr"">23</xref>). High <italic toggle=""yes"">PDPN</italic> expression has also been found to be associated with lower survival rates in patients with astrocytomas with mutated or wild-type isocitrate dehydrogenase (<italic toggle=""yes"">IDH</italic>) and in patients with glioblastoma with wild-type <italic",28_17,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"patients with glioblastoma with wild-type <italic toggle=""yes"">IDH</italic>. Research has shown that the knockdown of <italic toggle=""yes"">PDPN</italic> hinders the growth of glioma cells and reduces the levels of phosphorylated Akt (protein kinase B) and phosphorylated mTOR proteins (<xref rid=""r23"" ref-type=""bibr"">23</xref>). The overexpression of <italic toggle=""yes"">PDPN </italic>is correlated with mTOR pathway activity and stimulates the mTOR pathway, resulting in enhanced growth, infiltration, and",28_18,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"resulting in enhanced growth, infiltration, and metastasis of tumor cells. Further, the activation of the mTOR pathway also induces tumor cells to express more <italic toggle=""yes"">PDPN</italic>, forming a positive feedback loop that further promotes tumor development (<xref rid=""r24"" ref-type=""bibr"">24</xref>,<xref rid=""r25"" ref-type=""bibr"">25</xref>). Collectively, these findings reflect the research value of <italic toggle=""yes"">PDPN</italic> in TSC-associated epilepsy. The GSEA of the DEGs revealed",28_19,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"epilepsy. The GSEA of the DEGs revealed that the common DEG <italic toggle=""yes"">PDPN </italic>was enriched in both data sets in the signaling pathways related to platelet activation, aggregation, and the GPVI-mediated activation cascade. These pathways have also been implicated in epilepsy. Notably, Kopeikina<italic toggle=""yes""> et al. </italic>(<xref rid=""r26"" ref-type=""bibr"">26</xref>) reported that platelets were significantly enhanced in a pentylenetetrazol-induced seizure mouse model. Platelets have",28_20,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"seizure mouse model. Platelets have also been found to actively secrete serotonin, a neurotransmitter that facilitates enhanced blood-brain barrier (BBB) permeability and has been detected in the CNS during seizures. Further, research has shown that platelets induce oxidative stress in neurons by directly stimulating neuronal electrical activity and inducing the expression of genes associated with early neuronal reaction, neuroinflammation, and oxidative phosphorylation (<xref rid=""r26""",28_21,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"and oxidative phosphorylation (<xref rid=""r26"" ref-type=""bibr"">26</xref>). Kopeikina<italic toggle=""yes""> et al. </italic>(<xref rid=""r27"" ref-type=""bibr"">27</xref>) found that platelet activation in the CNS occurs when platelets recognize significant brain gangliosides on the surfaces of neurons and astrocytes. This activation results in the release of neurotransmitters and pro-inflammatory neurotrophic factors. Platelet-derived factors promote the formation of new synapses and axonal regeneration toward",28_22,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"of new synapses and axonal regeneration toward the injury site by directly stimulating neuronal electrical and synaptic activities. The disruption of the BBB may be closely related to neuronal damage during epilepsy and psychiatric disorders. Additionally, we identified high levels of <italic toggle=""yes"">PDPN</italic> expression in the cerebral cortex of the model mice via immunohistochemistry; however, no significantly positive neurons were observed in the cerebral cortexes of the control group mice.",28_23,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"the cerebral cortexes of the control group mice. These results suggest that <italic toggle=""yes"">PDPN</italic> may have a significant effect on the progression and onset of TSC-associated epilepsy. Our findings may also provide a foundation for future<italic toggle=""yes""> in vitro </italic>and<italic toggle=""yes""> in vivo </italic>studies. One significant limitation of this study is the potential for confounding factors that were not accounted for in the analysis. Since the comparison was made between",28_24,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"analysis. Since the comparison was made between patients with TSC-associated epilepsy and healthy controls, it remains unclear whether the observed upregulation of <italic toggle=""yes"">PDPN</italic> and other DEGs are specifically associated with TSC-associated epilepsy or if they might also be influenced by other factors such as general epilepsy, the effects of antiseizure medication, TSC-associated neuropsychiatric disorders, or other common manifestations of TSC. To address this limitation, future",28_25,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"of TSC. To address this limitation, future research should include additional control groups, such as patients with non-TSC epilepsy and those with other TSC manifestations without epilepsy, and those with sporadic focal epilepsies (<xref rid=""r28"" ref-type=""bibr"">28</xref>). These comparisons will help to disentangle the specific contributions of these genes to the pathophysiology of TSC-associated epilepsy. Furthermore, functional studies are needed to validate the roles of the identified genes and",28_26,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"to validate the roles of the identified genes and pathways in TSC-associated epilepsy and to explore their potential as therapeutic targets. Several regulatory factors influence the progression of TSC-associated epilepsy. The identified key genes and signaling pathways provide insights into the molecular processes involved in the development of TSC-associated epilepsy. Further, these findings may provide a theoretical basis for research into targeted clinical treatments.",28_27,Screening for biomarkers of tuberous sclerosis complex–associated epilepsy: a bioinformatics analysis,29 7 2024,,Tuberous_Sclerosis
"PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by mutations in the TSC1 or TSC2 genes, which lead to the upregulation of the mammalian target of rapamycin (mTOR) complex [<xref rid=""bib1"" ref-type=""bibr"">1</xref>]. This disorder is a multiorgan syndrome manifesting with several benign and malignant tumors, with renal lesions present in 80%–85 % of",29_0,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"tumors, with renal lesions present in 80%–85 % of individuals with TSC. Among these, renal angiomyolipomas (RAMLs) are the most prevalent renal abnormalities [<xref rid=""bib2"" ref-type=""bibr"">2</xref>,<xref rid=""bib3"" ref-type=""bibr"">3</xref>]. Moreover, RAMLs are the leading cause of mortality in TSC adult patients due to the risk of life-threatening hemorrhage and are associated with severe chronic kidney disease [<xref rid=""bib4"" ref-type=""bibr"">4</xref>].The updated TSC management recommendations",29_1,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"updated TSC management recommendations emphasize that mammalian target of rapamycin complex 1 (mTORC1) inhibitors are the primary therapy to preserve renal function and minimize the risk of complications, aligning with the primary therapeutic goal for TSC-related renal angiomyolipomas (TSC-RAMLs) [<xref rid=""bib5"" ref-type=""bibr"">5</xref>]. However, nearly 40 % TSC-RAMLs patients treated with mTORC1 inhibitors fail to reach clinical remission levels (tumor volume reduction of ≥50 %) [<xref rid=""bib6""",29_2,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"volume reduction of ≥50 %) [<xref rid=""bib6"" ref-type=""bibr"">6</xref>,<xref rid=""bib7"" ref-type=""bibr"">7</xref>]. Therefore, we need a simple and effective biomarker to predict the treatment efficacy of mTORC1 inhibitors. Premelanosome protein (PMEL), also known as gp100 and Pmel17, is predominantly expressed in pigment cells of the skin and eyes. It plays a crucial role in the formation of melanosomal fibrils during the transition from stage I to stage II melanosomes [<xref rid=""bib8""",29_3,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"stage I to stage II melanosomes [<xref rid=""bib8"" ref-type=""bibr"">8</xref>]. Recent studies demonstrate that PMEL, as the target of the HMB-45 antibody, has a sensitive and specific expression in angiomyolipomas (AMLs) [<xref rid=""bib9"" ref-type=""bibr"">9</xref>]. Single-cell and single-nuclei RNA sequencing results also shows that PMEL is an expression marker of lymphangioleiomyomatosis (LAM), a metastatic neoplasm associated with TSC gene mutations [<xref rid=""bib10"" ref-type=""bibr"">10</xref>]. Our",29_4,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"rid=""bib10"" ref-type=""bibr"">10</xref>]. Our previous study demonstrated that PMEL has significantly higher expression in TSC-RAMLs and might serve as both prognostic and diagnostic biomarkers [<xref rid=""bib11"" ref-type=""bibr"">11</xref>]. However, whether PMEL can predict the treatment efficacy of mTORC1 inhibitors in TSC-RAMLs requires further clinical validation. Building upon previous single-cell sequencing and proteomic research, the objective of this study is to demonstrate that whether PMEL could",29_5,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"study is to demonstrate that whether PMEL could function as a predictive biomarker for monitoring the treatment efficacy of mTORC1 inhibitors.   Renal angiomyolipomas (RAMLs) are present in 80 % of patients with Tuberous Sclerosis Complex (TSC), and the rupture and bleeding of renal RAMLs are the leading causes of death among TSC patients [<xref rid=""bib14"" ref-type=""bibr"">12</xref>,<xref rid=""bib15"" ref-type=""bibr"">15</xref>]. Moreover, as RAML increases in size, the risk of rupture and bleeding",29_6,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"in size, the risk of rupture and bleeding significantly rises. Therefore, treating RAMLs in TSC patients appears particularly crucial [<xref rid=""bib16"" ref-type=""bibr"">16</xref>]. For patients with TSC-RAMLs, mTORC1 inhibitors could serve as a promising method to manage tumor growth while preserving renal tissue and are recommended as the first-line therapy according to TSC diagnostic criteria and management guideline [<xref rid=""bib16"" ref-type=""bibr"">16</xref>,<xref rid=""bib17""",29_7,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"ref-type=""bibr"">16</xref>,<xref rid=""bib17"" ref-type=""bibr"">17</xref>]. Moreover, most AMLs in TSC patients do not regenerate and rarely bleed during mTORC1 inhibitor treatment, offering long-term clinical benefits [<xref rid=""bib18"" ref-type=""bibr"">18</xref>,<xref rid=""bib19"" ref-type=""bibr"">19</xref>]. Even though mTORC1 inhibitors show promising effectiveness across various clinical trials linked to TSC-RAMLs [<xref rid=""bib18"" ref-type=""bibr"">[18]</xref>, <xref rid=""bib19"" ref-type=""bibr"">[19]</xref>,",29_8,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"<xref rid=""bib19"" ref-type=""bibr"">[19]</xref>, <xref rid=""bib20"" ref-type=""bibr"">[20]</xref>], there remains nearly 40–50 % patients still cannot achieve the level of clinical remission (RAML volume reduction rate ≥50 %), and approximately 70 % patients suffer from the adverse events of mTORC1 inhibitors [<xref rid=""bib7"" ref-type=""bibr"">7</xref>,<xref rid=""bib21"" ref-type=""bibr"">21</xref>]. Hence, there is a necessity to investigate additional predictive indicators for screening and identifying patients",29_9,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"indicators for screening and identifying patients who could potentially benefit from mTORC1 inhibitor therapy. PMEL, found abundantly in melanosomes, serves as the melanin-producing organelles within melanocytes, playing a crucial role in the structural organization of premelanosomes [<xref rid=""bib22"" ref-type=""bibr"">22</xref>]. Previous studies have found that most cases of pulmonary lymphangioleiomyomatosis (LAM) are caused by the spread of cells from renal AMLs through the bloodstream to the lungs",29_10,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"renal AMLs through the bloodstream to the lungs [<xref rid=""bib23"" ref-type=""bibr"">23</xref>,<xref rid=""bib24"" ref-type=""bibr"">24</xref>]. Furthermore, PMEL could be highly expressed in both RAMLs and pulmonary LAM, which were the diagnostic criteria and typical symptoms of TSC patients [<xref rid=""bib10"" ref-type=""bibr"">10</xref>,<xref rid=""bib25"" ref-type=""bibr"">25</xref>]. The main reason might be that both AMLs and pulmonary LAM belong to the family of perivascular epithelioid cell neoplasms (PEComas),",29_11,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"epithelioid cell neoplasms (PEComas), originating from perivascular epithelioid cells that express a combination of muscle and melanocytic markers, including HHF-35, PMEL, HMB-50, and others [<xref rid=""bib26"" ref-type=""bibr"">26</xref>,<xref rid=""bib27"" ref-type=""bibr"">27</xref>]. Moreover, immunohistochemistry confirmed the high expression of PMEL in RAMLs, and plasma proteomic and metabolomic profiling using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) also demonstrated the high",29_12,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"spectrometry (UPLC-MS) also demonstrated the high expression of PMEL in TSC patients [<xref rid=""bib11"" ref-type=""bibr"">11</xref>,<xref rid=""bib26"" ref-type=""bibr"">26</xref>]. Therefore, we aimed to prove that PMEL in plasma can serve as a biological marker for the diagnosis and monitoring of therapeutic progress in TSC-RAML in this study. Our study firstly proved that PMEL expression positivity correlated with the tumor size of TSC-RAMLs both before (r = 0.30, p = 0.026) and after mTORC1 inhibitor",29_13,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"(r = 0.30, p = 0.026) and after mTORC1 inhibitor treatment (r = 0.41, p = 0.0017). Many studies have proved that TSC patients with larger RAML lesions had poorer response to mTORC1 inhibitor treatment compared to TSC patients with smaller AML volumes, and tumor size was a predictor of mTORC1 inhibitor efficacy in patients with TSC-RAMLs [<xref rid=""bib12"" ref-type=""bibr"">13</xref>,<xref rid=""bib13"" ref-type=""bibr"">14</xref>]. Therefore, we explored the relationship between PMEL expression and the reduction",29_14,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"between PMEL expression and the reduction rate of TSC-RAMLs after mTORC1 inhibitor treatment. Results proved that PMEL expression negatively correlated with the reduction rate of TSC-RAMLs after treatment, with a correlation coefficient of −0.50 (p = 0.0022), both after 3 months (r = −0.47, p = 0.048) and 6 months of treatment (r = −0.52, p = 0.028). The above results demonstrate that PMEL might be a predictive marker for the response to mTORC1 inhibitors in TSC-RAMLs. However, there are several",29_15,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"in TSC-RAMLs. However, there are several limitations in our study. Firstly, the number of enrolled patients and blood sample size was relatively small. Secondly, treated patients enrolled in the study received various mTORC1 inhibitors (Sirolimus and Everolimus), potentially introducing bias. However, earlier research has demonstrated the clear efficacy of both Sirolimus and Everolimus in managing TSC-RAMLs, with both being endorsed as primary therapies [<xref rid=""bib21"" ref-type=""bibr"">21</xref>,<xref",29_16,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"rid=""bib21"" ref-type=""bibr"">21</xref>,<xref rid=""bib28"" ref-type=""bibr"">28</xref>,<xref rid=""bib29"" ref-type=""bibr"">29</xref>]. The predictive function of PMEL as proved by our study might extend to a broader population of TSC patients undergoing treatment with Sirolimus or Everolimus. Thirdly, we designated the largest TSC-RAML in kidneys as the target tumor for analysis, potentially introducing specific biases when extrapolating findings to evaluate all tumors. The specific mechanism by which PMEL",29_17,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"all tumors. The specific mechanism by which PMEL predicts the shrinkage of tumors induced by mTORC1 inhibitors also requires further investigation. The positivity of PMEL expression correlated with the tumor size of TSC-RAMLs both before and after treatment with mTORC1 inhibitor, and inversely correlated with the reduction rate of TSC-RAMLs after mTORC1 inhibitor treatment. PMEL could serve as a predictive marker for the response to mTORC1 inhibitors in TSC-RAMLs. This study was approved by the Ethics",29_18,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
TSC-RAMLs. This study was approved by the Ethics Committee of Peking Union Medical College Hospital (I-23PJ093). Written informed consent was obtained from all individual participants included in the study. This study was funded by the grant from National High Level Hospital Clinical Research Funding (2022-PUMCH-A-151). The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. All authors approved the manuscript. <bold>Dongxu Qiu:</bold>,29_19,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"approved the manuscript. <bold>Dongxu Qiu:</bold> Writing – original draft, Visualization, Software, Formal analysis, Data curation. <bold>Zhan Wang:</bold> Methodology, Investigation, Funding acquisition, Formal analysis, Conceptualization. <bold>Xu Wang:</bold> Visualization, Validation, Software, Resources, Data curation. <bold>Yutao Wang:</bold> Writing – review & editing, Validation, Methodology, Investigation. <bold>Wenda Wang:</bold> Supervision, Project administration, Methodology, Investigation,",29_20,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
"administration, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Yushi Zhang:</bold> Project administration, Investigation, Funding acquisition, Conceptualization. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",29_21,PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients,25 7 2024,,Tuberous_Sclerosis
